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CC-1065  and the duocarmycins are highly potent anticancer agents,  exerting their 
biological activity through covalently reacting with adenine-N3 in the minor groove 
of AT-rich sequences. The alkylation properties and cytotoxicity of a series of novel 
chiral  analogues are reported in this thesis.  Structural  modifications of established 
pharmacophores resulting in novel alkylating functionalities as well as variations of 
the  DNA  binding  domain  were  introduced  in  the  analogues  considered,  The 
sequence  specificity  of these  compounds  was  assessed  by  a  Taq  Polymerase  stop 
assay,  identifying  the  sites  of  covalent  modification  on  plasmid  DNA  and  the 
purine-N3  adducts  probed  by  a  thermally-induced  strand  cleavage  assay.  The 
cytotoxic potency of the analogues was determined against human, chronic myeloid 
leukemia, K562, cells, using a MTT based growth inhibition assay.
The importance of the chiral centre present in the natural products was subsequently 
investigated  with  a  series  of  achiral  analogues.  The  studies  established  that  the 
chiral  centre is not absolutely required for DNA  interaction and cytotoxicity. This 
finding offers the possibility of a new platform for the design of novel, active CC- 
1065/duocarmycin analogues.
A  key  chiral  and  an  achiral  analogue  were  selected  for  DNA  repair  studies.  The 
sensitivity of yeast mutants deficient in specific DNA repair pathways was assessed 
in order to delineate the mechanisms involved in the repair of the relevant adenine- 
N3  adducts.  Nucleotide excision  repair (NER)  and  post replication  repair mutants 
were  the  most  sensitive  to  the  two  analogues.  Single-strand  ligation  PCR  was 
employed to follow the induction and repair of the lesions at nucleotide resolution. 
Adduct  elimination  of  both  agents  was  by  transcription-coupled  NER,  and 
dependent  upon  functional  Rad 18.  Finally,  the  involvement  of  NER  as  the 
predominant  excision  pathway  was  further  confirmed  in  mammalian  DNA  repair 
mutant cells.
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carboxylate
16CPzI  l,2,8,8a-tetrahydro-5H-cyclopropa[c]pyrazolo[4,3-e]indoI-4-one
CS in CSA, CSB  Cockayne’s syndrome
CT  Calf thymus
DARP  Duocarmycin-DNA adduct recognising protein
DHFR  dihydrofolate reductase
DMA  N,N-dimethyl-acetamide
DMSO  Dimethyl sulfoxide
DNA  Deoxyribonucleic acid
dNTP  Deoxynucleoside triphosphate
Dp  3-(dimethylamino)propylamine
DTT  Dithiothreitol
DUMA  Duocarmycin A
DUMs  Duocarmycins
DUMSA  Duocarmycin SA
EDTA  Ethylemediamine tetraacetic acid
F2CBI  9,9-difluoro-l,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one
FCS  Foetal calf serum
FDA  Food and drug administration
Fn  Furan
FUra  5-Fluorouracil
GG-NER  Global genome nucleotide excision repair
G  Guanine
g  Gram
Hepes  N-[2-Hydroxyethyl]piperazine-N’-2[2-ethanesulfonic  acid]
hnRNP L  Heterogenous nuclear ribonucleoprotein L
Hp  Hydroxypyrrole
HNSCC  Head and neck squamous cell carcinoma
Ht  3-hydroxy  thiophene
Hz  hydroxybenzimidazole
Im  Imidazole-2-carboxamide
IP  Intraperitoneally
17Ip imidazo [4,5-b] pyridine
ISC Interstrand crosslink
IV Intravenous
kb kilobase
Kd dissociation rate constant
kDa Kilodalton
LTR Long terminal repeats
M Molar
MARs Matrix associated regions
MAT Mating-type genes
mg Milligram
ml Millilitre
mM Millimolar
\xM Micromolar
MM Multiple myeloma
MTD Maximum tolerated dose
MTT 3-(4,5-dimethylthiazoI-2-yI)-2,5-diphenyl tetrazolium bromide
MTX Methotrexate
NCE New chemical entities
NCI National Cancer Institute
NCP Nucleosome core particle
NER Nucleotide excision repair
ng Nanogram
NTS Nontranscribed strand
OD Optical density
ODN Oligodeoxyribonucleotides
PBDs Pyrrolo[2,1  -c] [ 1,4] benzodiazepines
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PDE l,2-dihydro-3H-pyrrolo[3,2-e]indole
18pmol Picomoles
Py Pyrrole-2-carboxamide
Pz N-methylpyrrazole
rpm revolutions per minute
RPA Replication protein A
SC subcutaneous
SRB Sulphorhodamine B
SSA Single-strand annealing
SSB Single-strand break
STS Soft tissue sarcoma
SV40 Simian virus 40
T Thymine
TAE Tris-acetic acid EDTA buffer
TBE Tris-boric acid EDTA buffer
TCA Trichloroacetic acid
TC-NER Transcription-coupled nucleotide excision repair
TFO Triple helix forming oligonucleotide
TGCT Testicular germ cell tumour
Th 4-methylthiazole
TLS Translesion synthesis
TMI T  rimethoxy indole
Tn 3 -methy lthiopene
TS Transcribed strand
U Enzyme unit
UV ultraviolet
XP in XPA, XPB etc  Xeroderma Pigmentosum 
YEPD  Yeast extract-peptone dextrose
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20CHAPTER 1
INTRODUCTION
1.1  Cancer: Facts and Figures
Cancer is a group of diseases characterised  by  uncontrolled  growth, accumulation 
and spread of abnormal cells. It involves a pathological breakdown in the processes 
that control  cell  proliferation,  differentiation  and death.  The causal  factors can  be 
external  (tobacco,  chemicals,  mutagens,  radiation,  sunlight,  infectious organisms), 
internal  (inherited  faulty  genes,  mutations,  hormones,  immune  conditions)  and 
lifestyle factors such as obesity, physical inactivity, nutrition etc.
Worldwide,  approximately  10 million  people  are  diagnosed  with  cancer annually 
and  more than  6 million die of the disease every year.  Currently,  over 22 million 
people are cancer patients rendering cancer a global major disease burden (Stewart 
& Kleihues, 2003).
Cancer is the  second  leading cause of death  in  the  US  (22.7% of all  deaths)  after 
heart  disease  (28%  of all  deaths-US  mortality  data 2003).  However,  compared  to 
the rates in  1950, heart disease’s death rate had decreased in 2003  by 60.6% while 
cancer death rate was marginally (0.2%) higher in 2001  and 2% lower in 2003. The 
American  cancer  society  estimates  that  564,830  cancer  deaths  were  expected  to 
occur in 2006, that is more than  1,500 people a day, with cancer accounting for 1   in 
every  4  deaths.  Lung  and  bronchus  (31%  in  men  and  26%  in  women)  are  the 
leading sites of these fatal cancers, followed by colon and rectum (10%) in men and 
breast (15%) cancer in women.  Lung cancer accounts therefore for most deaths of 
cancer.  About  1.4 million  new  cancer cases  were  expected to be diagnosed  in  the 
US, in 2006, along with more than  1   million cases of basal and squamous cell skin 
cancers.  Prostate (33%) in men and breast (31%) in women are the leading sites of 
the estimated new cases for 2006.  In 2003 the first time since  1930, when relevant 
mortality data began to be compiled, a decrease in number of cancer deaths among
21men  was  recorded.  According  to  most  recent  data,  the  National  cancer  institute 
estimates that approximately 9.6 million Americans with  a history of cancer were 
alive in January 2000, with some of these individuals being cancer-free, still having 
evidence of cancer and/or undergoing treatment (All US related data extracted from 
the American cancer society website; www.cancer.org).
In the UK, four types of cancer, breast, lung, large bowel (colorectal) and prostate, 
account  for  over  half  of  the  new  diagnosed  cases.  Breast  cancer  is  the  most 
common, although rare in men, with over 40,000 new cases (15% of all  cancers), 
followed  by  lung  cancer  with  38,000  diagnosed  cases  each  year  (incidence  data 
refer to 2002). In the UK in 2004, there were 153,397 deaths from cancer, with lung 
cancer patients accounting for 22% of these deaths.  Overall  mortality from cancer 
has decreased  in  the  period  1975-2004 by  14%  despite  increasing  incidence.  The 
state has a target of further reducing the cancer death rate in  people under 75,  by 
20% by 2010. Approximately  1.2 million people, (2% of the population of the UK) 
are alive and have received a cancer diagnosis (All UK related data extracted from 
the Cancer research UK website; www.cancerresearchuk.org).
Cancer  is  treated  by  surgery,  radiation,  chemotherapy,  hormones,  and 
immunotherapy, either alone or in combination. Chemotherapy is now given in the 
setting  of certain  paediatric  malignancies,  germ  cell  tumours  and  some  types  of 
lymphomas  with  curative  intent.  The  gains  of cure  rates  however,  in  most  other 
cases  have  been  small  (Stewart &  Kleihues,  2003).  Drugs  are  used  at  some  time 
during the course of the illness of most cancer patients. The intracellular target of 
many such anticancer drugs used in the clinic is DNA.
1.2  DNA as a target for chemotherapeutic agents.
The emergence of DNA as a target for cancer therapy coincided with the dawning 
of  modern  cancer  chemotherapy  signalled  by  the  clinical  observation  during  the
22World War II, that sulphur mustard  gas,  developed and  used  since  1917  as a war 
gas could lower the white-blood-cell count of exposed military personnel. The more 
stable nitrogen mustards followed and their therapeutic potential particularly against 
lymphomas was reviewed by Gilman and Philips in  1946, marking the introduction 
of this class of compounds as cancer therapeutics (Gillman & Philips,  1946). One of 
the first  nitrogen  mustards  shown  to  be effective,  mechlorethamine  hydrochloride 
(or chlormethine) is still used as an anticancer drug. The nitrogen mustards were the 
archetypal DNA reactive drugs of the broader class of the alkylating agents. 
Alkylating  agents  covalently  interact  with  DNA.  These  are  highly  reactive 
compounds  that  form  covalent  bonds  with  a  number  of  nucleophilic  groups  on 
DNA. Monofunctional agents having a single reactive group can induce single base 
modifications (monoadducts) at various nucleophilic centres in  DNA  (Figure  1.1). 
The  positions  N7  of guanine  along  with  the  N3  position  of adenine  are the  most 
reactive  DNA  sites  to  alkylating  agents.  Two  monofunctional  alkylating  agents, 
ET-743  and  (+)-CC-1065  are  discussed  in  sections  1.3.3  and  1.3.4.  Base 
modifications by alkylation weaken the N-glycosidic bond, leading to depurination 
/depyrimidination and the appearance of alkali labile abasic sites (Friedberg et al., 
1995). Agents possessing two reactive groups can potentially react with two sites on 
DNA,  are  termed  bifunctional  and  comprise  the  majority  of  the  clinically  used 
alkylating agents. They can form crosslinks by reacting with two nucleosides on the 
same (intrastrand) or opposites (interstrand) strands of DNA.  Figure  1.2 shows the 
various modes of interaction of crosslinking drugs with DNA.  Medicinal chemistry 
efforts  during  the  1950s  resulted  in  the  development  of  modified,  crosslinking 
mustard  derivatives  such  as  chlorambucil  and  melphalan  (phenylalanine  mustard; 
Alkeran),  both  still  being  a  mainstay  of  cancer  treatment.  Serendipity  played  a 
major  role  in  the  discovery  of  another  clinically  useful,  bifunctional  alkylating 
agent, cisplatin.  In  1963, Rosenberg and co-workers observed that proliferation of 
Escherichia coli in an electrolysis chamber equipped with platinum electrodes and 
aerated with oxygen, was inhibited. The active agent was deduced to be a platinum 
salt  (Rosenberg  et  al.,  1965).  The  compound  cisplatin,  (c/5-
23diamminedichloroplatinum  (II))  is  still  one  of  the  most  widely  used 
chemotherapeutic agents. Figure  1.3 shows the different, cisplatin-specific types of 
adducts, which can be formed following intracellular hydrolysis of the drug.
Alkylating agents  have  an  extensive  range  of structures,  differing though  limited 
sequence  specificities  and  often  dramatically  differing  tumour  specificities, 
potencies and toxicity profiles (Hartley, 2002).
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Figure 1.1  Nucleophilic centres in DNA, which are potential reaction sites for alkylation 
(adapted from Friedberg et al.,  1995). The N7 position of guanine and N3 of adenine are 
the most reactive (in pink). The alkylated N3 positions of adenine and guanine, the N2 of 
the guanine amino group and the 02 position of cytosine occupy the minor groove of the 
DNA helix. Other sites of alkylation in bases such as 06 in guanine, 04 in thymine and N7 
in guanine occupy the major groove.
Antitumour antibiotics such as the anthracyclines have been part of the arsenal  of 
chemotherapeutic  drugs  since  the  1960s.  In  contrast  to  the  agents  mentioned
24previously,  these  compounds  bind to  DNA  primarily  by  intercalation,  which  is a 
non-covalent, reversible interaction.
Monoadduct  Interstrand crosslink
DNA protein 
crosslink
Intrastrand crosslink
Figure  1.2  Modes  of  interaction  of  crosslinking  drugs  with  DNA  (taken  from 
McHugh et al., 2001).
Intercalating agents share some common structural features such as the presence of 
planar  polyaromatic  systems,  which  bind  by  insertion  between  DNA  base  pairs. 
Bisintercalators have two potential  intercalating ring systems connected by linkers 
varying in length and rigidity. The anthracyclines daunomycin (duanorubicin) and 
doxorubicin (adriamycin) possess the anthraquinone ring system. The formation of 
a  ternary  complex  with  DNA  and  topoisomerase-Il,  trapping  the  “cleavable 
complex”  and  inhibiting  the  religation  step,  thus  inducing  topoisomerase-II- 
mediated,  DNA  double strand breaks is believed  to be the critical  event for their 
anticancer activity  whereas free radical  mediated  DNA  cleavage is possibly  more 
closely related to their cardiotoxic side effects (reviewed by Brafia et al., 2001).
Apart from the DNA reactive agents, there are also drugs, which act by inhibiting 
nucleic  acid  synthesis.  The  antimetabolites  such  as  antifolates,  antipurines  and 
antipyrimidines,  interfere  by inhibiting the production of precursors necessary for 
nucleic acid synthesis  synthesis or they resemble  in  structure  normal  purines and
25pyrimidines  and  they  substitute  them  in  the  anabolic  nucleotide  pathways, 
eventually  getting  incorporated  into  RNA  and  DNA  instead  of  their  normal 
counterparts.
Other types of adduct
Monoadduct  Interstrand adduct (<1%)  Intermotecutar adduct
Intrastrand adduct*
(About 65%)  (Atout 25%)
Figure  1.3  After  undergoing  hydrolysis  in  cells,  cisplatin  can  attach  to  DNA. 
Intrastrand  crosslinks  between  adjacent guanines  are  the adducts  most frequently 
observed  followed  by  the  same  type  of  adduct  between  adjacent  adenine  and 
guanines. It can also stretch across a base to link two guanines, on the same strand. 
Cisplatin  can  also form  interstrand  crosslinks  (<I%),  which  although  infrequent, 
they  are  believed  to  be  the  most  toxic  of  the  lesions,  monoadducts  and  links 
between DNA and proteins (taken from Masters & Koberle, 2003).
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26Chronologically,  this  was  the  second  class  of anticancer  drugs  to  be  used  in  the 
clinic.  Methotrexate,  (MTX,  amethopterin)  inihibits  the  enzyme  dihydrofolate 
reductase  (DHFR)  leading  to  inhibition  of  thimidylate  synthesis  and  purine 
biosynthesis  (Jolivet  et  al.,  1983).  Eight  years  after  the  discovery  of  antifolates, 
methotrexate would provide the first example of drug-induced cure of a cancer, that 
of women with gestational choriocarcinoma (Li et al.,  1958). The purine analogues 
6-Mercaptopurine  (6-MP)  and  6-Thioguanine  (6-TG),  analogues  of  hypoxanthine 
and  guanine  respectively  have  been  useful  drugs  for  the  treatment  of leukemias, 
while the antipyrimidines 5-fluorouracil (FUra) and cytosine arabinoside, are both a 
mainstay of antileukemic therapy.  Both these classes of anti metabolites can inhibit 
the synthesis of and be incorporated into nucleic acids. Other antimetabolies include 
sugar modified analogues such as cytarabine (ara-C) and ribonucleotide reductase 
inhibitors (Hydroxyurea) (Pratt et al,  1994).
Compounds can  also act on  events downstream  of the inflicted damage on  DNA, 
like the evoked damage response. There are for example a number of agents, being 
developed to target the nucleotide excision repair (NER) pathway, which acts upon 
a  variety  of  lesions  including  damage  by  some  alkylating  agents  (Barret  et  al., 
2002).
DNA  is an evolving target for cancer therapy offering  various sites and  modes of 
interaction  for  potential  intervention  with  chemotherapeutic  agents.  Figure  1.4 
summarises  the  molecular  interactions  with  DNA,  of  various  types  of  DNA- 
interactive  agents.  Secondary  DNA  structures,  such  as  G-quadruplex  formed  at 
telomeres and also identified in promoter regions of a number of oncogenes,  have 
emerged as such molecular targets for DNA-interactive compounds (Hurley, 2002) 
along  with  other  domains  of  particular  sequence  content  such  as  the  AT-islands 
(Woynarowski,  2002) (the latter are discussed  with  respect to CC-1065  analogues 
in section  1.3.4.4).
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Figure  1.4  Different types of interaction  with  DNA  by  various classes  of DNA- 
interactive agents.
The  minor  groove  is one  structural  feature  of DNA,  which  has  been  extensively 
pursued as the target for the design of a range of agents, often based on naturally 
occurring lead structures.
1.3 Sequence selective DNA minor groove-interactive agents
The minor groove of double helical B-DNA is the site of many non-covalent as well 
as  covalent,  highly  sequence-specific  interactions,  for  a  large  number  of  small 
molecules and as such,  has been the target for the design  of novel  DNA  ligands. 
DNA  minor  groove  binders  comprise  a  distinct class  of DNA  interactive  agents, 
with  some  members  possessing  antiviral,  antibacterial  and  antitumour  properties 
(reviewed by Reddy et al.,  1999; Baraldi et al., 2004). In the sections that follow, a 
class of agents that non-covalently interact with DNA, the polyamides, and agents, 
which  can  covalently  modify  DNA  including  SJG-136,  capable  of  producing 
interstrand  crosslinks  and  ET-743,  CC-1065  and  the  duocarmycins,  and 
yatakemycin, producing monoadducts and having different sequence specificitites, 
are discussed.
281.3.1  Polyamides
Netropsin  and  distamycin  are  crescent  shaped,  naturally  occurring  oligopeptide 
antibiotics which possess antibacterial, antiviral and antitumour properties and bind 
in the minor groove of DNA. Netropsin is a pyrrole amidine antibiotic consisting of 
two  pyrrole  (Py)  rings  with  guanidinium  and  propylamidinium  end  groups  while 
distamycin  has  three  pyrrole  groups  with  formamide  and  propylamidinium  end 
groups (Figure 1.5).
NH;
Netropsin N H . “ N H -
N ----
•NH
Distamycin
Figure 1.5 Structures of the minor groove antibiotics netropsin and distamycin.
The preference of the two agents for AT-rich regions has been established through 
biophysical methods (Wartell et al.,  1974) and footprinting experiments (Van dyke 
et al.,  1982; Fox & Waring,  1984; Portugal & Waring,  1987). Netropsin requires a
29target  site  of  four  AT  base  pairs,  while  distamycin  binds  optimally  to  five 
contiguous  AT  base  pairs,  on  account  of  its  larger  size.  Both  distamycin  and 
netropsin  bind  to  d(A)n*d(T)n   better  than  d(AT)n   (Zimmer  et  al.,  1979)  and  the 
presence  of a TpA  (but  not ApT)  step  reduces  the  binding  affinity  (Ward  et al.,
1988).  However,  distamycin  is  more tolerant of a GC  base  pair at the end  of the 
binding  site  (Portugal  &  Waring,  1987;  Churchill  et  al.,  1990).  Since  the  main 
feature that distinguishes a GC base pair from an AT base pair in the minor groove, 
is  the  N-2  amino  group  of guanine,  the  lack  of binding  to  GC  rich  regions  was 
thought to be the result of steric clash between this protruding group and netropsin 
and distamycin.  Replacement of one or more pyrrole units that consitute netropsin 
with  a  heterocycle  capable  of  accepting  a  hydrogen  bond  from  guanine-2-NH2 
should  alter  its  strict  preference  for  (AT)n   binding  and  permit  GC  base  pair 
recognition (Kopka et al.,  1985; Lown et al.,  1986). The resulting compounds were 
termed  “lexitropsins”  or  information-reading  oligopeptides  and  are  currently 
referred  to  as  polyamides  due  to  their  repeating  peptide  linkers.  The  imidazole 
group (Im), which bears an N atom in place of the C-H bond of the pyrrole (Figure 
1.7), should correct the steric conflict and provide the opportunity for a hydrogen 
bond.  The  prototype  lexitropsins  incorporated  one  or  more  imidazole  groups  in 
place of the guanine-excluding pyrrole groups in the netropsin molecule (Lown et 
al.,  1986).  These  dicationic  netropsin-based  analogues  exhibited  a  progressively 
decreasing  preference  for  AT  sites  in  binding  studies  and  a  corresponding 
acceptance of GC base pairs. DNAse I footprinting studies revealed that this series 
of compounds  could  recognize  and  bind  GC  rich  sites  yet  still  retained  a  strong 
memory for the original  sequence  selectivity of the parent netropsin (Lown et al., 
1986).  In  an attempt to further decrease the attraction for AT  sites,  which  have  a 
strong  negative  electrostatic  potential,  second  generation  lexitropsins  were 
synthesized  (Krowicki  &  Lown,  1987).  These  replaced  the  cationic  N-terminal 
guanidinium  head  with  a  non-polar  N-formyl  end  group,  characteristic  of 
distamycin, resulting to a singly positively charged molecule.  Footprinting studies 
confirmed a dramatic change in the sequence specificity of these analogues, which
30exhibited increased selecitivity for GC rich sites (Kissinger et al.,  1987).  Studying 
the  complex  of  a  monocationic  diimidazole  polyamide  and  the  oligonucleotide 
d[CATGGCCATG]2,  it  was  revealed  that  the  analogue  would  bind  over  the  5’- 
CCAT-3’ site, with its N-terminus oriented at the 5’ end and the C-terminus located 
above  the  3’  thymine.  It  was  deduced  that  the  dominant  factor  determining  the 
reading of the 3’-terminal  AT  base pair is the Van  der Waals  interaction  between 
the methylenes at the carboxyl terminus of the lexitropsin and the DNA (Lee et al., 
1988a).  These  methylene  groups enter into steric contact  with  the  guanine-2-NH2 
group  of  a  GC  base  pair,  thereby  preventing  the  binding  of  the  C-terminus  of 
netropsin analogues to a GC site and forcing the recognition of an AT pair instead. 
Removal  of the  offending  methylene  group  resulted  in  a  “truncated”  lexitropsin, 
bearing only one methylene group at the C-terminus, allowing recognition of the 5’- 
ATTG site of a d[CGCAATTGCG]2 oligonucleotide, in contrast to the unmodified 
lexitropsin which would bind to 5’-AATT (Lee et al.,  1988b). An overview of the 
strategy followed to obtain agents that would achieve GC recognition is presented 
in Figure 1.6.
A  major  advance  was  the  discovery  by  NMR  studies  of a  new  type  of complex, 
with  distamycin  being capable of binding in the minor groove of a 5’-AAATT-3’ 
sequence as a side-by-side antiparallel homodimer, at higher concentrations and in a 
widened minor groove (Pelton & Wemmer,  1989). Study of the binding of the two 
peptides  distamycin  A  and  l-methylimidazole-2-carboxamide-netropsin  (2-ImN) 
revealed  that  they  are  also  capable  of  a  side-by-side  antiparallel  binding  as  a 
heterodimer  allowing  successful  targeting  of  a  single  GC  base  pair  (Mrksich  & 
Dervan,  1993a). In light of the 2:1  binding mode of homodimeric or heterodimeric 
complexes,  the  recognition  rules  for  the  side-by-side  pairing  of  pyrrole  and 
imidazole  groups  in  the  minor  groove  with  the  geometry  of  hydrogen  bonding, 
lending specificity,  were elucidated.  A  pairing of an  imidazole opposite a  pyrrole 
targets a GC base  pair,  whereas a Py opposite  an  Im targets a CG  base  pair. The 
Py/Py could target both TA and AT pairs, in preference to GC/CG. The introduction 
of hydroxypyrrole (Hp) (Figure 1.7) as a thymine-selective recognition element,
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Figure 1.6 Evolution in the rational design of GC recognising polyamides.
32designed  to  discriminate  between  AT  and  TA  base  pairs,  thanks  to  specific 
hydrogen bonds between the 3-hydroxy and 4-carbomido groups of Hp with the 02 
of T,  completed  the  recognition  code  for  all  base  pairs.  The  Hp/Py  pair  would 
specify TA  from AT,  while  Py/Hp targets AT  in  preference to TA  (White  et al., 
1998; Kielkopf et al., 2000). Table  1.1  shows the resulting recognition pairing rules 
and Figure 1.7 features the structures of the relevant peptide fragments.
OH
CH;
Im
N V
Figure 1.7 Peptide fragments referred to in the pairing rules of Table 1.1.
Pair GC  CG  TA  AT
Im/Py +
Py/Im +
Hp/Py +
Py/Hp +
Table  1.1  Dimeric pairing rules for minor groove  recognition  by  Py,  Im and  Hp. 
Plus and minus signs indicate favoured and disfavoured interactions, respectively.
In  an  attempt  to  further  increase  specificity  for  desired  sequences,  the  covalent 
linking of the polyamide strands was considered, in order to achieve unambiguous 
register of the ring pairing, as opposed to homodimers, which could afford “slipped
33motifs”.  A  homodimer  series  of  linked  polyamide  subunits  (Mrksich  &  Devan, 
1993b) with different length linkers and a heterodimer (Mrksich & Dervan,  1994) 
version  were  designed,  both  achieving  enhanced  sequence  specific  recognition  of 
designated  target  sequences  over  the  unlinked  ligands.  The  second  linking 
mechanism, entailing the attachment of the head of one molecule to the tail  of the 
other with a group capable of a tight turn, fold back configuration, thus preserving 
the  antiparallel  binding,  introduced  the  hairpin  motif  design  strategy.  Various 
linkers were subsequently investigated with the three carbon linker (gamma amino 
butaric  acid  -  y)  providing  the  highest  affinity  (Swalley  et  al.,  1998).  Different 
linking  schemes  have  produced  compounds  ranging from  polyamides  of a  cyclic 
configuration  (Herman  et al.,  1999a),  to  linking  whole  hairpin  units  and creating 
“tandem hairpin” ligands (Herman et al.,  1999b). Apart from the  purely  ring/ring 
paired analogues, incorporation of a flexible P-Alanine residue designed to relax the 
curvature  of  the  polyamides  allowed  for  improved  selectivity  and  affinity  of 
polyamides particularly towards GC base pairs with the p/Im pair being specific for 
CG  base  pairs  and  the  p/Py  and  p/p  pairs  specific for A, T  over G,C  base  pairs 
(Turner et al.,  1998). Other structural modifications to the classic Im/Py polyamide 
design  include  the  incorporation  of  alternative  five-membered  aromatic 
heterocycles  into  DNA-binding  polyamides.  N-methylpyrazole  (Pz)  and  3- 
methylthiopene  (Tn)  retained  AT  selectivity  when  paired  with  Py  while 
incorporation  of  4-methylthiazole  (Th),  furan  (Fr)  or  3-hydroxythiophene  (Ht) 
abolished binding, suggesting that there is a very narrow window of five-membered 
ring  architectures  that  can  be  successfully  accommodated  in  a  polyamide 
conformation  (Dervan  &  Edelson,  2003;  References  therein).  While  the  above 
attempts  did  not  yield  any  new  specificities,  the  difficulty  of  targeting  certain 
sequences  that  would  evade  the  consensus  of the  pairing  rules,  probably  due  to 
sequence-dependent changes in the microenvironment of the DNA, maintained the 
interest  to  find  novel  recognition  elements  and  new  leads  for  sequence 
discrimination.  The  repertoire  of aromatic  heterocycles  used  for  recognition  was 
broadened  with  the  introduction  of the  fused  heterocycles  imidazoI4,5-b]pyridine
34(Ip)  and hydroxybenzimidazole (Hz),  paired  with  Py  in  eight-ring  polyamides.  It 
was shown that Ip/Py would mimic an Im/Py pair, exhibiting the same preference 
for GC, while most importantly the Hz/Py pair distinguishes a TA base pair from an 
AT  base  pair,  rendering  Hz  a  strong  candidate to  replace  Hp  which  can  degrade 
over  time  in  the  presence  of acid  or free  radicals  (Renneberg  &  Dervan,  2003). 
Pairing of Hz with benzimidazole (Bi) was also capable of discriminating TA from 
AT  base  pairs,  successfully  departing  from  the  N-methylpyrrole-carboxamide 
framework (Marques et al., 2004).
Polyamides  can  bind  to  a  wide  range  of  DNA  sites  and  competitively  displace 
proteins  from  their  binding  sites,  as  they  possess  comparable  affinities  and 
specificities (Trauger et al.,  1996, Dickinson et al., 1998).
Transcription  inhibition  by  blocking  transcription  factors  from  binding  to  their 
cognate  sequences  by  polyamide  binding  has  been  demonstrated  in  various 
biological  systems  (Gottesfeld  et  al.,  1997;  Dickinson  et  al.,  1998).  Figure  1.8 
presents  various  examples  of  DNA-binding  proteins  that  have  been  inhibited  by 
Py/Im hairpin polyamides.
Polyamides  have  also  been  used  for  the  opposite  effect  of  gene  activation  by 
recruiting or derepressing the transcriptional machinery. Inhibition of the binding of 
repressor  IE86  to  upregulate  transcription  of  the  human  cytomegalovirus 
(Dickinson  et al.,  1999)  and  inhibition  of the  binding  of the  human  protein  LSF 
involved in the derepression of the  integrated  HIV-1  long terminal  repeats (LTR) 
(Coull  et  al.,  2002),  have  been  reported.  Additionally,  polyamide-peptide 
conjugates  can  mediate  transcriptional  activation  by  functioning  as  artificial 
transcription factors (Mapp et al., 2000).
Despite their documented  in vitro  biological  effects,  extention  of these polyamide 
functions  in  vivo requires efficient cellular uptake  and  nuclear  localisation.  Initial 
studies  revealed  that  polyamides  would  localise  mainly  in  the  cytoplasm  with 
nuclear localisation observed only in CEM human cultured and human primary T- 
cells (Belitsky et al., 2002).
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Figure  1.8  Examples  of regulation  of gene  expression  by  competitive  binding  of Py-Im 
hairpin polyamides to binding sites of transcription factors. The coloured boxes indicate the 
binding site of the italicized protein. The promoter is identified below the DNA sequence. 
The black and open circles represent Im and Py rings respectively.  Diamonds represent (3- 
Ala residues.  Plus  signs next to diamonds  represent 3-(dimethylamino)propylamine (Dp). 
The  curved  line  connecting  the  sides  of two  circles  represent  the  y-tum.  The  half circle 
represents  a  propanolamine  -NH(CH2)CH3OH  group.  Approximate  Kd  values  are  given 
next to each polyamide. Open boxes indicate mismatches between the Dp tail and GC, base 
pairs (taken from Dervan & Edelson, 2003).
36An  eight-ring  polyamide-fluorescein  conjugate,  only  when  lacking  p-alanine,  was 
later shown to localise in the nucleus of 13 different mammalian cell lines (Best et 
al.,  2003).  A  poly ami de-FITC  conjugate  has  also  been  shown  to  localise  in  the 
nuclei of cultured HeLa cells (Olenyuk et al., 2004).
1.3.2 SJG-136
The pyrrolo[2,l-c][l,4]benzodiazepines (PBDs) are a family of naturally occurring 
antitumour  antibiotics,  which  include  anthramycin,  DC-81  (Figure  1.9), 
tomaymycin, and sibiromycin. They exert their biological activity through covalent 
binding to the exocyclic N2 group of guanine in the minor groove of DNA and have 
a preference for binding to purine-G-purine triplets (Hurley et al., 1988a). DSB-120 
(Figure  1.9),  a  C8-diether-linked  PBD  dimer  was  designed  as  part  of a  rational 
approach to generate more efficient and sequence selective PBDs. Indeed the agent, 
exhibited enhanced in vitro cytotoxicity and sequence specificity, compared to the 
monomer  DC-81  (Hartley  et al.,  2004;  References therein).  The  DNA  interstrand 
crosslinking  agents  SJG-136,  (NSC  694501)  represents  a  second-generation 
rationally  designed  PBD dimmer,  which  spans  6  bp  in  the  minor  groove,  with  a 
preference for binding to 5’-purine-GATC-pyrimidine sequences.  It comprises two 
C2-e;t0-methylene-substituted  DC-81  subunits tethered  through  their C8  positions 
via an inert propanedioxy linker. SJG-136 produces DNA interstrand crosslinks, as 
it covalently binds to N2-guanine positions on opposite strands and separated by 2 
bp (Figure  1.10).  SJG-136 was found to be significantly more cytotoxic and  more 
efficient DNA crosslinker than DSB-120 (Gregson et al., 2001). More specifically, 
its  high  affinity  for  DNA  and  its  ability  to  stabilise  the  helix  is  reflected  in  the 
increase  in  calf  thymus,  (CT)  DNA  melting  temperature  (A7m)  of  33.6°C. 
Molecular modelling studies of an SJG-136 cross-link show a snug fit of the agent 
in the minor groove and *ery little helical distortion (Gregson et al., 2001).
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Figure 1.9 Structures of DC-81, DSB-120 and SJG-136.
SJG-136  is  a  highly  efficient  DNA  interstrand  crosslinking  agent  in  naked  DNA 
(XL^O.045  pM, 440-fold  more  potent than  clinically  used  melphalan), as  shown 
in  a  plasmid-based  gel  electrophoresis  assay  (Gregson  et  al.,  2001)  and  also  in 
cultured cells and in human tumour xenografts, at a therapeutical  relevant dose, as 
determined  by  the  single  cell  gel  electrophoresis  (comet)  assay  (Hartley  et  al., 
2004).  The  agent’s  sequence  selective  crosslinking  has  beeen  confirmed  in 
footprinting  studies,  while  single-strand  ligation  PCR (sslig-PCR)  studies  showed 
that the agent reaches the cellular genome and binds to DNA in a sequence selective 
manner (Martin et al., 2005).
38SJG-136 is also highly cytotoxic in vitro, exhibiting an IC^ value of 0.0425 p,M in 
K562 cells following a 1   hour exposure and showing potent activity at the National 
cancer  institute  (NCI)  60  cell  line  anticancer  drug  screen  with  50%  net  growth 
inhibition conferred within a range of 0.14 to 320 nmol/L (the mean concentration 
was 7.4 nmol/L). Sensitive cell lines exhibit total growth inhibition (TGI) and 50% 
lethality  (LCso)  after treatment with  as  little as 0.83  and 7.1  nmol/L respectively. 
The  mean-graph  pattern  of  cell  line  sensitivity  suggests  that  SJG-136  exerts  a 
multilog, differential  cytotoxicity.  COMPARE analysis of the SJG-136 shows that 
the agent does not fit within clusters of other known agents, therefore might possess 
a distinct mechanism of action (Hartley et al., 2004).
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Figure  1.10  Schematic  representation  of  the  proposed  mechanism  for  the 
interstrand crosslinking of DNA by SJG-136 (X=purine and Y=pyrimidine).
Because  of  its  potent  in  vitro  antitumour  activity,  the  agent  progressed  in  the 
standard  NCI  hollow  fibre  assay.  Prominent  in  vivo  antitumour  activity  was 
confirmed,  with  growth  inhibition  exhibited  in  20 of 24 IP and 7  of 24 SC (total 
score  of 54)  and  cell  kill  observed  in  5  of the  12 cell  lines tested,  rendering this 
compound one of the most active compounds tested in this assay to date (top 5%). 
The agent proved highly efficacious and well tolerated in subsequent studies of ten 
human  xenograft  models  including  melanomas,  ovarian,  breast,  colon,  and  lung 
carcinomas, gliomas and promyelotic leukemia. Significant growth delays occurred 
in nine models, cell kill in six models and there were  1  to 4/6 tumour-free responses
39in six models (Alley et al., 2004). This agent also appears to confer a preferential 
cytostatic and/or cytosidal  effect in vitro  upon  leukemia cells  versus normal  bone 
marrow cells, as derived from a colony formation assay (Hartley et al., 2004).
The SJG-136 induced crosslinks were shown to be more difficult to repair in human 
tumour cells (K562) than those formed by the clinically used agent melphalan. At a 
dose of 0.45 mg/kg of SJG-136, crosslinks formed rapidly and were also detected in 
tumour cells of mice bearing the LS174T  human colon cancer xenograft,  within  1  
hour after administration.  The  level  of this  in  vivo  crosslinking  persisted  over 24 
hours  in  this  tumour,  in  contrast  to  crosslinks  produced  by  conventional 
crosslinking  agents  over  the  same  period.  These  observations  suggest  that  the 
difficulty of the SJG-136 crosslinks to be repaired,  possibly  because of their poor 
recognition, must be an important determinant of sensitivity to the agent (Hartley et 
al.,  2004).  The  desirable  pharmacological  properties  of  SJG-136  derived  from 
efficacy studies and its effective antitumour activity both in vitro and in vivo, render 
this  agent  the  lead  clinical  candidate  of  the  pyrrolobenzodiazepine  class  of 
compounds  and  is  currently  undergoing  phase  I  clinical  evaluation  in  the  United 
Kingdom (through Cancer Research UK) and the United States (through the NCI).
1.3.3. Ecteinascidin-743
Ecteinascidin  743  (ET-743,  NSC648766,  Yondelis™,  trabectedin)  is  a
carbinolamine-containing  antitumour  antibiotic,  composed  of  three  fused 
tetrahydroisoquinolone subunits (designated A, B  and C) forming a wedge-shaped 
molecule  (Figure  1.11).  It  is  a  natural  product  isolated  from  the  marine  tunicate 
Ecteinascidia  turbinate  that  grows  preferentially  on  mangrove  roots  in  the 
Caribbean sea. ET-743 binds in the minor groove of DNA and selectively alkylates 
the  N2-position  of a central  guanine  within  sets of three  consequtive  nucleotides. 
The preferred sequences were determined to be 5’-PuGC-3’  and 5’-PyGG-3’  while 
the  least  favoured  ones  were  5’-NG(A/T)-3’  (Pommier  et  al.,  1996;  Seaman  & 
Hurley,  1998).  DNA covalent adduct formation is believed to be mediated through
40an intramolecular acid-catalysed dehydration of the carbinolamine moiety (at the N- 
2 position), resulting in the formation of a cyclic electrophilic iminium, which is the 
DNA-reactive intermediate, as shown in Figure 1.11 (Pommier et al.,  1996).
Figure  1.11  Chemical  structure  of  ET-743  and  proposed  reaction  of its  reactive 
iminium intermediate with the guanine 2-amino group (Taken from Takebayashi et 
al.,  1999).
While  the  A-  and  B-  subunits  provide  the  scaffold  for  DNA  recognition  and 
bonding,  based  on  the  formation  of a  network  of hydrogen  bonds  with  the  three 
base  pairs  of the  binding  site,  the  C-subunit  protrudes  out  of the  minor  groove 
making  limited  contacts  with  DNA  (Moore  et  al.,  1997).  An  important 
characteristic of this agent’s interaction with DNA is the differential reversibility of 
its adducts, governed by the different patterns of hydrogen-bonding to DNA.  It has 
been  suggested  that  it is the  differences  in  the  rate of this  reverse  reaction  at the 
non-preferred, 5’-NG(A/T) sequences that dictates the sequence selectivity of ET- 
743.  The  agent  can  migrate  along  DNA  from  its  less  favoured  sequences  and
DNA/ minor  groove
Iminium  intermediate
41eventually  forms  stable,  irreversible  covalent  adducts  at  the  preferred,  target 
sequences (Zewail-Foote & Hurley, 2001). A unique feature of ET-743, among the 
DNA-interactive agents that occupy the minor groove, is that it bends DNA towards 
the major groove (Zewail-Foote & Hurley,  1999).
ET-743 targets DNA topoisomerase I in vivo but only at high concentrations while 
topoisomerase-I  deficient  cells  showed  no  difference  to  sensitivity  compared  to 
normal  cells indicating that the enzyme is not the primary target for the cytotoxic 
activity of the agent (Takebayashi et al.,  1999; 2001a). Nucleotide Excision Repair 
(NER)-defective mammalian cell lines were found to be more resistant rather than 
more sensitive to ET-743, compared to their isogenic parent cell lines (Takebayashi 
et  al.,  2001b;  Damia  et  al.,  1999).  This  NER-mediated  cytotoxicity  of  ET-743, 
distinctly different from the other DNA-interactive agents investigated to date, was 
proposed by the Pommier group to be specifically dependent on the transcription- 
coupled  (TC)  pathway  of  NER.  According  to  this  model,  ET-743  kills  cells  by 
inducing TC-NER-mediated, single strand breaks (SSBs) in transcribed genes. The 
TC-NER complex  is  stalled  after DNA  cleavage  and  produces  irreversible  SSBs, 
which  become lethal  to cells  (Takebayashi  et al., 2001b).  Based  on this proposed 
mechanism,  ET-743  was  expected  to  be  active  against,  for  example,  cisplatin- 
resistanj cells, which have an enhanced NER system. Adducts at preferred binding 
sites  were  shown  to  be  repaired  less  efficiently  by  the  bacterial  multisubunit 
nuclease  system  (UvrABC)  than  the  non-preferred,  less  stable  adducts.  This 
differential  incision  efficiencies  and  the  inefficient  repair  of  the  stable  adducts 
which in the presence of intact NER become toxic lesions, were used to rationalise 
the repair-dependent toxicity of ET-743  (Zewail-Foote et al., 2001).
Another characteristic of the mechanism of action of ET-743 is its ability to block 
transcription.  Studies on the HSP70 promoter showed that the agent could rapidly 
block  transcription  at  pharmacological  concentrations  (Minuzzo  et  al.,  2000). 
Transcriptional  inhibition  was  also  reported  for  several  other  promoters  like  the 
MDR1  promoter (Jin et al., 2000) and p21  (Friedman et al., 2002). Initially ET-743 
was thought to target a single transcription factor (NF-Y) but it was later suggested
42that  it  is  a  more  general  inhibitor  of  activated  transcription  by  multiple  stress 
inducers, with minimal effect on uninduced transcription (Friedman et al., 2002). 
ET-743  was  shown  to  cause  perturbation  of the  cell  cycle,  with  a  delay  of cells 
progressing  from  the  G,  to  the  G2  phase,  an  inhibition  of  DNA  synthesis  and 
causing an accumulation in the G2/M phase. Cells in G,  were the most sensitive to 
the agent (Erba et al., 2001).  At pharmacologically  relevant concentrations  (nM), 
the agent induces a potent apoptotic response,  which can account for its cytotoxic 
activity,  while  at  very  low  concentrations  it  produces  transcription-dependent 
growth arrest (Gajate et al., 2002).
ET-743  is  active  in  vitro  against  a  broad  class  of  solid  tumour  cell  lines  in  the 
nanomolar to subnanomolar range (Rinehart et al.,  1995). In phase I and II clinical 
trials in  Europe and the USA, the agent has shown  significant antitumour activity 
against  several  human  malignancies,  including  soft-tissue  sarcomas  and  ovarian 
carcinomas (Van Kesteren et al., 2003). Combination with cisplatin was found to be 
synergistic against human tumour xenografts (D’lncalci et al., 2003).
Sarcomas  of  soft  tissue  represent  a  heterogenous  family  of  malignancies  of 
mesenchymal origin that account for approximately  1% of adult neoplastic diseases 
diagnosed  annually  in  the  US.  The  median  survival  of patients  with  unresectable 
STSs  is  approximately  1   year.  Therapy  with  conventional  agents  such  as 
doxorubicin and ifosfamide demonstrated response rates ranging from  11% to 30%. 
However,  after  failure  of  first  line  therapy,  there  are  no  therapeutic  options  of 
proven benefit. Therefore effective new therapies are desperately needed.  In phase 
II  studies  of patients  with  advanced  pretreated  STSs,  ET-743  was  able  to  induce 
long-lasting  objective  remissions  and  tumour control  in  a subset of patients  (Van 
Glabbeke et al., 2002; Garcia-Carbonero et al., 2004). Therefore ET-743 represents 
the first active agent for this type of tumour in the last 25 years.
In  October  2004,  ET-743  was  granted  orphan  drug  status  by  the  U.S.  Food  and 
Drug Administration  (FDA) for the treatment of STSs  and  in  April  2005, for the 
treatment of ovarian cancer. The European Comission had already granted orphan 
drug  designation  for  the  above  mentioned  cancer  types,  in  2001  and  2003
43respectively. ET-743 is currently under study in a phase III pivotal trial in ovarian 
cancer, and is also being evaluated in phase II for prostate cancer. The agent is also 
being studied in phase I trials to evaluate its potential for use in combination with 
standard chemotherapies.  It is being co-developed  by PharmaMar (Madrid,  Spain) 
and  Johnson  &  Johnson  Pharmaceutical  Research  &  Development 
(www.pharmamar.com)
441.3.4 CC-1065 and the duocarmvcins
(+)-CC-1065 (NSC-298223), the fermentation product of Streptomyces Zelensis is a 
naturally  occurring  cytotoxic  antibiotic  discovered  by  scientists  at  the  Upjohn 
company in  1978 (Hanka et al.,  1978).  Improved isolation and characterisation of 
this agent were reported by Martin, et a/., in  1981. Elucidation of the molecular and 
crystal  structure  of  (+)-CC-1065  followed,  along  with  initial  circular  dichroism 
(CD) studies, suggesting the compound’s interaction with the minor groove of DNA 
(Chidester et al.,  1981).  Structurally, the (+)-CC-1065  molecule consists of three 
repeating pyrroloindole subunits (subunits A, B, and C) linked by amide bonds. The 
A  unit,  which  is  the  cyclopropane[clpyrrolo[3,2-e]indole-4(5H)-one  system,  also 
referred  to  as  CPI,  constitutes  the  agent’s  pharmacophore  containing  the  DNA 
reactive cyclopropyl ring  (Figure 1.12). The B and C units, together comprising the 
PDE-I2   dimer,  are  identical  and  display  a  strong  influence  on  the  binding  and 
biological potency of the agent (Hurley et al.,  1988b; Boger et al.,  1990a).
Figure  1.12  Chemical  structure  of  the  natural  enantiomer  of  (+)-CC-1065.  The 
component subunits are denoted as A, B and C.
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45(+)-CC-1065  has an overall  curved shape with a lipophilic inner surface while the 
hydrogen-bond  donors  and  acceptors  are  positioned  on  the  molecule’s  outer 
periphery  (Chidester et al.,  1981).  It exhibits a right-handed twist that mimics the 
pitch  of  B-form  DNA.  The  absolute  configuration  of  the  natural  product  was 
determined by X-ray crystallography to be that of Figure 1.12 (Martin et al.,  1988). 
At the time of its identification, (+)-CC-1065 was the most potent, small molecular 
weight  compound  investigated,  possessing  exceptionally  potent  in  vitro  cytotoxic 
activity against a wide variety of human tumours (Bhuyan et al.,  1982). It was also 
found  to  be  very  active  in  vivo  against  a  panel  of experimental  murine  tumours 
(Neil  et  al.,  1981).  Despite  its  high  potency  and  broad  spectrum  of  antitumour 
activity, CC-1065’s further development into a clinical agent was precluded due to 
an irreversible, delayed hepatotoxicity in  mice at subtherapeuric doses (McGovern 
et al.,  1984).
Later efforts disclosed  another class of structurally  related  antitumour antibiotics, 
the  duocarmycins  (DUMs).  The  first  of  these  agents,  is  (+)-duocarmycin  A 
(DUMA),  isolated  from  Streptomyces  DO-88  and  disclosed  in  1988,  concurrent 
with a series of related agents isolated from Streptomyces DO-89: duocarmycins B, 
and  B2,  C, (pyrindamycin  B)  and  C2  (pyrindamycin  A).  The  last  addition  to  this 
family  of  natural  products  was  (+)-duocarmycin  SA  (DUMSA),  isolated  from 
Streptomyces  DO-113  and  disclosed  in  1990  (Figure  1.13)  (Boger  et al.,  1997b; 
References therein).  Like (+)-CC-1065, the duocarmycins were also found to bind 
to the minor groove of DNA (Boger et al.,  1990b).
The  duocarmycins  A  and  SA  are  structurally  different from  (+)-CC-1065  in  that 
they  contain  a  unique  left-hand  alkylation  subunit;  a  functionalised 
spirocyclopropylhexadione  moiety.  All  of  the  duocarmycins  incorporate  the 
trimethoxyindole (TMI) group as their right hand, DNA binding subunit.
In a comparative evaluation, (+)-DUMA displayed the exceptionally potent in vitro 
activity characteristic of (+)-CC-1065 (Boger et al.,  1990b) and was the most potent 
agent  among  the  duocarmycins.  The  enhanced  potency  of  (+)-DUMSA  was
46attributed to its enhanced  solvolytic  stability  relative to  its predecessors,  hence its 
name, DUMSA (SA stands for Stable A).
Like  (+)-DUMA,  (+)-DUMSA  does  not  exhibit  the  delayed  fatal  hepatotoxicity 
characteristic of (+)-CC-1065 (Boger & Johnson  1996).
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Figure 1.13 Structures of the main members of the duocarmycins.
Both classes of agents have been shown to exert their biological activity through a 
highly  sequence  selective  alkylation  of  the  minor  groove  of  duplex  DNA,  at 
sequences rich in adenine-thymine (AT) base pairs.
1.3.4.1  Interaction with DNA
(+)-CC-1065  was  shown  to  interact  strongly  with  double  stranded  DNA  by 
preferential  interaction  at AT-rich  sites  in  a  non-intercalative  mode  (Chiderster et
47al.,  1981; Li et al.,  1982) while showing weak and reversible or no interaction with 
other  macromolecular  targets  (RNA,  mouse  chromatin,  proteins  like  histones, 
human serum albumin (Moy et al.,  1989). The mechanism through which it exerts 
its cytotoxic activity was therefore suggested to be, at least partly, the preferential 
inhibition  of DNA  synthesis.  Subsequent studies  concentrated  on  determining  the 
(+)-CC-1065’s sites of covalent interaction  with  DNA. The evidence that (+)-CC- 
1065  binds  primarily  in  the  minor  groove  of  DNA  was  provided  by  a  series  of 
observations.  Firstly,  (+)-CC-1065  was  able  to  react  with  T4  DNA,  which  has  a 
relatively  inaccessible  major  groove  due  to  glycosylation,  at  approximately  the 
same  extent  as  with  calf  thymus  DNA,  which  contains  no  major  groove 
modifications,  suggesting  that  major  groove  binding  is  not  involved  (Swenson  et 
al.,  1982).  In  competitive  binding  studies,  the  AT  selective,  minor  groove  agent 
netropsin,  inhibited  the  binding  of  (+)-CC-1065.  However  (+)-CC-1065  could 
slowly  displace  netropsin from  DNA.  Netropsin  on  the other hand  was  unable  to 
replace the  bound  (+)-CC-1065.  Anthramycin,  another  reagent,  that  preferentially 
binds GC-rich sites and covalently reacts with the N2-guanine in the minor groove, 
could  only  partially  block  the  binding  of (+)-CC-1065,  its  inability  of complete 
inhibition  of  binding  reflecting  the  different  base  specificity  of  the  two  agents 
(Swenson  et  al.,  1982).  Finally,  preferential  suppression  of  alkylation  by 
methylnitrosourea and  ethylnitrosourea  of bases  in  the  minor groove (and the  N3 
group  of  adenine  in  particular),  when  DNA  was  pretreated  with  (+)-CC-1065, 
pointed  to  this  minor  groove  group  as  the  major  potential  target  of  the  drug 
(Swenson et al.,  1982).
The  (+)-CC-1065  adduct was  later obtained  by  thermal  depurination  of a defined 
oligonucleotide duplex  (Needham-Van  Devanter et al.,  1984),  isolated,  and  NMR 
characterised  (Hurley  et al.,  1984),  confirming the  molecule’s  base  (adenine)  and 
heteroatom  (N3)  specificity.  Other  NMR  studies  of  thermally  released  adenine 
adducts, derived by a 12bp, (+)-CC-1065-interacted oligonucleotide, determined the 
covalently modified adenine to be in the N6 doubly protonated (amino) form (Lin & 
Hurley,  1990), with the positive charge delocalised over the entire adenine molecule
48and  alkylation  to  be  occurring  between  the  extracyclic  carbon  of the  cyclopropyl 
ring (C4) and the N3-adenine, with opening of the cyclopropyl ring system  (Figure 
1.14). This near exclusive alkylation event accounts for 80%-90% consumption of 
the agent in the presence of duplex DNA (Reynolds et al.,  1985).
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Figure 1.14 Reaction of (+)-CC-1065 with double stranded DNA at N3 of adenine 
to form  the  (+)-CC-1065-DNA  adduct.  The covalently  modified  adenine is  in  the 
doubly protonated 6-amino form.
(+)-CC-1065  binds covalently to N3  of adenine and  lies within  the  minor groove, 
extending over a 5  bp AT-rich  region for which  sequence  specificity exists.  Each 
site of (+)-CC-1065 alkylation proved to be an adenine residue flanked by two 5’-A 
or 5’-T residues. The sequence preference for the three base AT-rich alkylation site 
follows the order:  5’-AAA-3’  = 5TTA-3’ > 5TAA-3’ > 5’-ATA-3’  (A; alkylated 
adenine).  In addition, the agent exhibited a strong preference for the fourth 5’  base 
to be A or T, and an extended, weaker preference for the fifth 5’  base to be A or T 
and the same weak preference for the 3’  base preceding the alkylation  site to be a
49purine base. This selectivity for AT-rich sites corresponds to the length of the agent 
and  the  size  of  the  binding  site  required  to  accommodate  it.  The  consensus 
sequences that (+)-CC-1065 is highly reactive with were therefore suggested to be: 
5’-PuNTTA-3’ and 5’-AAAAA-3’ (Pu; purine, N; any nucleotide base, A; alkylated 
adenine)  (Hurley  et  al.,  1984;  Reynolds  et  al.,  1985).  Another  analysis,  under 
different experimental conditions from the above mentioned (24h incubation at 4°C 
rather  than  2h  at  37°C),  supported  a  consensus  sequence  of  5’-(A/T)(A/T)A-3’ 
(Hurley et al.,  1990).
The  orientation  of  the  sequence  specificity  of  (+)-CC-1065,  in  relation  to  the 
adducted  adenine  site,  as  established  by  the  thermally  induced  cleavage  assay, 
suggested the polarity of the molecule in the minor groove of DNA  (Hurley et al. 
1984)  and  was  later  confirmed  by  employing  the  footprinting  assay  (Needham- 
VanDevanter & Hurley  1986) and NMR (Scahill et al.,  1990). (+)-CC-1065 lies in 
the minor groove with a covalent bond between the opened cyclopropyl group and 
N3 of adenine and extends in the 3’ -> 5’ direction.
Oligonucleotide  CD  studies  also  revealed  sequences  that  go  through  a  transient 
phase of reversibly bound (+)-CC-1065 before converting to a covalent adduct, and 
others that create reversible only binding sites (e.g. 5’-GAATT-3’). Such reversibly 
bound species were found to compete with covalent adduct formation and inhibited 
the  rates of DNA  alkylation  (Krueger et al.,  1991). The  (+)-CC-1065  interactions 
with  calf thymus DNA,  however,  unlike those of simpler analogues,  could  not  be 
reversed  by  a  variety  of  experimental  manipulations.  Additionally,  the  lack  of 
observable  cytotoxicity  of the  formed  DNA-CC-1065  covalent  adducts,  indicates 
that (+)-CC-1065 interaction with DNA is effectively “irreversible” (Warpehoski et 
al.,  1992).
The structural similarities between the duocarmycins and (+)-CC-1065 suggest that 
these agents may  be acting by a common  mechanism derived from the reversible, 
stereoelectronically  controlled  adenine-N3  addition  to the  least  substituted  carbon 
of  the  activated  cyclopropane  within  selected  AT-rich  minor  groove  regions  of 
duplex  DNA.  Studies of the alkylation  properties of (+)-DUMA  and  (+)-DUMSA
50revealed that they  participate  in the characteristic  DNA  minor groove adenine-N3 
alkylation, in a fashion and at concentrations similar to those of (+)-CC-1065. The 
adenine ring becomes protonated upon duocarmycin adduct formation, resulting in 
charge  delocalisation  over  the  purine  ring  system  (Figure  1.15)  (Boger  et  al., 
1990b).
Both  (+)-DUMA  and  (+)-DUMSA  exhibit  strikingly  similar  DNA  sequence 
selectivity  to  (+)-CC-1065.  The  site  of  the  detected  alkylations  proved  to  be  an 
adenine flanked by two 5’-A or T bases and the preference for the sequence of the 
three  base  pairs  binding  site, follows  the  order of 5’-AAA-3’  > 5*-TTA-3*  > 5’- 
TAA-3’  > 5’-ATA-3\  There  also  proved  to  be a  preference,  though  not absolute 
requirement, for the fourth 5’  base to be A or T and a weak preference for the 3’ 
base preceding the alkylation site to be a purine base. The high affinity consensus 
sequences for (+)-DUMA-DNA alkylation have therefore been suggested to be: 5’- 
(A/TAAA)-3’ and 5’-(A/TTTAPu)-3\ Although each agent alkylates the same sites 
in DNA, two important distinctions lie in that the less reactive but more stable agent 
(+)-DUMSA  is  approximately  10-fold  more  efficient  in  alkylating  duplex  DNA 
compared to (+)-DUMA, and does so with a greater relative selectivity among the 
available alkylation sites (Boger et al.,  1994b). This selectivity extends in the 3’  -> 
5’  binding  directionality  from  the  alkylation  site,  with  the  hydrophobic  concave 
face  of  the  duocarmycins  deeply  imbedded  in  the  minor  groove,  the  polar 
functionality lying on the outer face of the complex and the bound agent spanning 
3.5  base  pairs,  complementing  the  topological  curvature  of  the  minor  groove. 
Duocarmycins  C,  and  C2   also  exhibited  identical  alkylation  selectivity  to  (+)- 
DUMA (Boger et al.,  1990b).
The  duocarmycin-adenine  covalent  adduct  was  isolated,  characterised  and 
quantified,  establishing  the  N3-adenine  alkylation  as  the  near  exclusive  DNA 
alkylation  event (accounting for 86%-92% consumption  of (+)-DUMA  and >92% 
of (+)-DUMSA,  in the presence of duplex  DNA  (Figure  1.15) (Boger & Johnson, 
1996;  References therein).  However,  in  conditions of DNA  treatment with  excess 
agent, and in the absence of high affinity adenine-N3 alkylation sites (Sugiyama et
51al.,  1993),  or  if  such  sites  are  protected  from  alkylation  by  pretreatment  with 
another minor groove binding agent (e.g. distamycin A) (Yamamoto et al.,  1993), a 
minor guanine-N3 alkylation was detected, but only in the case of (+)-DUMA.
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Figure  1.15  Schematic  diagram 
of the alkylation of the N3 group 
of  an  adenine  residue  by  (+)- 
duocarmycin  A.  The  resulting 
adduct  structure  is  also  shown 
for (+)-DUMSA (bottom right).
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Despite  the  similar nature  of DNA  alkylation  by  the  two  classes  of agent,  subtle 
differences in the alkylation profiles do occur, notably the lack of alkylation at 5’-
52CAAAG-3’  by  (+)-CC-1065,  attributed  to  its  extended  AT-rich  binding  site  size 
(Boger et al.,  1994b).  Another important distinction  between those two classes of 
agents  is  the  reversibility  of  the  covalent  reaction.  Unlike  (+)-CC-106,  which 
essentially  irreversibly alkylates double stranded  DNA  under the conditions of the 
relevant studies, (+)-DUMA and (+)-DUMSA have been shown to do so reversibly. 
The rate or ease of reversibility proved dependent upon the relative reactivity of the 
agent and the expected stability of adducts as well as the extent of the noncovalent 
interactions.  Consistent  with  this  interpretation,  the  (+)-DUMA  retroalkylation 
reaction  is much slower that that of (+)-DUMSA, as (+)-DUMA  is more reactive. 
The  reversibility  of  the  DNA  alkylation  reaction  was  sensitive  to  the  reaction 
conditions and parameters such as pH, temperature, time, and to a lesser extent salt 
concentration (Boger & Yun  1993).
1.3.4.2  Modification of the pharmacophore
As  stated  earlier,  the  duocarmycins  and  (+)-CC-1065  are  not  only  structurally 
related  but also  share  similarities  in their properties of the  DNA  alkylation event. 
Between the two classes of agents a common pharmacophore has been identified. 
Synthesis  of  simplified  functional  analogues  of  (+)-CC-1065,  incorporating  the 
exceptionally  reactive,  parent left hand,  (1,2,7,7a-tetrahydrocyclopropf 1,2-clindol- 
4-one) (Cl) alkylation subunit, exhibit marked similarities in their DNA alkylation 
profiles with the authentic CPI  bearing corresponding agents,  hence Cl  constitutes 
the minimum potent pharmacophore of the agent (Figure  1.16) (Boger & Wysocki
1989). The Cl subunit derives by the removal of the pyrrole segments from the CPI 
and  the  (+)-DUMA  alkylation  subunit  (DA).  The  subsequent  synthesis  and 
comparative  evaluation  (in  vitro cytotoxic  activity,  DNA  alkylation  properties)  of 
the  analogue  CI-TMI,  illustrated  that  this  agent  bears  the  minimum  potent 
pharmacophore  of  the  duocarmycin  alkylation  subunit  and  also  the  common 
pharmacophore  of the  duocarmycins  /  (+)-CC-1065  alkylation  subunits  (Boger  et 
al.,  1990b; Boger et al.,  1990c) (Figure  1.16).
53Minimum potent pharmacophore of the alkylation subunit.
DA
OCHj
(+)-duocarmycin A  CI-TMI
COMMON
PHARMACOPHORE
c h 3
r
HN,
CPI C l
Figure 1.16 The minimum potent and common pharmacophore (Cl), of the CPI and 
DA alkylation subunits.
However,  Cl  alkylates  DNA  in  a  less  efficient  manner,  resulting  in  decreased 
cytotoxic potency of its analogues, highlighting the need to further improve on the 
subunit’s alkylation efficiency (Boger & Wysocki, 1989).
Replacement  of the  fused  pyrrole  ring  with  a  fused  benzene  ring,  results  in  the 
l,2,9,9a-tetrahydrocycloporpa[c]benz[e]indol-4-one  (CBI)  subunit.  Even  though 
CBI  is chemically less reactive, it was found that the more synthetically accessible 
CBI  analogues  were  four  times  more  stable  and  four  times  more  potent than  the 
corresponding CPI  ones (Boger et al.,  1995a).  CBI  agents were found  to alkylate 
DNA  with  an  unaltered  sequence  selectivity,  with  greater intensity  and  at a faster 
relative  rate  than  their CPI  counterparts,  resulting  in  enhanced  cytotoxic  potency, 
and  indicating  that  the  simplified  CBI  subunit  possesses  distinct  advantages  over
54the authentic CPI pharmacophore (Boger et al.,  1989; Boger & Munk,  1992). These 
improved  properties  of  the  CBI  analogues  validate  therefore  the  approach  of 
introducing  deep-seated  modifications  in  the  (+)-CC-1065  and  duocarmycin 
alkylation subunits.  Additionally such modifications seem to be well  tolerated and 
can  lead  to  potent  cytotoxic  agents  that  exhibit  improved  in  vivo  efficacy,  as 
reported for the (+)-CBI-indole2 agent, which also lacks the delayed hepatotoxicity of 
(+)-CC-1065.  Extension  of  these  studies  includes  the  preparation  of  other  CBI 
derivatives like MCBI (Boger et al.,  1996a), CCBI (Boger et al.,  1996b), C5-C02Me- 
CBI (Boger et al., 2001), in an attempt to determine the substituent electonic effects on 
functional  reactivity. The study of the CBI analogues also suggested that the CPI 7 
centre  (CH3),  may  hinder  the  accessibility  to  the  adenine-N3  alkylation  site, 
decelerating  the  rate  of  the  alkylation  reaction  and  accounting  for  the  lower 
efficiency of the CPI analogues.  In addition, a direct relationship between stability 
and  biological  potency  was confirmed  by the  observed  trend  of the  solvolytically 
more stable derivatives to be the most potent (Boger et al.,  1995b).
An example of a substitution of the reactive centre of the natural products is the 9,9- 
difluoro-1,2,9,9a-tetrahydrocyclopropalc]benzle]indol-4-one  (F2CBI),  a 
difluorocyclopropane  analog  of the  (+)-CC-1065  and  the  duocarmycin  alkylation 
subunits.  The  reactivity of the agents bearing this modified  subunit was increased 
by  500-fold,  and  they  were  found  to  be  (500-1000)-fold  less  cytotoxic  than  the 
corresponding  unmodified  CBI  derivatives  (Boger  &  Jenkins  1996).  Fluorine 
substitution has played a key role in drug development with a number of fluorinated 
compounds and analogues currently investigated, among others, SJG-136 (Kamal et 
al., 2004).
A  ring expansion  of the five-membered  ring of the CBI  to a fused  six-membered 
ring,  results  in  the  formation  of  the  2,3,10,10a-tetrahydrocyclopopa[dl- 
benzo[fJquinol-5-one, (CBQ) subunit. CBQ agents were found to alkylate the same 
sites as their corresponding agents containing the DSA, CPI, CBI, or Cl alkylation 
subunits.  In agreement with their relative reactivity, they exhibited less selectivity
55among the available alkylation sites, alkylating DNA with a lower efficiency (100- 
to  1000)-fold,  while  being  equally  less  potent  in  cytotoxicity  (Boger  &  Mesini 
1995).
A  seven-membered  C-ring  of  the  alkylation  subunits  of  (+)-CC-1065  and  the 
duocarmycins  constitutes  the  1,2,3,4,11,1 la-Hexahydrocycloproplc]naptho[2,l- 
b]azepin-6-one (CNA) pharmacophore.  Incorproration of this seven-membered C- 
ring  system  to  functionalised  agents  increased  their  reactivity  by  4750-fold 
compared to the five-membered  ring (CBI)  bearing counterparts. The CNA  based 
agents  exhibited  cytotoxic  activity  that  was  less  potent  than  the  corresponding 
duocarmycin  based  agents  but  more  potent  than  the  Cl  bearing  ones  (Boger  & 
Turnbull,  1997).
Another  reported  variation  is  the  l,2,9,9a-tetrahydrocyclopropa[cJbenz[e]-3- 
azaindol-4-one  (CBA)  alkylation  subunit.  CBA  contains  an  aza  variant  of  the 
natural  products’  subunit and  proved  structurally  identical  to its carbon  analogue, 
CBI.  However  CBA-bearing  derivatives  were  much  less  effective  in  DNA 
alkylation  ( 1000-fold)  and  biologically  much  less  potent (100- to  1000)-fold  than 
the corresponding CBI analogues (Parrish et al., 2003a).
A  number  of  modified  heteroaromatic  core  structures  of  the  CC-1065  or 
duocarmycin alkylation subunits have also been reported, where the fused pyrrole is 
replaced with a different heterocycle.
Incorporation  of  the  1,2-dihydro-1  -(chloromethyl)-5-hydroxy-8-methy 1-3H-
furano(3,2-e]indole  (CFI)  generated  an  agent  which  exhibited  an  identical 
alkylation  profile  with  (+)-CC-1065  at the  major site  of alkylation,  and  was  only 
subtly  distinguishable,  at the  low-affinity  sites.  It was comparable or slightly  less 
effective  at  alkylating  DNA  than  (+)-CC-1065  (1-5  times),  which  was  consistent 
with the relative in vitro cytotoxic potency (Mohamadi et al.,  1994).
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Figure 1.17 Structures of the authentic pharmacophores of (+)-CC-1065, (+)-DMA, 
(+)-DUMSA,  and  of  those  derivatives  bearing  the  most  profound  structural 
modifications.
57The  methyl  l,2,9,9a-tetrahydrocyclopropa[c]pyrido(3,2-e]indol-4-one-7- 
carboxylate (Cpyl), contains a one carbon  expansion on the  pyrrole ring found  in 
DSA.  Its  unique  8-ketoquionoline  core  structure,  was  designed  in  an  attempt  to 
provide a means to effect activation via in situ selective metal cation complexation. 
CPyl was found to be (3-4)-fold less stable than CBI and DSA but possesses greater 
stability  compared  to  (+)-CC-1065  and  (+)-DUMA.  CPyl  analogues  exhibited 
identical  DNA  alkylation  sequence  selectivity  and  near  identical  alkylation 
efficiencies compared  to the  natural  products  and  displayed  a trend  of increasing 
cytotoxic potency with increasing the length of the DNA binding subunit (Boger & 
Boyce,  2000).  In  the  presence  of  metal  cations,  the  simplified  (+)-N-BOC-CPyI 
agent exhibited dramatically enhanced  levels and  rates of alkylation, depending to 
the  concentration  of  the  cations  and  their  established  stabilities.  Its  resulting 
alkylation  selectivity  was  identical  to  the  (+)-DUMSA  and  (+)-CC-1065  lead 
compounds, and for one metal cation (Zn+2) in particular, alkylation was achieved at 
unprecedently  low  concentrations  for  such  a  simple  analogue,  with  an  efficiency 
within  only  10-fold  of that  of the  natural  products.  In  the  absence  of the  metal 
cations, the CPyl bearing agents interact with DNA at an identical manner, albeit at 
a reduced rate and efficiency (Boger et al., 2000a).
The  pyrazole  analogue  of CPI,  l,2,8,8a-tetrahydro-5H-cycIopropa[c]pyrazoIo[4,3- 
elindol-4-one  (CPzI)  has  also  been  reported  (Baraldi  et  al.,  1997).  This  new 
derivative  showed  low  cytotoxicity  against  L1210  murine  leukemia  (IC5o=3064 
nM).
Figure  1.17  shows  the  structures  of  the  modified  alkylation  subunits  discussed 
above.
Other  modifications  include  the  study  of  the  effect  of  even  more  pronounced 
structural changes as in the case of the isomeric analogues, iso-CPI, iso-CI, and iso- 
CBI, in efforts to address the importance of the location of the conjugated carbonyl 
and  the  impact  on  the  reactivity  of  the  activated  cyclopropane.  Additional
58modifications in the DNA alkylation subunits in some other examples of heteroaryl 
derivatives are shown in Figure 1.18.
Figure 1.18 Some examples of other modifications of the alkylation subunits.
1.3.4.3  Origins  of  the  sequence  selectivity  -   Mechanisms  of  catalysis  of  the 
alkylation reaction.
There has been considerable debate over the primary driving force for the sequence 
selectivity  and  the  source  of  catalysis  of  the  DNA  alkylation  reaction  by  the 
CC1065/duocarmycin class of agents.
The  relative  importance  of the covalent and  noncovalent  interactions  provided  by 
the  component  structural  subunits  of the  (+)-CC-1065  molecule  in  mediating  the 
agent’s  sequence  specificity  was  initially  probed  by  a  series  of selected  synthetic 
analogues possessing structural  modifications and  variations to the natural  product 
as well as a series of unnatural enantiomeric counterparts.
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59The alkylation model
The alkylating potency and sequence specificity of analogues containing the DNA 
reactive  subunit  (CPI)  linked  to  zero,  one  or  two  indole  subunits,  as  well  as  an 
analogue with the structure of (+)-CC-1065 but lacking the hydroxyl and methoxyl 
substituents  in  the  B  and  C  subunits  (Figure  1.19),  were  determined  using  the 
thermally-induced  strand  breakage  assay.  Since  all  analogues  exhibited  nearly 
identical  sequence  selectivity,  the  Hurley/Upjohn  group  reported  the  key  finding 
that  the  A  subunit  (CPI),  plays  the  predominant  role  in  sequence  specific 
recognition, as it alone has sufficient structural information to mediate the sequence 
specificity of the entire molecule (Hurley et al., 1988b).
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Figure 1.19 Structures of the partial analogues containing the DNA reactive cyclopropane 
ring, CPI, linked to (a) acetyl, (b) one, and (c) two indole groups, and (d) that of the (+)- 
CC-1065 structure lacking the hydroxyl and methoxyl substituents in the B and C subunits, 
all constructed to evaluate subunit effects on the sequence specificity of alkylation by (+)- 
CC-1065.
60However,  the  a  and  b  analogues,  require  104  -  and  103  -  fold  higher  drug 
concentrations respectively, to show  levels of covalent binding comparable to that 
of c.  As the  CPI  group can  contribute  very  little  to the  hydrophobic  and  van  der 
Waals noncovalent interactions shown by the extended analogues and (+)-CC-1065, 
Hurley postulated that noncovalent interaction is not sufficient for determining the 
molecule’s sequence selectivity. In agreement with that proposal was the finding in 
oligonucleotide  studies  that the  5’-GCGAATT-3’  sequence  would  only  bind  (+)- 
CC-1065  reversibly  (albeit  strongly),  and  would  fail  to  form  a  covalent  bond, 
suggesting  that  high  affinity  binding  is  not  the  only  prerequisite  for  bonding 
(Krueger et al.,  1991). Covalent bonding therefore appeared to be determined by a 
sequence-dependent reactivity of certain adenines with the DNA alkylating subunit 
CPI.  The  two  pyrroloindole  units  (subunits  B  and  C),  however,  are  not  entirely 
passive as they dramatically increase the rate of adduct formation and “modulate or 
fine-tune” the sequence specificity through binding interactions between the inside 
edge  substituents  of  B  and  C  and  the  floor  of the  minor  groove  (Hurley  et  al., 
1988b).  This  is  particularly  evident  in  certain  incubation  conditions  (e.g.  37°C) 
where  alkylation  patterns  are  indistinguishable  only  between  the  fully  carbon 
framework  trimeric  analogue  d  and  (+)-CC-1065.  While  noncovalent  binding  is 
required to take place in the minor groove of DNA before bonding can be achieved, 
this binding can be very weak and need not be sequence selective, as in the case of 
a. Therefore, according to the Hurley group, the reported selectivity must originate 
in the bonding reaction.
The Hurley/Upjohn group were also the first to report a “telestability” effect of (+)- 
CC-1065  observed  in their thermally-induced  strand  breakage  studies,  in the form 
of either an enhanced background strand breakage, and / or evidence of breakage at 
one  presumably  non-(+)-CC-1065-binding  position  (Reynolds  et al.,  1985).  They 
also demonstrated the asymmetric effect of (+)-CC-1065 on local DNA structure, as 
revealed by the strand selective inhibition of both DNase I and Alu I cleavage, using 
a site-directed adduct (Hurley et al.,  1987).  (+)-CC-1065  was  shown to produce a 
selective conformational change in the structure of the covalently modified strand,
61which  extends as far as  11  bases to the 5’  side  of the  covalent  modification  site. 
Since only adenines in certain sequence contexts react with (+)-CC-1065, and since 
covalent binding of (+)-CC-1065 to DNA appears to require a deformation of DNA 
structure,  they  proposed  that  the  relative  propensity  of the  reactive  sequences  to 
undergo such conformational changes may play a role in the sequence selectivity of 
the  alkylation  event.  Based  on  footprinting  studies  of  their  simplest  synthetic 
analogue a (Figure  1.19), they proposed that the CPI group could alone mediate this 
asymmetric  effect,  offering  further  evidence  against  a  productive  role  of  the 
noncovalent  interactions  in  those  important  DNA  topological  changes  (Hurley  et 
al.,  1988).  Relevant  to  this,  the  DNA  helix  distortions  also  proved  to  be  highly 
sequence  dependent,  since  the  relative  distortion  energies  of different  sequences 
seemed  to  be  predictive  of  the  experimentally  determined  DNA  sequence 
specificity of (+)-CC-1065 (Zakrzewska et al.,  1987).
This sequence dependent conformational flexibility theory put forward would refer 
to adenines in certain environments that would be able to approach the methylene 
carbon  of the  cyclopropane,  sufficiently  closely  for  bond  formation.  It  was  later 
observed  that DNA  structure  would  bend  upon  covalent  modification  by  (+)-CC- 
1065 (Lee et al.,  1991; Lin et al.,  1992), resembling the intrinsic bending associated 
with  poly-adenine  tracts.  Again  the  CPI  subunit  of (+)-CC-1065  was  claimed  to 
have  sufficient  structural  information  to  mediate  this  effect.  The  reactivity  of the 
established  consensus  sequence  5’-AAAAA-3’  towards  (+)-CC-1065  and  the 
observation of the above mentioned bending of DNA upon covalent bonding, both 
suggest  a  critical  involvement  of a  bent  DNA  conformation  in  the  (+)-CC-1065 
sequence  selectivity,  accounting  for  at  least  one  set  of  the  reported  optimum 
bonding/consensus  sequences.  Sequences such as  5’-TTA-3’  which  are equally,  if 
more,  reactive  do  not  exhibit  an  intrinsically  bent  DNA  structure,  but  possess 
several  local  structural  perturbations  (propeller  twisting,  narrowing  of  the  minor 
groove)  which  upon  reaction  with  (+)-CC-1065  induce  bending  (Lin et al.,  1992; 
Sun et al.,  1993).  The reaction of (+)-CC-1065 with DNA was envisaged to entrap 
this transient bending of the DNA duplex to eventually form covalent bonding.
62In  conjunction  with the sequence dependent conformational flexibility proposal  as 
the  basis  for  sequence  selectivity,  Hurley  also  developed  a  sequence  dependent 
catalytic activation model, an adduct formation mechanism involving positioning of 
the  N3  group  of  adenine  of  an  “active  site”  within  bonding  distance  of  the 
cyclopropyl  methylene carbon  and at the same time,  positioning a proton, from  a 
phosphate group close to the C4 carbonyl oxygen atom which eventually becomes a 
phenolic group in the final  adduct. The hydrogen  bonding interaction  between the 
new  phenolic group and an anionic oxygen of the phosphate on the noncovalently 
modified strand, distant by two base pairs from the covalently modified adenine in 
the  5’direction,  was  suggested  to  be  involved  in  general  acid  catalysis  of  the 
alkylation  reaction  (Warpehoski  &  Hurley,  1988). This proposed  model  was  later 
further  refined  with  the  addition  of two  critically  positioned  water  molecules  at 
opposite ends of the covalent reaction site.  One bridging water molecule  is placed 
between a phenolic proton on the alkylating subunit of (+)-CC-1065 and an anionic 
oxygen  in  the  phosphate  on  the  noncovalently  modified  strand,  and  a  second 
ordered  water  molecule  is  associated  with  one  of  the  protons  on  N6  of  the 
covalently modified adenine (Figure 1.20) (Lin etal.,  1991).
In contrast to the natural  enantiomeric analogues, Hurley concluded that the mode 
of  sequence  recognition  for  the  unnatural  enantiomer  (-)-CC-1065-DNA  adduct 
formation,  was different from  the  natural  product and  was  primarily  governed  by 
the  AT-rich  sequence  selective  noncovalent  minor  groove  interactions  (Hurley  et 
al.,  1990). They reported that (-)-CC-1065 lies in the opposite direction in the minor 
groove,  alkylates a distinct  set of adenines and  exhibits a different  selectivity for 
covalent adduct formation,  while the  smaller simplified  analogues do not alkylate 
DNA, (with the exception of the smallest (-)-N-acetyl-CPI). The dramatic increase 
in  the  alkylation  rate  achieved  by  attachment  of  the  full  carbon  skeleton  of the 
natural product to (-)-CPI, implied that it is the specific AT-recognising interactions 
associated  with  the  pyrroloindole groups which  play  the dominant role  in  (-)-CC- 
1065’s reactivity (Hurley et al.,  1990).
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Figure  1.20 Proposed mechanism for the catalysis of the covalent bond formation 
of the cyclopropane ring of (+)-CC-1065 with an adenine-N3 group, involving two 
strategically placed water molecules (taken from Lin et al.,  1991).
The noncovalent model
An alternative theory about the relative role of the central and right hand segments 
of the (+)-CC-1065  molecule in its reported alkylation  selectivity  was put forward 
by  the  Boger  group.  Boger  initially  focused  on  the  synthesis  and  evaluation  of 
aborted  and  extended  synthetic  analogues  of  the  CDPI  and  PDE-I  frameworks 
(Kelly et al,  1987; Boger et al.,  1987). These analogues were structurally related to 
CC-1065  but  incapable  of  covalent  bond  formation,  constituting  potentially 
selective,  high  affinity,  noncovalent,  minor  groove  binding  agents  (Figure  1.21). 
The group initially  provided experimental  evidence of a substantial  preference for
64AT-rich  noncovalent  binding  of  the  simplified  agent  CDPI3  methyl  ester.  The 
studies were later extended to include a whole series of CDPIn  methyl esters (n=l- 
5)  and  PDE-In   methyl  esters  (n=l-3),  all  exhibiting  high  affinity,  AT  rich,  minor 
groove  binding  (Boger  et  al.,  1990d).  This  binding,  principally  derived  from 
hydrophobic interactions and noncovalent van der Waals contacts was shown to be 
sufficient to produce a potent cytotoxic effect. The initial noncovalent, AT-specific, 
minor  groove  interaction,  is  optimal  for  the  trimeric  CDPI3/PDE-I3 agents,  while 
PDEI3/DNA  complexes  were  shown  to  be  more  stable.  Those  findings  led  the 
Boger  group  to  suggest  that  (+)-CC-1065  is  best  represented  as  a  selective 
alkylating  group  superimposed  on  the  rigid  CDPI3  skeleton.  The  removal  of the 
hydroxy and methoxy substituents (PDEIn-» CDPIn) had only a small impact on the 
binding affinity and no effect on the AT-rich binding selectivity.
In later similar studies, the Boger group synthesised and studied the DNA binding 
properties  of two  other  series  of  agents,  ACDPIn   (n=l-4)  and  TACDPIn   (n= 1  -3) 
(Figure  1.21) (Boger & Sakya, 1992).
Figure  1.21  Structures of the partial analogues constructed to evaluate subunit effects on 
the sequence specificity and affinity of binding.
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65Comparable  to  observations  made  with  the  CDPIn   series,  both  the  ACDPIn   and 
TACDPIn  agents exhibited a marked  selectivity for AT-rich  versus GC-rich  DNA 
(most pronounced for ACDPIn). Again, the trimeric agents ACDPI3 and TACDPI3 
proved to  be the optimal  agents for groove  binding.  However, the  ACDPIn  series 
exhibited  a  substantially  reduced  DNA  binding  affinity,  compared  to  the  parent 
CDPIn  agents,  while in contrast, the TADCPIn   series significantly  surpassed  it.  In 
the  case  of  ACDPIn   agents,  the  reduced  binding  affinity  was  attributed  to  the 
destabilising electrostatic  interaction of the amine  group on the  peripheral  face of 
the  agent,  with  the  negatively  charged  phosphate  backbone  of  DNA.  When  this 
amine group was converted to an electropositive substituent, such as a quarternary 
amine (as is the case of the TACDPIn  series), DNA binding affinity was increased. 
The introduction of stabilising electrostatic interactions, therefore, greatly enhanced 
the noncovalent affinity for DNA minor groove binding, whilst having little impact 
on the intrinsic, preferential AT-rich binding selectivity.
When coupling such simplified analogues to the CPI pharmacophore, the resulting 
(+)-CPI-CDPI2 agent  proved  indistinguishable from  (+)-CC-1065  in  both  in  vitro 
cytotoxic  potency  (Boger  &  Coleman,  1988)  and  alkylation  selectivity  profile 
(Boger et al.,  1990a). The profile of covalent alkylation  by (+)-CPI-CDPI3 proved 
nearly  identical  to  that  of (+)-CC-1065/(+)-CPI-CDPI2,  however,  (+)-CPI-CDPI, 
exhibited  a  perceptibly  different  profile.  It  was  this  indistinguishable  alkylation 
pattern  of  (+)-CC-1065/(+)-CPI-CDPI2   versus  that  of  (+)-CPI-CDPI,  (for  the 
enantiomeric  counterparts  it  was  (-)-CC-1065  =  (-)-CPI-CDPI2  *  (-)-CPI-CDPI,) 
that lead Boger suggest that it is the structural differences of (+)-CPI-CDPI2 versus 
(+)-CPI-CDPI, which embody the principal determinant of (+)-CC-1065’s sequence 
selectivity.  Hence,  Boger assigned a critical  role to the potential of the CPI-CDPI2 
agent for additional noncovalent binding interaction (Boger et al.,  1990a).
Central to the interpretations of the two distinct proposals for the origin of the DNA 
alkylation  selectivity  that  emerged  have  been  the  perceived  similarities  or
66distinctions  in  the  alkylation  profiles  of  the  simple  derivates  of  the  alkylation 
subunit versus the natural products. A key finding of the Boger group, was therefore 
the demonstration that the simplified analogues, (+)-N-acetyl-CPI and (+)-N-BOC- 
CPI,  apart  from  being  far  less  potent  in  cytotoxicity  and  alkylation  potency 
(requiring  104- to 107- fold the concentration of (+)-CC-1065 to achieve comparable 
potency),  they  also  exhibited  substantially  different  and  less  selective  alkylation 
profiles (Boger et al.,  1990a), albeit in a different DNA fragment and with different 
experimental  conditions to those employed  by Hurley. That finding alone directly 
conflicted one of the main arguments of Hurley’s proposed model.
The  above  pattern  also  applies  to  (+)-DUMSA  and  its  simple  derivative,  (+)-N- 
BOC-DSA, which was also shown to possess a substantially reduced cytotoxic and 
alkylation  potency  (104-  fold  less  efficient  compared  to  the  parent  agent),  while 
exhibiting a clearly distinct and less selective DNA alkylation profile (Boger et al., 
1994b;  Boger et al.,  1997d).  Unlike (+)-CC-1065, the structurally and chemically 
related agents (+)-DUMSA, (+)-DUMA and the simplified (+)-N-BOC-DSA, were 
found  to  reversibly  alkylate  DNA  under  the  relevant  study’s  experimental 
conditions (Boger et al.,  1994b). The faster rate of retroalkylation exhibited by (+)- 
N-BOC-DSA, as well  as the  lack of such alkylation reversibility  by (+)-CC-1065, 
suggests that the extent and the rate of this reverse reaction is inversely dependent 
upon the extent of the noncovalent binding stabilisation of the agents, provided by 
the  PDE-I2  and  the  trimethoxyindole  (TMI)  subunits  of  the  CC-1065  and  the 
duocarmycins, respectively.
The near thermally neutral and inherently reversible alkylation reaction is, therefore 
rendered  less  reversible or irreversible  by  the stabilising effect of the  noncovalent 
interactions.  Consistent  with  this  interpretation,  simplified  analogues  of  (+)-CC- 
1065  with  aborted  binding  subunits,  also  reversibly  alkylate  DNA.  Another 
functional role of the (+)-CC-1065 central and right-hand subunits, therefore, is that 
of promoting  and  stabilising  a  thermodynamically  poor and  potentially  reversible 
covalent alkylation, a theory also known as binding -  driven bonding (Boger et al., 
1989: footnote (14); Boger et al.  1990a).
67Retaining  the  CDPI,  and  CDPI2  framework,  Boger  synthesised  a  number  of 
analogues  incorporating  different  alkylating  pharmacophores,  such  as  the 
exceptionally reactive Cl (Boger & Wysocki  1989; Boger et al., 1991a) and the CBI 
(Boger et al.,  1989) electrophiles.  As in the case of the CPI containing analogues, 
the incorporation of the Cl subunit into the (+)-CI-CDPI2 agent, conveyed enhanced 
alkylation  specificity  compared  to  the  simple  (+)-N-BOC-CI  analogue,  and 
remarkably similar to that of (+)-CC-1065. This was attributed to the restriction in 
the  number  of  available  alkylation  sites  dictated  by  the  enhanced  noncovalent 
selectivity  of the  agent.  The  identical  DNA  binding  properties  of (+)-CBI-CDPI2 
and  (+)-CC-1065  and  their  equipotent  cytotoxic  activity,  proved  that  alternative 
electrophiles  incorporated  into  structurally  related  agents  act  similarly  and  can 
participate in the characteristic sequence selective alkylation reaction.
In what was later described as “the first definitive test” of Boger’s proposed model, 
the  agents  of  Figure  1.22  were  considered  (Boger  et  al.,  1991b).  It  was 
demonstrated that agents  1-3 had identical DNA alkylation profiles, irrespective of 
their absolute configuration,  and  were  in  turn  identical  to the selectivities of both 
enantiomers of N-BOC-CI and N-BOC-CPI. Similarly the DNA alkylation profiles 
of the natural enantiomers of 4-6 were identical, indistinguishable from that of (+)- 
CI-CDPI2.  The  selectivities of the CDPI2 agents were  strikingly  similar to that of 
(+)-CC-1065 and substantially more selective that that of N-BOC-CI and of agents 
1-3.  One conclusion  drawn from the above studies is that absence of noncovalent 
binding (afforded by the CDPI2 framework) allows a “nonselectivity” of the simple 
alkylation event, which would proceed with identical selectivities, independently of 
the  nature  of the  incorporated  electrophile.  This  “nondiscriminant”  nature  of the 
alkylation  event  indicated  yet  again  a  more  prominent  role  for  (+)-CC-1065’s 
noncovalent binding. Another important point is that the methyl ether 2 and agent 3 
and  similarly  the  methyl  ether  5  and  agent  6,  cannot  close  to  the  putative 
corresponding Cl agents, yet alkylate the same sites. This finding illustrates that the
68cyclopropane  is  not  obligatory  for  observation  of  the  Cl  characteristic  DNA 
alkylation and therefore a sequence dependent phosphate protonation and activation 
cannot be the critical event that determines the alkylation selectivity (Boger et al., 
1991b).
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Figure  1.22  Structures  of  the  agents  considered  in  the  “first  definitive  test”  of 
Boger’s  proposed  model  of  the  role  of the  noncovalent  binding  in  the  reported 
sequence selectivity of CC-1065 and the duocarmycins.
Two structural characteristics of a run of AT base pairs as opposed to GC base pairs 
are  of  particular  importance  for  this  noncovalent  binding  selectivity  and 
stabilisation.  The  lack of the  amino  substituent that extends  in  the  minor groove, 
present  in  a  GC  base  pair,  and  the  constricted  width  associated  with  AT
69attenuations, renders an AT-rich minor groove more sterically accessible, permiting 
deeper  penetration  and  most fully  achieving  the  stabilising  hydrophobic  contacts 
(Boger et al., 1991a; References therein).
In an extention of the earlier mentioned studies with ACDPIn  and TACDPIn  agents, 
the role of such stabilising electrostatic interactions, was again highlighted through 
the  introduction  of  the  positively  charged  trimethylammonium  group  on  the 
peripheral face of a series of seco-CBI-indole agents (Figure  1.23). That structural 
alteration,  as  in  the  previous  case,  resulted  in  enhanced  DNA  alkylation 
efficiencies. The agents b-d were found to be  100-fold more effective than a, which 
lacks the positively charged group. This was attributed to the increased noncovalent 
DNA binding affinity (Boger et al.,  1995a). Additionally, the alkylation selectivity 
of these analogues was influenced by the exact positioning of the positively charged 
substituent. When lying on the peripheral face of the agents (b and c), the positively 
charged substituent did not alter the DNA alkylation selectivity. In contrast, groove 
placement of the large trimethylammonium salt (d) resulted in an altered and more 
discriminating AT-rich adenine N3 alkylation.
Figure  1.23 Structure of the seco-CBI-indole parent agent (a) and those analogues 
resulting  from  strategic  placement  of the  positively  charged  trimethylammonium 
substituent on  the  peripheral  face (b, c) of the agents,  or within  the minor groove
(+)-duocarmycin SA a. R =  H
b.  R = 7-NMe
c. R = 6-NMc
d.  R = 5-NMe
(d).
70Boger’s  model  in  which  the  alkylaton  selecitivity  derives  from  the  noncovalent 
binding selectivity,  preferentially  in the narrower,  sterically  more accessible AT  - 
rich minor groove, was also used to accommodate the observed reverse and offset 
AT-rich  adenine-N3  alkylation  selectivity  of  the  enantiomeric  pairs  of  agents 
related  to  CC-1065  (Boger  et  al.,  1994a)  and  the  duocarmycins  (Boger  et  al., 
1994b; Boger et al.,  1997d).
The unnatural enantiomers bind in the reverse 5’-»3 direction in the minor groove, 
so as to permit access to the electrophilic cyclopropane and  resulting in  an  offset 
AT-rich selectivity, since the binding site necessarily starts at the 5’  base adjacent 
to the alkylation site. This alkylation selectivity within an offset AT-rich site is the 
natural  consequence of the diastereomeric  relationship of the adducts. This model 
requires that (+)-CC-1065 / (+)-DUMSA / (+)-DUMA and (+)-N-BOC-CPI / (+)-N- 
BOC-DSA exhibit distinct alkylation selectivities.  For the simple derivatives of the 
alkylation subunit, sufficient minor groove access to the reacting centre is possible 
with  a  single  5’  A  or  T  base  adjacent  to  the  alkylation  site.  However  for  the 
extended  agents  sufficient minor groove penetration  requires a larger 3.5  or 5  bp, 
AT-rich  region,  with two or more adjacent A or T bases. This AT-rich selectivity 
nicely  corresponds to the  size  of the  agent  and  conflicts  Hurley’s  proposal  of an 
identical sequence selectivity of (+)-CC-1065 and (+)-N-BOC-CPI.
Another observation that supports Boger’s proposal  of a dominant role of the AT- 
rich  noncovalent  binding  selectivity  and  steric  accessibility  of the  N3  alkylation 
site,  derived from the study of the impact of relocation  of the C4 carbonyl  of the 
(+)-CC-1065 and the duocarmycin alkylation subunits.  It was revealed that despite 
this most substantial structural modification, the resulting agents (Figure  1.24) react 
at comparable rates and possess identical  sequence selectivity to the parent agents 
(Boger  et  al.,  1997c).  The  natural  enatiomer  ijo-CBI-TMI,  although  having  the 
carbonyl  buried in the minor groove and therefore no more accessible to the DNA 
phosphate  backbone,  as  is  the  case  of  the  parent  compounds,  alkylates  in  an 
identical  manner,  albeit  50-  to  100-fold  less  efficiently,  and  at  comparable  rates.
71This  observation  is  inconsistent  with  Hurley’s  proposal  of  alkylation  selectivity 
being controlled by a sequence dependent C4 carbonyl protonation by strategically 
located DNA backbone phosphates (Boger et al.,  1997c).
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Figure 1.24 Structures of the natural enantiomers of (+)-CBI-TMI and (+)-/so-CBI- 
TMI and their corresponding alkylation subunits,  the latter containing an isomeric 
structural modification of the C4 carbonyl relocated to the C8 position.
Further support for the  noncovalent binding  model  was the  disclosure,  in  what  is 
referred to as the  second  definitive test of Boger’s proposed  model, that a simple 
reversal  of  the  orientation  of the  DNA  binding  subunits  of  the  agent  (+)-DSA- 
CDPI2,  results  in  reversal  of  the  enantiomeric  alkylation  selectivity  (Boger  & 
Johnson  1995).  One  unique  feature of (+)-DUMSA  is the  C6 methyl  ester on the 
left  hand  side  of  DSA  which  complements  the  right-hand  side  linking  amide,
iso - CBI - TMI
DNA minor groove
A
72providing  the  ability  to  introduce  DNA  binding  subunits  on  either  side  of DSA. 
Both  (+)-DSA-CDPI2  and  (-)-DSA-CDPI2  agents  alkylate  the  single  high  affinity 
sites of (+)- and (-)- CC-1065, respectively. The natural enantiomer of the reversed 
agent, (+)-CDPI2-DSA (Figure  1.25), was shown to alkylate the same high affinity 
alkylation  site  of  (-)-DSA-CDPI2  and  (-)-CC1065.  Similarly  the  unnatural 
enantiomer, (-)-CDPI2-DSA was found to alkylate the same sites as (+)-DSA-CDPI2 
and  (+)-CC-1065  (Boger  &  Johnson,  1995).  According  to  the  Boger  group  this 
incorporation and conversion of a natural enantiomer of the (+)-DUMSA alkylation 
subunit, into an agent that exhibits the selecitivity of a typical unnatural enatiomer, 
by  simple  reversal  of the  orientation  of the  DNA  binding  subunits  of the  agent, 
could only  be supported by a model, where the alkylation selectivity is controlled 
by  the  AT-rich  noncovalent  binding  selectivity  and  steric  accessibility.  In  the 
opposite case (Hurley’s model),  where alkylation selectivity  is independent of the 
binding  selectivity,  the  two  natural  enantiomers  (+)-DSA-CDPI2  and  (+)-CDPI2- 
DSA should alkylate the same sites.
O   H
(+) - DSA - CDPI,
Figure  1.25  The  natural 
enantiomers of the extended: 
(+)-DSA-CDPI2, 
and reversed:
H
(+)-CDPI2-DSA,  analogues 
of (+)-duocarmycin SA.
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73Complementary to the above study, was that of another structurally novel analogue 
of  (+)-DUMSA,  CDPI-DSA-CDPI,  referred  to  as  the  “sandwiched”  analogue 
(Figure  1.26).  Both  enantiomers  of this  agent,  containing  a  single  DNA  binding 
subunit attached to each side of the alkylation subunit, alkylated the same sites and 
their selectivity proved distinct from either enantiomer of the previously mentioned 
extended or reversed agents, consistent with the noncovalent binding model (Boger 
et al.,  1997a).
These  studies  established  that  the  preferential  AT-rich  noncovalent  binding 
selectivity  of  the  agents  controls  the  DNA  alkylation  selectivity  and  that  both 
natural  and  unnatural  enantiomers  of this  class  of agents  are  subject to  the  same 
polynucleotide recognition features.
NH?
(+) CDPI-DSA-CDPI
Figure 1.26 The natural enantiomer of the “sandwiched” analogue of duocarmycin 
SA, (+) CDPI-DSA-CDPI.
While  alkylation  by  the  reversed  agents  proceeds  at  exceptionally  low  rates 
(comparable to the  small  simple derivatives),  a rapid  rate of DNA  alkylation  was 
observed  for  the  sandwiched  analogue  at  a  new  set  of  alkylation  sites,  and 
independently of the absolute configuration of the agent. This observation suggests 
that the source of catalysis is not uniquely embedded in the original DNA alkylation
74sites but could be a function of the presence of the right-hand heteroaryl  N2 amide 
substituent. This substituent is the distinguishing feature between the reversed and 
the  extended  or  sandwiched  analogues  and  could  be  the  factor  conveying  this 
enhanced DNA reactivity.  It was suggested that the inherent twist of the N2 amide 
of the reversed agents is not altered upon binding, thus the agents are not activated 
for nucleophilic addition. This explains why they undergo DNA alkylation at rates 
comparable  to  those  of the  simple  derivatives.  Therefore,  in  addition  to  the  the 
alkylation selectivity being governed by the noncovalent binding selectivity, Boger 
also proposed as a source for catalysis, a binding-induced conformational change in 
the  agent  that  disrupts  the  ability  of  the  N2  nitrogen  to  convey  stability  to  the 
alkylation subunit through vinylogous amide conjugation (Boger et al.,  1997d).
The  rigid,  bridged  aromatic A  and  B  subunits of the  duocarmycins  and  CC-1065 
molecules are coplanar in the X-ray structure of the free agents. Upon binding in the 
minor groove,  an  intersubunit twist is observed, as the two subunits are driven to 
maximize hydrophobic contacts with the DNA, as shown in Figure  1.27. This twist 
is distributed across the torsion angles Xi , X2 and X 3 'n the linkage between  them. 
The perturbation of Xi  dihedral  angle (the vinylogous amide) is found to correlate 
very well  with the rate of the reaction and most directly relates to DNA alkylation 
activity (Boger & Garbaccio 1999a; Smith et al, 2000).
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Figure 1.27 Structure of the natural enantiomer of (+)-DUMSA. The subunit naming and 
atom numbering scheme is shown, and the torsion angles Xi, X 2 and X 3  indicated.
75This activation is not uniquely alkylation site dependent,  but rather a consequence 
of forced adoption of a helical conformation  upon AT-rich minor groove binding. 
This source of catalysis requires an extended and rigid N2  amide substituent.
The  amide’s  fundamental  role  in  catalysis  was  established  in  experiments  where 
replacement of the amide by a methylene group in the (+)-CBI-TMI agent, therefore 
essentially eliminating the source of catalysis, resulted in complete abolishment of 
any DNA alkylation capabilities for the modified analogue accompanied  by a  In ­
fold loss in cytotoxic potency (Boger et al.,  1998) (Figure  1.28).
Figure  1.28  Structures  of the  (+)-CBI-TMI  agent  (left)  and  a  modified  analogue 
(right), which replaces the linking N2  amide with a methylene group.
Since the extent of this binding induced conformational change is dependent on the 
shape of the minor groove, the agent’s destabilisation would be greater within the 
narrower, deeper AT-rich minor groove sites, where the inherent twist in the linking 
amide and helical  rise of the bound conformation is greatest. Therefore, the shape- 
selective  recognition  (preferential  AT-rich  noncovalent  binding)  and  shape- 
dependent catalysis (binding induced twist of the amide), work in concert to restrict 
alkylation to accessible adenine N3  sites. This synergism is epitomised by the left- 
hand subunit C6 methyl ester and the C5 methoxy substituent of the TMI subunit of 
the  duocarmycins,  which  both  substantially  enhance  alkylation  potency  and 
increase  biological  potency.  Not  only  do  these  two  substituents  contribute  to  the
(+)-CBI-TMI
76noncovalent binding stabilisation by being imbedded in the minor groove, but they 
also increase the rigid length of each subunit and the inherent twist in a DNA-bound 
helical conformation (Figure 1.29).
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Figure 1.29 Structure of the natural enantiomer of (+)-duocarmycin SA. The minor 
groove imbedded substituents that extend rigid subunit lengths are indicated.
The  effect  of  methoxy  substituents  on  the  activity  of  (+)-DUMSA  analogues  is 
summarised in Table  1.2.
Replacement  of  the  TMI  binding  subunit  of  (+)-DUMSA  with  a  simple  indole 
results  to  the  DSI  agent  (Figure  1.30).  This  modification  not  only  alters  the 
noncovalent  binding  potential  of the  agent but  also allows for deeper penetration 
into the DNA minor groove due to the absence of the bulky methoxy groups of TMI 
and more extensive favourable van de Waals interactions.  Despite the fact that the 
deeper  groove  penetration  accentuates  the  twisting  requirement,  the  intersubunit 
twist angle is decreased by 8° and results in less disruption of the ligand vinylogous 
amide, manifested as a 20-fold slower rate in DNA alkylation (Schnell et al,  1999).
Figure 1.30
Structure of the 
indole derivative of 
(+)-duocarmycin 
SA, DSI.
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77Relative DNA Alkylation 
efficiency
IC50.  LI 210.  pM
indotei
Table  1.2 The effect of methoxy  substituents on the activity of the corresponding 
duocarmycin SA analogues (taken from Boger & Garbaccio  1999a).
In conclusion, in the absence of an extended right-hand subunit, DNA minor groove 
binding no longer requires an induced twist in the N2  amide linkage, depriving the 
agent of the additional activation toward DNA alkylation. This in turn results in the 
slow alkylation rates observed with simple derivatives of the alkylation subunits.
This  theory  further  contributes  to  the  distinction  in  the  behaviour  of  the 
enantiomeric  pairs.  From  NMR  studies  of  oligonucleotides,  it  has  been  reported 
(Boger & Garbaccio  1997) that the natural enantiomer of (+)-DUMSA, in its bound 
adopted  conformation,  contains  an  average  twist  of  41°,  while  in  contrast,  the 
unnatural  enantiomer,  within  the same  binding  site,  when  bound,  exhibits a  much 
smaller, 28° twist between the right and left-hand subunits. This greater twist angleis thought to result in  greater disruption of the vinylogous amide  stabilisation  and 
preferentially accelerates the alkylation event for the natural enantiomer.
The  role  of  the  vinylogous  amide  was  further  clarified  with  the  synthesis  and 
evaluation  of a  carbocyclic  analogue  of the  (+)-CC-1065  and  the  duocarmycins, 
CBIn, which lacks N2 and the vinylogous amide  (Figure  1.31) (Boger & Turnbull,
1998).
CBIn
Figure  1.31  Structure  of the  l,2,9,9a-tetrahydro-[H-cyclopropa[c]benz[e]inden-4- 
one  (CBIn),  a  carbocyclic  C-ring  analogue  of the  alkylation  subunits  of (+)-CC- 
1065 and the duocarmycins.
The comparison of CBIn with CBI directly established that the presence of N2  and 
the vinylogous amide increases stability by 3200-fold at pH3, and  by (MO3 to  104)- 
fold  at  pH  7,  relative  to  its  structural  CBI  homologue.  The  expanded  analogues 
CNA  and  CBQ  (Figure  1.17)  exhibited  increased  reactivity  in  the  order  CAN  > 
CBQ > CBI,  mirroring the relative extent of vinylogous amide conjugation. Thus, 
the  vinylogous  amide  found  in  the  naturally  occurring  alkylation  subunits  is 
responsible  for  their  unusual  stability,  while  disruption  of the  vinylogous  amide 
stabilisation caused by a DNA binding-induced conformational change, seems to be 
providing the necessary activation (reactivity) for the alkylation reaction (Boger & 
Turnbull,  1998). A study of the solvolysis pH-rate profiles of the N-BOC analogues 
of CBQ  and  CAN,  which  are  reactive  throughout the  pH  range  2-12,  showed  no 
evidence  of solvolysis  rate  -  pH  dependence,  indicating that the  DNA  alkylatiojn 
reaction need not be acid-catalysed (Boger & Garbaccio  1999b).
79Finally,  in  another  demonstration  of  the  duocarmycin  and  (+)-CC-1065  DNA 
alkylation  reaction  not relying on  the  DNA  phosphate  backbone for catalysis, the 
Boger group  replaced  the  backbone  phosphates  proximal  to the  C4 carbonyl  of a 
(+)-DUMSA molecule bound to an oligonucleotide containing a single high affinity 
alkylation  site,  by  methylphosphonates.  Despite  this  modification,  alkylation 
proceeded at comparable rates (Ambroise & Boger 2002). This observation is again 
incompatible with an active backbone participation in the DNA alkylation reaction 
as  proposed  by  Hurley.  The  main  findings  concerning  the  two  models  are 
summarised in Table  1.3.
Alkylation site model  Non covalent Binding model
•  (+)-CC-1065 and the (+)-CPI •  (+)-CC-1065 and the (+)-CPI
have identical alkylation selectivtities are distinct.
selecitivities. •  (+)-CC-1065 is best represented as
•  Selectivity inherent and a selective alkylating agent
embodied in the CPI subunit. superimposed on the CDPI
•  The alkylation reaction controls the trimer skeleton
selectivity irrespective of •  Alkylation selectivity is controlled
noncovalent binding. by binding selectivity
•  Sequence dependent phosphate •  Alkylation within sterically
activation through carbonyl accessible, AT rich sites.
complexation / protonation. •  Alkylation not controlled by
C4 carbonyl required. phosphate protonation, not relying
•  Alkylation at junctions of bent DNA. on phosphate backbone for
•  Different features control (-)-CC- catalysis.
1065 enantiomeric selectivity. C4 carbonyl not required.
•  Same features control (-)-CC 1065 
enantiomeric selectivity.
•  pH  independent  catalysis  derived 
from  a  DNA  binding  induced 
conformational change.
Table 1.3 Summary of the most important features of the two proposed models regarding 
the  origin  of  sequence  specificity  and  alkylation  catalysis  of  CC-1065  and  the 
duocarmycins.
801. 3.4.4 Biological Properties
The potent cytotoxic and antitumour effects of (+)-CC-1065 have been attributed to 
the  DNA  alkylation  event  addressed  earlier and  are  thought  to  be  produced  as  a 
direct  consequence  of the formation of the  (+)-CC-1065  -  DNA  covalent adduct. 
This  results  in  characteristic  structural  modifications  on  the  DNA,  which  can  be 
linked to the observed biological properties of the agent.
Effects on local DNA structure
DNA helix
Early studies suggested that (+)-CC-1065 stabilises the DNA helix.  Evidence came 
from  a dose  dependent  increase  in  the  melting temperature  of calf thymus  DNA, 
inhibition  of  S,  nuclease  activity  and  resistance  to  ethidium-induced  intercalative 
unwinding attributed to stiffening of the helix (Swenson et al., 1982).
(+)-CC-1065  induces DNA  bending of about  14-19°,  with a directionality towards 
the  minor groove (Lee et al.,  1991). The direction  and the  magnitude of the drug- 
induced bending, and the associated narrowing of the groove, correspond well  with 
the general features of the intrinsic bending in a 5-6 bp, AT tract. Drug modification 
however results in loss of temperature dependency of the intrinsic bending (Sun et 
al.,  1993).  The  special  reactivity  of the  3’  adenine  of the  consensus  sequences to 
(+)-CC-1065,  the  shift in  the  locus of bending of an A5 tract about 0.5  base  pairs 
toward the 3’ of its centre, and the additive effect on the magnitude of bending upon 
drug  modification,  provide  support for  the  proposed  “junction  bend”  model.  The 
interaction of the inside edge substituents of the  B and C subunits of (+)-CC-1065 
with  the  floor of the  minor  groove  cause  winding  of the  DNA  helix  and  are  also 
associated with DNA stiffening (Lee et al.,  1991; Hurley & Sun,  1994a). The helix 
stabilising property of (+)-CC-1065 also extends to RNA-DNA duplexes as well as 
DNA with modified internucleotide linkages (Kim et al.,  1995).
81Chromatin
The interaction of (+)-CC-1065 with DNA was also characterised when  DNA is in 
the  form  of chromatin.  (+)-CC-1065  does  bind  to  chromatin  isolated  from  P388 
mouse  leukemia cells  but significantly  less  strongly  compared to  naked  DNA  and 
through what is a primarily reversible reaction. (+)-CC-1065 was also found to bind 
very weakly and nonspecifically to histones (Moy et al.,  1989).
In a study of drug-induced damage to cellular DNA, more damage (at the same drug 
to  DNA  ratio)  was  observed  in  cell  lysates  than  to  whole  cell  DNA.  This  was 
attributed partly to a greater accessibily of the drug to the protein-dissociated DNA 
(Zsido et al.,  1991).  However,  extensive formation  of irreversibly  bound  (+)-CC- 
1065  covalent  adducts,  both  in  the  absence  and  in  the  presence  of  chromatin 
proteins,  in  purified  and  intracellular  SV40  DNA,  respectively,  has  also  been 
reported  (McHugh  et al.,  1994).  Increased  concentration  of drug  was  nonetheless 
required  to  react  with  SV40  DNA  in  infected  cells  in  order  to  achieve  the  same 
level  of  damage  as  with  purified  DNA.  Matrix  associated  regions  (MARs),  are 
domains  that  anchor  cellular  DNA  to  the  nuclear  matrix,  a  proteinaceous 
scaffolding that organizes chromatin fibres into looped domains. Given their critical 
role  in  the  organisation  of nuclear  chromatin,  they  too  have  been  investigated  as 
targets of the (+)-CC-1065 and analogues and are discussed later.
The  structural  changes  in  DNA  induced  by  its  interaction  with  (+)-CC-1065  have 
biochemical consequences as they affect the activity of, and reactions mediated by, 
enzymes which are highly sensitive to such  structural  changes and which  play  key 
roles in various aspects of the DNA metabolism. Such examples include:
DNA polymerases
Inhibition  of  DNA  synthesis  represents  a  major  mode  of action  of (+)-CC-1065, 
which exhibited a pronounced inhibitory effect on purified DNA polymerase a (Li
82et al.,  1982).  A  single stranded template containing a site-directed adenine adduct 
induced  by  (+)-CC-1065  and  analogues,  was  also  shown  to  block  (though  not 
absolutely) the in vitro DNA synthesis mediated by Klenow fragment, E.Coli DNA 
polymerase  I,  and  T4  DNA  polymerase.  A  strong  selective  hinderance  of 
polymerisation from a primer site containing a drug lesion in a duplex region, was 
associated with the ethano bridges of the pyrroloindole subunits of the parent agent 
and the relevant analogues (Sun & Hurley,  1992a). The (+)-CC-1065-DNA adduct 
was  particularly  prone to  misincorporation  of the nucleotide  prior to the  modified 
adenine in the highly reactive sequence 5’-GATTA-3’ (A; adducted adenine).
The  sequence  specificity  of  adozelesin  bound  on  purified  plasmid  DNA  was 
previously determined based on the identification of termination sites of a modified 
form of bacteriophage T7 polymerase, Sequenase (Weiland & Dooley,  1991). This 
property  of  (+)-CC-1065  and  analogues  to  impede  the  progression  of  DNA 
polymerase was further utilised by polymerase chain reaction (PCR) based assays, 
to map DNA alkylation sites of selected analogues at the single-nucleotide level  in 
human  genomic  DNA  (Passadore  et  al.,  1997;  Lee  et  al.,  1994;  Bianchi  et  al.,
1999).  In  all  these  studies  the  inhibition  of  DNA  replication  due  to  the  strong 
irreversible binding of (+)-CC-1065 to double stranded DNA was considered to be 
responsible for its cytotoxicity.
Helicases
The  DNA  helicases  are  enzymes  that  separate  the  strands  of  DNA,  coupling  the 
hydrolysis  of ATP,  which  provides  the  necessary  energy,  with  the  unwinding  of 
duplex  DNA  at  the  replication  fork  and  providing  the  DNA  polymerase  with  a 
single standed template. The helicases therefore play an important role in nearly all 
aspects  of  nucleic  acid  metabolism,  including  replication,  repair,  recombination, 
and transcription.
(+)-CC-1065  was found to inhibit unwinding of duplex  DNA catalysed  by the dda 
protein  of phage T4 and  DNA  helicase  II  (UvrD)  of Escherichia  coli,  relative  to
83unmodified substrates.  Strand-specific inhibition  was strictly exhibited for the dda 
protein-mediated  reactions.  Yet,  both  helicases  were  shown  to  get trapped  by  the 
drug-DNA complex, generating an unusual  secondary structure in the DNA during 
the protein mediated unwinding (Maine et al.,  1992).
The  E.Coli  rep  protein  was  also  found  to  be  inhibited,  in  the  same  pattern  as 
helicase  II  with which  it shares the  same polarity  of translocation (Sun &  Hurley, 
1992b).  The  extent  of  DNA  unwinding  inhibition  by  helicase  II  is  much  more 
significant for extended analogues that bear the full carbon skeleton of the (+)-CC- 
1065,  responsible  for  the  unique  winding  effect  of  the  parent  molecule  (Sun  & 
Hurley,  1992b; Aristoff et al.,  1993). The increase in the extent of inhibition is also 
dependent upon the orientation of this winding effect which has to be opposite with 
respect to the direction of the helicase II translocation.
The  activity  of another DNA  helicase,  Rad3,  was also reported to  be inhibited  by 
(+)-CC-1065  adducts  (Naegeli  et  al.,  1993).  Rad3  activity  inhibition  is  strand 
specific and  was observed only  when damage was confined to the DNA  strand on 
which Rad3 binds and translocates.
Chinese  hamster  ovary  (CHO)  cell  lines,  deficient  in  the  XPB/ERCC3  and 
XPD/ERCC2  helicases,  both  exhibited  the  same,  increased  sensitivity  to  (+)-CC- 
1065 compared to the parental repair proficient cell line (Damia et al.,  1996). These 
observations  indicate  the  involvement  of functional  helicases  in  the  repair of the 
(+)-CC-1065 adducts.
Ligase
T4  DNA  ligase  catalyses  the  formation  of  a  phosphodiester  bond  between 
juxtaposed  5’  phosphate  and  3’  hydroxyl  termini  in  duplex  DNA.  Covalent 
modification by (+)-CC-1065 and analogues was found to preferentially inhibit the 
T4  DNA  ligase  catalysed  reaction  and  to  prevent  nick  sealing  on  the  non-drug 
modified stand of DNA to the 5’  side of the covalent adduct, but enhanced ligation 
of the  covalently  modified  strand. Two types of inhibition  have  been  described,  a
84proximal one attributed to the DNA winding and helix stabilising effects of (+)-CC- 
1065 which causes the differential effect on each strand, and a distal one, associated 
with  an  unusual  helix  stiffening  effect  of  the  parent  molecule  and  extended 
analogues (Sun & Hurley,  1992c).
Protein -  DNA complexes
DNA  complexed  with  proteins,  rather than  naked  DNA,  presents a  more  accurate 
consideration of the ultimate cellular target of (+)-CC-1065.
Transcription is regulated by promoter and enhancer elements recognized by gene- 
specific  DNA-binding  proteins,  by  general  transcription  factors,  and,  at  a  higher 
level,  by  chromatin  structures.  Impairment  of  the  complex  interactions  between 
activators  and  their  DNA  targets  could  lead  to  a  change  in  the  pattern  of  gene 
expression.  Interference  at  this  level  by  alkylating  drugs  through  DNA 
conformational changes, direct occupation of recognition sites or interference with 
crucial  protein-protein  interactions  essential  for  promoter  activation,  might  be 
responsible for critical biological functions.
(+)-CC-1065 has been shown to prevent the general transcription factor TATA box 
binding  protein  (TBP) from  binding to the adenovirus major late  promoter,  with a 
much greater efficiency (at nM doses) than reversible minor groove binding agents 
(200-fold more effective than distamycin A) or intercalating agents (8000-fold more 
effective  than  ethidium  bromide  and  300-fold  more  effective  than  hedamycin) 
(Chiang  et  al.,  1994).  Preincubation  of  DNA  with  TBP  alone  or  with  TBP  and 
TFIIA,  a  factor  that  enhances  TBP  association  with  DNA,  followed  by  drug 
addition,  requires  10-fold  greater  (+)-CC-1065  concentration  to  prevent  complex 
formation, suggesting that access to DNA is important for the drug binding.  In this 
case, drug binding was thought to directly hinder minor groove binding of TBP to 
the TATA box.
Binding of Specificity Protein  1   (Spl) to 6 GC boxes present in the simian virus 40, 
(SV40)  promoter  region  has  also  been  shown  to  be  inhibited  by  (+)-CC-1065
85binding to the two 5’-AGTTA drug modification sites in the GC box region. In this 
case,  the  inhibition  in  Spl  binding,  particularly  at  the  3’-GC  box  is  attributed  to 
structural distortions in DNA associated with helix stiffening caused by the covalent 
adduct formation (Hurley & Sun,  1994b).
(+)-CC-1065  has also  proved to  be a useful  probe for monitoring  protein-induced 
DNA  structural  alteraltions  such  as  bending,  due  to  its  own  unique 
entrapped/induced  bend  in  DNA  and  its  similarities  to  an  A-tract’s  structural 
properties.  In such studies the directionality and locus of the phage Mu transposase 
(A-protein) induced bending have been elucidated (Ding et al.,  1993) while the Spl 
binding sites (GC boxes) within the three 21  base pairs repeat region of the SV40 
promoter were shown to assume a looping structure, based of their interaction with 
(+)-CC-1065 (Sun & Hurley,  1994). CC-1065 has also offered insights into binding 
of  the  SV40  large  tumour  antigen,  T-antigen  (T-ag)  with  the  SV40  replication 
origin.  Based  on  observations of the  differential  effect this  interaction  had  on  the 
ability of (+)-CC-1065 and bizelesin to alkylate the AT tract located in that region, 
it was deduced that the SV40 origin is in a straight conformation upon T-ag binding 
(Han & Hurley,  1996).
Judging  from  the  extent  and  nature  of  the  structural  effects  of  (+)-CC-1065  on 
transcription binding sites, it can be envisaged that (+)-CC-1065 could additionally 
modulate  transcription  by  trapping  the  DNA  in  a  transcriptionally  active  state, 
mimicking  the  activation  by  transcription  factors.  Alternatively  the  induced 
structural modifications could potentially create artificial binding sites.
The  (+)-CC-1065  class  of  compounds  has  also  been  shown  to  affect  cellular 
processes  such  as  DNA  replication,  in  an  “indirect”  way.  Adozelesin  selectively 
blocks  SV40  DNA  replication  at  the  level  of  initiation  of  nascent  DNA  chains 
(Cobuzzi  et al.,  1996).  Bizelesin  on  the other  hand  inhibits  both  initiation  and,  at 
greater  doses,  elongation  of SV40  replication.  While  the  inhibition  of elongation 
was  suggested  to  occur  in  a  direct  /  “cis”  manner  through  the  covalent  adduct
86formation,  the  inhibition  of  initiation  was  thought  to  be  mediated  through  a 
secondary factor which acts indirectly i.e. in a “trans” manner. That would probably 
involve the induction of production of a SV40 DNA replication inhibitor (McHugh 
et al.,  1999a).
Altering the DNA  helix and the chromatin  structure and  hence affecting processes 
such as transcription and ultimately gene expression can also occur at critical  sites 
at  some  distance  from  the  actual  drug  binding  site  due  to  the  asymmetric 
“telestability”  effect,  addressed  earlier.  Bizelesin  adducts  have  been  suggested  to 
exert  inhibitory  effects on  cellular  DNA  replication  at a  substantial  distance  from 
the actual  location  as only one to two bizelesin adducts per ~ 106 are needed for a 
genome-wide  inhibition  of replicon  initiation  (Woynarowski  2002).  The  targeting 
of  crucial  genes  or  nearby  regulatory  sequences  offers  therefore  a  plausible 
rationale for the exceptional cytotoxic efficiency exerted by the adduct formation of 
this class of compounds.
Targeting the genome
Since the early studies of the (+) CC-1065-induced damage to cellular DNA, it was 
speculated that part of the drug’s exceptional  potency could be due to its selective 
reactivity with critical targets within the genome (Zsido et al.y   1991).
The availability of tritiated adozelesin enabled the investigation of the intracellular 
localization  of  CPI  adducts  on  nuclear  DNA  of  cultured  human  HT-1080  cells 
through  restriction  enzyme  analysis.  The  telomeres  of  each  human  chromosome 
possess  clusters  of  the  repetitive  DNA  sequence  (TTAGGG)n   that  are  potential 
binding sites for the agent and comprise a critical and highly abundant target. It was 
observed in that study that adozelesin binds predominantly to nuclear DNA at sites 
other  than  those  telomeric  repeat  sequences.  However,  there  were  other  distinct 
repeat  elements  that  clearly  exhibited  increased  drug  bonding,  relative  to  other 
regions of the genome (Weiland & Dooley,  1991).
87The formation and location of (+)-CC-1065 adducts within the SV40 DNA genome 
have also been reported (McHugh et al.,  1994). Structural damage to DNA has been 
monitored  by  assaying  the  conversion  of SV40 topological  forms  with  increasing 
concentrations  of  (+)-CC-1065.  The  extensive  conversion  to  the  linear  form, 
indicative  of double-strand  damage,  at  even  low  drug  concentrations  suggested  a 
clustering of highly reactive bonding sites.
AT-rich  region  specific  damage  on  eukaryotic  genomic  DNA  has  been 
demonstrated  for  (+)-CC-1065  (McHugh  et  al.,  1994),  adozelesin  and  bizelesin 
(Woynarowski  &  Beerman,  1997). The  AT-rich,  matrix-associated  region  (MAR) 
of  intracellular  SV40  DNA  was  among  the  preferred  targets  of those  CPI  drugs, 
consistent with their binding specificity on naked DNA.
Study of the genome targeting by those agents has also been further refined with the 
use  of  PCR-based  technology.  The  distribution  and  the  binding  motifs  of  the 
targeted  adducts  have  been  assessed  by  quantitative  polymerase  chain  reaction 
(QPCR)  on  specific  human  gene  sequences.  One  such  study  involved  the  “AT 
islands”.  These  constitute  another  paradigm  of a  repetitive  and  critical  domain  of 
clusters  of potential  binding  sites for the  (+)-CC-1065  class of compounds,  other 
than the telomeric (TTAGGG)n   sequence mentioned earlier. AT islands are distinct 
minisatellite  regions  which  consist typically  of 200-1000  bp  long  tracts,  of up  to 
~85-100%  A/T  DNA.  Such  domains  are  believed  to  function  as  strong  MARs, 
responsible for organising DNA loops on the nuclear matrix. Long AT islands were 
shown to represent a critical, selective target for bizelesin. While adozelesin induces 
more  frequent,  less  strictly  localised  lesions,  bizelesin  preferentially  targeted  the 
MAR domains of the  c-myc and  apolipoprotein  B  (apoB)  genes (Woynarowski  et 
al.,  2000).  This  targeted  damage  by  bizelesin  markedly  exceeds  genome  average 
and  preferentially  occurs  within  MAR  regions  over non-MAR domains as clearly 
exhibited  by the  lack of binding to a  non-MAR,  AT-poor domain  in  the (3-globin 
gene.
88This  directed,  nonrandom,  clustering  of  bizelesin  lesions  in  the  AT  islands  is 
observed along with the need of formation of very few lesions for bizelesin to block 
cell  growth.  More  specifically  two  bizelesin  adducts  per  cell  are  estimated  to  be 
required  for  a  GI^  lethality  compared  to  other,  non-region  specific  alkylating 
agents, such as tallimustine and cisplatin (220 and  14,000 estimated adducts per cell 
at GI50, respectively) (Woynarowski 2002). Overall, bizelesin induces two orders of 
magnitude fewer lesions in cellular DNA than (+)-CC-1065 and adozelesin.
The  interaction of another (+)-CC-1065  analogue,  U-71184 (analogue c  in  Figure 
1.19)  with  human  genomic  DNA  has  been  documented  as  selective  inhibition  of 
PCR-mediated amplification of a 5’ upstream region of the human estrogen receptor 
gene,  from  DNA  derived  from  drug-treated  MCF7  human  breast  cancer  cells, 
known to possess many AT-rich, binding motif sites. The lack of such inhibition on 
Ha-ras  oncogene  and  the  chromosome  X-linked,  (CGG)-rich  fragile  X  mental 
retardation-1   gene  (FMR-1)  sequences,  which  are  both  GC-rich,  further 
demonstrates  the  agent’s  expected  region  specific  and  sequence  selective  effect 
(Passadore  et  al.,  1997).  In  a  similar  study  for  analogues  possessing  a  pyrazole 
substituted  CPI  grpup  (CPzI),  the  same  sequence-dependent  inhibition  of  PCR- 
amplification of genomic regions was observed (Bianchi et al.,  1999).
AT  islands,  such  as those targeted  by  bizelesin,  are  in  general  inherently  unstable 
(expandable) domains found in various loci of genomic instability, such as AT-rich 
fragile  sites.  The  cellular  MAR  function  of AT  islands  may  differ  in  cancer  and 
normal  cells.  The abnormally expanded AT  islands in  the  FRA16B fragile  site  in 
leukemic  CEM  cells  act  as  strong,  permanent  MARs,  while  their  unexpanded 
counterparts  in  normal  cells  are  loop  localized.  Given  their  instability  and 
involvement in the remodelling of the nuclear architecture, AT islands may actually 
contribute  to  cancerous  phenotypes.  They  have  been  in  particular  implicated  in 
leukemias and  lymphomas,  including acute  lymphoblastic leukemia (ALL), one of 
the most frequent pediatric malignancies (Wyonarowski, 2002; References therein). 
The  abnormal  structure/function  of  AT  islands,  such  as  their  expansion  and
89acquired  strong  MAR  properties  and  their  increased  abundance  in  hypersensitive 
cell  lines,  like the  CEM  cells,  may  sensitize certain tumours to the  bizelesin-type 
drugs.  Highly localised lesions such as the ones described above are several orders 
of  magnitute  more  lethal  than  non-region-specific  damage,  consistent  with  the 
critical role of MAR domains in DNA replication (Wyonarowski, 2002).
An agent’s preference for region specific damage does not always coincide with its 
inherent binding specificity. This is clearly demonstrated by the bizelesin analogue 
U-78779.  U-78779  was  designed  to  recognise  mixed  A/T  -   G/C  motifs,  that 
distribute uniformly at the genome level. However, the clustering of the minor, pure 
AT, binding motifs take precedence over drug binding preference and outcompetes 
isolated,  mixed  sites  in  drug  binding  (Herzig  et  al.y   2002).  Sequence  specificity 
alone,  on  the other hand,  is  not sufficicent for region  specificity.  Tallimustine for 
example,  which  also  prefers  mixed  motifs  and  is  highly  sequence  specific 
(consensus sequence: 5’-TTTTGPu-3’) fails to induce region-specific lesions and is 
less lethal that both bizelesin and U-78779 (Herzig et al., 2002). These observations 
highlight the importance of region specific targeting and its potential implication in 
the biological outcome of the drug action.
DNA repair
(+)-CC-1065  adducts  are  probably  the  best  characterised  minor  groove  sequence 
specific  lesion  in  terms of DNA  repair.  These adducts are  known  to be  substrates 
for bacterial and human nucleotide excision repair in vitro (Gunz et al.,  1996; Selby 
&  Sancar  1988).  A  protein,  named  duocarmycin-DNA  adduct  recognising  protein 
(DARP),  which  binds  with  increased  affinity  to  duocarmycin  damaged  DNA  has 
also been identified (Asai et al.,  1999).
This  topic  is  covered  in  more  detail  in  chapter  4  and  in  the  general  discussion 
(Chapter 6).
90Figure  1.32  summarises  the  biological  sites  of  action  of  (+)-CC-1065  and  the 
affected cellular processes covered in the text.
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Figure  1.32  Summary  of  the  inter-related  biological  sites  of  action/cellular 
processes,  of  (+)-CC-1065  and  analogues,  addressed  in  the  text,  (adapted  from 
Turner & Denny, 2000).
911.3.4.5 Cytotoxicity
(+)-CC-1065  and  the  duocarmycins  are  extremely  potent  cytotoxic  agents,  as 
demonstrated  by  in  vitro  studies,  achieving  cytotoxicity  in  the  pM  range.  The 
concentration  of (+)-CC-1065  required for a  50 and  90%  inhibition  of L1210  mouse 
leukemia cells’  growth,  was  reported  to be 0.017  ng/ml  and 0.05  ng/ml  respectively, 
when the agent was in contact with the cells for 3 days (Li et al.,  1982). The 50% lethal 
doses for exponentially growing B16 melanoma and Chinese Hamster ovary cells, after 
a 2 h exposure to the agent, were 0.44 and 0.14 ng/ml, respectively, as determined in a 
clonogenic  assay  (Bhuyan  et al.,  1982).  In the  human tumour cloning assay, (+)-CC- 
1065 caused >50% decrease in the colony forming units of tumour cells (1  h exposure 
to 0.1  ng/ml) from  patients with  cancer of the  breast,  lung,  ovary,  pancreas,  multiple 
myeloma,  stomach,  testis,  small  bowel  and  adenocarcinoma  of  unknown  origins 
(Bhuyan et al.,  1982).  It was also active in vivo against experimental tumours such as 
P388, CD8F,  mammary, and colon 26 at doses ranging from  1   to 50 pg/kg (Bhuyan et 
al.,  1983,  references  therein).  The  extent  of  cellular  growth  inhibition  in  the  above 
studies  was  shown  to  be  dose  and  exposure  time,  dependent.  A  fundamental 
relationship between the agents’ chemical  stability and their in vitro cytotoxic potency 
has been defined. Initially a direct relationship between the electrophile’s reactivity and 
its  cytotoxic  potency  was  proposed,  based  on  observations of a  series of simple  CPI 
analogues  (Warpehoski  et  al.,  1988).  The  reverse  relationship  however,  was  later 
established and proved to be general for both simple (BOC) and extended (CDPI, TMI) 
analogues  (Boger  et al.,  1991c;  Boger  &  Yun,  1994b)  containing  various  alkylation 
subunits.  As  shown  in  Figure  1.33,  in  the  series  of the  simple  BOC  analogues,  the 
compound with the greatest solvolytic stability (t'/2) exhibits the most potent cytotoxic 
activity against L1210 cells.
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Figure 1.33 The stability towards solvolysis (t'/2   in h, at pH 3) and in vitro cytotoxicity (IC50 in 
nM, against the L1210 cells) for the simple analogues of a range of alkylation subunits.
93This  is  interpreted  to  reflect  the  ability  of the  chemically  more  stable  derivatives  to 
more  effectively  reach  their  intracellular  biological  target,  the  DNA.  This  same 
relationship between an agents’s solvolysis stability and its in vitro cytotoxic potency is 
also mirrored in extended analogues such as (+)-DUMSA. The most chemically stable 
of the duocarmycins.  (+)-DUMSA also exhibits the greatest cytotoxic activity with an 
IQ*, value of 6 pM  in  LI210 cells.  At the same time the IQo value for the less stable 
(+)-duocarmycin A is only  lOOpM (Boger,  1994).
Exceptions  to  this  general  correlation  have  been  reported  for  a  series  of 
cyclopropaneindolones,  which  exhibited  the  originally  described  direct  relationship 
between solvolytic reactivity and cytotoxic potency (Castedo et al., 2001).
A more recent study of N2-aryl derivatives of CBI however, served to further establish 
a  parabolic  relationship  between  solvolysis  stability  (-log  k,  pH3)  versus  cytotoxic 
potency (-log IC^, L1210), also applicable to all the N-BOC derivatives of Figure  1.33 
(Parrish  et  al.,  2003b).  The  correlation  between  solvolytic  stability  and  potency 
displays the following order of cytotoxicities for the main alkylation subunits: N-BOC- 
DSA>N-BOC-CBI>N-BOC-CPI>N-BOC-DA>N-BOC-CBQ>N-BOC-CI  (Boger  & 
Johnson,  1996).
The general  consensus suggests that an analogue  should  possess  sufficient stability to 
reach  their target  (DNA),  yet  maintain  sufficient  reactivity  upon  binding,  in  order to 
alkylate DNA, describing in this way a balance between stability and reactivity (Parrish 
et al., 2003b).
The cytotoxic activity has also been shown to be influenced by the structural variations 
of  the  DNA  binding  domain  linked  to  the  various  alkylation  subunits.  The  DNA 
binding subunits of (+)-CC-1065  and  the duocarmycins contribute  in  several  ways to 
the properties of the natural products. As discussed earlier, extensive structure- activity
94HN,
CPI
R
MtOjC
ICso. t!  210 <pw)
b)
c
‘OH
OMt OH
COPi;
H
TMI
~ CO^-OM. H  I 
OMc
A •  NH, O', B ■ NH, O, S 
OM«
- C O
H
pym >i*
** ?  CPI  CBI  OSA
20  20
20
20
2-40  2-5
3-40  6-10  3
5-10
30  10
50-200  2700-  85 
5000
2000
R=5-C0Me  IC^2pM 
R=5-C0B  IC*=3pM
N‘
H
Figure  1.34  a.  The  cytotoxic  potency  resulting  from  attachment  of different  DNA  binding 
subunits to the CPI, CBI and DSA natural  pharmacophores (adjusted from Boger & Johnson, 
1996.  so as  to  include all  (differing)  reported  IC50 values,  b.  structure of the  C5-substituted 
CBI-indole derivatives.
95relationship studies of a series of modifications confirmed that it is this portion of the 
molecule  that  conveys  binding  affinity  to  the  DNA  minor  groove,  selectivity  for 
binding at AT-rich sites, stabilises the covalent adduct formation, accelerates the rate of 
DNA  alkylation  and  overall  plays an  important  role  (the degree  varying according to 
the distinct models of the catalysis of alkylation proposed) in the alkylation event.
The  potentiation  of  the  cytotoxic  activity  of agents  bearing  the  CPI,  CBI  and  DSA 
pharmacophores tethered to varying binding subunits is shown in Figure  1.34a.
Further to this,  variations  in  the  size,  rigid  length,  and  shape  of the  binding subunits 
afforded  by  appropriate  substitutions  can  have  a  profound  effect  in  the  resulting 
cytotoxicity.  This  is  exemplified  by  the  C5  acyl  derivatives  of the  CBI-indole  agent 
featured in Figure  1.34b. The derivatives possessing the methyl and ethyl group at the 
indole  C5  position  were  1000-fold  more  potent  (IC5o=2-3pM)  than  the  parent  CBI- 
indole,  agent  (IC^  =2700pM),  also  surpassing  the  activity  of  both  the  CBI-TMI 
(IC5o=30pM)  and  even  the  natural  parent  compounds  CC-1065  (^^=20  pM)  and 
DUMSA (IC ^-lO pM ) (Boger et al., 2001b),
Apart  from  variations  in  the  size  (extensions  and  simplifications)  of  the  attached 
binding  subunits  or  crucial  substitutions,  other  approaches  include  the  design  of 
analogues  bearing  deep  seated  structural  modifications.  Such  modifications  may 
involve  the  incorporation  of  heteroatoms,  as  is  the  case  of  a  nitrogen  capable  to 
function as a hydrogen bond acceptor or donor (Boger et al.,  1995c) or introduction of 
different linkers and terminal amides (Wang et al.,  1996; Wang et al., 2000)
The role of the nature of the  DNA  binding domain  is now  believed to extend  beyond 
simply providing DNA binding selectivity and affinity, but also actively contributing to 
the  catalysis  of  the  DNA  alkylation  reaction,  through  the  shape-dependent  catalysis 
model of the binding induced activation (Boger & Garbaccio,  1999a).
961.3.4.6 Cell Cycle Effects-Cell death
The effects of (+)-CC-1065 and analogues have also been studied on CHO and B16 cell 
progression  and  their  phase-specific  toxicity.  (+)-CC1065  was  most  cytotoxic  to 
mitotic  cells,  and  toxicity  decreased  as  cells  entered  the  S-phase  however,  other 
analogues exhibited a different phase specific toxicity profile.  In general, this class of 
compounds, does not inhibit progression from G1 to S, but slows progression through S 
and blocks cells in G2-M (Bhuyan et al.,  1983; Adams et al.,  1988). As shown for CBI 
bearing  analogues  (Wang et al., 2000),  as well  as the duocarmycins (Wrasidlo et al., 
1994),  the  mechanism  of tumour cell  death  is  through  induction  of apoptosis,  and  is 
accompanied by morphological changes and internucleosomal DNA fragmentation.
1.3.4.7 Cellular uptake
The  cytotoxic  activity  exerted  by  the  alkylation  of  DNA  which  is  the  ultimate 
intracellular target of the CC-1065 class of compounds,  is also a function of effective 
cellular  uptake.  This  is  manifested  particularly  in  cases  where,  in  contrast  to 
expectations based on the relative efficiencies of alkylation of naked DNA, analogues 
exhibited  diminished  cytotoxic  potencies.  Such  an  example  are  the  CBI-indole 
analogues containing a peripheral quaternary ammonium salt which, although shown to 
alkylate  DNA  at  the  same  relative  efficiency  as  (+)-CC-1065  and  (+)DUMSA,  were 
approximately  1000 times less potent (Boger et al.,  1995b). This diminished cytotoxic 
potency was attributed to ineffective cellular penetration.
The alkylation of intracellular DNA by CC-1065 and analogues has been demonstrated 
as discussed earlier. The only study, however, of intracellular distribution and cellular 
uptake  involved  a  fluorescently  labelled  seco-CBI-pyrrole  polyamide  conjugate 
(Kumar et al., 2004). Cellular localisation was evaluated using confocal laser scanning 
microscopy and the molecule was shown to be located primarily in the cytoplasm and
97organelles.  However, this is a hybrid molecule with relatively large molecular weight, 
which  may  hinder its cellular uptake, as observed for other functionalised polyamides 
examined to date.
1. 3.4.8 Adverse Toxicity
Despite CC-1065’s potent cytotoxic  properties described earlier, clinical  development 
of the  agent as an anticancer therapeutic  was  precluded due to its limiting toxicity  of 
delayed  lethality  in  mice,  at  subtherapeutic  doses.  More  specifically,  initial  toxicity 
studies showed that mice receiving high doses of the drug (400-800 pg/kg single dose, 
50-200  pg/kg/day,  five  daily  doses)  died  by  day  9.  Mice  receiving  lower  doses, 
appeared  normal  between  days  6-30,  but  on  day  30  expressed  loss  weight,  hunched 
posture and  ruffled fur.  Between  days 32  and  38,  all  of the  mice  at every  dose  level 
died. Observations of the high-dose dead animals revealed pale livers and kidneys. The 
low-dose  animals  displayed  ascites  and  a  lack  of  body  fat.  Noted  cellular  changes 
included marked morphological alterations of the mitochondria. Studies of tissues other 
than the liver appeared normal (McGovern et al.,  1984).
Several analogues of (+)-CC-1065 were studied in an attempt to separate the cytotoxic 
from  hepatotoxic  properties  of the  molecule  by  tracing  the  structural  element of the 
parent agent responsible for the delayed lethality (Figure  1.35). This undesired property 
was finally attributed to the ethano bridges of the central and right-hand pyrroloindole 
units.  Their  removal,  apart  from  elimination  of the  characteristic  delayed  death  also 
results in increase of the activity against P388 and L1210 cells (Table  1.4). It has been 
suggested that the delayed lethality of (+)-CC-1065 or (+)-CPI-CDPI2 may be directly 
related to the irreversibility of the alkylation reaction due to the extended noncovalent 
binding  stabilisation  provided  by  the  full  carbon  skeleton  of the  pyrroloindoles.  The 
ethano groups contribute to the stong noncovalent binding through van der Waals and 
hydrophobic interactions with the floor of the minor groove. This noncovalent binding
98stabilisation  may  either  prevent  the  reverse  reaction  after  alkylation  has  occurred 
(Boger  et  al.,  1994b)  or  keep  the  drug  bound  so  that  it  realkylates  the  same  site 
(Warpehoski et al.,  1992).
(+)-CC-1065  (+)-CPI-CDPl2
(+)-CPI-indole2
Figure  1.35  Analogues  considered  in  order  to  determine  the  structural  feature 
responsible for the delayed toxicity phenomenon
(+)-CC-1065 0.05 62 Yes
(+)-CPI-CDPI2 0.05 77 Yes
(+)-CPI-indole2 0.004 4/6a No
Table  1.4  In  vitro (IC5o=  Drug concentration  causing 50%  inhibition of cell  growth  with  3- 
days  incubation)  and  in  vivo  (%ILS  =  percent  increase  in  life  span  of  treated  compared  to 
control  mice) activities  of the  analogues  of Figure  1.35.  8   Number of day  30 survivors/total 
number mice in test group. (Data as reported in Hurley et al.,  1988b).
Other analogues such as adozelesin or DUMSA, which lack those ethano bridges or the 
full carbon framework are devoid of the delayed lethality.
991.3.4.9 Novel analogues of CC-1065 and the duocarmycins
CC-1065  and  the  duocarmycins  are  naturally  occurring  agents with  potent  anticancer 
activity  and  they  should  be considered as “dynamic”  leads provided  by  nature,  rather 
than  static  solutions  that  need  no  further  optimisation.  Various  drug  development 
programmes,  still  ongoing,  aim  in  exploiting  those  leads,  through  different  rational 
design approaches, to acquire more selective, more efficacious, and more potent agents, 
that  would  ultimately  prove  useful  as  therapeutics.  Some  of  these  analogues  have 
reached  the  clinical  trial  evaluation  stage,  highlighting  the  potential  and  the  positive 
outcome of such synthetic efforts.
Rational design approaches
Bisalykylators
The  pharmacophores  of  both  CC-1065  and  the  duocarmycins  have  been  used  as 
monomeric units for dimerisation, leading to novel crosslinking agents. Such agents are 
anticipitated  to  have  increased  sequence  selectivity  as  they  should  be  more  sequence 
discriminating,  possess  enhanced  cytotoxicity,  increased  size  of recognition  site,  and 
ideally an increased selectivity for predefined DNA sites in tumour cells, compared to 
the  parent  monoalkylating  compounds.  Unsymmetrical  cross-linking  agents  derived 
from the combination with a PBD pharmacophore have also been reported.
Bifunctional Alkylating agents derived from (+)-CC-I065
Early studies showed that some synthetic compounds which contain two CPI  moieties 
linked by variable length flexible methylene chains, are significantly more potent than
100CC-1065 both in vitro and in vivo (Mitchell et al.,  1989).  Such dimers are exemplified 
by bizelesin (Figure 1.36).
Figure 1.36 Structure of bizelesin, (U-77,779).
Bizelesin (U-77,779) is a symmetrical dimer of the spiro cyclopropyl alkylating subunit 
of (+)-CC-1065.  The  two  seco-CPI  units  are  linked  by  a  rigid  bis  (indolecarboxylic 
acid) linker. Bizelesin very efficiently induces 6- or 7- nucleotide interstrand crosslinks 
(ISC)  and  has  also  been  shown  to  induce  monofunctional  alkylation  of DNA  within 
sites  of potential  ISC.  The  most  preferred  site  for  ISC formation  is  the  6-nucletodie 
sequence  5’-TAATTA,  where  A  is  the  alkylated  adenine,  which  represents  a 
palindromic  sequence  joining  two  adjacent  5’-TTA  triplets.  Thus,  the  two  adenine 
alkylation  sites  are  located  on  opposite  strands  of  DNA  and  are  separated  by  4 
nucleotides.  There  is  also  a  preference  for  the  6-nucleotide  sequence  5’-TAAAAA* 
where the asterisk represents the alkylation site on the top strand and the underlined T 
indicates the location of alkylation on the complementary strand (Lee & Gibson  1993). 
Bizelesin also induces a 7-nucleotide DNA ISC at the sequence 5’-TAAAAAA-3’. An 
ISC  at  this  sequence  occurs  to  a  2-fold  greater  degree  than  the  corresponding  6- 
nucleotide  DNA  ISC 5’-TAAAAA*A-3’  when  both sites are located  within the  same 
duplex. The monoalkylation sequences are generally of the sequence 5’-(A/T)(A/T)A, 
Bizelesin  is  both  more  sequence  selective  and  cytotoxic  than  the  monomeric  agents 
from which it derived (Lee et al.,  1994).
101Another variation  of this rational  design approach  includes the  synthesis of seco-CB1 
dimers.  Some  of  those  analogues  showed  promising  activity  in  the  NCI  in  vitro 
preclinical screening assay (Jia & Lown, 2000).
Bifunctional agents derived from the duocarmycins.
A series of four dimers derived from head to tail coupling of the two enantiomers of the 
duocarmycin SA alkylation subunit have been reported (Boger et al., 2000b).
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Figure 1.37 Structure of the (+)(+)-DSA2 analogue.
The  (+)(+)-DSA2 and  (+)(-)-DSA2 agents  proved to  be 2-3-fold  more  potent than  (+)- 
DUMSA  and  approximately  2000-fold  more  potent than the  simplified  N-BOC-DSA. 
The  left-hand  subunit  was  found  to  dominate  the  charactreristics  of  the  agents, 
responsible for the first and primary site of DNA alkylation, while the right hand DSA 
alkylation  subunit serves the same function as TMI  subunit of the duocarmycins. The 
agent  in  Figure  1.37  as  well  as  the  (-)(-)-DSA2  are  capable  of intrastrand  crosslinks 
only,  as  both  cyclopropanes  are  oriented  toward  the  same  strand  of DNA,  while  the 
agents (+)(-)-DSA2 and (-)(+)-DSA2 were expected to display ISCs.
102Unsymmetrical bifunctional agents
Given  the  initial  success  of dimerisation  in  providing  biologically  active  molecules, 
the  CPI,  CB1  and  PBD  units  have  since  been  combined  to  generate  a  new  class  of 
unsymmetrical  crosslinking agents.  The advantage of this approach  is the creation  of 
interstrand crosslinking agents that could alkylate guanines on one strand and adenines 
on the opposite strand, enabling recognition and binding to mixed DNA sequences.
a)
b)
Figure  1.38  Structure  of  reported  agents  combining  the  CPI,  CBI  and  PBD 
pharmacophores.
The  single  CPI-PBD  dimer (a)  was  demonstrated  to  crosslink the  6  bp  sequence  5’- 
CAATTA-3’  (Zhou  et  al.,  2001).  The  set  of  compounds  depicted  in  structure  (b), 
designed to crosslink between N3 of adenine and N2 of guanine, in the minor groove of 
DNA,  showed  great  variation  in cellular toxicity with  the  most potent ones exhibiting 
IC^s  in  the  pM  range.  One  CBI-PBD dimer from  this  set  was  observed  to  crosslink
CPI PBD
seco-CBI PBD
103cellular  DNA  at  1000-fold  lower  concentrations  than  the  related  symmetrical  PBD 
dimer.  The  CBI  portion  of the  agents  controlled  the  alkylation  selectivity  while  the 
PBD substituent increased the overall efficiency of the reaction (Tercel et al., 2003).
Hybrid molecules
CC-1065  pharmacophores  have  also  been  used  as  scaffolds  to  attach  other  chemical 
moieties  in  an  attempt  to  acquire  hybrid  agents  with  an  altered  sequence  selectivity. 
Some examples of these efforts are presented below.
Bleomycin A2
Hybrid  agents  incorporating the C-terminus  DNA  domain  of bleomycin  A2,  linked  to 
the CBI have been reported (Figure  1.39).
R-SM*
R.atopte
R-8M»
Figure  1.39  Structures  of  the  CBI  and 
bleomycin  A2  hybrid  agents  incorprorating  a 
shorter  rigid or longer flexible linkers
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104The  resulting agents exhibited  little or no enhancement of DNA  alkylation  efficiency 
and  demonstrated  identical  selectivity  to  that  of  simple  CBI  derivatives  such  as  N- 
BOC-CBI. They also possessed diminished cytotoxic activities (Boger & Han,  1997).
Mitomycin
Synthetic  hybrids  have  been  prepared  combining  the  DNA  alkylation  features  of the 
duocarmycins and the  reductive activation of the  mitomycins,  by  incorporation of the 
quinone of the mitomycins, which is thought to confer tumour selectivity as a result of 
preferential  reduction  in  hypoxic  environments,  into  the  AT-selective  binding 
framework of the duocarmycins. An activation cascade for such agents was envisioned 
to involve bioreduction, followed by spirocyclization and eventual alkylation.
The  resulting  agents  confirmed  the  proposed  reaction  cascade,  as  the  quinone-based 
analogue would not alkylate DNA under nonreductive conditions.  In its reduced form, 
as a hydroquinone,  it would alkylate  DNA  in a sequence specific manner identical  to 
(+)-DUMSA, albeit 100-fold less efficiently.
MeO.
i Me
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Figure  1.40  Chemical  structures  of  mitomycin  A  and  the  hybrid  agent  bearing  the 
quinone group of the mitomycins incorporated in the AT-selective binding framework 
of the duocarmycins and designed to be capable of mitomycin-like reductive activation 
and duocarmycin-like DNA alkylation.
105A  study  of the  cytotoxic  potency  of these  analogues established  that they  were  more 
potent in a DT-Diaphorase-enriched cell  line versus a deficient one, consistent with a 
preferential activation by DT-Diaphorase (Boger & Garbaccio 1999c).
Lexitropsins
Another  approach  for  the  design  of  hybrid  molecules  is  coupling  the  reactivity  and 
alkylation function of a CC-1065/duocarmycin moiety with the DNA-reading ability of 
the  imidazole  (Im)  and/or  pyrrole  (Py)  moieties,  aiming  to  further  exploit  binding- 
driven bonding, tailor the binding preference and manipulate sequence specificity. 
Initital  studies  involved  simple  CPI-oligopyrrole  conjugates  incorporating  amide 
groups of different sizes and flexible or rigid linkers (Wang et al.,  1996). Certain such 
conjugates  exhibited  up  to  10,000  higher  potency  than  CC-1065  against  KB  cancer 
cells.  Another  variation  was  the  design  of  unsymmetrical  bis-lexitropsin  conjugates 
incorporating the CBI pharmacophore (Jia et al.,  1999) (Figure  1.41  a and b)
Figure 1.41 Chemical structures of a) the CPl-N-methylpyrrole synthetic conjugates and b) and 
usymmetrical bis-lexitropsin-CBI.
a )
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106The  discovery  that  distamycin  A  dramatically  modulates  the  sequence  specificity  of 
DNA  alkylation  by  DUMA,  so  to  preferentially  alkylate  G-N3  groups  through 
cooperative  binding  of a  heterodimer  between  DUMA  and  distamycin  in  the  minor 
groove (Yamamoto et al.,  1993) (Figures  1.42 and  1.43a)  presented the  possibility of 
controlling the sequence specificity of DUMA in a predictable manner in the presence 
of Py  /  Im  triamides  and following  Dervan’s  binary  code  of the  side-by-side  pairing 
between Py and Im carboxyamides (Figure  1.43) (Fujiwara et al.,  1999).
After modulation of specificity  was achieved in the presence of appropriate triamides, 
novel hybrids were created coupling the alkylation subunit of duoacarmycin A (DA) to
Figure  1.42  Schematic 
representation of the heterodimeric 
binding  model  of duocarmycin  A 
and  distamycin  to  the  minor 
groove  of  d(CAGGTGGT)-
d(ACCACCTG).  Hydrogen  bonds
between the drugs and DNA are in 
dashed  lines.  The  hydrogen  bond 
between the 03 of duocarmycin A 
and  the  N2  amino  group  of  G6 
helps  anchor  the  drug  in  its 
position (Taken from  Sugiyama et 
al., 1996).
(R )  Q ammo proton
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b)
Imlmlm
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5’  -   A  C  C  C  G  -  3’
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= Imidazole
3’  -  T  G  G  G  C  -  5’
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5’-CAGGTGGT-3’
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3’  -  GTCCACCA-5’
/ \  = alkylation moiety (segment A ol 
duocarmyon A
Figure  1.43 The chemical structures of the agents / conjugates and a schematic representation 
of examples  of recognition  and  alkylation  through  cooperative  binding  with  distamycin  and 
relevant triamides. The arrows denote the location of alkylation (adapted from Fujiwara et al., 
1999).
108Py/Im  diamides,  and  targeting  the  heterodimeric  binding  with  distamycin,  efficiently 
and with high specificity at predetermined DNA sequences (Tao et al., 1999a).
This approach  evolved  to the  rational  design  of conjugates  incorporating the  DUMA 
alkylation  moiety  into  Im  /Py  hairpin  polyamides.  Such  molecules  demonstrated  the 
altered  reactivity  at  guanine  and  targeted  purines  proximal  to  the  polyamide  binding 
site (Tao et al.,  1999b). Conjugate a of Figure  1.44 exclusively alkylated an adenine of 
a seven base pairs target site, within a ~ 400 bp DNA fragment.
A = alkylation moiety (segment A ol 
duocarmycin A
©   = Pyrrole  #  = Imidazole
a)  X=CH b)  X=N
5’-GTTGTAAAAC-3’  
#-«-«)—A
b) I
5’ -  CAAGTCAGAG-3’
m -e -e — A
3’-CAACATTTTG-5’ 3’  -  GTTCAGTCTC-5’
Figure  1.44 Chemical structure and schematic representation of recognition and alkylation of 
target sequences  in  oligonucleotides,  by conjugates of duocarmycin  A  alkylation  subunit and 
Im/Py hairpin polyamides. The arrows represent the location of alkylation (adapted from Tao et 
al., 1999b).
109Similarly  alkylation  by  conjugate  b  occurred  exclusively  at  a  G  of  a  target  site. 
Alkylation of target sequences by both conjugates was however of very low efficiency, 
even after 7 days (Tao et al., 1999b).
The alkylating moiety incorporated in subsequent conjugates was therefore changed to 
segment  A  of  DU-86  (segA-Du86).  That  in  combination  with  the  introduction  of  a 
vinyl  linker,  dramatically  enhanced  alkylating  efficiency,  while  a  new  mode  of 
recognition  in  which  the  Im/vinyl  linker  (L)  pair  targets  GC  base  pairs,  emerged 
(Bando et al., 2002) (Figure 1.45).
Segment A of DU-86
JOjCH,
\
5’-CAAGTCAGAG-3’
n=1
n=2
3’  - GTTCAGTCTC-5’
alkylation moiety (segment A of Du-86)  ®   = pyrrole  ®  = lmidazo,e  ^  = vinyl linker
Figure 1.45 Chemical structures and schematic representation of the recognition and alkylation 
of target  sequences  in  oligonucleotides  by conjugates of segment A  of DU-86 and  Im  /  Py 
hairpin polyamides. The arrows indicate the location of alkylation. Adapted from Bando et al., 
2002)
110More extended hairpin conjugates, such as ImPyPy-Y-ImPyLDu86 (Oyoshi et al., 2003) 
or  PyImImImIm-y-PyPyPyLDu86 (Takahashi et al., 2003) have also been reported and 
their biological effect investigated in studies examining inhibition of transcription and 
targeting of the human telomere repeats, respectively. Such studies further highlight the 
potential  use  of  Py/Im  polymides  as  versatile  recognition  components  of  novel  CC- 
1065 / duocarmycin conjugates.
Another application of the use of the Py/Im polyamides was the design of novel  CC- 
1065/duocarmycin conjugates that could  produce  highly  sequence  selective  ISCs, and 
unlike  bizelesin  which  possesses  intrinsic  sequence  selectivity,  could  target 
predetermined base pairs. One mode of crosslinking involved DNA dialkylation by the 
formation of a homodimer by Im/Py diamide-(segA-DU86) conjugates incorporating a 
vinyl  linker.  Highly  efficient  alkylation  occured  at  predetermined  sequences, 
simultaneously  on  both  strands  at  nanomolar  concentrations.  Again,  the  homodimer 
would dialkylate both strands according to the base-pair recognition rule of the Py/Im 
polyamides  (Tao  et al.,  2000)  (Figure  1.46a).  This  concept  was  further  extended  by 
synthesising alkylating triamides (Fujimoto et al., 2002).
Crosslinking  would  also  be  achieved  by  covalent  dimers  of  Im/Py  and  segADu86, 
connected using different linkers, by the formation of a heterodimer in the presence of 
a  partner  triamide  (Bando  et al.,  2003).  Interstrand  crosslinking  proceeds  sequence- 
specifically according to Dervan’s  pair recognition  rule  (Figure  1.46b).  Alternatively, 
conjugates  were  designed  bearing  two  alkylating  moieties  linked  with  pyrrole  and 
imidazole  bearing polyamides by  a flexible  methylene chain  of variable  length,  as  in 
the case of a series of bis-(seco-CBI)-Py/ Im polyamides (Kumar & Lown, 2003).
Ill•>  i
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alkylation moiety (segment A of Du-86)  ©   = Pyrrole  ®  = Imidazole  ^  -  vinyl linker
Figure  1.46  The  chemical  structure  of  the  ImPyLDu86  conjugate  and  a  schematic 
representation  of the  recognition  mode  of the  depicted  selected  oligonucleotides  and 
their crosslinking through the formation of a a) homodimer of two conjugate molecules 
and b) heterodimer of the covalent dimer of the conjugate, with the ImlmPy triamide. 
The  arrows  indicate  the  location  of  alkylation.  Adapted  from  Tao  et  al.,  2000  and 
Bando et al., 2003.
CPI -  ODN complexes
Racemic  CPI  has  been  conjugated  to  the  3’  and  5’-end  of  18-mer 
oligodeoxyribonucleotides (ODN), thereby replacing the B and C subunits of CC-1065
ImPyLDu86
b>  |
5’  - Py G G C A G C C  Pu - 3’
tnm-m
3’  - Pu C C G T C G G Py - 5’
t
112with a much  more sequence specific moiety (the ODN). The 3’-CPI-ODN conjugate, 
once  hybridised  to  a  complementary  30-mer  target  DNA  strand,  showed  highly 
efficient and rapid alkylation of the complementary strand in the duplex, with the same 
polarity and preference for AT-rich regions as observed for CC-1065, while remaining 
totally inactive when incubated with a non-complementary control. This result suggests 
that  CPI-ODNs  could  be  potential  candidates  as  sequence-specific  hybridisation- 
triggered crosslinking agents for targeted gene modification (Lukhtanov et al.,  1996). 
Conjugation  of  the  non-reactive  CDPI3  binding  framework  of  CC-1065  to  various 
ODNs  has  also  been  reported.  Such  conjugates  form  unusually  stable  and  specific 
hybrids with  complementary  DNA  in  which  the  tethered  CDPI3  group  resides  in  the 
minor groove (Kumar et al.,  1998).  ODN  conjugates  with  CDPI3  can  make  effective 
primers (as short as 8-10 mers) for PCR amplification (Afonina et al., 1997),
Finally, CPI has been attached to triplex-forming oligonucleotides (TFOs), for triplex- 
directed covalent modification, in such a way to either reach from the major to a minor 
groove by wrapping around one DNA strand via long linkers (Lukhtanov et al.,  1997) 
or to “thread”  DNA  from the  major-groove  bound TFO to the  minor groove binding 
site  of CPI  via  linkers containing  aromatic  rings  (Dempcy et al.,  1999).  In  the  latter 
case, efficient alkylation of the duplex target was achieved.
Other analogues
Three  different  glycosides  of the  seco-CI-TMI  (Figure  1.47)  have  been  reported,  as 
prodrugs.  Glycosides  can  be  cleaved  by  glycohydrolases  in  order  to  release  the 
cytotoxic  seco-Cl-TM\  agent.  In  the  presence  of the  corresponding  glycohydrolases, 
which removed the sugar moiety from the phenolic hydroxy group, all three prodrugs 
displayed nearly the  same cytotoxicity as that of seco-CI-TMI.  With the exception of 
the  j^co-CI-TMI-glycoside,  which  possessed  an  inherent  high  cytotoxicity,  the  two
113other prodrugs displayed a highly differential cytotoxicity in the presence and absence 
of (3-galactosidase and a-D-mannosidase (Tietze et al., 2001a).
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Figure  1.47 Structures of the  glycosides -  prodrugs  and  the “released” seco-CI-TMl 
active agent.
Glycosylated prodrugs of a seco-CB\ and a methyl-seco-CB\ analogue have also been 
reported (Tietze et al., 2001b).
In  another  such  effort  a  conjugate  comprised  of  a  cephalosporin  and  a  CC-1065 
analogue  has  been  synthesized.  Activation  of  the  prodrug  to  the  toxic  CC-1065 
derivative  would  in  this  case  be  effected  by  ^-lactamase.  The  preliminary  in  vitro 
studies show that the prodrug was  10-fold  less toxic that the free drug,  validating the 
approach (Wang et al., 2001).  Finally,  a biotinylated, CBl-bearing CC-1065 analogue 
was synthesised and its cytotoxicity against U937 leukemia cells assessed (Figure 1.48) 
(Wang et al., 2002). Although the biotinylated compound was 7-fold less toxic than its 
unconjugated precursor (IC^ values of  0.7 and 0.09 nM respectively), it was still much 
more potent than doxorubicin (IC^ = 100 nM).
114Figure 1.48 Structures of the biotinylated, CBI-bearing analogue (right) and its unconjugated 
precursor (left).
1.3.4.10  Clinically investigated analogues
Adozelesin (U-73,975) (Figure  1.49) is a synthetic, highly potent, monofunctional, CPI 
analogue  of the  antitumour  antibiotic  CC-1065,  Like  CC-1065,  adozelesin’s  primary 
intracellular target is DNA and does not react appreciably with protein, RNA or single­
stranded  DNA  (Weiland  &  Dooley  1991).  A  consensus  sequence  for  adozelesin 
bonding  is:  5’-(T/A)-T/A-A,  where  A  is  the  site  of alkylation,  while the  parentheses 
indicate  a  bias  but  not  absolutely  required  occurrence  of  those  deoxynucleotides 
(Weiland & Dooley,  1991). Two bonding consensus sequences on genomic DNA have 
been  identified:  5’-  (A/T)(A/T)A  and  5’-(A/T)(G/C)(A/T)A,  where A  is the alkylated 
3’  adenine (Lee et al.,  1994).  Adozelesin  has a broad spectrum of antitumour activity 
against a variety of murine and human tumour xenograft models and does not produce 
the  CC-1065  characteristic  delayed  lethality.  Because  of  its  solubility,  stability  and 
extreme  potency,  adozelesin  was  the  first  of  the  CC-1065  analogues  to  enter  into 
clinical trials. A number of phase I trials were conducted, and myelosuppresion was the 
dose limiting toxicity in all cases (Shamdas et al.,  1994, Foster et al.,  1996, Fleming et 
al.,  1994).  In  a  study  involving  33  patients  who  had  refractory  solid  tumours,
115adozelesin was given at a range of 6-30 pg/m2/day through a  lOmin IV infusion, for 5 
consecutive  days  every  three  weeks.  The  maximun  tolerated  dose  (MTD)  was 
determined  to  be at 30 pg/m2/day.  A  partial  response  was observed  in  a patient  with 
refractory  soft tissue  carcinoma  (Foster  et al.,  1996).  In  another  study,  involving 47 
adult  patients  with  solid  malignancies,  the  MTD was  defined  at  180  pg/m2.  A  minor 
response with  a 4 month  duration  was  reported in one previously treated  patient with 
melanoma  (Shamdas  et  al.,  1994).  In  either  studies,  there  was  no  objective  clinical 
responses.
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Figure  1.49  Structures  of  the  CC-1065/duocarmycin  analogues  that  have  been 
clinically evaluated; adozelesin, bizelesin, carzelesin, and KW-2189.
Bizelesin  (U-77,779, NSC 615291) (Figure 1.49) serves effectively as a prodrug which 
can  form  two  DNA-reactive  cyclopropylpyrroloindole  subunits  connected  by  a  rigid 
indole-ureido-indole segment. As a symmetrical dimer, bizelesin is capable of forming 
ISCs.  Bizelesin  was  active  against  a  broad  spectrum  of  murine  tumours  and  human
116tumour  xenografts  in  mice  and  did  not  produce  delayed  deaths  at  therapeutic  doses 
(Carter  et  al.,  1996).  Again  myelosuppression  was  the  dose-limiting  toxicity. 
Preliminary  testing  of  in  vitro  myelotoxicity  with  bizelesin  demonstrated  significant 
(>10,000-fold) difference between species (Volpe et al.,  1996). A  starting dose of 0.1 
pg/m2/day  was  chosen  for  a  phase  I  clinical  trial,  involving  19  patients.  Bizelesin 
administered  every  4  weeks  as  an  IV  push  was  well  tolerated  with  a  dose-limiting 
toxicity of neutropenia. The MTD was defined as 0.8 pg/m2, administered once every 4 
weeks.  However  no  objective  responses  were  seen  in  these  19  patients  (Pilot  et al., 
2002).  In another phase I study, 62 patients were treated with  185 courses of bizelesin 
at  eight  dose  levels  ranging  from  0.1  to  1.5  pg/m2.  Myelosuppression  was the  most 
common toxicity observed. A 40% reduction in measurable disease lasting 24 months 
was noted in one patient with advanced ovarian carcinoma (Schwartz et al., 2003).
Carzelesin  (U-80244)  (Figure  1.49)  is  a  synthetic  cyclopropylpyrroloindole  prodrug 
containing a relatively nonreactive chloromethyl precursor to the cyclopropyl function. 
Activation  of  carzelesin  requires  two-steps.  Hydrolysis  of  the  phenylurethane 
substituent  followed  by  a  ring  closure  produces  the  CPI-containing  product.  In  its 
prodrug  form,  carzelesin  is  relatively  non-reactive  and  thus  may  be  capable  of 
penetrating deeper into tissues before being converted to the active species. Although 
less potent in terms of in  vitro  cytotoxicity,  carzelesin  proved to  be more efficacious 
than  adozelesin,  against  mouse  L1210  leukemia  and  mouse  pancreatic  ductal  02 
adenocarcinoma (Li et al.,  1992).
In a phase I study, carzelesin was given as a 4-weekly  10 min IV infusion to 51  patients 
with advanced solid tumours. Again the dose limiting toxicity was haematological and 
consisted mainly of neutropenia and to a lesser extent thrombocytopenia. The MTD for 
a  single  course  was  300  pg/m2 while  the  dose  level  with  the  best  dose  intensity  for 
multiple courses was  150 pg/m2(Awada et al., 1999).
117A total of 140 patients were entered in a phase II trial. The drug was given as a bolus 
infusion at a 4-weekly dose of 150 pg/m2. In general the compound was well tolerated. 
Myelotoxicity  was the  most common  toxicity.  Only  one  partial  response  in  a  patient 
with  melanoma  was  seen,  hence  at  this  dose  and  schedule,  carzelesin  did  not  yield 
activity in the types of tumours studied (Pavlidis et al., 2000).
KW-2189 (Figure  1.49)  is a  water soluble,  semi-synthetic  derivative of duocarmycin 
B2.  It was designed to  be a prodrug requiring enzymatic  hydrolysis of the carbomoyl 
moiety,  however  research  demonstrated  that  the  prodrug  itself  covalently  alkylated 
DNA  without  activation  of  the  prodrug  to  the  drug.  It  was  proposed  that  this 
mechanism  occurs  by  a  rate-determining  formation  of  the  reactive  cyclopropane  in 
aqueous solution. In a phase I trial involving 22 patients with solid tumours, KW-2189 
was  administered  as  a  rapid  IV  bolus  daily  for  5  days  every  6  weeks.  Leukopenia, 
neutropenia, and thrombocytopenia were the dose limiting toxicities. Four patients had 
stable disease over two to four cycles of treatment and showed no cumulative toxicity 
(Alberts et al.,  1998).
In a phase II trial, 40 patients with metastatic renal cell carcinoma, received 0.4 mg/m2 
as an IV infusion for cycle  1. Cycles were repeated every 5 to 6 weeks with escalations 
to  0.5  mg/m2.  The  most  common  drug-related  toxicity  was  haematological-delayed 
neutropenia and thrombocytopenia.  No patient had an objective response (Small et al., 
2000). Two other concurrent Phase  II  trials accrued patients with advanced malignant 
melanoma, with and without prior treatment.  KW-2189 was administered IV on day  1  
of a  6-week  cycle.  None  of the  15  previously  treated  patients  responded  to therapy. 
Five  of  the  previously  untreated  patients  achieved  a  partial  remission  /  regression. 
Response duration ranged from 2.8 to 16.6 months (Svetomir et al., 2002).
Presently, only bizelesin remains under clinical evaluation. Clinical studies on the other 
three  compounds  were  discontinued.  The  most  significant factor that  undermined  the
118clinical  effectiveness  of  those  analogues,  still  remains  a  severe  nonselective  bone 
marrow toxicity. Therefore the need to design novel analogues is still a very pragmatic 
one.
1.3.4.11  Yatakemycin
Yatakemycin represents the newest and now most potent (IC5o= 3 pM, L1210) member 
of the  CC-1065/duocarmycin  class  of  naturally  occurring  antitumour  compounds.  It 
was  isolated  from  the  culture  broth  of Streptomyces sp.  TP-A0356,  in  the  course  of 
screening for novel antifungal agents (Igarashi et al., 2003).
Yatakemycin  represents  a  remarkable  hybrid  of  the  preceding  natural  products 
containing  a  central  alkylation  subunit  identical  to  that of duocarmycin  SA,  a  right- 
hand indole based DNA binding subunit similar to that found in duocarmycin SA and a 
unique,  left-hand  binding  subunit  similar  in  structure  to  the  central  and  right-hand 
subunits  of  CC-1065,  a  structure  reminiscent  of  the  previously  reported  synthetic 
“sandwiched” duocarmycin analogues.  Distinct from the preceding natural products, it 
represents  the  first  naturally  occurring  member  of this  class  that  incorporates  DNA 
binding subunits flanking each side of the alkylation pharmacophore.
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Figure 1.50 Structure of (+)-Yatakemycin.
119(+)-Yatakemycin alkylated DNA with a selectivity distinct from either (+)-CC-1065 or 
(+)-duocarmycin  SA/A  (Parrish  et  al.,  2003c).  All  alkylation  sites  were  adenines, 
flanked  essentially  exclusively  by  a  5’  and  3’  A  or  T  base  with  a  preference  that 
follows  the  order  :  5’-AAA  > 5’-AAT  2s  5’-TAA  > TAT,  where  A  is  the  alkylated 
adenine.  In  addition,  there  was  a strong  preference,  but not absolute  requirement for 
both  the  second  5’  and  3’  bases  to  be  A  or  T.  Thus,  yatakemycin  preferentially 
alkylates the  central  adenine  of a five  base pair AT  site (e.g.,  5’-AAAAA),  differing 
significantly  from  (+)-CC-1065  or  (+)-duocarmycin  SA/A,  which  alkylate  the  3’ 
terminal adenine of a 5 base pair (CC-1065) or 3-4 base pair (duocarmycins) A/T sites 
(Parrish et al.,  2003c).  Relative efficiencies of DNA  alkylation  by yatakemycin,  CC- 
1065  and  duocarmycin  SA  were  indistinguishable.  Yatakemycin,  however,  alkylated 
DNA faster than the other natural products,  1.2-fold faster than the previsouly reported 
sandwiched  analogue  CDPI-DSA-CDPI,  and  200,000-fold  faster  than  the  simple 
derivative N-BOC-DSA. In addition, like CC-1065, the yatakemycin DNA alkylation is 
essentially irreversible under the conditions employed, distinguishing it in that respect 
from the duocarmycins (Parrish et al., 2003c).
1.3.4.12  Consideration of the chiral center in the duocarmycins and CC-1065
One issue of potential concern in the development of novel analogues of CC-1065 and 
the  duocarmycins  is  chirality.  The  analogues  discussed  thus  far,  all  contain  a  chiral 
centre. Their enantiomeric pairs can display distinctly different properties ranging from 
opposite  binding  orientation  in  the  minor groove  (Figure  1.51) to different rates and 
efficiency of alkylation (Table  1.6), and differing cytotoxic potencies and/or biological 
outcome in experimental animals (Table 1.5).
120Figure 1.51 Space-filling model  illustrating the alkylation at the same site within w794 DNA 
(duplex 5 ’ -d( G  ACT  A  ATT FIT)) by (+)-DUMSA (left) and (-)-DUMSA (right). The binding of 
the natural enantiomer extends in the 3’-* 5’  direction from the alkylated adenine, across the 
sequence  5’-CTA,  while  the  unnatural  enantiomer  binds  in  the  reversed  5’-*  3’  direction, 
across the 5’-AATT site (taken from Boger & Johnson,  1996).
(+)-DUMSA 10 no
(-) -DUMSA 100 no
(+)-CC-1065 20 yes
(-) -CC-1065 20 no
(+)-CPI-CDPI2 20 yes
(-) -cpi-c d pi2 20 no
(+)-CPI-In-In 40 no
(-)- CPI-In-In 1000 no
Table 1.5 Cytotoxic potencies and occurrence of the delayed lethality in experimental 
animals for a number of enantiomeric pairs (Data from  Hurley et al.,  1990; Boger et 
al., 1995b).
121Duocarmycin SA 10 10
Duocarmycin A *110 * 100
CBI-TMI 100 100
CI-TMI 1.0 0.5-2.0
Table  1.6  a  IQo  (L1210)  of  unnatural  (-)/natural  (+)  enantiomer.  b   Relative 
concentrations of unnatural  (-)/natural  (+)  enantiomer,  required  to detect  w794 DNA 
alkylation (taken from Boger & Yun,  1994b).
The  differences  between  enantiomeric  pairs  have  proven  clearly  distinguishable  with 
simple derivatives of the alkylation  subunits themselves (e.g.  N-BOC analogues),  are 
most prominent with the dimer based agents (e.g. TMI bearing analogues) and are less 
prominent  or  not  readily  distinguishable  with  the  larger  trimer-  or  tetramer-  based 
agents  (e.g.  CDPI2  bearing  agents).  While  the  unnatural  enantiomers  in  general  form 
intrinsically less stable adducts which are more readily reversed, full biological potency 
and  efficient  DNA  alkylation  have  been  achieved  only  with  elaborate  unnatural 
enantiomeric analogues that contain two large binding subunits. That is because of the 
additional  noncovalent  binding  interactions  of  the  extended  analogues,  which  can 
overcome  the  destabilising  steric  interactions  of the  unnatural  enantiomer  alkylation 
(Boger et al.,  1995b;  Boger  &  Johnson  1996).  The  extended  unnatural  enantiomeric 
analogues  are  strikingly  differentiated  in  their  biological  action,  from  their  naturally 
occurring  counterparts,  in  that  they  are  devoid  of the  characteristic  delayed  lethality 
phenomenon (Hurley et al.,  1990).  In agreement with these observations, (-)-CC-1065 
alkylates  DNA  with  the  same  efficiency  to that of the  natural  enantiomer (albeit at a 
nonidentical  set of adenines), exhibits indistinguishable cytotoxic potency and in vivo
122antitumour  activity,  and  importantly  does  not  cause  delayed  lethality.  The 
distinguishing  behaviour  of the  unnatural  enantiomers  is  suggested  to  derive from  a 
pronounced steric interaction of the CPI/DSA C7  (CH3) or CBI  C8 centre with the 5’ 
base  adjacent to the  adenine  N3  alkylation  site  present  in  the  unnatural  enantiomeric 
5’-*3’ binding model. As the steric bulk surrounding this centre is reduced or removed, 
the distinguishing differences in DNA  alkylation efficiencies and biological  potencies 
of the pairs of enantiomers are diminished (Boger & Yun, 1994b). Fully consistent with 
this  proposal  is  the  fact  that  less  distinctions  were  observed  with  the  Cl  and  DSA 
enantiomeric pairs, both of which lack substituents or steric bulk at this position (Table
In  a  racemic  drug  formulation,  one  enantiomer  may  affect  the  activity  and  the 
properties of the other enantiomer, and they can exhibit different activities in vivo due 
to varying interactions with their target. The differences displayed by the enantiomeric 
pairs  discussed  above,  warrants  the  preparation  of enantiomerically  pure  compounds 
and  full  characterisation  of  their  properties.  This  can  be  both  time-consuming  and 
costly. Importantly, the synthesis of pure enantiomers requires an assymetric synthesis 
or resolution of racemates, decreasing the net yield.
1.6).
Cyclopropylindolone Bischloromethyl-5eco-C2BI
Figure 1.52 Structures of the previously reported achiral analogues.
123Thus  far,  only  two  synthetic  efforts  of  achiral  analogues  of  CC-1065  and  the 
duocarmycins  have  been  reported.  One  report  described  the  synthesis  of  a 
spiro[2,5]cyclopropanecyclohexadienone  derivative,  but  no  biological  evaluation  was 
conducted  (Figure  1.52-left)  (Bryson&  Roth,  1988).  Another  effort  involved  the 
synthesis  of  the  bischloromethyl-seco-QBI)  subunit  (Figure  1.52-right),  and  its 
incorporation  to  various  functional  analogues  bearing  the  CDPI,,  CDPI2, TMI  and 
indole2  DNA  binding  subunits.  The  achiral,  precursor,  seco-C2BI  were  designed  as 
adenine-adenine interstrand crosslinking agents (Figure  1.25) (Boger & Palanki,  1992; 
Boger et al.,  1993).  The  C2BI  agents  were  shown  to constitute  efficient crosslinking 
agents.  However, in comparison to the parent CBI-agents, the C2BI  analogues proved 
(100-10,000)-fold less effective at DNA alkylation and less potent in in vitro cytotoxic 
activity (Boger et al.,  1993).
1241.4 Experimental aims
The aim of chapters 2 and 3  is to evaluate the alkylation properties and cytotoxic 
activities of a number of novel chiral and achiral CC-1065/duocarmycin analogues. 
The effect of modification on the non-covalent DNA binding component of chiral 
agents bearing the established Cl functionality as well as the introduction of a novel 
alkylation subunit as a possible alternative to the established pharmacophore CBI, 
are being investigated in Chapter 2. The Taq polymerase stop assay is employed to 
reveal  the  sites  of  covalent  modification  by  the  agents,  on  plasmid  DNA. 
Comparison of the efficiency and the sequence selectivity of the DNA alkylation by 
the novel analogues will define the effect these structural modifications have on the 
sequence  specific  interactions  of  this  class  of  compounds  with  DNA.  The 
thermally-induced cleavage assay is also employed to specifically probe the A-N3 
alkylations of the agents in the minor groove of DNA. The MTT cytotoxicity assay 
is used to investigate the effect of the modifications on the potency of the agents to 
inhibit the growth of tumour cells.
The  effect  of the  chiral  centre  present  in  the  natural  lead  compounds  and  all  the 
synthetic  analogues  reported  to  date,  on  the  biological  activity  of this  class  of 
compounds and their interaction with DNA is investigated in Chapter 3. A series of 
achiral analogues was synthesised to this effect and are evaluated as the chiral ones, 
in  order  to  establish  whether  the  chiral  centre  is  absolutely  required  for  the 
characteristic  DNA  alkylation  and  cytotoxicity.  The  result  of this  study  would 
confirm whether this synthetic strategy can generate active compounds which could 
potentially comprise a new class of agents and a new focus for the design of novel 
CC-1065/duocarmycin analogues.
125CHAPTER  2
SEQUENCE SPECIFIC ALKYLATION AND CYTOTOXICITY OF A 
SERIES OF NOVEL CHIRAL CC-1065/DUOCARMYCIN ANALOGUES
2.1 Materials and Methods
2.1.1 Materials 
Investigational compounds
All  compounds  were  kindly  provided  by  Professor  Moses  Lee,  Department  of 
Chemistry, Furman University, Greenville, South Carolina, USA. A minimum of 1  
mg of each compound was dissolved in DMA at a  10 mM stock concentration and 
stored at -20°C until  immediately prior to use.  Dilutions were freshly prepared for 
each  experiment  in  lxTEOA  buffer.  Adozelesin  was a  kind  gift from  Dr.  Robert 
Kelly of Pharmacia & Upjohn.
Plasmid DNA
Plasmid  pUC18  was  purchased from  Sigma,  at a concentration  of 237  pg/ml  and 
stored at a 10 mM Tris-HCl, pH 8.0,  ImM EDTA storage buffer, at -20°C until use.
Radioisotope
|y-32P]  ATP  (5000  Ci/mmol,  lOmCi/ml)  was  purchased  from  Amersham 
International.
Chemicals
Tris-hydroxymethyl-methylamine  (Trizma®  base),  ethylemediamine  tetraacetic 
acid  disodium  salt  (dihydrate)  (disodium  EDTA),  boric  acid  (H3B03),  sucrose,
126bromophenol  blue,  xylene  cyanol,  formic  acid,  phenol:chloroform:isoamylalcohol 
(25:24:1), ethidium  bromide,  magnesium chloride,  ammonium  persulphate (APS), 
piperidine, phenol, tetranolamine (hydrochloride), phosphate buffered saline (PBS), 
sodium  acetate,  sodium  chloride,  N,N-dimethyl-acetamide  (DMA),  dimethyl 
sulfoxide (DMSO), ammonium acetate, and MTT were purchased from Sigma. 
Isopropanol,  ethanol,  triethylamine  ((C2H5)3N),  trisodium  citrate, formamide,  and 
concentrated hydrochloric acid were purchased from BDH.
BiogeI-P6 gel (fine grade 45-90 pm) was purchased from Biorad.
Electrophoresis grade agarose was purchased from Invitrogen.
Glycogen (20 mg/ml) was purchased from Boehringer Mannheim.
Ultrapure  deoxynucleoside  triphosphates  (dNTPs)  solutions  (100  mM)  were 
purchased from Pharmacia.
X-Omat (35x43 cm) Kodak film was purchased from Anachem.
Enzymes
T4 polynucleotide  kinase  (10  units/pl)  supplied  in  50 mM Tris-HCl  (pH  7.6),  25 
mM KC1, 5  mM  DTT, 0.1  pM ATP, 0.2 mg/ml  BSA and 50% (v/v) glycerol  was 
purchased from Invitrogen.
Taq  DNA  polymerase  (5  units/pl)  supplied  in  50mM Tris-HCl  (pH  8.0 at 25°C), 
lOOmM  NaCI, O.lmM  EDTA,  ImM  DTT,  50%  glycerol  and  1% Triton® X-100, 
was purchased from Promega.
Hind III (10 units/pl) supplied in  lOmM Tris-HCl  (pH 7.4), 250mM NaCI, O.lmM 
EDTA, ImM DTT, 0.5 mg/ml BSA, 50% glycerol was purchased by Promega. 
Bacterial  Alkaline  Phosphatase  (BAP),  (10  units/pl)  supplied  in  lOmM Tris-HCl 
(pH 8.0),  120 mM NaCI and 50% (v/v) glycerol was purchased by Invitrogen.
127Buffers
Forward  reaction  buffer  (5X)  consisting  of 350  mM  Tris-HCl  (pH  7.6),  50  mM 
MgCl2,  500  mM  KC1  and  5  mM  2-mercaptoethanol  was  supplied  with  the 
purchased T4 polynuleotide kinase from Invitrogen.
Thermophylic DNA polymerase  10X, magnesium free buffer (when diluted  1:10 it 
has  a composition  of  10  mM  Tris-HCl  (pH  9.0 at 25°C),  50  mM  KC1  and  0.1% 
Triton®  X-100)  was  supplied  with  the  purchased  Taq  DNA  polymerase  from 
Promega.
10X Restriction Enzyme buffer consisting of 60 mM Tris-HCl (pH 7.5),  1   M NaCI, 
60 mM  MgC12 and  10 mM  DTT  was  supplied  with  the  purchased Hind III from 
Promega.
10X  Dephosphorylation  Buffer  consisting  of  100  mM  Tris-HCl  (pH  8.0)  was 
supplied with the purchased BAP from Invitrogen.
Biogel-P6 spin column solution: 8% P-6-biogel (w/v), 0.02% sodium azide (w/v) in 
distilled and deionised water.
Sucrose  loading  buffer:  6%  sucrose  (w/v),  0.04%  bromophenol  blue  (w/v)  and 
0.04% xylene cyanole (w/v) in distilled and deionised water.
Formamide  loading  dye:  0.04%  bromophenol  blue,  0.04%  xylene  cyanol,  98% 
deionised formamide.
10X TEOA buffer:  1   mM disodium EDTA, 25 mM triethanolamine, pH 7.2 
50X  TAE  agarose  gel  running  buffer:  40mM  Tris,  20mM  acetic  acid,  2mM 
disodium EDTA, pH 8.1.
10X Tris-boric acid buffer (TBE):  89mM Tris, 89mM boric acid, 2mM EDTA, pH 
8.3.
Stop solution: 0.6M sodium acetate, 20 mM Na2EDTA,  100 pg/ml Yeast tRNA
128Strand Separation Buffer: 30% DMSO,  ImM Na2EDTA, 0.04% bromophenol blue, 
and 0.04% xylene cyanol in distilled and deionised water.
DNA size markers
1   kb  DNA  ladder (lmg/ml)  in  10 mM Tris-HCl,  pH 7.5,  50mM  NaCI  and  1   mM 
EDTA was purchased from Invitrogen.
10  bp  DNA  ladder  (lpg/pl)  in  10  mM  Tris-HCl  (pH  7.5),  1   mM  EDTA  was 
purchased from Invitrogen.
Kits
A  ready-to-use  SequaGel®-6  sequencing  system,  consisting  of  SequaGel-6 
monomer  solution  (19:1  acrylamide:  bisacrylamide,  8M  urea)  and  SequaGel 
complete buffer solution  (0.89 M Tris  borate,  0.89 M  boric  acid, 20 mM EDTA) 
was purchased from National Diagnostics.
A BiolOl GENECLEAN® II kit comprising of a 6 M solution of Nal, Glassmilk®, a 
specially prepared aqueous suspension of proprietary silica matrix, TBE modifier, a 
proprietary  mixture of concentrated  salts from removing DNA from TBE-buffered 
gels,  and  “NEW  wash  concentrate”,  a  concentrated  solution  of  NaCI,  Tris,  and 
EDTA to which water and ethanol are added, was purchased from Q-biogene.
BESS  Mutascan™  Mutation  characterisation  Kit comprising of d-UTP containing 
dNTP  mix,  BESS  T-Scan  excision/cleavage  enzyme  mix,  BESS  G-Tracker 
modification  reagent,  a  10X  Excision  Reaction  buffer  and  a  stop/loading  buffer, 
was purchased by Epicentre.
129Synthetic oligodeoxynucleotide primers
The  synthetic  primer 5’-CTC ACT  CAA  AGG  CGG TAA TAC-3’,  identified  as 
pUCl, binds to the sequence region 749 to 769 of the bottom strand of the pUC18 
plasmid and was used to extend the top strand.
The synthetic primer 5’-TGG TAT CTT TAT AGT CCT GTC G -3’, identified as 
pUC5, binds to its complementary (top) strand at position 956-935 and was used to 
extend the bottom strand.
Both primers were purchased from MWG Biotech, and were used to examine drug- 
induced damage on the bottom strand of pUC18.
2.1.2  Methods
2.1.2.1.Generation of a 5’-singly end-labelled fragment 
5'end labelling of  primer pUC5 with [y-32P] ATP.
4 pmol of primer pUC5 (stored in a stock of 2 pmol/pl) were 5’ end-labelled with 2 
pi  (20 units) of the purchased  stock T4 polynucleotide kinase and  [y-32P] ATP (30 
pCi) in  lx forward reaction buffer in a final volume of 10 pi made up with distilled 
and deionised  H20  (dd  H20).  The  reaction  mixture  was  incubated  at 37°C for 45 
minutes. Following incubation, the labelled primer was placed at a 65°C heat block 
for 20 minutes to heat inactivate the kinase reaction and was then stored until use at 
4°C.
Exponential Primer Extension:
The exponential amplification of the 749-956 region of pUC18 was carried out with 
the  10 pi of the above reaction  mix containing 4 pmoles of the labelled pUC5 and 
an equal amount of the unlabelled primer pUCl  (from a stock of 2 pmol/pl) specific 
for the complementary strand.  Extension  proceeded in a total  volume of 50 pi also 
containing  10 ng of template DNA  (linearised pUC18 plasmid, from a stock of 10
130ng/pl). 2 pi of dNTPs prepared as a  10 mM mix, 2 pi of the supplied 25 mM stock 
of MgCl2, 4.5  ml  of the  10X  stock reaction  buffer provided  with  Taq polymerase 
and  1   unit  of the  enzyme.  PCR  was  carried  out  using  a  PTC-100  Programmable 
Thermal  Cycler (MJ  Research) and the cycling conditions consisted of an initial 4 
minute denaturation step at 94°C, followed by a cycle of 1   minute at 94°C,  1  minute 
annealing  at  56°C  and  1   minute  extension  at  72°C,  for  a  total  of 35  cycles.  An 
unlabelled extension reaction was carried out in parallel.
Purification of the double stranded single-end labelled fragment:
Following amplification of the target pUC18 sequence defined by the two primers, 
pUCl  and pUC5, 30 pi of ddH20 were added to the 50 pi of the PCR product and a 
total  volume  of  80  pi  was  loaded  onto  a  Biospin-6  column.  The  column  was 
prepared  immediately  prior to  use  by  loading  1   ml  of Biospin-6  solution  into an 
empty column, which was then spun at 1200 g to pack and remove residual storage 
buffer. The packed column was then washed through twice with 200 pi of distilled 
H20. The 80 pi of the PCR product were loaded onto the dry column and spun for 5 
minutes at  1200 g to elute the end-labelled fragment. The eluant was taken up in  10 
pi  of  lOx  sucrose  loading  buffer  and  loaded  in  aliquots  onto  a  2%  agarose  gel 
(dimensions 8 x  10.5 x  1cm) containing 0.4 pl/ml of ethidium bromide, alongside  1  
pg of a  1   kb DNA  size  marker.  Electrophoresis was carried out for 2 hours at 50 
volts  in  IX  TAE  buffer.  At  the  end  of  the  electrophoresis,  the  208  base  pair 
fragment was visualised using UV fluorescence, generation of a single product was 
confirmed  and  the  band  corresponding  to the  amplified  target DNA  excised.  The 
DNA fragment was then recovered from the agarose gel slices using the constituent 
reagents  of  the  GENECLEAN®  II  Kit,  following  the  manufacture’s  standard 
protocol.
1312.1.2.2 Thermal Cleavage assay
The  thermal  cleavage  assay  described  by  Reynolds  et al.  (1985),  detects  adducts 
susceptible to thermal  glycosidic  bond cleavage,  and  in the form employed in  our 
studies,  exclusively  A-N3  and  G-N3  alkylations,  which  constitute  the  suspected 
type of lesions induced by our investigational compounds.
Buffers:
Sodium Citrate buffer:  1.5 mM sodium citrate,  15 mM NaCI, pH 7.2.
Drug:DNA reactions:
The  compounds  under  investgation  in  each  instance,  were  incubated  at  various 
concentrations, with 500 cps of the 5’  singly end-labelled fragment of the pUC18, 
prepared as described above in a TEOA  buffer solution (final  volume of 50 pi) at 
37°C for five hours. Upon completion of the incubation, the reaction mixtures were 
precipitated  with  0.3  M  sodium  acetate  and  3  vol  of  95%  ethanol,  in  a  dry 
ice/ethanol bath for 15 min. Samples were spun at 13000 rpm, for 5 min at 4°C. The 
resulting pellet was washed twice with 200 pi of 70% ethanol and spun for a further 
10 mins, at  13000 rpm. After the final  wash, the supernatant was removed and the 
samples were lyophilised to dryness.
Thermally induced cleavage:
It has been established in prior studies by the Boger group, that rapid thermolysis at 
high temperature (95-100°C), neutral to low pH (6-7) and at low salt concentration, 
minimizes  a  potentially  competitive  reversible  DNA  alkylation  reaction  and 
optimises thermal depurination leading to stoichiometric thermal strand cleavage at 
the  sites  of DNA  alkylation  Conversely,  thermal  depurination  conducted  at  lower 
temperature  or  higher  pH  (8.0)  favoured  the  retroalkylation  reaction.  It  was  also 
demonstrated that thermal treatment of the alkylated DNA for longer than 30 mins 
at 100°C does not lead to additional cleavage (Boger et al.,  1994b).
132The dried  samples  were taken  up  in  100 pi  of sodium citrate buffer (pH 7.2) and 
heated at 95°C for 30 minutes. Following heat treatment, samples were chilled in an 
ice bath, precipitated with 0.3 M sodium acetate and 3 vol of 95% ethanol, spun and 
lyophilised  dry.  Samples  were  finally  resuspended  in  4  pi  of formamide  loading 
dye, heat denatured for 5 minutes at 90°C and cooled on ice prior to loading on a 
6% denaturing polyacrylamide gel.
Maxam Gilbert Sequencing Lanes:
A purine specific marker lane was generated using ~1000cps each time, of the same 
5’  single-end  labelled  DNA.  20  pi  total  volume  of labelled  DNA  in  ddH20,  was 
incubated  at  room  temperature  for 5  minutes  with  50  pi  of 95%  stock  of formic 
acid.  Following  incubation,  samples  were  snap frozen  with a dry  ice/ethanol  bath 
and dried by lyophilisation. The DNA pellet was resuspended in 65 pi of a freshly 
diluted and kept chilled on ice,  10% piperidine solution and incubated at 90°C for 
30 minutes.  DNA was then precipitated with 0.3  M sodium acetate and 2 volumes 
of absolute isopropanol  and left on  a dry ice bath for  15min. The pellet was  spun 
and washed twice with 80% ethanol and lyophilised dry. Samples were taken up in 
4 pi  of formamide  loading  dye  and  prior to  loading  onto the  polyacrylamide  gel, 
heat denatured at 90°C for 5 minutes and placed on ice until loading.
Polyacrylamide Gel Electrophoresis:
Electrophoresis was carried out on  a  BioRad  Sequi-Gen sequencing gel  apparatus 
using a gel size of 21cm x 50cm x 0.4mm. Gel plates were tightly clamped in a 21 
cm  casting  tray  containing  a  silicone  gasket.  The  6%  polyacrylamide  denaturing 
sequencing  gels  were  prepared  from  a  National  Diagnostics  SequaGel-6  kit 
comprised  of  a  ready-to-use  SequaGel-6  monomer  solution  and  a  SequaGel 
complete buffer solution. For each gel, 94 ml of SequaGel-6 monomer and 24 ml of 
complete  buffer  were  mixed  with  300  pi  of 25%  freshly  prepared  APS  solution. 
Following polymerisation, each gel  was prerun with TBE buffer for approximately 
30 minutes in order to bring the temperature of the gel  up to approximately 50°C.
133Once  loaded,  samples  were  electrophoresed  at  1500- 1800V,  maintaining  the  gel 
temperature at 50-55°C at all times.  Each electrophoresis run was terminated when 
the  bromophenol  blue  marker had  migrated  approximately 40cm.  Gel  plates  were 
then  separated  and  the  gel  peeled  away  from  the  back  plate  using  a  sheet  of 
Whatman  3MM  chromatography  paper.  An  extra  sheet  of  DE81  filter  paper  was 
placed  underneath  and  onto the  porous gel  drying  support.  Gels were dried  under 
vacuum for 2 hours at  80°C  using a  Biorad  5850  gel  dryer and  exposed  to X-ray 
film (X-OMAT, Kodak) overnight.  Exposure times for the gels varied, but were on 
average overnight for  both  thermal  cleavage  and  Taq  polymerase  stop assay  gels, 
without an intensifying screen.
2.1.2.3  Taq Polymerase stop assay
This assay previously described by Ponti et al. (1991), is used for the identification 
of the  sites of covalent DNA  modification  and  it is not limited to a single type of 
DNA  lesion, as is the thermal  cleavage assay, which is purine-N3 damage specific 
only.
Plasmid linearization:
The plasmid pUC18 was linearised with the restriction enzyme Hind III, which has 
a unique recognition site at position 399 of pUC18 and will  provide a downstream 
block  for  the  Taq  polymerase.  The  20  pg  of  the  purchased  plasmid  DNA  were 
linearised  with 30 units of enzyme in  the provided  reaction buffer, for one hour at 
37°C.  The  restriction  reaction  was  terminated  with  ethanol  precipitation  and  the 
pelleted  DNA  was  resuspended  into  an  appropriate  volume  to  provide  a  stock 
solution of 0.5 pg/10 pi.
In all the Taq polymerase stop assay experiments,  linearised  DNA  was used as the 
template  DNA for primer extension.  However, it has been  previously  reported that 
plasmid  DNA  in  a  negative  supercoiled  state,  when  linearised  with  a  restriction 
endonucleose  and  subsequently  treated  with  adozelesin,  yielded  a  result  identical
134with  that of unrelaxed  DNA.  Identical  sites were  occupied  by  adozelesin  at equal 
intensities in  both types of DNA,  suggesting that negative  supercoils have  little,  if 
any, effect on the agent’s sequence selectivity (Weiland & Dooley,  1991).
Drug:DNA reactions:
0.5  pg  of  DNA  were  used  per  experimental  point  and  drug  reactions  were 
performed in a total volume of 50 pi TEOA buffer.  Incubations were for 5 hours at 
37°C,  followed  by  precipitation  with  sodium  acetate  and  95%  ethanol.  Samples 
were  washed  with  70%  ethanol  twice  and  dried  by  lyophilisation.  Drug-reacted 
DNA was resuspended in 50 pi of ddH20.
5-end labelling of primer with [y-i2P] ATP:
For examination of the damage on the bottom strand of pUC18, the synthetic primer 
pUCl  primer was labelled.  A  standard  reaction  mix  was prepared for  10 samples. 
For more experimental  points, the  mix  volumes were adjusted accordingly.  5pl  of 
pUCl  (from a stock of 10 pmoles/pl) were incubated with [y-32Pl ATP (30 pCi) and 
10 units of polycleotide T4 kinase in  lx forward reaction buffer,  in a total  volume 
of  25  pi.  Incubation  and  heat  inactivation  conditions  were  as  described  in  the 
relevant  section  of 2.1.2.1.  Following incubation, the  primer reaction  mixture  was 
loaded  onto  a  Biospin  column,  freshly  prepared  as  before.  As  5  pi  of  labelled 
primer are  required  per experimental  point  (i.e.  50  pi  for the  planned  mix for  10 
samples),  at  least  25  pi  of ddH20  are  added  on  top  of the  25  pi  of the  labelling 
reaction mix so as the collected eluant can provide the required volume of labelled 
primer which is then aliquoted directly into the primer reaction mixtures.
Primer extension:
In a total  volume of  100 pi  per sample containing the 50 pi  of template  DNA (0.5 
pg  per  experimental  point),  5  pi  of the  labelled  primer  from  the  eluted  stock  (5 
pmoles) were added, along with  125 mM of each dNTP,  1   unit of Taq polymerase, 
the  provided  lOx  reaction  buffer,  2.5  mM  MgCI2,  and  0.05%  gelatin.  PCR  was
135carried  out  using cycling conditions consisting of an  initial  4 minute denaturation 
step at 94°C, one minute at 60°C and one minute at 72°C, for a total  of 30 cycles. 
After  primer  extension  the  samples  were  precipitated,  washed  and  dried  by 
lyophilisation. They were finally taken up in 4 pi of formamide loading dye prior to 
polyacrylamide electrophoresis.
Electrophoresis was carried out as described before.
Sequencing lanes
During  electrophoresis,  the  drug  reacted  DNA  samples  were  run  with  internal 
controls with known sequence  specificity (such as adozelesin) or sequencing lanes 
to help identify and appoint the exact sequence on the band corresponding to each 
polymerase block.
One  way  for  obtaining  a  sequence  reference  was  the  amplification  of the  pUCl- 
pUC5  template  DNA,  with  pUCl  being  the  labelled  primer,  extending  the  top 
strand.  The  resulting fragment  was then  subjected  to a  Maxam  and  Gibert formic 
acid  treatment,  to  provide  cleavage  at  purines.  When  run  alongside  the  Taq 
Polymerase assay samples, this sequencing lane would provide the sequence of the 
top strand and  would therefore  be complementary to the  sequence of the observed 
polymerase termination sites at damaged bases situated on the bottom strand.
An  alternative  method employed  in  these  studies  involved  utilisation of the  BESS 
Mutascan™ mutation characterisation kit, which allows detection of sites involving 
thymine (BESS T-Scan system) or guanine (BESS G-tracker system). The BESS T- 
Scan  system  detects  mutations  by  incorporating  limiting  amounts  of dUTP  into  a 
PCR product.  Subsequent treatment of the product results in  removal  of uracil  and 
cleavage  of  the  phosphodiester  bonds  at  these  sites  to  produce  a  DNA  ladder 
virtually identical to a “T” sequencing ladder. The BESS G-tracker system involves 
treatment  of  a  PCR  product  to  modify  guanine  residues  followed  by  enzymatic 
cleavage at the modified bases, generating a “G” sequencing ladder.
136For  the  Taq  stop  gel  of  Figure  2.7  for  example,  the  following  procedure  was 
followed:
The primer pUCl  was 5’labelled with  [y-32P| ATP and T4 polynucleotide kinase in 
a final volume of 10 pi, as described in 2.1.2.1.
Subsequently  a  PCR  amplification  reaction  was  set  in  a  final  volume  of  25 pi 
containing  10 ng of the template DNA, 2 pi of the modified dNTPs mix supplied in 
the  kit (dUTP-containing dNTP mix) (200 pM dATP, dTTP, dGTP, dCTP, and  16 
pM dUTP final  concentrations), 5  pmoles of the reverse  primer pUC5 and half the 
kinase  reaction  volume  (therefore  half the  amount  of the  labelled  forward  primer 
pUCl, i.e. 2 pmoles). The reaction mixture is then subjected to PCR amplification. 
Following PCR, 25 pi of dH20 is added to the PCR products containing dUTP and 
loaded onto a Biogel  column to remove unicorporated radiocactivity. The eluant is 
then  collected  and  constitutes  the  probe  for  the  subsequent  excision/cleavage 
reactions.
A.  BESS  T-Scan  Excision/Cleavage  Reaction:  For  a  single  cleavage  reaction 
containing a total  reaction volume of 10 pi, 3 pi of PCR product containing 
dUTP is incubated  with 0.5  pi  of BESS T-Scan excision enzyme mix,  1   pi 
of  10X  Excision Enzyme buffer (IX final  concentration) and the remaining 
volume, ddH20.  All  the  reagents are  kept on ice  prior to use.  Reactions are 
incubated at 37°C for 30 minutes and terminated with addition of 5 pi of the 
kit supplied stop/loading buffer (containing xylene cyanol and bromophenol 
blue like the loading buffer prepared in the lab). The cleavage products can 
then  be  run  on  the  polyacrylamide  sequencing  gel  (following  heat 
denaturation  prior  to  loading),  alongside  the  drug-treated,  PCR  amplified, 
Taq stop assay samples.
B.  BESS  G-Tracker  Excision/Cleavage  reaction:  5  pi  of  the  PCR  product 
containing  dUTP  is  incubated  with  1   pi  of  BESS  G-Tracker  modification 
reagent  and  1   pi  of  BESS  lOx  excision  enzyme  buffer  (IX  final 
concentration)  in  a  total  volume  of  10  pi  (the  remaining  made  up  with
137dH20).  A  light box is turned on 5  minutes before using. The reactions are 
placed on the pre-warmed light box and the following steps are performed:
•  Illuminate 5 minutes
•  Vortex mix samples for 30 seconds
•  Illuminate 5 minutes
•  Vortex mix samples for 30 seconds
•  Illuminate 5 minutes
An extra  1   pi of BESS G-tracker Excision Enzyme mix is added to the tube 
and mixed thoroughly. The reactions are incubated at 37°C for 30 minutes 
and terminated with the addition of 5 pi of the stop/loading buffer.
The cleavage products can then  be subjected to electrophoresis after being 
heat denatured prior to loading
As mentioned before, the results produced by the BESS mutascan kit are virtually 
identical to the “T” (NESS T-scan) and “G” (BESS G-tracker) lane sequence of the 
DNA  product  being analysed.  The  products generated  by the kit’s reactions,  will 
migrate  approximately  1  base  faster  than  those  products  generated  by 
dideoxynucleotide  sequencing.  Approximately  40-50%  of  the  PCR  product  will 
remain full length after treatment with the Excision Enzyme mix.
In the case of the gel in Figure 2.7, the labelled top strand was subjected to T and G 
cleavage  using  the  kit’s  reactions.  The  bands  visualised  on  the  gel,  correspond 
therefore to “A” and “C” sequencing lanes of the bottom strand. This allows for a 
direct identification of the covalently modified bases located on the bottom strand.
2.1.2.4  Detection of interstrand crosslinking in plasmid DNA
This agarose gel-based method was previously described by Hartley et al. (1991).
138Dephosphorylation of linear DNA:
20 pg of pUC18 DNA were linearised by digestion with Hind III and taken up in 
304 pi of ddH20.  DNA was incubated with 3 pi of Bacterial Alkaline Phosphatase 
(BAP) (stock of 10 units/pl) and 80 pi of 5X BAP buffer (IX final concentration) in 
a total volume of 400 pi made up with ddH20. Incubation lasted for an hour at 65°C. 
The mixture was then left to cool at room temperature and DNA phenol:chloroform 
extracted by vortexing with an equal amount of phenol: chloroform: isoamylalcohol 
(25:24:1),  spinning for 5  minutes at  13000 rpm and  removing the  upper aqueous 
layer containing the dephosphorylated DNA into a fresh Eppendorf. This was then 
ethanol precipitated with sodium acetate and 95% ethanol, left for 15 mins in a dry 
ice/ethanol  bath  and  lyophilised  dry.  The  20  pg  of  linearised  dephosphorylated 
DNA were resuspended in a final volume of 40 pi of ddH2 0 (5 pg/10 pi) and stored 
at -20°C.
5'-end labelling of the linearised and dephosphorylated DNA:
10  pi  of  the  above  “stock  DNA’’   was  radiolabelled  with  Iy-32P|  ATP  and  T4 
polynucleotide kinase  in a final  volume of 20 pi, as detailed before. The reaction 
was terminated with the addition of an equal  volume of 7.5 M ammonium acetate 
(NH4OAc)  and  3x  vol  95%  ethanol.  The  resulting  DNA  pellet  was  further 
resuspended  in 50 pi  of 0.3  M sodium acetate and  10 mM EDTA and precipated 
again  with  3x  vol  of 95%  ethanol.  Once  dry,  DNA  was  redissolved  in 40  pi  of 
ddH20,  resulting  in  a  concentration  of  125  ng/pl.  From  this,  8  pi  (lpg)  of 
radiolabelled  DNA  was further diluted  in  a total  volume of  100 pi  of  IX TEOA 
buffer  allowing  100  ng  of  DNA  per  experimental  point,  for  a  10  samples 
experiment. For more samples, volumes were adjusted accordingly.
Drug: DNA react ions:
10 pi  (containing  100 ng) of the above diluted, radiolabelled plasmid  DNA, were 
treated with a range of drug concentrations in TEOA,  in a total  volume of 50 pi. 
Reactions were terminated by the addition of an equal volume of stop solution and
139DNA was precipitated by the addition of 3 vol of 95% ethanol. The DNA pellet was 
dried  by  lyophilisation  and  the  samples  redissolved  in  alkali  loading  buffer  (6% 
sucrose, 0.4%  sodium  hydroxide, 0.04%  bromophenol  blue). The alkali denatured 
samples  were  vortexed  well,  pulse  centrifuged  and  loaded  onto  the  gel.  Control 
undenatured  samples  were  dissolved  in  10  pi  sucrose  loading  buffer and  loaded 
directly on the gel.
Agarose Gel Electrophoresis:
Electrophoresis was performed on 20 cm long 0.8% submerged horizontal agarose 
gels (20cm x 25cm x 0.5cm; made up by 2.4g agarose in 300 ml  IX TAE buffer) at 
20V for  16 hours, in TAE buffer. After electrophoresis the gels were placed onto a 
sheet of 3MM Whatman filter paper and one layer of DE81 filter paper and dried on 
a BioRad Model 5850 gel dryer for 2 hours at 80°C. The dried gels were exposed 
on  X-ray  film  overnight  (X-OMAT,  Kodak)  or  until  an  image  of  satisfactory 
intensity was obtained. Densitometry was carried out on a BioRad GS-670 imaging 
densitometer.
2.1.2.5  MTT cytotoxicity assay
The ability of agents to inhibit the growth of human myeloid leukemia K562 cells 
in culture was measured using the MTT assay (Mosmann et al.,  1983). The original 
assay was later modified by Carmichael et al. (1987) to give better solubilisation of 
the MTT formazan crystals by using the DMSO solvent.
Cell line and Cell Culture conditions:
The  human  chronic  myelogenous  leukameic  cell  line  K562  was  grown  as  a 
suspension  culture  at  37°C  in  an  atmosphere  of  5%  (v/v)  C02  in  RPMI  1640 
medium purchased by VWR and supplemented with 5% fetal calf serum and 2 mM 
glutamine.  Cells were  maintained at a concentration of between 5xl04and  lxlO6, 
within log phase growth.
140Drug treatment:
Cells from the culture were spun, their supenatant discarded and diluted in a total 
volume of 25 ml of fresh serum free medium, at a density of 5xl04 cells/ml. This is 
sufficient for  10 experimental points, each consisting of 2 ml of cell suspension and 
allowing for pipetting errors. The final number of cells to be plated out per well is 
lxlO4 cells/ml.
The 25 ml of cell suspensions were aliquoted out into 2 ml volumes, in  10 ml tubes. 
Drug was then added at an appropriate concentration and the tubes were inverted to 
mix the cells with the agent and then  left to incubate for one hour in the dark at 
37°C.  Drug dilutions were all performed in sterile filtered PBS or ddH20, with the 
drug  concentrations calculated  for  a  final  volume  of 2  ml.  In  a continuous drug 
exposure  experiment  cells  at  this  point  were  transferred  to  plates.  For an  1-hour 
exposure and following incubation, the tubes were spun down  (1200 rpm for five 
minutes, at 37°C), the supernatant poured off and cells were resuspended in 2 ml of 
fresh serum-free medium. Tubes were respun, supernatant discarded and cell pellets 
resuspended in 2 ml of fresh medium with  10% serum. The cells were plated at 200 
pl/well,  in  a 96-well  round  bottom  microtitre  plate, allowing  8 wells per sample. 
The plates were left to incubate for three nights in the dark, at 37°C in a humidified 
atmosphere containing 5% C02. The assay is based on the ability of viable cells with 
active  mitochondria  to  reduce  a  yellow  soluble  tetrazolium  salt,  3-(4,5- 
dimethylthiazolyl-2,5-diphenyltetrazolium  bromide)  (MTT)  to  a  blue  formazan 
precipitate.  At  the  end  of  incubation,  20  pi  of  a  5mg/ml  solution  of  MTT  in 
phosphate-buffered saline (PBS) were added to each well and the plates were left to 
incubate at 37°C for a further 5 hours. The plates were subsequently centrifuged for 
5 min at  1200 rpm and the bulk of the medium is carefully aspirated from the cell 
pellet,  leaving  10 to 20 pi  in  each  well.  DMSO (200 pi) is finally added to each 
well and the pellets are completely dissolved in the solvent by mixing, ensuring that 
no air bubbles form in the wells during resuspension.
141The optical density is then read at a wavelength of 550 nM on a Titertek Multican 
ELISA  plate  reader.  The  absorbance  reading,  an  average  of the  eight  wells  per 
sample is calculated as a percentage of the absorbance of the control untreated lane. 
The  ICj o   values  are  extrapolated  from  the  percent  absorbance  versus  drug 
concentration  plots,  and  correspond  to  the  concentration  of  drug  at  which  the 
absorbance percentage has been reduced by half.
1422.2  C- and N- terminus conjugates of N-methylpyrrole polyamides with 
5ico-cyclopropaneindole
2.2.1  Introduction
Distamycin  and  Netropsin are  well  studied,  naturally occurring oligopeptides that 
exhibit antiviral  activities and  reversibly  bind at AT  rich sites of the  DNA  minor 
groove. The reactive moieties of several antitumour compounds have been tethered 
to  the  distamycin  or  netropsin  pyrrole-amide  framework,  to  form  novel  hybrid 
compounds.  DNA  binding  agents  of  this  type  are  known  as  lexitropsins  or 
information reading oligopeptides (Lown,  1988). The rationale has been to use such 
polyamides  as  “vectors”  for  the  delivery  and  targeting  of  a  DNA  reactive 
appendage (e.g.  the pharmacophore of an alkylating agent), in an attempt to alter 
the individual component’s mode of interaction with the DNA, or to develop novel 
properties for the conjugates. This hybrid approach has had varied results. Tethering 
DNA  minor  groove  binders  structurally  related  to  distamycin,  to  the  antitumour 
antibiotic enediyne, for example, did not yield any increase in potency compared to 
the  enediyne  effector alone  (Xie  et  al.,  1997).  There  have  been  cases  where  the 
conjugates  lost  the  activity  of  the  antitumour  moiety  incorporated,  as  when 
combining the anticancer bioreductive  mitomycin C with  a distamycin-like frame 
(Paz  et  al.y   1999).  In  sharp  contrast,  attachment  of  the  polypyrrolic  frame  of 
distamycin A to benzoic acid mustard (BAM) produces the conjugate tallimustine 
(FCE  24517),  which  alkylates  DNA  more  efficiently  and  is  more  cytotoxic  than 
BAM alone.  In this case the hybrid molecule would exhibit new properties, as the 
tethered  benzoyl  mustard  moiety changed from  being exclusively a major groove 
alkylator (N7  of guanine) to a  highly  sequence  specific  minor groove one,  when 
part of the conjugate (Broggini et al.y   1995).  Enhanced potency was also reported 
for a distamycin A - Uramustine (uracil  mustard) hybrid, compared to each of its 
individual components, with maximal activity shown by the analogue containing six 
pyrrole  units  (Baraldi  et  al.,  2002).  Linking  a  distamycin-like  frame  with  a
143podophyllotoxin  derivative  generated  novel  agents  that  were  (lO-lOO)-fold  more 
potent than etoposide (Ji et al.,  1997). Hybrid molecules containing a PBD moiety 
and minor groove oligopyrrole carriers (1-4 pyrrole units) have also been designed 
and evaluated (Baraldi et al.,  1999). The hybrids exhibited different DNA binding 
activity  to  both  distamycin  A  and  PBD,  and  a  direct  relationship  between  the 
number  of  pyrroles  present  in  the  hybrid  molecule  and  the  stability  of  the 
DNA/drug  complexes  was  established.  Increase  in  the  length  of the  polypyrrole 
backbone  leads  to  an  increase  of  in  vitro  antiproliferative  activity,  with  the 
congugate containing four pyrroles being the most active.
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Figure 2.1 Structures of the examples of hybrid molecules mentioned in the text.
144The  hybrid  approach  has  also  been  applied  for  the  design  of  novel  CC-1065 
analogues.  The  objective  has  been  to  modify  the  selectivity  of alkylation  and/or 
enhance the  DNA  binding characteristics of the  lead compound, aiming to obtain 
compounds that  would  retain  CC-1065’s  potency  in  tumours  but  would avoid  its 
unwanted side effects. The CPI pharmacophore was the first to be studied due to its 
natural occurrence in CC-1065.  For that reason, the racemic compounds shown in 
Figure 2.2, were synthesised, retaining the CPI pharmacophore and replacing the B 
and  C subunits of CC-1065,  which  have  been  shown to  influence  DNA  binding, 
with  N-methyl  pyrrole  moieties  as  the  DNA  binding  domain  of  the  hybrid 
molecules. Among the synthesised compounds, the two most potent hybrids were 
the compounds having the CPI  unit linked to one or two N-methyl  pyrroles via a 
trans double  bond  (Figure  2.2-d).  The  propyl  end  group  has  also  been  found  to 
increase  the  bioactivity  of these  compounds,  which  were  shown  to  be extremely 
cytotoxic  (ICso for  KB  cells of 0.76 and  0.95  fg/L,  respectively)  (Fregeau  et al., 
1995; Wang et al., 1996).
Figure 2.2  Structures of reported N-methylpyrrole conjugates incorporating the CPI 
alkylation functionality.
R = C H .C H .C H .
L = no linker 
L = CH2 
L = CH2CH2 
L = trans CH=CH
C d  n =  1-2
145DNA  cleavage  studies  revealed  that  the  DNA  alkylation  selectivity  pattern  for the 
synthetic agents of the a category in  Figure 2.2, was distinct from that of CC-1065 
(Wang et al.,  1996). Agents of the d category also had different sequence preference 
from CC-1065 (Fregeau et al.,  1995). The covalent adduct of the racemic conjugate d 
for  n=l,  appeared  to  be  quite  stable,  showing  no sign  of reversibility  as  has  been 
earlier reported with other CPI-derived agents.
Individually, CPI and the pyrrole groups, both prefer to non-selectively bind to AT- 
rich minor groove sequences. When joined together, the CPI-N-methylpyrrole hybrids 
of Figure 2.2 avoid the major alkylation sites of CC-1065, yet all alkylated minor sites 
such as 5’-AATA-3\ The alkylation  patterns were exclusive at adenines, within the 
binding site consensus sequence of 5’-N(A/T)(A/T)A-3’ (Wang et al, 1996).
Other hybrid  molecules studied  include the enantiomeric pairs in  Figure 2.3.  In this 
case,  the  alkylating  moiety  chosen  was  a  chemically  stable  3-chloromethyl-6- 
hydroxy-2,3-dihydroindole,  which  is  a  precursor  of the  pharmacophore  commonly 
present  in  CC-1065  and  the  duocarmycins.  Different  sized  pyrrole  amides  were 
chosen as the DNA minor groove-binding portion of the conjugates. While the hybrid 
molecules with natural  configuration showed  moderate DNA-cleaving activity, their 
unnatural  counterparts  exhibited  potent activities  depending  upon  the  length of the 
binding moiety, drug concentrations and reaction times.
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Figure  2.3 Structures of the natural and unnatural sets of the seco-CI hybrid agents.
146The site of alkylation was shown to be an adenine by DNA cleavage studies. As for 
the  difference  in  potency  of  both  enantiomers,  this  was  attributed  to  the  closer 
proximity in the case of the unnatural enantiomer between the least substituted carbon 
of the cyclopropane and adenine-N3, as derived from molecular models (Shishido et
Another set of reported conjugates involves the combination of an oligopolypyrrolic 
frame and two pyrazole analogues of the CPI (Figure 2.4, structures 1  and 2).
Figure 2.4 Structures of the two pyrazole alkylating moieties (up) and the series of 
hybrids (bottom) reported by Baraldi et al. 2001.
Simplified  pyrazole agents (N-BOC-CPzI) showed  limited sequence specificity, low 
affinitiy for DNA and poor water solubility. The objective again was to increase the 
potency  of the  pyrazole CPI  analogues  by  increasing their affinity to DNA through 
tethering  these  alkylating  compounds  to  DNA  minor  groove  “vectors”  such  as 
polypyrrole amides. The hybrid agents 3-8, shown in Figure 2.4 were approximately 
8-  to  70-  fold  more  potent  than  the  original  alkylating  unit  against  five  different
a/.,  1997).
N
F 1.R, = H. R, = CH3
2. R, = Bn, R, = H
3. R, = H,R2  = CH„ n= 1
4. R, = H,R: = CH„n = 2
5. R, = H,R: = CH„ n = 3
6. R, = Bn, R: = H, n = I
7. R, = Bn, R -, = H, n = 2
8. R, = Bn, Rj = H, n = 3
147cancer cell  lines  in  vitro.  The  group of analogues  bearing  the  benzyl  group at the 
azaindole  moiety  (6-8)  failed  to  exhibit  significant  DNA  alkylation.  However  the 
other  hybrids  (3-5),  lacking  the  benzoyl  group,  showed  unique  DNA  sequence 
specific  alkylation  in  AT  rich  sequences.  The  three  pyrrolic  ring  bearing  analogue 
(agent  3)  alkylates  the  denoted  underlined  adenine,  in  the  sequence  5’- 
ACAAAAATCG-5’, within a 400 bp fragment, eliciting the strongest and most highly 
sequence specific alkylation activity. This compound was also the most cytotoxic with 
an ICjo of 7.4 nM against L1210 cells (Baraldi et al., 2001).
Synthesis of unsymmetrical  bis-lexitropsin-CBl  precursor conjugates  has  also  been 
reported (Jia et al.,  1999).
From  the  above  studies,  it  is  highlighted  that  the  hybrid  approach  can  generate 
conjugates capable of enhanced DNA binding and thus increased cytotoxic activity. In 
the  case  of the  CPI  analogues  proposed  by  Lown,  reversibility  of alkylation  was 
overcome, while in the case of the pyrazole analogues, a weak effector (N-Boc-CPzI 
exhibiting  10-fold lower cytotoxicity in L1210 than the reference compound N-Boc- 
CPI),  when  tethered  with  the  appropriate  binding  domain,  afforded  a  hybrid  agent 
both highly sequence selective and more cytotoxic.
2.2.2  Compounds
Three  novel  racemic conjugates of polyamides and the seco-propaneindoline (seco- 
Cl)  alkylation  subunit  are  studied  in  this  section.  Extensive  structure-activity 
relationship studies, as discussed in the introduction, have previously identified Cl as 
the minimum potent and common pharmacophore of CC-1065 and the duocarmycins 
(Boger et al., 1990b; Boger et al., 1990c).
148JT-III-149A, n = 1  
JT-IV-31B,  n = 2
JT-IV-3
Figure 2.5 Structures of the compounds investigated in this study.
Compounds JT-III-149 and JT-IV-3 IB consist of a seco-C  I group attached to the C- 
terminus of either one or two N-methylpyrrole units, respectively. These compounds 
are linked to the Cl pharmacophore via the carboxylic acid moiety on the pyrrole unit 
and the amine on the Cl. JT-IV-3 in contrast is unique in that the seco-C  I effector is 
attached to the  N-terminus of a one pyrrole-containing analogue of distamycin. The 
N-terminus of this compound contains a butanamide moiety. The longer alkyl moiety 
is incorporated to enhance activity, as previously shown for CPI hybrids (Wang et al.,
1996).
The aim of this study was to determine the effect of two structural variations, the size 
of  the  oligopyrrole  frame  and  the  orientation  of  the  attachment  of  the  alkylating
149moiety,  on  the  cytotoxic  activity  of the conjugates  and  the  sequence  selectivity  of 
alkylation.
2.2.3  Results and discussion
The  in  vitro  cytotoxicity  of  each  conjugate  was  determined  in  the  K562  human 
myeloid leukemia cell line for a one hour exposure to the drug and measured using a 
MTT assay. The assay is dependent on the cellular reduction of MTT, a tetrazolium 
based  compound,  by  the  mitochondrial  dehydrogenase  of  viable  cells  to  a  blue 
formazan product, which can be measured spectrophotometrically (Carmichael et al., 
1987).  The  C-terminus  linked  conjugates  JT-III-149A  and  JT-IV-31B  exhibited 
similar cytotoxic potencies as shown in Figure 2.6. The IC^ values (corresponding to 
the  dose  required  to  reduce  the  optical  density  to  50%  of the  control  value)  were 
extrapolated from the relevant curves and are presented in Table 2.2.
The  extension  of  the  DNA  binding  domain  of  the  hybrid  molecule,  with  the 
incorporation  of an  additional  pyrrole group did  not  result  in  a  marked  increase  in 
cytotoxicity.  The  N-terminus  linked  hybrid  JT-IV-3  was  substantially  less  active, 
despite  bearing one  pyrrole  unit, just like JT-III-149A. JT-IV-3  constitutes the first 
reported example of a Cl-polyamide conjugate with the alkylating moiety attached to 
the N-terminus of the polyamide. At physiological conditions, this agent would bear a 
positively  charged  dimethylpropylamino group. The  protonated functionality  should 
increase the conjugate’s affinity for DNA, but it has also been suggested that it might 
actually  contribute  to  reduced  cytotoxicic  potency  by  reducing  intracellular 
accessibility.  More  specifically,  conjugates  of  the  “b”  class  (Figure  2.2)  which 
incorporated uncharged alkyl groups were found to be much more potent towards KB 
cells than conjugates of the “a” type which bear a protonated dimethylamino group, 
supporting the view of a reduced cellular uptake of the latter (Wang et al,  1996). The 
lack  of  activity  of JT-IV-3  could  also  infer  that  this  particular  orientation  of the 
alkylating species has a detrimental effect on its ability to interact and alkylate DNA, 
reflected in its lack of cytotoxic potency.
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Figure 2.6 Plot of the absorbance as a fraction of the control (untreated cells) versus 
the concentration of JT-III-149A and JT-IV-3 IB (in pM). JT-IV-3 is not included as 
no increase in sensitivity was observed even at a concentration of 30 pM. The error 
bars represent the standard error of the mean of three independent experiments.
Compounds IC50 values (pM)
JT-III-149A 1.6 ±0.36
JT-IV-3 IB 2.1 ±0.26
JT-IV-3 >30
Table 2.1  In vitro cytotoxicity of the three conjugates against human chronic myeloid 
leukemia K562 cells, following a one hour drug exposure. The IQq values represent 
the average of three independent experiments and the S.D values are also included.
151The  DNA  alkylating efficiencies and  sequence specificity of alkylation of the three 
compounds  were  subsequently  studied.  Initially,  alkylation  by  the  compounds  was 
examined on the pUC18 plasmid, using the Taq polymerase stop assay (Ponti  et al, 
1991).
The plasmid was linearised with the restriction endonuclease Hind III, which cuts at 
only one site in the plasmid (position 399), providing a stop for the Taq polymerase 
downstream  from  the  primer.  The  synthetic  oligonucleotide  primer employed,  was 
specific for the bottom strand,  binding at positions 749-769. This assay should help 
pinpoint the position of the compounds’  binding sites on the plasmid DNA and reveal 
their sequence specificity.
The seco-C  I agents have been shown to serve as stable in vitrolin vivo precursors of 
the  reactive  Cl  agents,  possessing  identical  alkylation  properties  to  the  putative 
cyclopropane  agents  (Boger &  Wysocki,  1989).  Cl  can  be formed  by  ring closure 
with the  loss of HC1 from the seco-C  I  precursor.  Cl  agents were shown to alkylate 
DNA  at  the  same  sites  as  the  corresponding  CPI  based  agents  but  with  lower 
efficiency and less selectivity among the available sites (Boger et al., 1991a).
Figure 2.7 shows the autoradiographs of Taq polymerase gels examining the damage 
patterns of the three agents on pUC18. A predominant site of polymerase stop for all 
three  compounds  was  the  cluster  of  the  five  adenines  ’-A  A  AAA-3’  8 6 5 ,  which 
constitutes one of the reported consensus sequences of CC-1065 (Hurley et al., 1984). 
Unlike  previously  reported  CPI-N-methylpyrrole  hybrids,  which  avoided  the  CC- 
1065  major sites of alkylation, these seco-C  I  hybrid compounds therefore retain the 
pharmacophore’s  intrinsic  selectivity  for  its  consensus  sequence.  The  sequencing 
lanes  specific  for  the  upper  strand  were  produced  by  the  BESS  (Base  Excision 
Sequence Scanning) Mutascan™ Mutation detection and localisation kit, utilising the 
BESS  T-Scan  and  BESS  G-Tracker  systems  and  offering  an  alternative  way  for 
producing sequencing lanes. Due to complementarity, these sequencing ladders can be 
considered  as  A  and  C  specific  respectively,  for  the  bottom  strand  which  is  the 
relevant strand for the drug induced damage assessment.
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Figure  2.7  Portion  of an  autoradiograph  from  a  Taq  polymerase  gel  examining 
damage on the bottom strand of pUCI8.  For comparison, damage induced by  100 
nM  adozelesin  and  1   pM  CC-1065  is  also assessed.  10  bp  is  a  DNA  molecular 
weight marker, while 0 is the untreated control. C and A sequence lanes refer to the 
bottom  strand.  Arrows  indicate  the  positions  and  sequence  of the  binding  sites. 
Drug: DNA incubations were for 5 hours at 37°C.
153Another CC-1065  and  adozelesin  alkylation  site  on  this fragment, ^ ’-TTTA-S’843 
gives distinct  binding  profiles for the three  agents as evident  by  the corresponding 
cluster of stopping sites. JT-IV-3 alkylates this site at least as efficiently as the cluster 
of the five adenines and more efficiently than CC-1065 and adozelesin. JT-IV-3 IB, 
while there are traces of covalent binding at this site, overwhelmingly favours 
AAAAA-3,865for interaction. Finally, JT-III-149 interacts with the AT site to the least 
extent of all  the agents featured in the gel. At the concentration range of the agents 
studied in Figure 2.7, considerable damage is induced even at the lowest value of 10 
pM.  In Figure 2.8 smaller concentrations were used allowing for the early detection 
and  a  gradual  increase  of  the  damage  load  on  the  plasmid.  This  is  particularly 
important for the 8465’-TTTA-3’843 site,  which the agents discriminately  recognised. 
The relative reactivity of this site, as judged by the minimum concentration of each 
agent  required  for the  appearance  of  polymerase  blocks,  follows  the  order JT-IV- 
3»JT-IV-31B>JT-III-149A with JT-III-149A barely showing any binding. Strikingly 
JT-IV-3 binds to this sequence with the same efficiency as the cluster of adenines at 
865. Regarding this latter site and the C-terminus compounds, the addition of an extra 
pyrrole  group  increased JT-IV-3 IB’s affinity for the  site  by approximately  10-fold, 
compared to JT-III-149A. JT-IV-3  binds to this site with an intermediate efficiency 
compared to the other two.
A  thermally-induced  strand  cleavage  study  was  subsequently  performed to confirm 
the  binding  of  the  three  conjugates  in  the  minor  groove  and  probe  the  covalent 
modifications  as alkylations  at  adenine-N3  positions.  One  important feature of this 
strand breakage assay, previously extensively applied for the study of other (+)-CC- 
1065 analogues, is that the reactivity of the agents for a specific site can be gauged by 
the concentration of drug required to produce detectable cleavage. Also the extent of 
covalent  adduct formation,  as  established  by  this  assay,  correlated  closely  with  the 
biological potency of the analogues studied (Hurley et al.,  1988b; Hurley et al., 1990).
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Figure  2.8  Portions  of the  autoradiographs  from  Taq  polymerase  gels  examining 
damage to the bottom strand of pUC18, induced  by the conjugates JT-III-149A, JT- 
IV-3 (left) and JT-IV-3 IB (right), at the denoted  concentrations. G+A  is the purine 
marker (formic  acid)  specific  for the  5’-32P  radiolabelled,  208  bp  fragment  of the 
upper strand of the  plasmid. The sequence of the detected bands has been assigned 
based  on  their  complementarity  to  the  G+A  sequencing  lane.  0  is  the  untreated 
control. Arrows indicate the position and sequence of the binding sites.
155The radiolabelled bottom strand of a 208 base pair region of pUC18 defined from 749 
to 956 was examined. This sampling of DNA is of mixed A and T (47%) and G and C 
(53%) base content, contains high affinity CC-1065 sequences (runs of contiguous As 
and mixed AT sites), and includes the region of the strand employed as a template and 
visualised in the original  Taq polymerase studies. This allows for direct comparison 
between the alkylation profiles of the agents, as determined by the two assays. The 
autoradiograph of the thermal-cleavage  gel  is  shown  in  Figure 2.9. The  gel  reveals 
similar sites of covalent  reaction  on  DNA  as observed  in  the  Taq polymerase  stop 
assay.  Relative band intensity is indicative of the reactivity of the agents for, and the 
extent of alkylation of the adenine at which subsequent cleavage occurs. JT-III-149A 
and JT-IV-3 IB exhibit an identical  sequence selectivity to CC-1065 and adozelesin, 
on this specific fragment and under the specific incubation conditions, albeit at  100- 
fold  greater concentrations  and  with  varying  intensities  among  the  alkylated  sites. 
Again a predominant site of alkylation is the consensus sequence “^ ’-AAAAA-3’865, 
most strongly alkylated by JT-IV-3 IB, as was the case in the Taq stop studies.  While 
for CC-1065 and adozelesin the alkylated adenine is the one lying on the 3’   end of 
this alkylation  site, for these three  conjugates, a directly adjacent 5’   adenine  might 
also be prone to alkylation. However, this cannot be verified on this particular gel, as 
the fragment examined for damage  in this assay  and  subjected to sequencing  is 5’- 
Iabelled, and the heat cleavage products containing a modified sugar (Sugiyama et al., 
1994)  do  not  comigrate  with  the  fragments  produced  by  the  Maxam  And  Gilbert 
sequencing reactions, which possess a 3’-phosphate terminus. For the other CC-1065 
site, ^ ’-TTTA^’8 4 3 , JT-IV-3 exhibits the greatest affinity among the conjugates and 
seems to alkylate the A (843) with the same efficiency as it alkylates the 3’  adenine 
within  the  As cluster (869-865).  Again,  the  other two agents alkylate this  site  to a 
much  lesser degree.  In  all  instances,  the  alkylation  sites detected  by  the thermally- 
induced cleavage assay, proved to be an alkylated adenine flanked by at least two 5’- 
A or T bases.
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G  G+A  0  0.1  0.1  10  30  100  10  30  100  10  30  100
A 843 
T 
T 
T
C 
A
A 857
c
4  A  865 
A 
A 
A 
A
Figure  2.9 Thermal cleavage gel showing purine-N3 lesions to the bottom strand of a 5’-3 2 P 
labelled 208 bp fragment of pUC18, defined from 749 to 956. G and G+A are the sequencing 
lanes, specific  to the  (same)  bottom  strand.  0  is  the  untreated  control.  Thermal  cleavage 
conditions as described in the Methods section. Arrows indicate the position and sequence 
context of the alkylated adenines (underlined and in bold). Drug: DNA incubations were for 5 
hours at 37° C.
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Figure 2.11 Plot of the absorbance as a fraction of the control (untreated cells) versus 
the  concentration  of JT-I II-149,  JT-IV-3 IB  and  JT-IV-3  (in  pM).  The  error  bars 
represent the standard error of the mean of three independent experiments.
Compounds ICS0 values (pM)
JT-III-149A 0.28 ± 0.05
JT-IV-3 IB 0.6 ± 0.08
JT-IV-3 1.3 ±0.26
Table 2.2  In vitro cytotoxicity of the three conjugates against human chronic myeloid 
leukaemia K562 cells, following continuous, 4 days drug exposure. The IC^ values 
represent  the  average  of  three  independent  experiments.  The  S.D  values  are  also 
included.
159JT-IV-3 exhibits an IC^ value of 1.3 pM suggesting that the lack of cytotoxic potency 
observed in the one hour exposure was probably due to slow cellular uptake or slow 
reactivity with DNA. The alkylation studies which confirmed the alkylation capability 
of  JT-IV-3  on  plasmid  DNA  were  performed  for  drug  incubations  of  5  hours, 
therefore cannot serve as an indication of the efficiency of interaction of JT-IV-3 with 
DNA for the shorter, acute exposure. Yet, JT-IV-3 remained the least cytotoxic of the 
three agents.
The  structural  modifications  introduced  to  these  seco-C  I  compounds can  influence 
their  sequence  selectivity  and  resulting  cytotoxicity.  Attachment  of the  CPI  or Cl 
pharmacophores  to  the  N-terminus  of  polyamides,  instead  of  the  C,  offers  an 
alternative approach for the development of novel conjugates with distinct properties. 
While  JT-III-149A  and  JT-IV-31B  differed  in  their  relative  reactivity  among  the 
alkylation sites, the different orientation of the Cl appendage to the polyamide of JT- 
IV-3 produced a compound with alterations in the intrinsic sequence selectivity of the 
pharmacophore.  Even  subtle differences  in  sequence  specificity, among structurally 
related  agents,  if  occuring  in  vivo  can  have  possibly  important  biological 
consequences,  as  proved  in  early  studies  between  (+)-CC-1065  and  the  (+)-CPI- 
indole2 ((+)-U7 1 1 8 4 , (+)-ABC) and (+)-CPI-CDPI2 ((+)-AB’C’) analogues (Hurley et al, 
1990).
1602.3 Furano analogues of Duocarmycin Cl and C2: seco-iso-CFI and seco-CFQ
2.3.1  Introduction
Since the disclosure of CC-1065 and later the duocarmycins, extensive efforts have 
been  made  to  define  the  role  of  their  structural  features  and  subunits  in  the 
alkylation event considered to be the source of the agents’   biological effect. Part of 
this  effort  to  determine  the  fundamental  principles  underlying  the  relationships 
between stucture, chemical reactivity and biological activity was the synthesis and 
evaluation of key  partial  structures and  modified analogues as well  as structurally 
modified  alkylation  subunits.  A  relationship  between  functional  reactivity, 
solvolytic  stability  and  cytotoxic  potency  has  been  established  (as  discussed  in 
section 1.3.4.5).
As a successful example of modification of the parent CPI pharmacophore, Boger 
first  reported  the  synthesis  of  CBI  (Boger  &  Ishizaki,  1990),  where  the  fused 
pyrrole ring of the CPI is replaced with a fused benzene ring. Incorporation of CBI 
into functional  analogues  results in chemically  more stable and  biologically more 
active  agents  than  their  CPI  counterparts.  Since  increasing  the  stability  of  the 
alkylation subunit has proved a key determinant of the exerted biological potency, 
another modification to this effect was the replacement of CPI  with a fused furan 
ring,  which  is metabolically  more inert than the pyrrole ring,  resulting in the CFI 
subunit (Mohamadi et al.,  1994). One analogue bearing the CFI subunit in place of 
the CPI  was LY296329 shown  in  Figure 2.12. This agent had identical  alkylation 
selectivity  and  alkylated  DNA  at  comparable  or  slightly  less  effective  rate  (1-5 
times)  to  (+)-CC-1065.  Its  unnatural  enantiomeric  counterpart,  LY2979  (figure 
2.12)  exhibited  an  alkylation  profile  essentially  identical  to  that  of (-)-CC-1065, 
alkylating DNA, 33-100 times less efficiently than LY296329. LY296329 was toxic 
with  an  IC*, of 0.17  ng/mL against human  lung epidermoid carcinoma (T222) in 
vitro, but also inhibited the growth of T222 solid tumours in mice by up to 85% at a 
dose of 0.2 mg/kg, administered IV (Mohamadi et al.,  1994).  In another study, the
161alkylation  subunit of (+)-DUMSA  was  also  modified  by  again  incorporating the 
fused furan  ring,  generating the seco-prodrug LY307918  with the construction of 
the  (chloromethyl)indoline  alkylation  subunit  (Figure  2.12).  The  natural 
enantiomer was active at pM concentrations and was 5-70 fold more potent than its 
unnatural  enantiomeric  counterpart  in  in  vitro  cytotoxicity  assays  (Patel  et  al.,
1997). These studies highlighted the potential of the use of the CFI subunit in the 
design of novel active analogues of CC-1065 and the duocarmycins.
LY 29632 LY29795
CO*M
LY 307918
Figure 2.12 Structures of the reported analogues incorporating a fused furan ring in 
the alkylation subunit.
In studies of CPI  derivatives, it has been shown that the introduction of electron- 
withdrawing groups causes a linear decrease in speed of the acidic solvolysis. This 
in  turn,  enhances  the  stability  of  cyclopropaindolines  in  plasma  and  causes  an 
increase  in  in  vivo cytotoxic  potency.  The effects of the introduction  of electron- 
withdrawing groups in the stability of an analogue can vary from significant, as in
162the case of N2 substituents (Boger & Yun,  1994), to more moderate or minimal as 
in the case of a C7 substituent which is para to C4 carbonyl (Boger et al.,  1996a 
Boger et al.,  1996b). Attachment of an electron withdrawing group to the extended 
aromatic moiety also improves the chemical stability of the pharmacophore. These 
findings suggested  that the best candidates for drug development would be those 
analogues with greater electron - deficiency.
2.3.2  Compounds
Figure  2.13  Structures  of  the  jeco-iso-CFI  indoline  (top)  and  the  reco-CFQ 
quinoline (bottom) compounds along with their respective methylated counterparts.
R = H, TH-III-149 
R = CH3, BL-1-127
R = H, TH-III-151
R = CH3, AS(BL)59
163In  the  present  study,  novel  racemic  seco-prodrugs  of  iso-CFI  analogues  of 
duocarmycins are being investigated. This subunit has a fused furan ring in place of 
the benzene ring of CBI. The difference between these analogues and the previously 
reported  ones  (Figure  2.12)  lies  in  the  orientation  of  the  fused  ring.  During 
preparation, radical cyclisation of the iso-CFI  intermediate gave equal  amounts of 
the iso-CFI  indoline and quinoline CFQ precursors (Pati et al., 2004).  Subsequent 
conjugation to the TMI  moiety  provided the  indoline (TH-III-149 and  BL-1-127) 
and quinoline (TH-III-151 and AS(BL)59) analogues of the duocarmycins as shown 
in  Figure  2.13.  More  specifically,  the  j^co-iso-CFI  compounds  are  analogous  to 
duocarmycin C2 while the seco-CFQ ones are congeners of duocarmcyin Cl.
As  mentioned  before,  5eco-prodrugs  readily  lose  HC1  in  cells  or  in  cell  culture 
media to generate the corresponding cyclopropane containing agents (Figure 2.14). 
It  has  been  shown  that  the  seco  agents  exhibit  biological  properties  and  DNA 
alkylation  profiles  identical  to the  agents  containing  the  preformed  cyclopropane 
(Boger & Wysocki,  1989; Boger et al.,  1990b; Boger et al., 1990c).
Figure 2.14  Stucture of the ultimate cyclopropane containing iso-CFI-TMI agent.
The ultimate alkylating agent iso-CFI was designed on the basis that the attachment 
of the furan ring containing the electron withdrawing oxygen atom would stabilise 
the cyclopropylindoline functionality toward nucleophiles. The extension of the Cl 
unit with inclusion of the furan ring, should, as in the case of the extension of Cl to 
CBI, enhance chemical stability and cytotoxicity.
164Many antitumour agents act by crosslinking DNA. Synthetic compounds containing 
two CPI  moieties and  able to interstrand crosslink  DNA,  have been  shown to be 
significantly  more potent than CC-1065  both in  vitro and in  vivo (Mitchell  et al., 
1989;  Mitchell  et  al.,  1991).  Cyclopropaindolone  dimers  are  exemplified  by 
bizelesin  which  proved  both  more  sequence  selective  and  cytotoxic  than  the 
monomeric  agents  it derived  from  and  is  the  only  CC-1065  analogue  to  be  still 
undergoing clinical trials.  Synthesis and  biological evaluation of seco-CBI  dimers 
bearing flexible methylene linkers (Jia & Lown, 2000) and seco-C  BI  with pyrrole 
and  imidazole  bearing  polyamide  conjugates  (Kumar  &  Lown,  2003)  have  been 
previously  reported.  In  an  attempt  to  improve  the  potencies  of the  novel  furano 
analogues,  two  N3-N3  dimers,  shown  in  Figure  2.15  were  synthesised  and 
evaluated.
CP-75
CP-67
Figure 2.15  Structures of the N3-N3, jeco-iso-CFI dimers incorporating a linker of 3 (top) 
and 4 (bottom) carbons.
165Finally, the seco-CBI-TMI agent in Figure 2.16 has also been included as a control 
in some cases, for comparison.
Figure  2.16  Structure  of the  reference  compound  jeco-CBI-TMI  (Boger  &  Yun, 
1994; Atwell et al.y   1997).
2.3.3  Results and discussion
The  sites of covalent modification  induced  by  the compounds  under investigation, 
were  examined  using  the  Taq  polymerase  stop  assay.  The  same  set of sequences 
that react with adozelesin, also reacted with the four furano analogues.  Figure 2.17 
shows the polymerase stop sites induced  by the  binding to DNA of adozelesin, the 
s^co-CFQ  agent,  TH-II-151  and  its  methylated  counterpart,  AS(BL)59.  The 
predominant  site  of  drug  binding  for  all  three  compounds  is  the  cluster  of  five 
adenines  at  positions  865-869  which  constitutes  a  (+)-CC-1065  consensus 
sequence.  While  the  sequence  selectivity  of  covalent  alkylation  for  the  two 
investigational agents is indistinguishable, the intensity of the DNA modification is 
much greater for TH-II-151. The As(865) cluster is far more reactive to this agent, 
judging  by  the  at  least  10-fold  greater  concentration  required  for  AS(BL)59  to 
induce detectable damage at that site, and still  not at a level  comparable to TH-III- 
151. The presence of the methyl substituents should provide compounds AS(BL)59 
and BL-1-127 with added stability. Incorporation of the methyl group in the iso-CFI 
pharmacophore  should  provide  rigidity  between  the  two  portions  of the  molecule
166(iso-CFI  and TMI) and  enhance the  DNA-binding  activation  of the  agent towards 
alkylation at the  N3  of adenine.  As in  the case of the  left-hand  subunit C6 methyl 
ester  of  (+)-DUMSA  and  the  C7  substituent  of  CBI-TMI  analogues,  simply  the 
presence  of the  methyl  which  extends the  length  of the  rigid  furanoindole  group, 
would  cause  upon  binding,  a  larger  angular  twist  between  the  alkylation 
pharmacophore and TMI, and should serve to enhance DNA alkylation efficiencies 
and biological properties (Boger & Garbaccio 1999a). Yet, as shown in Figure 2.17, 
the methylated CFQ agent, AS(BL)59 has poor alkylation capabilities.
Figure  2.18  shows  the  gel  of  another  Taq  polymerase  stop  assay  which  also 
features the  seco-iso-CFI  indoline  analogues.  In  this case,  the  methylated  iso-CFI 
agent,  BL-1-127  has  an  indistinguishable  alkylation  profile  (regarding  both 
selectivity and intensity) to TH-III-149.  It produces equally strong, dose-dependent 
bands  at  the  ^ S ’-AAAAA^ ’865  binding  site.  In  the  same  gel,  AS(BL)59  again 
demonstrates limited alkylation efficiency.
The  thermally-induced  strand  cleavage  assay  was  subsequently  performed  to 
confirm  the  covalent  interaction  of the  furano  analogues  with  the  N3  position  of 
adenine bases in the minor groove.
The probe DNA sequence was obtained from PCR amplification of base pairs 749- 
956 of the  linearised  with  Hind III,  pUC18  plasmid,  so that  it contains  the  DNA 
fragment previously visualised and examined with the Taq polymerase gels.
Figure  2.19  shows  the  autoradiograph  of  a  thermal  cleavage  gel  confirming  the 
ability of TH-III-149 and TH-III-151  to recognise and alkylate the 3’ adenine of the 
8695’-AAAAA-3’ 865  site  with  similar  efficiencies.  The  pattern  of  alkylation  was 
similar to that  produced  by  the  reference  compound seco-CBI-TMI.  However,  the 
i^co-CBI-TMI agent slightly differentiates in its ability to alkylate adenines even at 
the  lower  concentration  employed,  at  the  AT  site  7945’-TTAT-3’791  and  the  “ 'S*- 
CAAC-3’ 858 site.
167Adozelesin  TH-lll-151  AS(BL)59
I   I   1   I   1
5'
3'
10bp
A
A
A
A
A
8 6 5
Figure  2.17  Portions  of  the  autoradiograph  of a  Taq  polymerase  assay  gel  examining 
damage to the bottom strand of pUC18, induced by the jeco-CFQ agent, TH-III-151  and its 
methylated counterpart AS(BL)59, at the denoted concentrations. Adozelesin was included 
as an internal standard.  lObp is a DNA molecular weight marker. 0 is the untreated control. 
The arrow  indicates the position and sequence of the common  major binding site.  Drug: 
DNA incubations were for 5 hours at 37° C.
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Figure  2.18  Portion  of  the  autoradiograph  of  a  Taq  polymerase  gel  examining 
damage to the  bottom strand of pUC18,  induced  by  both the iso-CFI  and seco-CFQ 
agents and  their  methylated  counterparts,  at  the  denoted  concentrations.  Adozelesin 
was included as an internal standard.  lObp is a DNA molecular weight marker, while 
C and  A  are  sequencing  lanes  specific for the Gs and Ts  respectively, of the  upper 
strand,  produced  by  the  BESS  (Base  Excision  Sequence  Scanning)  Mutascan,N 1  
Mutation  detection  and  localisation  kit.  Due  to  complementarity,  these  sequencing 
ladders can  be  read  as A  and  C specific for the bottom  strand  which  is the  relevant 
strand for the drug induced damage assessment. 0 is the untreated control. The arrow 
indicates the position and  sequence of the common,  major binding site.  Drug:  DNA 
incubations were for 5 hours at 37° C.
169An  agarose  gel  electrophoresis  method  (Hartley  et  al.,  1991)  was  employed  to 
assess the efficiency of the two N3-N3 furano dimers, CP-75 and CP-67, to produce 
interstrand  crosslinks  in  plasmid  DNA.  Linearised,  singly  5’-32P-end  labelled 
pUC18 was completely denatured, thus migrating faster in the agarose gel than the 
nondenatured, double stranded control.  DNA treated with a range of concentrations 
of the  two investigational  analogues  was  also  subjected  to denaturation.  CC-1065 
and the duocarmycins produce heat-labile adducts and this has been the basis of the 
employment  of the  thermal-cleavage  assay  for  the  identification  of the  damaged 
adenines. Thermal  denaturation of the  DNA  would therefore lead to the release of 
the  covalently  modified  bases introducing single  nicks,  necessitating therefore  the 
use  of  alkaline  denaturation  instead.  Cisplatin  treated  DNA  was  included  as  an 
internal standard. The presence of a crosslink between the two strands prevents the 
complete  separation  of the  strands  upon  denaturation,  resulting  in  renaturation  of 
the crosslinked DNA in the neutral gel, which runs as double stranded DNA. Figure 
2.20 shows the autoradiograph of such an agarose gel. Cisplatin, as expected, fully 
crosslinked  plasmid  DNA  at  a  concentration  of  10  pM.  CP-75  induced  a 
concentration-dependent  increase  in  the  amount  of  cross-linked  DNA.  However, 
under  the  conditions  employed  for  this  assay  (concentration  and  incubation  time 
range),  100%  crosslinking  of pUC18  DNA  was  not  achieved.  In  contrast,  CP-67 
was  not  capable  of any  interstrand  crosslinking  even  at concentrations  as  high  as 
100  pM.  The  graph  in  Figure  2.21  presents  the  concentration  dependent 
crosslinking ability of CP-75 as derived from densitometric quantification of the gel 
in  Figure  2.20.  Previously  reported seco-C BI  dimmers  have  not  been  assessed  for 
their crosslinking efficiencies. However the position and length of the linker greatly 
affected the  biological  potency of those compounds with the N3-N3  linked dimers 
being the most potent set investigated (Jia & Lown, 2000).  In flexibly linked seco- 
CPI  dimers,  crosslinking  ability  and  cytotoxicity  were  found  to  be  related  to  the 
number of carbons in the linking polymethylene chain (Mitchell et al.,  1989).
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Figure 2.19 Thermal cleavage gel showing purine N-3 lesions to the bottom strand of a 5’- 
32P labelled 208 bp fragment of pUC18, defined from 749 to 956. 0 is the untreated control. 
Thermal  cleavage  conditions  as  described  in  the  Methods  section.  Arrows  indicate  the 
position and sequence context of the alkylated adenines (underlined and in bold). Adenines 
on the upper portion of the gel have been appointed from previous experiments Drug: DNA 
incubations were for 5 hours at 37° C.
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Figure  2.20  Autoradiograph  of  an  agarose  gel  showing  DNA  interstrand 
crosslinking by CP-75 in linear pUC18 DNA. Drug treatments were for 2 hours for 
cisplatin  and 5  hours for the furano dimers,  at 37° C.  Denaturation for 2 mins by 
treating  with  alkali.  (DS)  is  double  stranded  control  and  (SS)  is  single  stranded 
control.
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Figure 2.21  Double stranded and  single stranded  DNA  bands from the above gel 
were  quantified  using  laser densitometry  to  produce  the  dose  response curve for 
CP-75 induced crosslinking.
172More  specifically  the  flexible  CPI  dimers  bearing  a  methylene  chain  of n=3  and 
n=5 (where n is the number of carbons in the polymethylene linker) were far more 
toxic and efficient in crosslinking  DNA, than the ones of n=2 and  n=4. This same 
clear  pattern  has  also  been  seen  for  PBD  dimmers  (Bose  et  al.,  1992b)  and  also 
unsymmetrical  crosslinking  agents  combining  the  seco-CB\  and  PBD 
pharmacophores  where  again  crosslinking  ability  and  toxicity  was  dependent  on 
chain  length  and  was  of  the  order  n=2<  1< 4<  5;s  3  (Tercel  et  al.,  2003).  That 
pattern  was  also  seen  for  the  furano  dimers  examined  in  this  study,  with  CP-75 
which  incorporates a methylene chain of n=3, being able to crosslink DNA,  unlike 
CP-67 where n=4.  Presumably this is due to a better match between the separation 
of the alkylating subunits of the dimer with n=3 and the base pair register.
The  novel  agents  were  also  tested  for their in  vitro  cytotoxicity  potency  using  an 
MTT  based  growth  inhibition  assay.  Cellular  toxicities  were  determined  as  IC*, 
values after  1   hour and 4 days  of continuous drug exposure  in  the  K562 cell  line 
and  are  presented  in  Table  2.3.  The  agents TH-III-149 and  TH-III-151  which,  as 
discussed earlier,  would  undergo a loss of HCI  in  biological  medium and  generate 
the  same  ultimate  cyclopropane  agent  were  indeed  shown  to  possess  similar 
cytotoxicities  and  were  approximately  6-fold  less  potent  than  the  5ec<?-CBI-TMI 
reference compound  in a  continuous exposure and approximately  15  times for the 
one hour treatment. The presence of the methyl group in the iso-Me-CFI agent, BL- 
1-127,  potentiated  its cytotoxicity  compared  to that of TH-III-149 by 4-6 fold (for 
both  Ih  and  continuous  drug  exposure).  The  improved  cytotoxic  activity  is 
presumably due to the increased stability and enhanced activation on binding in the 
minor groove of DNA, conferred by the extended alkylation subunit.  However, the 
Ae*cY;-Me-CFQ  agent,  AS(BL)59  failed  to  demonstrate  the  same  effect.  On  the 
contrary  its  cytotoxicity  was  lower  than  its  non-methylated  counterpart,  in 
accordance  with  its  decreased  DNA  alkylation  capability  as  demonstrated  in  the 
alkylation studies. The IC*, values of all the agents were comparable between the  1  
hour and the 4 days exposure. The lack of potentiation of the cytotoxicity during the
173extended  exposure  suggests  that  the  cells  are  affected,  presumably  through  the 
reaction of the agents with  DNA and the induced alkylation  event,  within the first 
hour of exposure.
IC^ values (pM)
Compounds
4 days  1  hour
TH-III-149 0.019 ±0.002 0.017 ±0.002
BL-1-127 0.003 ± 0.002 0.004 ±0.0014
TH-III-151 0.018 ±0.003 0.015 ±0.02
AS(BL)59 0.037 ±0.017 0.075 ± 0.025
CP-75 0.0018 ± 0.0008 0.002 ± 0.0005
CP-67 0.03 ±0.015 0.04 ± 0.007
seco-C BI-TMI 0.0028 ± 0.001 0.0011  ± 0.000
Table  2.3  In  vitro  cytotoxicity  (IC^  in  pM)  of the  investigational  agents  and  the 
reference compound, seco-CBI-TMI, against human chronic myeloid leukaemia K562 
cells,  following  a  one  hour  and  4  days  continuous  drug  exposure.  The  IC*,  values 
represent  the  mean  of  at  least  two  independent  experiments.  S.D  values  are  also 
presented.
CP-75, the dimer with the linker chain size previously identified as optimal for both 
toxicity  and  crosslinking  ability,  was  the  most  toxic  agent,  suggesting  that  its 
crosslinking  ability  could  be  a  contributor  to  its  enhanced  cytotoxic  potency.  It 
exhibited  a  10-fold  increase  in  cytotoxicity  compared  to  its  parent  monoalkylator, 
TH-II-149 and was comparable to the sectf-CBI-TMI agent.  In contrast, CP-67 that 
failed to crosslink DNA  was more than 20-fold  less toxic. The enhanced cytotoxic
174activity  exhibited  by  CP-75  is  in  agreement  with  previous  studies  comparing 
bifunctional  and  monofunctional  agents.  The  IC^  of  the  monofunctional 
counterparts  of melphalan  and  SJG-136  were  shown  to  be 4-  and  60-fold  higher 
then  the  parent bifunctional  agents in  wild type CHO cells. Thus it was suggested 
that  bifunctional  adducts  are  a  more  cytotoxic  form  of  DNA  damage  than  the 
respective  monoadducts (Clingen  et al., 2005).  Similarly,  in  earlier studies,  DSB- 
120,  a  PBD  dimer  forming  interstrand  crosslinks  by  covalently  interacting  with 
guanines on  opposite  strands was found to  be > 650-fold  more cytotoxic  than  the 
parent  DC-81  molecule,  presumably  as a  result of the formation of the crosslinks 
(Bose et al.,  1992a).
1752.4 Hairpin conjugates of a racemic seco-Cyclopropaneindoline-2- 
benzofurancarboxamide and polyamides
2.4.1  Introduction
Hairpin  polyamides  are  the  only  cell  permeable  small  molecules  capable  of 
recognising  extended,  specific,  predetermined  sequences  of DNA  with  an  affinity 
comparable  to  DNA  binding  proteins,  as  discussed  in  Chapter  1.  Hence  their 
potential role in molecular biology and medicine as diagnostic tools and as reagents 
capable  of  modulating  gene  expression  has  attracted  much  attention  and  various 
synthetic efforts in  designing  such agents have  been  reported.  Hairpin  polyamides 
have  been  linked  to  various  DNA  modifying  agents,  one  of  which  has  been 
duocarmycin.  What  initiated this approach of combining the  hairpin  motif and the 
DUMA alkylating subunit was the initial observation of the ability of distamycin A 
to dramatically modulate the sequence specificity of DUMA, causing the alkylation 
to shift primarily to the G residues in GC-rich sequences (Yamamoto et al.,  1993). 
NMR  strectroscopy  later  revealed  that  this  modulation  of  sequence  specificity 
involves  the  cooperative  heterodimeric  binding  of  DUMA  and  distamycin  to  the 
minor  groove  in  a  side-by-side  arrangement  (Sugiyama  et al.,  1996).  Apart from 
DUMA’s ability to form heterodimers with distamycin, cooperative alkylation was 
later also observed in the presence of Py / Im triamides (Fujiwara et al.,  1999). This 
approach consequently evolved in the design of hybrid molecules between segment 
A  of DUMA  and  Py/Im diamides.  Such  hybrids  would  retain  the  parent  DUMA’s 
alkylation selectivity, primarily alkylating the 3’  A of AT-rich sequences.  However 
they  would  be  able  to  specifically  and  efficiently  alkylate  G  residues  of 
predetermined  DNA sequences through formation of a heterodimer in the presence 
of distamycin, following  Dervan’s binary  code for base pair recognition  by  Py/Im 
polyamides (Tao et al.,  1999a).  In concurrent and  later attempts to further modify 
the  sequence  selectivity  of  duocarmycin’s  alkylation  in  a  predictable  manner, 
hairpin polyamides were synthesised.
176The  hairpin  polyamide  motif which  was first envisaged  to  mimic  the 2:1  side-by- 
side  antiparallel  binding  of  unlinked  polyamides,  proved  to  have  some  distinct 
advantages  over  the  traditional  dimer  systems.  Previous  studies  have  shown  that 
covalently  linking  two  antiparallel  polyamide  strands  with  y-aminobutyric  acid 
(GABA),  forms  a  hairpin  structure  which  exhibits  specific  binding  to  designated 
target  sites  with  > 100-fold  enhanced  affinity  relative  to  the  unlinked  dimers 
(Mrksich  et al.y   1994).  Unlike  the  homodimeric  binding  of unlinked  polyamides, 
which can afford “slipped motifs’’, hairpins are positioned unambiguously between 
the two DNA strands, as the y-turn “locks” the register of the ring pairings. Also the 
individual  compounds  no  longer have  to interact  in the  minor groove to form  the 
dimer, which is a significant advantage, particulary in the case of a heterodimer, as 
a  secondary  homodimer forming  is  possible  since  a complex  equilibrium  dictates 
the  formation  of  a  homodimer  or  heterodimer.  With  the  hairpin  approach,  the 
alkylating moiety incorporated in the conjugates, such as that of DUMA can display 
a  different  DNA  sequence  specificity  afforded  by  the  polyamide’s  heterocycles’ 
sequence and selectively alkylate matched sequences. Also the hairpin motif offers 
a means to target an alkylating pharmacophore to either more biologically relevant 
sites or to increase the actual size of the targeted binding site and hence the chances 
of recognising a unique site in the genome. On the other hand, polyamides linked to 
an  alkylating  effector can  benefit  from  a  covalent  binding  to  DNA,  which  would 
enhance  the  stability  of  the  polyamide-DNA  complex  and  influence  the  ensuing 
biological  activity,  which  could  be  also  affected  by  the  alkylation-induced  DNA 
damage.
Pyrrole-imidazole  polyamide  conjugates  incorporating  the  natural  enantiomer  of 
segment A  of DUMA  (Tao et al.,  1999b)  and  segment A  of DU-86 along  with  a 
trans-vinyl (L) linker (Bando et al., 2002) have been discussed in Chapter 1   (section 
1.3.4.9).  Finally, in another study, an eight-ring hairpin polyamide was shown to be 
able  to target opposite  strands of the  DNA  depending on  the enantiomer of seco- 
CBI conjugated at its turn (Chang & Dervan, 2000).
1772.4.2 Compounds
Conjugates  of  racemic  seco-cyclopropaneindoline-2-benzofurancarboxamide  (CI- 
Bf)  and  four diamides  (Imlm  (RBH-III-23),  ImPy  (JT-IV-99),  Pylm  (JT-IV-101) 
and  PyPy  (JT-IV-83),  where  Py  is  pyrrole  and  Im  is  imidazole),  linked  by  a  y- 
aminobutyrate group, were synthesised and their structures are presented in  Figure 
2.22.
X=Y=N 
X=N, Y=CH 
X=CH, Y=N 
X=Y=CH
Figure 2.22 Structures of the agents under investigation in this study.
In  these  agents,  as  in  the  analogues  discussed  in  section  2.2,  the  seco-CI 
pharmacophore  was  utilised  as  the  alkylating  “warhead”,  unlike  the  previously 
reported studies employing the DUMA and DU-86 alkylation subunits and the CBI.
JT-IV-83 :
178Although  DUMA  prefers to alkylate the N3 of A at the 3’  ends of consecutive AT 
sequences, it has been observed that DUMA could also undergo a N3 alkylation of 
guanine  as  in  the  case  of  (G7)  of  d(GCAATTGC)2  (Sugiyama  et  al.,  1993). 
DUMA’s potential for guanine alkylation, not observed for DUMSA or CC-1065, is 
attributed to its greatest reactivity among all  members of the duocarmycin class of 
agents. Cl on the other hand, is also an exceptionally reactive electrophile (Boger et 
al.,  1991a). The terminal free amine of the conjugates, at physiological  pH of 7.4, 
will  remain protonated,  resembling the distamycin A termini. This charged species 
should enhance the water solubility of the conjugates and could also enhance DNA 
binding.  The  linker used  in  this  series  of agents,  derives from  glutaric  anhydride. 
This  linker  is  very  similar  in  both  the  length  and the  chemical  structure  to  the y- 
aminobutyric acid  (GABA)  linker employed  in  the  hairpin  molecules designed  by 
Dervan and Tao in previous studies (Mrkish et al., 1994; Tao et al., 1999b).
2.4.3  Results and discussion
The main goal of designing the above agents was to combine the inherent reactivity 
of the  Cl  pharmacophore  with  the  binding  specificity  of the  hairpin  polyamides. 
Such  compounds  can  potentially  be  endowed  with  the  ability  to  more  efficiently 
recognise distinct  and  unique  sequences of DNA. The thermally-induced cleavage 
assay  was utilised to probe the sites of covalent interaction of this series of hairpin 
conjugates with purine-N3 in the minor groove.
Damage  was  examined  on  the  bottom  strand  of  the  same  fragment  of  pUC18 
employed  as  the  reference  DNA  in  the  previous  studies.  As  can  be  seen  on  the 
autoradiograph  in  Figure 2.23,  all  four compounds retain a memory for alkylating 
adenine N3 within the A5(865) cluster, 8695’-AAAAA-3’ 865, a site that constitutes a 
consensus  sequence  for  CC-1065  and  which  was  readily  recognised  by  the 
compounds in section 2.2 which also incorporate the same seco-Cl pharmacophore.
179Covalent A-N3  alkylation  is also evident by all four hairpin conjugates, at the AT 
sites  situated  3’  of the  common  major  A5  cluster,  5’-767ATTA-3’764,  ^ S ’-ATAA- 
V 171  and  8465’-TTTA-3’843  (the  3’-alkylated  adenine  is  underlined).  What 
differentiates the  alkylation  profiles of these  agents  is the  ability  of the  imidazole 
bearing compounds RBH-III-23 (Imlm) and JT-IV-99 (Pylm) to alkylate the minor 
but  unique  for  these  two  conjugates,  site  8905’-TCAG-3’ 887.  This  sequence  is  less 
reactive than the run of the five adenines, as alkylation is only evident at the higher 
(10 pM) concentration studied. Since the DNA fragment in Figure 2.23 has been 5’- 
32P-radiolabelled, a 3’- end heterogeneity is evident, manifested by the presence of a 
pair of closely  migrating  bands (more  pronounced for the 8905’-TCAG-3’887 site  at 
the  bottom  part  of  the  gel,  due  to  increased  band  separation).  The  band  that 
migrated  slower,  is  thought  to  represent  a  species  containing  the  modified 
deoxyribose  moiety,  while the lower molecular weight band (higher gel  mobility), 
constitutes  a  thermal  cleavage  product  that  has  resulted  from  the  loss  of  the 
modified  sugar,  and  as  such  constitutes  a  3’phosphate  terminated  molecule, 
therefore  comigrating  with  the  Maxam  and  Gilber  sequencing  products.  Thus  the 
bands observed at the bottom of the gel  in Figure 2.23, unique for RBH-III-23 and 
JT-IV-99,  represent  the  thermal  cleavage  product  of the  adenine  at  position  888, 
which is thought to be the reacting base within this specific sequence context. These 
two compounds therefore exhibit the ability to recognise a GC-containing sequence. 
Alkylation  at  the  8905’-TCAG-3’887 can  be  explained  by  the  mode  of  recognition 
shown in Figure  2.24-B.
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Figure 2.23 Thermal  cleavage gel  showing purine-N3  lesions to the bottom strand of a 5’- 
32P labelled  208  bp fragment of pUC18, defined  from  749 to 956 induced  by the denoted 
hairpin polyamide agents.  0 is the untreated control.  G / G+A are the sequencing markers. 
Thermal  cleavage  conditions  as  described  in  the  Methods  section.  Arrows  indicate  the 
position and sequence context of the alkylated adenines (underlined and in bold). Adenines 
on  the  upper,  non  resolvable  portion  of  the  gel  have  been  appointed  from  previous 
experiments.  Drug:  DNA incubations were for 5 hours at 37° C.
181In  this  proposed  model  the  seco-CI-Bf  and  polyamide  subunits  fold  to  form  a 
hairpin resulting in the side by side pairing of an imidazole unit with the benzofuran 
moiety, allowing interaction with a GC base pair in a fashion similar to the pyrrole / 
imidazole  pairing  that  is  capable  of  recognising  a  C/G  base  pair.  The  enhanced 
tolerance of mixed AT/GC sequences exhibited by the two agents is consistent with 
previous findings that imidazole containing polyamides are capable of altering the 
sequence  selectivity  of DUMA from AT to GC-rich  sequences.  It is  unlikely  that 
these conjugates would bind to this sequence in an extended conformation because 
the  pyrrole  group  of  JT-IV-99  would  then  be  unfavourably  placed  next  to  a 
G(891)/C  base  pair.  Additionally,  the  benzofuran  moiety,  would  also  have  to 
unfavourably bind to a C(889)/G base pair (sequence in Figure 2.24-A). It has been 
shown,  in other studies in our group, that like seco-CI-TMI, seco-C I-Bf also binds 
to the cluster of the A adenines at 865 and not to GC-containing sites.
This study  was an  extension  of the  study  described  in  section  2.2 and  part of the 
effort to modulate the sequence specificity of the duocarmycins. Capitalising on the 
findings of GC recognition in the presence of triamides (Fujiwara et al.,  1999), this 
series of conjugates adopted  the  hairpin  motif. These agents are  the  first  reported 
hairpin  CC-1065/duocarmycin  analogues  incorporating  the  seco-C I  alkylating 
moiety. Another distinctive feature from other duocarmycin hairpin analogues is the 
inclusion of the benzofuran moiety as part of the DNA binding domain, rather than 
only pyrrole and imidazole groups. Two imidazole containing conjugates exhibited 
enhanced tolerance to mixed GC/AT sequences, highlighting a possible recognition 
mode for the benzofuran / Imidazole pairing.
The cytotoxic  potency of these agents  was also determined against the  K562 cells 
for both a one hour and 4 days continuous drug exposure, using the MTT assay. The 
ICjq values are presented in Table 2.4.
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4 days 1 hour
RBH-III-23 2.16 ±0.28 2.83 ± 1.89
JT-IV-99 2.05± 0.07 5.05 ±4.17
JT-IV-101 2.83 ±0.28 22.5 ± 10.6
JT-IV-83 2.5 ±0.7 19± 1.4
Table  2.4  In  vitro  cytotoxicity  (IQo  in  pM)  of  the  investigational  agents  against 
human  chronic  myeloid  leukaemia  K562  cells,  following  a  one  hour  and  4  days 
continuous  drug  exposure.  The  IC^  values  (mean  of  at  least  two  independent 
experiments) and the S.D values are presented.
Judging  by  the  growth  inhibitory  effect  during the  one  hour exposure,  the  agents 
RBH-III-23  and  JT-IV-99 were  the  most  potent.  This enhanced  cytotoxic  activity 
could  either  be  due  to an  improved  cellular uptake or might be  related  to the fact 
that  these  two  compounds  exhibited  distinct  DNA  sequence  selectivity.  After the 
extended, continuous exposure, all agents demonstrate comparable activity.
As  such  agents  are  most  likely  going  to  be  employed  as  reagents for  modulating 
gene expression,  it is the enhanced  selectivity for designated target  sequences and 
not  the  high  toxicity,  which  is  the  primary  objective  for  designing  them.  To  this 
effect,  hairpin  pyrrole-imidazole  polyamides  incorporating  the  DU-86  alkylating 
moiety  have  been  shown  to  target  and  bind  adenine  in  the  telomere  repeats  5’- 
CCCTAA-3’  extending sequence recognition to a six-base pair sequence (Takahasi 
et  al.,  2003).  Another  DU-86  incorporating  hairpin  has  been  shown  to  inhibit 
transcription  in  the  coding  region  of  the  GFP  gene  (Oyoshi  et  al.,  2003)  while 
longer polyamide-DU-86 hybrid  hairpins could selectively suppress the expression 
of luciferase activity in living cells by targeting coding regions of renilla and firefly
184luciferase  (Shinohara  et  al.,  2004).  These  findings  highlight  the  potential  of 
“effective”  DNA  alkylation  as  a  promising  strategy  for  designing  new  types  of 
gene-regulating  agents.  The  hairpin  motif  provides  therefore  the  framework  for 
“tailor-made”  antitumour  agents  by  introducing  further  sequence  selectivity  or  a 
modified  sequence  specificity  for  predetermined,  site-specific  targeting  to 
established alkylating agents.
185CHAPTER  3
SEQUENCE SPECIFIC ALKYLATION AND CYTOTOXICITY OF A 
SERIES OF NOVEL ACHIRAL 
CC-1065 / DUOCARMYCIN ANALOGUES
3.1 Introduction
Three of the four CC-1065/duocarmycin analogues that have advanced into clinical 
trials,  bizelesin,  carzelesin  and  KW-2189  are  seco  prodrugs,  as  they  do  not 
incorporate the preformed cyclopropane ring of the parent compounds. As has been 
mentioned  before,  seco  agents  readily  close  to  the  corresponding  cyclopropane 
containing agents in biological media, through elimination of HC1 prior to induction 
of alkylation (Figure  3.1  ).
Cr
\
♦
Figure 3.1 Activation of the seco prodrugs by the loss of HCI in biological media.
Past studies have  shown that seco agents incorporating the Cl  (Boger & Wysocki, 
1989; Boger et al.,  1990c; Boger et al.,  1990b) or the CBI (Boger & McKie,  1995; 
Boger  et  al.,  1995b,  Boger  et  al.,  1995c)  pharmacophores,  exhibit  biological 
properties  and  DNA  alkylation  efficiencies  and  selectivities,  identical  to  those  of
186their cyclised counterparts. In one instance, the seco-CI-TMI precursor proved to be 
(lO-lOO)-fold  more  efficient  alkylator  than  CI-TMI  and  five  times  more  toxic  in 
L 1210 cells, attributed to the relative instability of the latter agent to the conditions 
of  the  assay  (Boger  et  al.,  1990c).  The  stability  of  the  analogues  in  the  seco 
configuration  and  their ability  to serve as stable  in  vivo  precursors of the  reactive 
agents  provides an  attractive  strategy  for drug design.  Hence,  all  the  analogues  in 
the studies  presented  thus far have  been  uncyclised precursors.  However, just like 
the  three  clinically  investigated  compounds,  they  all  possess  a  chiral  centre.  The 
advantages  of  the  omission  of  this  feature  and  alternatively  the  development  of 
active achiral analogues have been outlined in the Introduction (section  1.3.4.12).
In  the  quest  for  improved  antitumour  agents  of this  type  and  based  on  previous 
studies on  seco  versions  of CC-1065  analogues,  we  sought  to develop  an  achiral 
pharmacophore  that  would  be  capable  of  the  CC-1065  characteristic,  sequence 
specific,  minor  groove  alkylation  and  subsequently  incorporate  it  into  functional 
analogues. In order to determine the minimum structural requirements of a potential 
achiral  pharmacophore,  for a “CC-1065  mode” of interaction  with  DNA, the  2-p- 
hydroxyphenethyl  (HPE)  halides  were  considered,  previously  studied  for  their 
cytotoxicity  and  DNA  alkylating  ability  (White  et  al.,  1995).  These  analogues 
which  are  the  simplest  seco  CPI  functional  agents  were  chosen  in  place  of  the 
spiro(2.5Jocta-l,4-dien-3-one  group  (Figure  3.2).  This  group  lacks  the  fused 
aromatic  and  pyrrolidine  functionality  of  the  CPI  and  other  known  alkylating 
subunits and is formed as an intermediate in a reaction involving Ar-3’ participation 
in  the  phenoxide anion  of 2-aryl-1-ethyl  halides.  However,  it is too  hydrolytically 
unstable to be studied in biological systems (Baird & Winstein,  1963).
Assessment of the in  vitro cytotoxicity of the 2-/?-hydroxyphenethyl  (HPE) halides 
featured  in  Figure  3.3  showed that the alcohols were much  less cytotoxic than  the 
corresponding halides against the cell  lines HeLa and MM96L. The IC^ value of p- 
hydroxyphenethyl  bromide  (HPEB)  was  determined  to  be  32  pM  towards  the 
murine melanoma B16 cell  line, which is comparable to the reported values for N- 
BOC-CPI (>3.3 pM) and is approximately 34 times that for N-BOC-CBI.
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Figure  3.2  The formation of spiro[2,5]octa-l,4-dien-3-one as an intemediate in the 
reaction of bromide with a nucleophile.
The decreased activity of the halide compared to these other alkylating subunits, is 
consistent  with  the  inverse  relationship  between  chemical  stability  and  cytotoxic 
potency  as  previously  suggested  (Boger  &  Yun,  1994).  Overall,  the  p- 
hydroxyphenethyl  chloride and  bromide (HPEC and  HPEB) exhibited the greatest 
potency  and  were  more cytotoxic  than the  m-methoxy  and p-methoxy derivatives. 
The  relative  cytotoxicities  of the  methoxy  derivatives  correlated  with  the  leaving 
group ability, i.e.  I > Br > Cl. A derivatised hydroxy group for HPEC and HPEB is 
therefore detrimental for the cytotoxicity of these agents.
OR = p-OH 
OR = w-OH 
OR=p-OCH3  
X = OH, Cl, Br
Figure  3.3  Analogues of 2-p-hydroxymethyl (HPE) compound.
188The above  results indicated the importance of the  presence of an  intact /?-hydroxy 
group  for  the  elimination  of  HX  in  order  to  produce  the  reactive 
cyclopropylhexadienone intermediate.
The  hydroxyphenethyl  halides  readily  eliminate  hydrogen  halide  and  cyclise  to 
form  the  reactive  spiro|2.51cyclopropylcyclohexadienone  intermediate  which 
covalently  reacts with  DNA. The alkylation  ability of /?-HPEB  was comparable to 
that  of  the  CPI  and  Cl  derivatives,  and  demonstrated  a  strong  preference  for 
adenines especially  when flanked  by  a 5’ T,  mirroring the  sequence  specificity  of 
CC-1065.  However,  it  was  less  sequence  discriminating  compared  to  the  Cl  and 
CPI pharmacophores and their seco precursors (White et al.,  1995).
The  above  studies  suggest that the p-hydroxyphenyl  halides feature  the  minimum 
structural  requirements  for  DNA  alkylation  and  biological  activity,  and  therefore 
offer the potential of being developed as an achiral pharmacophore. The basic seco- 
achiral Cl structure constitutes the first step in this general drug design strategy for 
the development of achiral  analogues.  An amino group is introduced to position-3 
of the spiroI2.51cyclopropylcyclopropylcyclohexadienone (Figure 3.4, structure 2).
Is-DNA •dS-DNA
HX
OH
Spiro[2,5]cyclopropyl-
cyclohexadienone
Achiral Cl DNA adduct
Hydroxyphenethyl (HPE) 
analogues
X = CI  (IC«,= 32 HM)
X = Br  (ICV ) =  18 ^M)
X = I (IC*, = 33 nM)
X = OH (ICW=  1420 nM)
Figure  3.4  Rationale  of design  and  proposed  mechanism  of 
activation and DNA alkylation of the achiral seco-C I moiety.
189This  structural  addition  should  provide  stability  to  the  intermediate  towards 
solvolysis and  would  allow  coupling  with  various  DNA  binding  domains  (Figure 
3.4, stucture 3).
According  to  this  hypothesis,  compounds  of the  general  formula  3,  could  induce 
highly  sequence  specific,  minor  groove  DNA  alkylation,  consistent  with  the 
mechanism of action of CC-1065 and the duocarmycins and exert potent biological 
activity.  Attachment  of appropriate  noncovalent  subunits  could  endow  the  novel 
conjugates  with  cytotoxicities  comparable  to  those  of  the  previously  reported, 
chiral, Cl or CPI analogues.
Utilising the basic seco achiral Cl structure and coupling it to the trimethoxyindole 
(TMI) subunit of the duocarmycins, the “first generation” of achiral analogues were 
synthesised  and  evaluated  for  their  sequence  specificity  and  cytotoxic  potency. 
Such studies would reveal  whether the chiral  centre present in all analogues of the 
CC-1065  class  of  compounds,  is  absolutely  necessary  for  DNA  interaction  and 
cytotoxicity.  The  achiral  Cl  pharmacophore  was  subsequently  replaced  with  the 
achiral  CBI  alkylation  subunit.  In  all  instances,  the TMI  group  was  maintained  as 
the DNA binding domain.
The  full  complexity  of the  natural  products  is  not  required  for  high  potency,  as 
exemplified by the analogue (+)-CBI-TMI  which is essentially as cytotoxic as (+)- 
DUMSA  in  cell  culture (IC^s of 30 and  10 pM,  respectively,  in  L1210 leukemia) 
(Boger & Yun  1994b). The DNA binding subunit is also thought to be implicated in 
the  occurrence  of the  delayed  fatal  toxicity,  characteristic  of (+)-CC-1065,  whose 
adducts  are  essentially  irreversible.  The  rate  of  adduct  reversibility  is  dependent 
upon the extent of the noncovalent binding stabilisation. The simplified and smaller 
structure of TMI, found  in the parent compounds of the duocarmycins seems to be 
providing  sufficient  binding  stabilisation  for the  induction  of a “more  reversible” 
adduct  and  of  such  an  extent  as  to  not  induce  delayed  lethality.  TMI  is  also 
proposed to be actively contributing to the catalysis of the DNA alkylation reaction, 
being  of  sufficient  rigid  length  (provided  by  the  presence  of  the  C5’  methoxy
190group)  to  increase  the  inherent  twist  of the  linking  N2  amide  upon  DNA  minor 
groove binding (Boger & Garbaccio,  1997; Boger & Garbaccio,  1999a).
Finally the novel achiral pharmacophores were incorporated into hairpin polyamide 
conjugates,  in  a  further  attempt  to  obtain  analogues  with  modified  sequence 
selectivity.
Two of the clinically investigated CC-1065 analogues, the carbamate-type prodrugs 
carzelesin and KW-2189, are prodrugs of the corresponding highly potent phenolic 
seco compounds and  undergo rapid  and  non-specific  hydrolysis to the  phenols  by 
plasma esterases. This type of prodrugs could potentially be used in tumour-specific 
targeting applications. However, as in the case of the two CC-1065 analogues, ester 
types  of  prodrugs  of  phenols  are  prone  to  non-specifically  releasing  the 
corresponding phenol in plasma, undermining their potential as effectors in prodrug 
strategies.  To  address  this  problem,  in  an  alternative  synthetic  approach,  amino 
analogues  of  the  phenolic  seco  forms  of  cyclopropanoindolinones  have  been 
developed (e.g.  6-amino-sec0-CI-TMI, 5-amino-seco-CBI-TMI), aiming to prepare 
relatively more stable prodrugs (Milbank et al.,  1999; Atwell et al.,  1998). Similarly 
in the following studies, amino analogues of both achiral pharmacophores were also 
synthesised and incorporated to the corresponding conjugates.
1913.2 Achiral seco-Cl and achiral seco-amino-CI compounds
3.2.1 Compounds
SC-III-147: X = OH 
JT-II-67: X = NH2
Figure 3.5  Structures of the  novel  achiral  seco-C I  (SC-III-147)  and  achiral  seco- 
amino-CI (JT-II-67) compounds.
The achiral  seco-Cl  analogues shown  in  Figure 3.5  were the first of this series of 
compounds to be designed due to their structural simplicity. Compound SC-III-147 
contains  the  hydroxyphenylethyl  halide  functionality,  coupled  to  the  TMI  DNA 
binding  side  chain.  As  discussed  earlier,  and  according  to  the  general  scheme  of 
Figure  3.4,  the  SC-III-147  analogue  should  lose  HC1  to  produce  the  putative 
cyclopropane containing  DNA  alkylating agent which was hypothesised to be able 
to  react  with  an  adenine-N3  group  in  AT-rich  sequences.  Compound  JT-II-67 
incorporates a 4-aminophenylethyl  functionality,  possessing  an  amino  group para 
to  the  seco-chloroethyl  group  and  the  same,  TMI  subunit  attached  to  the 
pharmacophore.  Similar to the loss of HC1 in seco-CC-1065 and .yeco-duocarmycin 
analogues, and  in an analogous fashion to SC-III-47, JT-II-67 should  revert to the
192ring-closed form in biological media, according to the scheme in Figure 3.6.  In the 
case  of the p-hydroxyphenyl  halides,  the  presence  of an  underivatised /?-hydroxy 
group  was  shown  to  be  essential  for  the  generation  of  potent  DNA  reactive 
analogues  (White  et al.,  1995).  We  wanted  to  assess  whether,  in  the  case  of the 
seco-Cl analogues, the 4-aminophenethyl chloride moiety is a feasible substitute for 
the  hydroxy  seco  analogues,  as  the  precedent  of  the  corresponding  racemic 
analogues  suggests.  In  that case,  the  racemic  6-ami no-seco-CI  TMI  analogue  was 
shown to function similarly to the corresponding phenol analogue, by alkylation of 
DNA  at  the  adenine-N3  group,  with  similar  sequence  specificity.  The  amino 
analogue  however  was  a  moderately  potent  cytotoxin  and  considerably  less 
cytotoxic than  its  hydroxy counterpart (IC^s in  AA8 cells, 4 h exposure; 320 and 
6nM, respectively) (Milbank et al.,  1999, references therein).
Figure  3.6  Proposed  mechanism  of activation  and  DNA  alkylation  of the  achiral 
seco-amino-CI moiety of compound JT-II-67.
3.2.2  Results and discussion
The DNA alkylation ability by the novel achiral agents was initially tested using the 
PCR-based,  Taq  polymerase  stop  assay,  to  pinpoint  the  exact  sites  of  covalent 
binding on the reference pUC18 DNA fragment. As shown in Figure 3.7-A, SC-III-
H
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Figure 3.7 A. Portion of the autoradiograph of a Taq polymerase assay gel examining damage to the 
bottom  strand  of  pUC18,  induced  by  the  achiral  seco-Cl  agent,  SC-III-147  at  the  denoted 
concentrations.  Adozelesin  was  included  as  an  internal  standard.  0  is  the  untreated  control.  The 
arrow  indicates  the  position  and  sequence  of  the  common  major  binding  site.  Drug:  DNA 
incubations were for 5 hours at 37° C. B. Thermal cleavage gel showing purine-N3 alkylations to the 
5’-32P labelled bottom strand of pUC18. 0 is the untreated control. Arrows indicate the position and 
sequence context of the alkylated adenine (underlined and in bold). Drug: DNA incubations were for 
5 hours at 37° C.
194147  strongly  interacts  with  the  site  ^ ’-AAAAA^’865,  containing  a  run  of five 
adenine residues, which also constitutes the major binding site of adozelesin  in the 
fragment  under  consideration.  The  sequence  specific  covalent  reaction  of SC-III- 
147 with the adenine-N3  group at the same site of contigious adenines was further 
confirmed  using  the  thermally-induced  strand  cleavage  assay  as  shown  in  Figure 
3.7-B. Only traces of alkylation at the highest SC-III-147 concentration are evident 
at the 8435’-ATTT-3’ 846 site, suggesting an increase in the sequence selectivity of the 
achiral agent over adozelesin.
The above results demonstrate for the first time that the chiral centre featured in all 
of the CC-1065/duocarmycins analogues studied thus far is not necessary for DNA 
interaction and the characteristic sequence specific adenine-N3 alkylation exhibited 
for this class of compounds. Selectivity for one of the reported CC-1065 consensus 
sequence  readily  recognised  by  all  the  racemic  analogues  investigated  in  the 
previous  chapters  is  preserved  in  the  case  of  the  achiral  agent  SC-III-147.  This 
finding  was  reproduced  in  the  DNA  binding  studies  performed  for  its 
aminophenelethyl  counterpart, JT-III-67  (Figure 3.8-A and  B). The substitution  of 
the hydroxyl  group by the amino group in the achiral  alkylating subunit produced 
an  achiral  pharmacophore  which  can  still  be  an  effective  alkylator,  as  the  agent 
exhibited  an  alkylation  profile,  indistinguishable  to  that  of adozelesin.  This  is  in 
accordance  to  the  observations  made  in  the  case  of the  same  substitution  in  the 
corresponding pair of racemic seco-C I compounds (Millbank et al.,  1999).  Both 4- 
hydroxyphenethyl  and  4 -aminophenethyl  chloride  moieties  therefore  constitute 
possible substitutes for the chiral seco-C PI pharmacophore.
After  characterising  the  interaction  of  the  novel  achiral  agents  with  their  DNA 
target,  their  biological  activity  was  assessed  by  determining  their  cytotoxicity 
against the K562 cells, using a MTT based growth inhibition assay. The IC^ values 
of  SC-III-147  and  JT-II-67  for  a  continuous,  4-day  exposure  of  the  cells  to  the 
agents, are presented in Table 3.1
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Figure 3.8 A. Portion of the autoradiograph of a Taq polymerase assay gel examining damage to the 
bottom  strand  of  pUC18,  induced  by  the  achiral  seco-amino-CI  agent,  JT-II-67,  at  the  denoted 
concentrations.  Adozelesin  was  included  as  an  internal  standard.  0  is  the  untreated  control.  The 
arrow  indicates  the  position  and  sequence  of  the  common  major  binding  site.  Drug:  DNA 
incubations were for 5 hours at 37° C.  B. Thermal cleavage gel showing purine-N3 lesions to the 5’- 
32P labelled  bottom strand of pUC18.  0 is  the  untreated control.  Arrows indicate the  position  and 
sequence context of the alkylated adenine (underlined and in bold) at the readable portion of the gel. 
Drug: DNA incubations were for 5 hours at 37° C.
196These  results  suggest  that  the  proposed  achiral  analogues  are  also  biologically 
active  and  therefore  the  chiral  centre  in  the  natural  products  and  the  various 
synthetic  analogues  is  not  essential  for  cytotoxicity.  Interestingly,  for  the  K562 
cells, the amino and  hydroxy analogues were  comparably cytotoxic,  in contrast to 
their  racemic  counterparts  where  the  introduction  of  the  amino  group  had  a 
considerable detrimental effect in cytotoxicity. More specifically the racemic amino 
compound  was  reported  to  be  (50-120)-fold  less  cytotoxic  than  its  phenol 
counterpart in a panel of cell  lines (AA8 Chinese hamster ovary cell  line UV4, and 
EMT6 , a murine mammary carcinoma cell line (Tercel et al.,  1996).
Compounds IQ , values (pM)
SC-III-147 1.43 ±0.273
JT-II-67 1.7 ±0.173
seco-CI-TMI 0.15
Table 3.1  In  vitro cytotoxicity  of the  achiral  agents  SC-III-147  and JT-II-67  and 
the  racemic  compound  seco-CI-TMI,  against  human  chronic  myeloid  leukaemia 
K562 cells, following a 4-days continuous drug exposure. The IC^ values represent 
the average of three independent experiments.
Protection  of  the  hydroxyl  group  in  SC-III-147,  led  to  a  dramatic  decrease  in 
cytotoxicity. The carbamate agent TH-III-81  shown in  Figure 3.9 gave  IC50 values 
of 75 pM and >100 pM against L1210 and P815 cells, while the IC^ values of SC- 
III-147  for  the  same  cell  lines  were  1.5  and  5.6  pM,  respectively  (Prof.  Lee  - 
personal communication).
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Figure 3.9 Structure of the protected SC-III-147 analogue, TH-III-81
The diminished cytoxic potency  by TH-III-81  coincides with the expected  lack of 
covalent  binding  on  naked  DNA,  as  shown  in  Figure  3.10,  which  confirms  the 
agent’s inability to interact with DNA when having an inaccessible hydroxy group. 
This further confirms the importance of the unprotected hydroxy group (or equally 
effective amino) and indicate that the seco-achiral halide compounds must eliminate 
HC1  to form spiro[2,5|cyclopropanecyclohexadienone intermediates that react with 
DNA (Figure  3.6) to elicit cytotoxic activity.
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Figure 3.10  Taq polymerase assay  gel  examining damage to the  bottom strand of 
pUC18, induced by the agent, TH-III-81, at the denoted concentrations. Adozelesin 
and  SC-III-147  were  included  as  controls.  0  is  the  untreated  control.  The  arrow 
indicates the position and sequence of the common major binding site. Drug:  DNA 
incubations were for 5 hours at 37° C.
1993.3 Achiral seco-CBI and sico-amino-CBI compounds
3.3.1  Introduction
The  achiral  Cl  analogues  reported  in  the  previous  section,  retained  the  ability for 
sequence selective alkylation at the 5’-AAAAA and 5’-ATTT sites, were cytotoxic 
exhibiting IQo values in the pM range and comparable to the racemic compounds, 
and  proven  active  in  preliminary  in  vivo  studies  (see  Chapter  6-General 
Discussion).  Having  established  that  the  chiral  centre  of  duocarmycins  and  CC- 
1065  is not absolutely needed for DNA  interactions and anticancer activities,  in an 
attempt  to  further  enhance  the  properties  of  the  novel  analogues,  the  achiral  Cl 
pharmacophore  was  replaced  by  the  achiral  CBI  alkylation  subunit.  There  are  a 
number of distinct advantages  into  incorporating the CBI  pharmacophore  over Cl 
and CPI, as have been established from early structure activity relationship studies 
of  structurally  altered  alkylation  subunits.  The  natural  enantiomers  of CBI-based 
analogues of CC-1065  have  been  shown to be four times more biologically  stable 
and  biologically  more  potent,  and  more  synthetically  accessible  that  the 
corresponding agents featuring the natural CPI subunit. In addition, the less reactive 
CBI  agents  have  been  shown  to  alkylate  DNA  at  an  enhanced  rate  (due  to  the 
absence of the C7 methyl group of CPI which sterically decelerates the rate of DNA 
alkylation) with greater efficiency and with a slightly greater selectivity among the 
available  sites  (Boger  et  al.,  1989;  Boger  &  Ishizaki,  1990;  Boger  et  al.,  1992; 
Boger et al.,  1995b). These observations are in agreement with the model of reverse 
relationship  between  the  electrophile’s  reactivity  and  in  vitro  cytotoxic  potency, 
proposed  by  Boger.  Incorporation  of  the  CBI  pharmacophore  should  therefore 
endow the novel achiral analogues with increased solvolytic stability, which should 
in turn confer enhanced potency.
Apart from being potent cytotoxic agents, CBI-based agents have also proved to be 
efficacious antitumour compounds. The  (+)-CBI-indole2 agent has been  evaluated 
in  vivo against the  murine  P388  leukemia,  murine  M l09 lung carcinoma and  B16
200melanoma,  and  human  A2780  ovarian  carcinoma,  achieving  some  inhibition  of 
growth and  increase in  lifespan (Boger et al.,  1995b).  Significant activity by other 
CBI analogues has been shown in mice bearing L1210 leukemia cells (Wang et al., 
2000).  Finally certain seco-CBI dimers have been evaluated in vitro by the NCI and 
showed significant activity against leukaemia, CNS cancer, melanoma and prostate 
cancer cell lines with GIso values < 0.01  pM (Jia & Lown, 2000).
Another advantage of the use of the CBI  pharmacophore, is the earlier observation 
that  the  natural  enantiomers  of CBI  analogues  are  substantially  more  potent than 
their CPI counterparts against resistant cell  lines. The cell  lines considered were a 
human  colon  carcinoma  cell  line  (HCT116)  and  two  resistant  variants 
HCT116/VM46 (MDR cell  line) and  HCT116/VP35  (resistant to topoisomerase II 
inhibitors). This hypersensitivity of the resistant cell lines was more pronounced for 
the  (+)-CBI-TMI  agent  in  particular,  which  was  even  more  cytotoxic  than  the 
parent  compound,  (+)-DUMSA  (Boger  et  al.,  1995b).  This  particular  property 
makes the CBI-TMI  an  interesting lead for further drug development as resistance 
is one  of the  most acute  problems  of conventional  chemotherapy  and  particularly 
so, for alkylating agents.
The  delayed  hepatotoxicity  associated  with  (+)-CC-1065,  precluded  its  clinical 
development. The only CBI  agent that has exhibited this phenomenon  is (+)-CBI- 
PDEI2   (Aristoff  et  al.,  1993).  However  another  form  of  systemic  toxicity, 
suppression of human bone marrow has proved to be the major limiting factor in the 
development  of  otherwise  potent  CC-1065  analogues  into  therapeutics.  Bone 
marrow  toxicity  has  been  shown  to  undermine  the  clinical  effectiveness  of 
carzelesin  and  KW2189  in  early  clinical  trials.  In  previous  studies  of novel  CBI 
congeners,  two  CBI-based  agents,  one  bearing  two  indoles  as  the  DNA  binding 
subunit and a cyclised analogue bearing one indole and one benzofuran group (both 
analogues possessing a terminal  acetamino group),  were shown to be highly active 
against L1210 leukemia in mice and most importantly, not to be myelosuppresive at 
therapeutically  effective  doses.  While  CC-1065,  at  a  dose  of 25  pg/kg,  severely 
suppressed  white  blood  cells (WBC),  both  these  novel  analogues had  no effect on
201WBC and platelet counts at double the dose (50 pg/kg), 27 days after administered 
to  mice  (Wang  et  al.,  2000).  This  critically  desirable  biological  property  further 
supports the pursuit of designing CBI based analogues.
3.3.2  Compounds
H
,N ,
AS-IV-104: X = OH 
AS-I-145: X = NHo
Figure 3.11 Stuctures of the novel achiral seco-CBI (AS-IV-104) and achiral seco- 
amino-CBI (AS-I-145) compounds.
3.3.3 Results and discussion
The alkylation ability of the novel achiral CBI compounds and sequence specificity 
for purine-N3 groups in the minor groove was assessed using the thermally-induced 
DNA strand cleavage assay. The bottom strand of the pUC18 fragment was used to 
probe  the  damage  induced  by  these  achiral  compounds.  Initially,  the  alkylation 
ability  of  both  the  phenolic  and  amino  achiral  CBI  agents  was  compared  to  the 
racemic .seco-CBI-TMI compound, also used as the reference compound in section 
2.3.  The  autoradiograph  of this  thermal  cleavage  experiment  is  shown  in  Figure 
3.12.
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Figure 3.12 Thermal cleavage gel showing purine-N3 lesions to the bottom strand of a 5’- 
32P labelled, 208 bp fragment of pUC18, defined from 749 to 956 induced by the achiral 
jeco-CBI-TMI  (AS-IV-104)  and  its  amino  counterpart  (AS-I-145).  0  is  the  untreated 
control. The  racemic seco-CBI-TMI  is  included  as  internal  control.  Arrows  indicate  the 
position and sequence context of the alkylated adenines (underlined and in bold). Adenines 
on  the  upper,  non-resolvable  portion  of  the  gel  have  been  appointed  from  previous 
experiments. Drug: DNA incubations were for 5 hours at 37° C.
203Both achiral agents readily recognise as their preferred site of covalent binding the 
865-869  cluster  of  five  consecutive  adenines,  displaying  a  dose-response  DNA 
alkylation effect. This site  is also the common,  high  affinity alkylation  site for the 
seco-CB\-TM\ control.  For all three instances, the 3’ adenine of the ^ ’-AAAAA- 
3,S65 is  the  most  reactive  and  this  site  the  most  prominently  alkylated  among  the 
available sites judging by  the  intensity of the  band of the cleavage  product.  While 
the  sequence  selectivity  of  covalent  alkylation  for  the  two  achiral  agents  is 
indistinguishable, the intensity of DNA modification is slightly different. The seco- 
hydroxy  compound,  AS-IV-104,  required  a  10-fold  higher  concentration  than  its 
amino  counterpart  (AS-1-145),  to  induce  a  comparable  covalent  alkylation  at  the 
major  (A)5  site.  Of  the  AT  mixed  sequences  alkylated  by  the  racemic  analogue, 
only one, ^ ’-AATA-S’775, is poorly alkylated by the achiral agents, while there are 
just  traces  of  alkylation  at  the  7643’-ATTA-5’ 767.  Both  AS-IV-104  and  AS-I-145 
therefore  were  more  sequence  discriminating  than  their  racemic  phenolic 
counterpart.  The  same  is  also  true  when  comparing  AS-IV-145  with  adozelesin 
(Figure 3.14). Figure 3.13 shows the proposed model for the activation and adenine- 
N3 alkylation by AS-I-145.
DNA-A-N3
OMe H
N
OMe
OMe
AS-1-145 
NSC D716970
NH
Figure 3.13  Proposed model of the activation and DNA alkylation of the achiral AS-I-145 
agent.
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Figure 3.14 Thermal cleavage gel showing the enhancement of the sequence selectivity of 
AS-I-145 over adozelesin.
205On the basis of the alkylation studies results of the achiral  CBI  agents,  it became 
evident, as in the case of the achiral Cl agents, that the stereocentre present in CC- 
1065 and the duocarmycins does not play an essential  role in controlling the DNA 
interaction properties of these analogues.
The alkylation efficiency/specificity of the more potent CBI based achiral agent, the 
amino  bearing  congener,  AS-I-145  was  compared  to  its  Cl  counterpart,  JT-II-67, 
studied  in  the  previous  section.  Such  a  comparison  can  be  seen  on  the 
autoradiographs of Figure 3.15. Figure 3.15-A shows the thermal cleavage analysis 
of AS-I-145, JT-II-67, and the racemic .seco-CBI-TMI  reference compound, while 
Figure 3.15-B confirms the position of the binding sites on the bottom strand of the 
same DNA fragment and region, using the Taq polymerase stop assay. Based on the 
intensity and extent of alkylation at the lowest drug concentration, as observed on 
Figure  3.15-A,  AS-I-145  is  at  least  a  10-fold  more  efficient  alkylator  than  the 
achiral seco-amino-CI agent, supporting the replacement of the Cl pharmacophore. 
At  the  highest  concentration  of  AS-I-145  (100  pM)  there  is  a  near  complete 
consumption of radioactivity on the gels, manifested as fading of the bands even at 
the most prominent alkylation site (865). This is due to complete cleavage of all 5’- 
end labelled fragments (in the thermal cleavage gel) and an overload of non-specific 
multiple alkylations resulting in single short DNA fragments, not examined on the 
gel.  Accordingly,  a  damage  overload  induced  by  binding  at  even  non-preferred 
sequences, forces the polymerase to stop at sites prior to the ones examined on the 
Taq  stop  gel,  resulting  in  amplification  of  shorter  DNA  fragments.  The  Taq 
polymerase assay once again confirms the enhanced alkylating ability of the achiral 
amino-CBI compound and its increased sequence selectivity over both its achiral Cl 
and racemic phenolic counterparts. These observations coupled to the relative ease 
of  synthesising  the  achiral-seco-CB\  compounds,  render  AS-I-145  the  most 
attractive candidate among the members of this new class of achiral compounds for 
future development.
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Figure 3.15 A.  Thermal  cleavage gel, comparing the purine-N3  alkylation ability 
of the achiral  5ec<?-amino-CBI  analogue (AS-I-145) and  its Cl  counterpart (JT-II- 
67)  along  with  the  racemic  seco-CBI-TMl  agent.  B.  Taq  Polymerase  stop  gel, 
examining the sites of covalent modification, on the same DNA region by the same 
set of agents. 0 is the untreated control. Arrows indicate the position and sequence 
context/binding sites of the alkylated adenines.  Drug:  DNA  incubations were for 5 
hours at 37° C.
However,  it  remains critical  for these analogues to possess cytotoxic  potency  and 
anti tumour efficacy. A  MTT-based growth inhibition assay was used to assess the
207cytotoxicity  of the  new  achiral  agents  against  the  human  K562  chronic  myeloid 
leukaemia.  The  IC^ values for a continuous 4-day  exposure  were  determined  and 
are shown in Table 3.2.
Compounds IC5 0 values (pM)
AS-IV-104 0.15 ±0.05
AS-I-145 0.045 ±0.015
(±)-seco-CBI-TMI 0.0028 ± 0.001
Table 3.2 In vitro cytotoxicity of the achiral CBI agents AS-IV-104 and AS-I-145 
and  the  racemic  compound  5eco-CBI-TMI,  against  human  chronic  myeloid 
leukaemia K562 cells, following a 4-day continuous drug exposure. The IC^ values 
represent the average of three independent experiments.
Both  achiral  CBI-based  agents  inhibited  the  growth  of  tumour  cells  at  sub­
micromolar  concentrations  and  proved  more  active  than  their  corresponding 
indoline  (Cl)  analogues.  Additionally,  the  amino  substitution  had  a  more 
considerable effect in the CBI series of compounds, with the amino CBI agent, AS- 
I-145  being approximately 3-fold more potent than the hydroxy derivative, AS-IV- 
104.  In a previous assessment of cytotoxicity of the corresponding chiral agents, no 
such  potentiation  was  evident.  In  that  case  the  natural  enantiomer  of  the  seco- 
amino-CBI agent exhibited an identical cytotoxicity across a panel of cell  lines (the 
Chinese hamster ovary AA8 , UV4 and the human EMT6) to the natural enantiomer 
of the jeco-phenolic counterpart (Atwell  et al.,  1998). That finding was in  marked 
contrast to the Cl  series, where the nature of the substituent group at the 6 -position 
(seco-C\  numbering)  had  a  very  large  influence  on  cytotoxicity  with  the  racemic 
.seco-amino-CI compound being (55-122)-fold less cytotoxic than the corresponding 
phenol, in the same panel of cell lines (Tercel et al.,  1996; Milbank et al.,  1999).  In 
all  cases  the  CBI  analogues  were  consistently  much  more  potent  than  the  Cl
208derivatives.  In  conclusion,  the  cytotoxicity  results  show  the  present  design  of the 
achiral  CBI  analogues to  be  successful,  with  the  amino substitution  resulting  in  a 
more potent product.  However past studies of racemic jeco-amino-CBI agents have 
indicated  the  possibility  of  dissociating  cytotoxicity  against  tumour  cells  from 
chronic  host  toxicity.  More  specifically  while  the  racemate  and  unnatural 
enantiomer  of  the  seco-amino-CBI-TMI  agent  both  produced  a  delayed  toxicity 
effect in treated mice, the more cytotoxic natural enantiomer-treated animals, at the 
same dose  regime,  had  no histological  manifestations of such toxicity at  necropsy 
(Atwell  et al.,  1999).  This  result further supports the concept of designing achiral 
agents,  particuarly  of this  class  of compounds,  as  in  vivo  studies  would  lack  the 
ambiguity of the enantiomeric pairs often having conflicting biological effects.
The above studies have established the achiral seco-amino-CBI agent, AS-I-145, as 
the  best candidate for further development and  the  leading compound  in  this new 
class  of  agents,  endowed  with  an  increased  ability  to  alkylate  DNA,  possessing 
enhanced sequence selectivity and resulting cytotoxic potency, among all  members 
of this  series  of  newly  synthesised  CBI  and  Cl  agents  lacking  the  characteristic 
stereocentre of CC-1065/duocarmycins.
2093.4 Hairpin conjugates of achiral seco-cyclopropaneindoline-2- 
benzofurancarboxamide and pyrrole-imidazole polyamides
3.4.1  Introduction
In  section  3.2  it  was  established  that  the  achiral  seco-CI  pharmacophore  can  be 
incorporated  into functional  analogues and afford potent alkylating agents,  despite 
lacking  the  parent  compounds’  stereocentre.  Yet,  all  the  achiral  compounds 
synthesised and evaluated for their sequence specificity retain the original chiral Cl 
alkylation  subunit’s  memory  for a  3’  adenine  alkylation  within  the  consensus  5’- 
AAAAA-3’ and AT mixed sequences.
The  racenic  sec0-cyclopropaneindoline-2-benzofurancarboxamide  (CI-Bf)  hairpin 
polyamides  discussed  in  chapter  2  offered  further  proof  that  the  concept  of 
conjugating the alkylating pharmacophore of CC-1065  and the duocarmycins with 
pyrrole/imidazole  polyamides  in  a  hairpin  configuration  may  provide  an  attractive 
strategy  for  the  discovery  of  a  new  class  of  minor  groove  sequence  specific 
alkylating agents. The Im-containing conjugates of that series were found to accept 
G  residues  within  their  binding  and  alkylating  site,  reminiscent  of the  DUMA’s 
sequence  modulation  demonstrated  in  the  presence  of  imidazole-containing 
triamides,  where  the  formed  -  in  that  case  -  heterodimer  was  forced  to  alkylate 
guanine-N3  groups  within  exclusively  GC  sequences  (Fujiwara  et  al.,  1999). 
Hybrid  compounds  of  a  hairpin  configuration  have  been  synthesised  with  the 
strategy  of  using  the  Py/Im  polyamides  as  recognition  components  to  deliver 
alkylating  agents  to  a  target  sequence.  Hairpin  polyamide  hybrids  incorporating 
segment A of DUMA (DA) have been  shown to alkylate with high specificity and 
with a fashion  that is thought to be a combination  of the  inherent reactivity of the 
alkylation  effector  (such  as  DA)  and  the  binding  specificity  of  the  hairpin 
polyamides  (Tao  et  al.,  1999b).  DUMA  being  the  most  reactive  of  the 
duocarmycins  has been  shown to be capable of G-N3  alkylation  (Sugiyama et al., 
1993). The racemic seco-C I, Im-containing conjugates in Chapter 2 were also found
210to tolerate the presence of a G  residue adjacent to an alkylated adenine.  However, 
those chiral  analogues retained  - as all  chiral  and achiral  analogues considered  in 
this thesis -  a significant “memory” for the 5’-AAAAA-3’site, the common, shared 
most reactive alkylation  site.  The challenge therefore for analogues possessing an 
altered reactivity to that of he parent compounds remains.
3.4.2  Compounds
HN'
H N'
CP-99A:  X=N, Y=CH HCI
CP-99B:  X=CH, Y=N
BL-I-147: X=Y=CH
Figure  3.16  Structures  of  the  achiral  seco-Cl  hairpin  polyamide  compounds 
investigated in this study.
Three  novel  hairpin  compounds  have  been  synthesised  incorporating  the  achiral 
seco-C I as the alkylating “warhead”. These are CP-99A (achiral-CI-Bf-Glutaryl-Py- 
I1 T 1-NH3CI),  CP-99B  (achiral-CI-Bf-Glutaryl-Im-Py-NH3Cl)  and  BL-I-147  (achiral 
CI-Bf-Glutaryl-Py-Py-NH3Cl) (where Py is pyrrole and Im is imidazole). The linker
211is  the  same  as  the  one  employed  in  the  racemic  seco-C I  hairpin  analogues  in 
Chapter  2.  Just  like  those,  the  terminal  free  amine  of  the  conjugates,  at 
physiological pH will remain protonated.
3.4.3  Results and discussion
The covalent sequence specificity of the analogues was assessed  by the thermally- 
induced  strand  cleavage  assay.  The  same  radiolabelled  probe  was  treated  with 
various  concentrations  of  the  analogues  and  subjected  to  electrophoresis  after 
thermal  denaturation.  A  typical  autoradiograph  obtained  from  these  studies  is 
shown in  Figure 3.17.  Unlike all previous analogues described in this thesis and  in 
sharp contrast to the racemic hairpins of Chapter 2, the present three agents did not 
retain  a  memory  for  alkylating  adenine-N3  within  the  A5  cluster  at  865-869.  All 
three achiral  hairpin conjugates alkylated the adenine (843) at the ^ ’-TTAC-3’842 
site  (alkylated  adenine  underlined).  Similarly  they  all  alkylated  the  adenines  A 
(792), A  (772) and A  (764)  in AT  mixed sequences on  the  top portion of the gel. 
The  sequence ^ S ’-TCAG-S’887,  which  was  selectively  alkylated  by  the  imidazole 
containing  racemic  seco-CI-Bf  hairpin  conjugates,  is  uniquely  recognised  and 
alkylated  by CP-99A  in this series of analogues.  Conversely, conjugate CP-99B  is 
the  only  agent  to  react  with  the  A  (856)  of  the  8585’-CAAC-3’ 855  site.  The 
distinctions  in  the  sequence  selectivity  of  the  two  agents  suggest  a  recognition 
pattern intimately linked with the presence and the relative position of the imidazole 
within  the  polyamide  portion  of the  molecule.  Figure  3.18  shows the  sequence  of 
the resolvable portion of the gel in Figure 3.17 and highlights the binding sites of all 
three  agents.  Based  on  the  model  proposed  for  the  binding  of  the  imidazole 
containing  racemic  hairpins  (JT-IV-99  and  RBH-III-23),  where  an  imidazole  unit 
would  pair  side-by-side  with  the  benzofuran  moiety  and  interact  with  a  GC  base 
pair (Chapter 2), a model of molecular interaction between CP-99A and its unique 
site of alkylation is shown in  Figure 3.19-1. Again, the imidazole group of CP-99A 
is envisioned to stack with the benzofuran to form a complex similar to the pyrrole / 
imidazole pairing, capable of recognising a C / G base pair.
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Figure 3.17 Thermal  cleavage  gel  showing  purine-N3  lesions  to  the bottom  strand  of a 5 ’- 
32P labelled, 208  bp fragment of pUC18  (defined  from  749 to 956),  induced  by  the denoted 
achiral  seco -C I-Bf  hairpin  polyamide  agents.  0  is  the  untreated  control.  G  /  G+A  is  the 
purine  marker  (formic  acid).  Thermal  cleavage  conditions  as  described  in  the  Methods 
section.  Arrows  indicate  the  position  and  sequence  context  of  the  alkylated  adenines 
(underlined and in  bold).  Drug:  DNA incubations were for 5  hours at 37° C.
213820  840  850  870
I  1   oar  I  .  I
5'-GGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGG-3'
3'-CCGGTCGTTTTCCGGTCCTTGGCMITTTCCGGCGCAACGACCGCAAAAAGGTATCC-5'
5'-CTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTC-3'
3-G AG
880  890  900  919
Figure 3.18 Diagram showing the resolvable portion of the thermal cleavage gel of 
Figure 3.17 examining the damage on the bottom strand of pUC18 induced by the 
three  achiral  seco-Cl  hairpin  conjugates  CP-99A,  CP-99B  and  BL-I-147.  Their 
binding sites are shaded and underlined while the alkylated adenine as identified by 
the thermal cleavage assay is bolded.
In  an  analogous  manner,  the  sequence  preference  of  CP-99B  which  uniquely 
alkylated  the  5’-CAAC-3’  site  can  be  attained,  by  having  its  imidazole  group 
stacked  with  the  linker  and  the  pyrrole  with  the  benzofuran.  In  this  case,  a  new 
mode of recognition involving the benzofuran is proposed, in which the Py/Bf pair 
behaves like the Py/Py pair of the polyamides (Figure 3.19-2).
BL-I-147 which lacks an imidazole group, failed to produce any alkylation at the A 
(856) and A (888) sites. This could be attributed to the steric hindrance between the 
G-2-amino group and  the  pyrrole-H3  atom,  which  is responsible for the  pyrrole’s 
lack of tolerance for G/C or C/G sites.  Consequently BL-I-147 would only bind to 
the 5’-TTA(843)-3’ site with the Bf/Py behaving like a Py/Py pair of the polyamide 
(Figure 3.19-4). This sequence  however must be  a conformationally preferred site 
for this class of compounds as it is also receptive for binding by CP-99A and CP- 
996, agents which do not possess structurally discriminating pyrrole-H3 atoms.
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Figure  3.19  Model  of  molecular  interaction  between  1.  CP-99A  (achiral-CI-Bf- 
Glutaryl-Py-Im-NH3C1) with its unique site 5’-TCA(888)G-3\ 2. CP-99B (achiral- 
CI-Bf-Glutaryl-Im-Py-NH3Cl)  with  its  unique  site  5’-CAA(856)C-3\  3.  CP-99A 
(for  X=N,  Y=CH)  and  CP-99B  (for  X=CH,  Y=N)  with  their  common  5’- 
TTA(843)C-3\ and 4.  BL-I-147  with  the same  site. The adenine-N3  is covalently 
bonded to the bolded A residue in each of the sequence in the pUC18 plasmid given 
in Figure 3.18.
215Incorporation of the achiral seco-C  I  pharmacophore into hairpin polyamides offers 
considerable  potential  for  the  future  design  of  functional  analogues  as  the 
conjugates  under consideration  in  this study  only  alkylated  at  selected  sites  in  the 
minor  groove  with  the  inherent  reactivity  conferred  by  the  seco-C I  moiety  and 
shown to be retained in the achiral configuration (Section 3.2), substantially altered 
by the polyamide component.
Chirality  can  dramatically  influence  the  behaviour  of  the  enantiomeric  pairs  of 
chiral  hairpin  polyamide conjugates.  For example the /^-configuration of a hairpin 
polyamide linked to a Hoechst 33258 analogue at the a-position of the hairpin turn 
amino acid,  exhibited  (10-30)-fold  higher binding affinities than  the S-enantiomer 
for the  DNA  sequences studied  by  Mallikarjuna et al., 2005.  In  another study, the 
two  different diastereomers  of a seco-CB\  unit  attached  to  the  hairpin  turn  of an 
eight  ring  hairpin  polyamide  conjugate  have  been  shown  to  alkylate  at  a  single 
adenine flanking the polyamide binding side in a strand-selective manner. The same 
hairpin  polyamide  therefore  can  be  used  to  target  opposite  strands  of  the  DNA 
depending on the enantiomer of the seco-CBI chosen.  Although  it has been  shown 
for  CC-1065  and  duocarmycin  analogues  that  the  S  or  (+)  enantiomer  is  more 
reactive than  the  R or (-),  in this series of conjugates,  as  in  the  series  reported  by 
Mallikarjuna,  the  unnatural  enantiomer exhibited  higher  alkylation  efficiency  and 
faster alkylation rate than the natural one (Chang & Dervan, 2000). Incorporation of 
an achiral pharmacophore can therefore provide a more simplified interaction of the 
hybrid molecules with DNA.
In a recent study of Py-Im hairpin  polyamides which  incorporate the CBI  and CPI 
groups as their DNA alkylating moieties, it was revealed that alkylation by the CBI 
conjugates occurred specifically at adenines in matched sequences, whereas the CPI 
conjugates  alkylated  both  adenines  and  guanines  in  matched  sequences,  despite 
having  similar orientations.  The enhanced,  adenine-exclusive,  sequence  selectivity 
of  the  CBI  bearing  conjugates  was  attributed  to  the  alkylation  group’s  lower 
electrophilicity and  higher stability compared to the CPI  (Bando et al., 2005). The 
conjugates of the  present  study  also exhibited  enhanced  sequence  selectivity.  It  is
216therefore  conceivable  that  incorporation  of  the  achiral  seco-CB\  pharmacophore 
(section 3.3), could endow a next generation of hairpin polyamide conjugates as the 
ones in this study with additional sequence selectivity for target sequences.
217CHAPTER  4
REPAIR STUDIES OF TH-III-151 AND AS-I-145 IN THE YEAST
Saccharomyces cerevisiae
4.1 Introduction
The definition of the molecular context that confers chemosensitivity is essential for 
the improvement of the efficacy of antitumour drugs. The recognition and the extent 
of the repair of specific drug-induced DNA  lesions are critical determinants of the 
cellular  response  to  DNA  damaging  agents,  the  resulting  sensitivity  or  resistance 
and  can  greatly  influence  their  clinical  outcome.  The  reduced  levels  of the  XPA 
protein  in  testicular  germ  cell  tumours,  for  example,  and  the  ensuing  defective 
repair of cisplatin-induced damage, was considered to be a major factor determining 
the enhanced sensitivity to the drug (Koberle et al.,  1999). In contrast, the increased 
level of repair of the interstrand crosslinks induced by melphalan in patients treated 
with the agent is thought to constitute a mechanism of clinical resistance to the drug 
in multiple myeloma (Spanswick et al., 2002).
The  yeast  Saccharomyces  cerevisiae  has  been  exploited  in  the  field  of  drug 
discovery and in particular the study of the repair mechanisms of many established 
and experimental anticancer agents.
4.1.1  Yeast as a model system
The budding yeast Saccharomyces cerevisiae presents a valuable model system for 
the study of processes and pathways of eukaryotic cells including their DNA repair 
mechanisms.  As  an  experimental  organism,  yeast  has  a  small  genome  (1.4  x  107  
bp/cell), requires simple and inexpensive conditions and media for growth, and has 
a  rapid  cell  division  (90-minute  population  doubling time),  allowing for relatively 
short experiments,  examining  effects  of e.g.  drug exposure  over  many  population
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sequenced (Goffeau et al.,  1996) and extensive annotation of most yeast genes has 
been  compiled,  yet  still  remains  an  ongoing  process  and  is  constantly  being 
updated.  To  this  effect,  a  new  resource  at  the  Saccharomyces Genome  Database, 
called  “Genome  Snapshot”,  has  been  created  and  can  be  found  at 
http://db.yeastgenome.org/cgi-bin/genomeSnapShot.pl).  Additionally,  a  number  of 
methodologies  allow  for  accurate  and  versatile  genetic  manipulation,  easy  gene 
deletions,  characterisation,  and  assignment of distinct genes to different pathways 
etc.
A  high degree of evolutionary conservation between yeast and mammalian cells in 
terms of protein functions and cellular processes exists, reflected as gene functional 
analogy or even  interchangeability  (Liu et al.,  1997; Teichmann et al.,  1997). The 
knowledge gained in yeast can often lead to an understanding of how similar genes 
might  function  in  mammals  and  predict  their function  even  before  being  cloned. 
This  is  particularly  important  since  several  yeast  proteins  possess  sequence 
similarity  to  proteins  implicated  in  human  diseases  including  cancer  (Hughes, 
2002;  Foury,  1997).  Xeroderma  Pigmentosum  for  example  is  a  recessive  skin 
disease  associated  with  high  predisposition  to  skin  cancers.  The  xeroderma 
associated gene XPD was cloned and found to be the homologue of the yeast RAD3 
which was the first NER gene to be sequenced and the DNA helicase activity of the 
gene product to be associated with the repair defect (Weber et al.,  1990; Sung et al., 
1987).  Later, XPA and XPB proteins were shown to be essential components of the 
TFHII  complex  of the  transcription  machinery,  the  same also  holding true for the 
yeast counterparts Rad3 and Rad25.  It was progressively established that all human 
NER  genes  have  a  yeast  homologue.  The  high  degree  of  conservation  with 
mammalian cells therefore, does not only apply to gene sequences and proteins but 
extends  to  the  function  of  whole  pathways.  Table  4.1  highlights  this  functional 
conservation of key  pathways between  humans and yeast,  which  when  altered are 
related to malignant phenotypes.
219Cancer-related pathway Human genes Yeast genes
DNA-damage checkpoint ATM, ATR RAD53
Replication checkpoint BLM,  WRNJ SGS1
Mitotic-spindle-assembly checkpoint BUB1, BUBR1 BUB1
Mismatch repair hMLHl MLHl
Repair of DNA double-strand breaks BRCA1 RAD50, RAD52
G1- to S-phase transition Cyclin Dl, cyclin E CLN2
Table 4.1 Conservation between yeast and human pathways altered in cancer. The 
human  and  yeast  genes  shown  are  functional  homologues  and  do  not  necessarily 
share sequence homology (taken from Simon & Bedalov, 2004).
Since  genetic  alterations  of  human  tumour  cells  frequently  involve  functional 
homologues in yeast, many of the insights gained using yeast can be extrapolated to 
mammalian  systems.  These  characteristics  have  expanded  the application  of yeast 
as a screening tool to the field of drug discovery, as it represents an inexpensive and 
alternative system to mammalian culture cells and enables screening of compounds 
in a cellular, eukaryotic environment.
4.1.2  Yeast in drug discovery
Target-based anticancer screens
Yeast-based screens can be used as a tool for the identification of targets, which can 
be  pharmacologically  modulated  by  appropriate  inhibitors,  thus  providing  novel 
leads  for  drug  development.  Proteins  that  are  linked  with  accelerated  growth  in 
human  cancers,  when  expressed  in  yeast,  can  lead  to an  arrest  in  cell  growth  and 
division  by  interfering  with  growth-regulatory  pathways.  Inhibition  of  the 
enzymatic  activity  of  the  foreign  protein  restores  normal  yeast  growth.  This 
principle allows for the  screening  of potential  inhibitors of the human enzymes in
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proteins are transformed in yeast. Those that block growth are identified as potential 
anticancer targets and can  be used  in  small-molecule screens for agents that could 
restore growth and therefore function as inhibitors of the human proteins.
One  such  screen  identified  several  novel  submicromolar  inhibitors  of poly(ADP- 
ribose) polymerase,  PARP1, which  is responsible for addition of ADP-ribose units 
to nuclear proteins. PARP activity in human cells is induced by DNA strand breaks. 
The  inhibition  therefore  of  PARP could  improve  the  efficacy  of  DNA-damaging 
agents.  PARP is not found  in yeast but when expressed causes a growth reduction 
phenotype. Based on their ability to reverse growth inhibition in PARP1-expressing 
yeast,  several  small  molecule  inhibitors  have  been  identified.  These  were  also 
shown to be active in a mammalian PARP biochemical assay, further validating the 
usefulness  of the  yeast  screen  (Perkins  et al.,  2001).  Similarly,  the  p 16 (INK4A) 
protein  and  flavopiridol  were  identified  as  cyclin-dependent  kinase  (CDK) 
inhibitors,  as  they  were  shown  to  restore  yeast  cell  growth  inhibited  by 
overexpression of human CDK4 (Moorthamer et al.,  1998).
Pathway-based screens
As well  as the  basis for screening inhibitors of identified targets, yeast can also be 
used  for  pathway-based  anticancer  screens.  In  this  case,  the  focus  shifts  on  the 
inactivation  of any  one  of several  enzymes  that  participate  in  a  single  functional 
pathway. A high degree of conservation of epigenetic regulation of gene expression 
exists  between  yeast  and  mammals.  Therefore  agents  identified  in  yeast-based 
screens to  inhibit  the  activity  of e.g.  yeast  histone-modifying enzymes,  could  also 
serve as potential anticancer drugs.
Yeast  Sir2  is  a  NAD+ -dependent  histone  deacetylase  required  for  chromatin- 
dependent  silencing  in  yeast,  and  functions  in  a  complex  with  Sir3  and  Sir4  to 
maintain silencing. Yeast cells cultured in uracil-deficient media require expression 
of the  URA3 gene for growth.  In  cells lacking the endogenous  URA3 gene (which
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inserted within an area of silenced chromatin, near a telomere. As expression of this 
telomeric URA3 is blocked by the activity of the pathways comprising of Sir2, Sir3 
and Sir4, a screen for growth in these conditions can identify those compounds that 
are capable of interfering with the function of any of the pathway components. The 
principle of such a positive-selection screen, where inhibition of the target leads to 
growth, is shown in figure 4.1.
URA3- cells 
No uracil n 
growth medium
Screen potential 
mfrtxtors of Sr2 
pathway
No Ura3 expression
Deacetyiated. stent 
chromatin
I  ►   Ura3 expression
Acetytated. 
active chromatin
No urac l svnthesis 
No growth
thesis
Uracil synthesis
Restoration of 
growtn
Figure 4.1  Example of a pathway-based,  positive-selection screen in yeast (taken 
from Simon & Bedalov, 2004).
This  screen  helped  identify  a  compound,  splitomycin,  which  disrupts  telomeric 
silencing from  a collection  of 6,000 compounds from  the  NCI  repository.  Whole 
genome  microarray  experiments  further  confirmed  that  splitomycin  selectively 
inhibits the Sir2 protein (Bedalov et al., 2001).
Positive  growth  selection  assays  with  appropriately  engineered  yeast  strains  have 
also  been  successfully  performed  for  the  identification  of  inhibitors  of  tyrosine 
kinases receptors (RTKs) (Barberis et al., 2005), ion channel-forming protein of the 
influenza  virus  (Kurtz  et  al.,  1995)  and  enzymes  like  p-secretase  (BACE) 
implicated  in  Alzheimer’s  disease  (Middenodorp  et  al.,  2004).  Thus  the
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associated not only with cancer but also other diseases.
Context-based anticancer screens - Yeast mutants for identification of determinants 
of chemosensitivity
One important application of yeast is its use for anticancer drug screens, as a large 
number of biologically  active  compounds  can  penetrate  the  yeast  cell  membrane. 
Additionally,  deletion  in  ERG6  (involved  in  ergosterol  biosynthesis)  leads  to 
increased  membrane  permeability,  while  deletions  in  PDR1  and  PDR3  (which 
regulate drug-resistance efflux pumps) reduces efflux-mediated detoxification, thus 
further increasing yeast’s sensitivity to drugs.
By  genetic  manipulations,  such  as gene deletions,  it is possible to evaluate certain 
genes  as  potential  determinants  for  sensitivity  to  anticancer  drugs  based  on  the 
differential growth inhibition. Single gene alterations can highlight the ability of the 
cell  to  respond  to a  particular cytotoxic  injury  focusing  on  the  effects of specific 
genes,  while  assignment  of  distinct  genes  to  different  pathways  can  be  obtained 
through  epistasis  analysis,  in  which  the  phenotype  of  a  double  mutant  strain  is 
compared to the corresponding single mutant strain.
The  developmental  therapeutic  program  of  the  NCI  has  developed  a  yeast 
anticancer drug screening employing key selected Saccharomyces cerevisiae single 
and double mutant strains, each defective in a particular DNA damage repair or cell 
cycle control function. Tens of thousands of compounds have been tested for their 
ability to inhibit the growth of these yeast strains.  All  screening was performed as 
part  of  the  “Seattle  Project”  at  the  Fred  Hutchinson  Cancer  Research  Center  in 
Seattle,  Washington.  The  project  involved  a  panel  of  isogenic  strains  bearing 
several  DNA  repair  mutations  (including  nucleotide  excision,  base  excision, 
mismatch, post-replication, recombinational repair and reversal of 0 6-alkylguanine) 
and  cell  cycle  checkpoint  mutations  (including  DNA  damage  G2/M,  and  S  phase 
checkpoint, mitotic spindle assembly checkpoint). The strains were also mutant for
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efflux.  The  experimental  design  comprise  three  stages,  stage  0  (crude  sensitivity 
screen), stage  1   (crude  selectivity  screen) and  stage 2 (dose response) (DTP Yeast 
Anticancer drug screen website http://dtp.nci.nih.gov/yacds/).
The cytotoxicity  profiles obtained for selected yeast mutants,  help to highlight the 
importance  of  defects  in  specific  DNA  repair  pathways  as  a  determinant  of 
chemosensitivity, clarify the contribution of specific eukaryotic genes in regulating 
sensitivity  or  resistance  to  antitumour  drugs,  and  identify  agents  selective  for 
specific genetic defects.
4.1.3  Repair of minor groove adducts
Key  yeast  mutants  have  been  studied  previously  in  the  laboratory,  in  order  to 
elucidate the mechanisms involved  in the excision  repair of the untargeted /V-alkyl 
purine  adducts  induced  by  clinically  important  anticancer  drugs  like  the  nitrogen 
mustards.  The  involvement  of  both  base  excision  repair  (BER)  and  nucleotide 
excision repair (NER) was confirmed with NER clearly dominating (McHugh et al., 
1999b; McHugh et al., 2000).
Little  is known  however, about the  repair of damage produced  by complex agents 
that bind  in the  DNA  minor groove.  CC-1065, an archetypal  representative of this 
class of compounds reacts with the N3 position of adenine to produce minor-groove 
targeted adducts. These sequence-specific adducts have been shown to be substrates 
for bacterial and human NER in vitro (Gunz et al.,  1996; Selby & Sancar,  1988).
In  previous  work  in  this  laboratory,  benzoic  acid  mustards  (BAMs)  tethering  1-3 
pyrrole  units  (Figure  4.2)  showed  increasing  DNA  sequence  selectivity  ranging 
from primarily guanine-N7 alkylation in the major groove (BAM and BAM-Py) to 
highly  sequence  specific  alkylation  in  the  minor  groove  (BAM-PyPyPy)  in  the 
sequence 5'-TTTTGPu (Pu=guanine or adenine) (Wyatt et al.,  1995).  Cytotoxicity 
of  these  analogues  in  human  cells  increased  with  increasing  the  number  of  the 
incorporated pyrrole units, reflecting the increasing sequence selectivity. A panel of
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functions,  was  screened  for  sensitivity  against  the  three  analogues.  Table  4.2 
shows  the  involvement  of  the  repair  pathways  in  the  elimination  of  the  DNA 
adducts  produced  by  the  three  oligopyrrole  compounds,  as  suggested  by  the 
survival  studies.  The  primarily  purine-N7  adducts  produced  by  BAM-Py,  in  the 
major groove,  are  repaired  by  both  BER and  NER with  a clear dominance of the 
BER  pathway  (unlike  the  nitrogen  mustard  major  groove  adducts)  (Brooks et al., 
2000).  The  purine-N3  minor  groove  adducts  induced  by  BAM-PyPy,  which 
possesses limited sequence selectivity, are good substrates for both BER and NER. 
In contrast, the  highly sequence  specific,  minor groove-targeted adducts by  BAM- 
PyPyPy were not processed by any known  BER or NER activities as no increased 
sensitivity  over  their  isogenic  parent,  was  evident  in  any  BER  or  NER  deficient 
yeast  strains  studied,  even  at  the  highest  concentration  of  the  agent  employed. 
However,  these  adducts  do  get  excised  in  the  parental,  repair  proficient  strain  as 
revealed  by a PCR-based technique,  yet the  radJ8 strain failed to eliminate them. 
Therefore  a  process  requiring  Rad 18  is  employed  for the  excision  of this  type  of 
minor groove damage (Brooks et al., 2000).
4.1.4  Excision and Post-Replication repair
Excision  repair  is  an  important  cellular  response  to  DNA  damage  by  a  broad 
spectrum  of  physical  and  chemical  agents.  The  two  principal  excision  repair 
pathways, from E.coli to human cells are base excision repair (BER) and nucleotide 
excision repair (NER).
Excision  repair  initiated  by  the  action  of  DNA  glycosylases,  a  specific  class  of 
DNA  repair enzymes,  is called  base  excision  repair.  DNA  glycosylases  incise the 
chemically modified bases by hydrolysis of the N-glycosyl bond linking the base to 
the sugar-phosphate backbone (Sancar & Sancar,  1988; Cunningham,  1997).
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Figure 4.2  Structures of the three oligopyrrole analogues of distamycin tethering 
BAM. The shift of the targeting from major to minor groove is denoted.
Compound Target Cytotoxicity Sequence
specificity
Repair
mechanism
BAM-Py, Major
groove
+ G-N7
A-N3
BER, NER
BAM-Py2 Minor
groove
++ AT tracts BER, NER 
Rad 18, Rad52
BAM-Py3 Minor
groove
+++ 5,  ttttgpu Rad 18
Table  4.2  Summary  of  the  properties  of  the  three  BAMs,  tethering  1-3  pyrrole 
units,  as  extracted  from  Wyatt  et al.,  1994;  1995.  The  repair  mechanism  in  bold, 
denotes  the  primary  repair  process  acting  upon  the  corresponding  adducts,  as 
determined  by  the  sensitivity  screen  of the  relevant yeast  mutants (Brooks  et al.y  
2000).The  resulting  sites  of  base  loss,  called  apurinic  or  apyrimidinic  (AP)  sites  are 
removed  by  a  second  class  of  base  excision  repair  enzymes,  the 
apurinic/apyrimidinic  (AP)  endonucleases,  which  cut  the  DNA  phosphodiester 
backbone  at  the  5’  side  of the  abasic  site.  Some  glycosylases  (bifunctional)  also 
possess  an  associated  AP  lyase  activity  (Doetsch  &  Cunningham,  1990).  The 
sequential  action of the two types of enzymes results in a single  nucleotide  gap in 
the  DNA  duplex  during  base  excision  repair.  Following  the  processing  of the  5’ 
terminus  by  deoxyribose  phosphodiesterase,  which  excises  the  5’-terminal  sugar 
phosphate, the gap is filled by repair synthesis by DNA polymerase and DNA repair 
is completed  by  DNA  ligase (Reviewed by  Friedberg et al.,  1995).  BER processes 
DNA  base  damage  that  causes  relatively  minor  disturbances  to  the  helical  DNA 
structure  and  includes  primarily  oxidative  damage,  alkylation  damage  such  as 
methylation,  damage  induced  by  radiation,  or  replication  errors,  all  induced  from 
environmental agents and endogenous sources (Memisoglu & Samson, 2000). 
Another mode of excision  repair involves the  incision of the affected  DNA strand 
on  both  sides  of the  base  damage,  generating  a  lesion-containing  oligonucleotide 
fragment.  This  excision  phenomenon  is  mainly  targeted  to  helix-distorting  bulky 
base  adducts  produced  by  physical  agents,  such  as  UV  radiation,  or a  variety  of 
chemical  agents (e.g.  cisplatin-induced  intrastrand  crosslinks).  In  eukaryotes  NER 
is  a  multi-step  process  involving  damage  recognition,  DNA  unwinding  and  dual 
incision.  This  entails  the  coordinated  action  of  around  30  polypeptides  and 
eventually  leads  to  the  release  of a  damage-containing 25-30-mer oligonucleotide 
(reviewed  by  Friedberg et al.,  1995;  Prakash & Prakash, 2000). The gap created is 
filled in by a DNA polymerase and ligation completes the repair. In Saccharomyces 
cerevisiae,  NER  is  dependent  upon  genes  of the  RAD3  epistasis  group.  Of these 
genes,  RADI,  RAD2,  RAD3,  RAD4,  RADIO,  RAD14  and  RAD25  are  absolutely 
required  for  the  recognition  and  incision  steps  of  NER  in  S.  cerevisiae.  More 
specifically,  the  initial  recognition  of a  DNA  lesion  is  probably  mediated  by  the 
Rad4/Rad23 (nucleotide excision repair factor; NEF2) and the Rad7/Radl6 (NEF4) 
complexes, the  latter showing ATP dependence for damage  binding and  is crucial
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binding protein factors are Rad 14 which has an affinity for UV-damaged DNA and 
replication protein A (RPA), which binds single stranded DNA and is also required 
for the incision  step of NER (Guzder et al.  1993;  1995).  Rad3  and  Rad25 (part of 
the NEF3 complex) are DNA  helicases, which translocate on single stranded DNA 
in  the  5’-*3’  and  3’-*5’  direction,  respectively,  topically  unwinding  the  DNA 
(Sung  et  al.,  1996).  These  two  proteins  constitute  two  of  the  subunits  of  the 
transcription factor TFIIH and are both essential for the incision step of NER (Sung 
et al.,  1996). Rad4 and Rad23, which together form NEF2, have been implicated in 
an early step of NER, as damage recognition factors, and no incisions are observed 
in  a  rad4  mutant  (Guzder  et  al.,  1998).  Radl-RadlO  which  form  a  tight 
heterodimeric  complex (NEF1) and Rad2 (NEF3), introduce incisions on the 5’ and 
the  3’  side  of the  damage,  respectively  (Bardwell  et  al.,  1994;  Habraken,  et  al.,
1993).  After  the  release  of  the  lesion-containing  oligonucleotide,  resythesis  is 
performed  by  DNA  polymerase  6  and  e  and  ligation  by  Cdc9  (DNA  ligase  I) 
(Prakash & Prakash, 2000).
NER proceeds at a faster rate on the transcribed strand of active genes than the non­
transcribed  strand,  and  this  phenomenon  is  known  as transcription-coupled  repair 
(TCR).  Yeast RAD26  disruption,  severely  impaired  the  preferential  repair of UV- 
induced cyclobutane pyrimidine dimers in the transcribed strand of the active RBP2 
gene  (Van  Gool  et  al.,  1994).  Rad26  has  been  suggested  to  enable  TCR  by 
increasing  accessibility  of  DNA  damage  to  repair  proteins  (Bucheli  &  Sweder, 
2004).
For the  lesions in  DNA formed  by  UV  or many DNA damaging agents which are 
not  removed  by  NER  or  BER,  error-free  and  error-prone  (mutagenic)  damage 
tolerance  and  translesion  synthesis  mechanisms  exist  in  S.  cerevisiae.  Both  these 
modes depend on genes within the RAD6 epistasis group and comprise the complex 
post-replicative  repair  pathway  which  can  be  further  dissected  in  multiple 
downstream subpathways (Figure  4.4).
228Figure  4.3  Schematic  representation  of  the  yeast  NER  damage  recognition  and 
incision steps.
RAD6 is the pivotal  gene of the  post-replicative repair pathway,  required for both 
error-free and error-prone modes of lesion bypass.  Ubiquitin is a highly conserved76-residue  protein,  often  found  covalently  joined  to  other  proteins.  It  is  the 
modification  of  proteins  by  conjugation  to  ubiquitin,  which  seems  to  be 
coordinating  the  various  /?AD6-dependent  DNA  repair  processes  (Hoege  et  al., 
2002). RAD6 itself encodes a ubiquitin-conjugating enzyme (Ubc2 or E2) (Jentsch 
et al.,  1987),  which  attaches  ubiquitin  to substrate  proteins and exists in  vivo  in  a 
complex  with  Rad 18.  Rad6 interacts  with  Rad 18,  an  interaction  necessary for the 
RAD6  DNA  repair functions,  and  together they form  a heterodimer (Bailly et al.,
1994). The DNA binding activity of Rad 18 presumably recruits Rad6 to the regions 
of stalled replication at a lesion site (Bailly et al.,  1994). The Rad6/Radl8 complex 
has been assumed to be required for all known subpathways within the RAD6 group 
(Prakash et al.,  1993; Lawrence,  1994).
MMS2,  UBC13  and  RAD5  genes  comprise  an  error-free  lesion  bypass  pathway, 
promoting  the  repair  of discontinuities  that  form  in  the  newly  synthesised  strand 
opposite  from  DNA  lesions,  presumably  through  a  “copy-choice”  (template 
switching) type of synthesis (Hoeijmakers, 2001, Zhang & Lawrence, 2005).
MMS2, required for resistance to the alkylating agent methanesulfonate (MMS) and 
UV,  encodes  a  protein  with  some  homology  to  ubiquitin-conjugating  enzymes, 
although  alone  it  lacks this activity  (Broomfield  et al,  1998).  UBC13 confers  UV 
resistance  and  encodes  an  ubiquitin-conjugating  enzyme  (Hoffman  &  Pickart, 
1999). MMS2 has been shown to act in the error-free pathway of RAD6-dependent 
damage bypass, based on the epistatic sensitivity of an mms2 mutant with rad6, the 
synergistic with rev3 and the proficient UV-induced mutagenesis of the mms2 cells 
(Broomfield et al.,  1998; Torres-Ramos et al., 2002). Similarly, the ubc!3 mutation 
was found to be epistatic to mms2 and rad6, and synergistic to rev3 with respect to 
UV  and  MMS  sensitivities  (Brusky  et al.,  2000). The epistatic  relationship of the 
two  genes  for  UV  damage,  suggests  that  they  act  in  the  same  DNA,  damage 
processing  pathway.  Additionally,  the  two  proteins  interact  and  form  a 
heterodimeric  complex,  which  promotes  the  assembly  of  polyubiquitin  chains 
linked via the lysine 63 of ubiquitin (Hoffman & Pickart,  1999).
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still occur in a radS mutant and a synergistic increase in UV sensitivity is exhibited 
when  combined  with  a  rev3  mutation  (Johnson  et  al.,  1992;  Cejka  et  al.,  2001). 
Additionally,  it was found to be epistatic for UV  sensitivity to MMS2 and  UBC13 
(Ulrich  &  Jentsch,  2000; Torres-Ramos  et al.,  2002).  The  gene  encodes  a  DNA- 
dependent ATPase (Johnson et al.,  1994) and has a ubiquitin ligase activity (Hoege 
et al., 2002).  Rad5  has been  shown to transiently  interact with the  Mms2 / Ubcl3 
complex, as well as with Rad 18 (Ulrich & Jentsch, 2000). It has been proposed that 
Rad5 recruits the Mms2 / Ubcl3 complex to DNA and acts as a bridging factor to 
bring  Ubcl3  and  Mms2  into  contact  with  the  Rad6  /  Rad 18  complex  (Ulrich  & 
Jentsch, 2000).
The Mms2 / Ubcl3 protein complex was therefore placed specifically in the RAD5- 
dependent subpathway of the RAD6 pathway and shown to be dependent on RADI8 
(Xiao et al,  1999; Ulrich & Jentsch, 2000).
POL30,  encoding  proliferating cell  nuclear antigen  (PCNA),  a  processivity factor 
for  DNA  polymerases and  POL3,  encoding  polymerase  6,  (Pol  6), have  also  been 
implicated  in  the  error-free  bypass  of  UV-damage  through  translesion  synthesis 
(Torres-Ramos  et  al.,  1997).  In  DNA  damaged  yeast  cells,  PCNA  becomes 
monoubiquitinated  by  Rad6 /  Rad 18,  sunbsequently  polyubiquitinated  by  Mms2 / 
Ubcl3, through the  ubiquitin  ligase activity of Rad5 and is also a substrate for the 
small  ubiquitin-related  modifier,  (SUMO)-conjugating  enzyme  (Hoege  et  al., 
2002). These modifications although affecting the same site on PCNA, direct it for 
alternative  actions,  further  confirming  the  role  of  ubiquitin  modifications  as  an 
important signal of the various cellular processes of PRR.
RAD30  is  another  member  of  the  RAD6  epistasis  group  encoding  for  the  DNA 
polymerase Pol r\ which catalyses, in response to UV damage, error-free translesion 
synthesis  past  a  thymine-thymine  cyclobutane  dimer  (TT  CDP)  (Johnson  et  al, 
1999). The RAD6-RAD18-RAD30 epistasis group has been shown to be distinct to 
the  branch  comprising  of  RAD6,  RAD 18,  RADS,  UBC13  and  MMS2,  for  UV 
sensitivity (Ulrich & Jentsch, 2000; Torres-Ramos et al., 2002).
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Figure 4.4 Schematic representation of the RAD6 dependent post-replication repair 
subpathways.  Recognition  and  binding  to  DNA  damage  by  the  Rad6/Radl8 
heterodimer is required for all subsequent processes, divided in error-free and error- 
prone  modes.  The  subdivision  has  been  based  on  epistasis  analysis  of  the 
sensitivities  of the  relavant  mutants  to  UV  damage  and  biochemical  assays  (see 
References in the text).
RAD6  and  RAD18  also  mediate  error-prone  processes  that  require  the  proteins 
encoded  by  REV  genes.  REV1,  REV3,  and  REV7  genes  function  in  mutagenic 
bypass as the corresponding yeast mutants, were found to decrease damage-induced
232mutagenesis.  Epistasis  analysis  indicated  that  the  three  REV genes  function  in  a 
process independent of Pol r\  or Mms2 / Ubcl3 mediated damage processing (Xiao 
et  al.,  1999),  therefore  representing  a  distinct  mutagenic  subpathway.  The  REV3 
and  REV7 genes  encode  subunits  of  DNA  polymerase  t, (Pol  £)»  which  has  been 
shown  to  synthesise  past  a  TT  DCP  and  an  abasic  site  and  other  replication- 
blocking lesions at the cost of elevated  mutation frequency  (Nelson et al.,  1996a). 
The deoxycitidyl transferase Revl, promotes incorporation of cytosine opposite an 
abasic site or UV photoproducts (Nelson et al.,  1996b).
The various branches and/or components of error free and error-prone PRR are not 
necessarily  exclusive,  as  in  the  case  of  the  (6-4)  TT  photoroducts,  translesion 
synthesis entails the cooridanted function of Pol r\ at the insertion step and of Pol £ 
at the extension step (Guo et al., 2001; Johnson  et al., 2001).  PCNA’s interaction 
with Pol r| is essential for the function of the polymerase and its monoubiquitination 
is thought to activate pol r| and pol £ translesion synthesis (Haracska et al., 2001). 
Rad5  has  also  recently  been  suggested  to  affect  the  TLS  polymerases  and 
contributing  to  the  efficiency  of  lesion  bypass,  possibly  by  the  ubiquitilation 
through  the  binding  of  the  TLS  polymerases  to  the  Rad6  /  Rad 18  complex,  a 
function  independent  of the  Mms2  /  Ubcl3  complex  (Gangavarapu  et al.,  2006). 
These examples highlight the complexity of the interactions of the members of the 
RAD6 epistasis group with new functions and interconnections of the member gene 
products, still emerging, depending on the type of DNA damage investigated.
2334.1.5 Objectives of the study
Mutants  of the  yeast Saccharomyces cerevisiae,  totally  deficient  in  specific  DNA 
repair pathways were used to identify the critical detereminants of sensitivity of the 
novel chiral agent TH-III-151  and the achiral one, AS-I-145. These two chemically 
closely  related  compounds  were  shown  in  chapters 2 and  3  to  specifically  induce 
adenine-N3  lesions,  in  a  comparable,  sequence  specific  manner.  It  is  known  that 
NER  is  important  in  processing  the  same  type  of  lesions  generated  by  the  lead 
compound CC-1065, however, in the case of the novel agents, the role of the other 
principal  excision  repair  pathway,  BER  was  also  investigated.  Using  isogenic 
strains disrupted for NER and BER genes, and with the inclusion of double mutants, 
the relative contributions of the two pathways was assessed. Large- scale sensitivity 
yeast screens, constructions of survival curves and epistasis analysis was performed 
(an outline of the experimental strategy is featured in Figure 4.5).
Based  on  previous findings  in  our lab,  which  implicated  Rad 18  in  the  removal  of 
other sequence specific minor groove adducts, the sensitivity of strains deficient in 
genes/members of the RAD6 epistasis group was also determined. Various members 
of the subpathways of the RAD6 controlled post replication repair were considered, 
in an attempt to further characterise the role of this pathway.
The induction of the damage and the  repair of the adducts at nucleotide  resolution 
was  examined  by  single-strand  ligation  PCR  (sslig-PCR),  on  both  the  transcribed 
and non-transcribed strands of an active gene, in repair competent and those mutant 
cells  which  had  exhibited  marked  sensitivity.  This  study  would  provide  further 
evidence  of  the  adduct  removal  mechanisms,  reveal  if  the  excision  event  is 
transcription  coupled  and  relate  marked  sensitivity  to  specific  adduct  elimination 
defects.
Conducting  the  above  studies  on  both  a  chiral  and  an  achiral  compound,  helped 
identify similarities in the repair mechanisms for the two classes of compounds and 
further  highlighted  the  role  of  Rad 18  in  the  repair  of  minor  groove  adducts 
establishing, in this case, a link between the RAD6 pathway and NER.
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Figure 4.5 Overview of the experimental strategy followed in the yeast DNA repair 
studies.
2354.2 Materials and Methods
4.2.1  Materials
Investigational compounds 
See section 2.1.1
Chemicals -  enzymes -  DNA size markers -  Radioisotope-Kits 
As in 2.1.1  unless otherwise specified in the text.
Saccharomyces cerevisiae -  Yeast strains
The S. cerevisiae haploid strains employed, their genotypes and source are listed in 
Table  4.3.  Cells  were  grown  on  yeast  extract-peptone-dextrose  (1%,  1%,  2% 
respectively) YEPD agar plates (stock), or YEPD liquid media, overnight at 28° C. 
For solid media,  17g of Agar /1 were added. All media components were purchased 
from Sigma, with the exception of mycological  peptone (Lab M, Lancashire,  UK). 
Media was sterilised by autoclaving.
4.2.2 Methods
4.2.2.1  Large scale sensitivity screen -  Colony spotting assay
Liquid  YEPD  medium  was  inoculated  with  a single colony  picked from  a freshly 
streaked (YEPD) stock plate of the strain under investigation, and grown overnight 
at 28°C with vigorous shaking.
Cells were counted  microscopically  and  only cultures with  between  1   and 4 x  107  
cells/ml  were used.  Cells were pelleted at 500 x g,  10 min, 20°C and adjusted to a 
final  volume  of  5  x  105  cells/ml  in  cold  phosphate  buffered  saline  (PBS).  1   ml 
aliquots  were  treated  with  increasing  concentration  of TH-III-151  and  AS-I-145 
(ranging from 0.01  pM to 10 pM), for 5 h at 28°C with vigorous shaking.
236Strain Genotype Source  Ref.
DBY 747 MATS his3-Al leu2-3, 112 trpl-289 ura3-52 W. Xiao Xiao etal.,  1996
WXY 9394 DBY 747 with rad4A::hisG-URA3- hisG W. Xiao Xiao etal.,  1996
LP14A DBY 747 with rad!4A::URA3 R. Waters -
JC 8901 DBY 747 with magi A: :hisG-U  RA3-hisG L. Samson Chen etal.,  1990
WXY 9345 DBY 747 with rad4A::hisG-URA3- hisG magiA::hisG W. Xiao Xiao etal.,  1996
WXY 9326 DBY 747 with radl8A::TRPl W. Xiao Xiao etal.,  1996
PJM 35 DBY 747 with rad4A::KanMX4 radl8A::TRPl P.J.McHugh -
WXY 9376 DBY 747 with rad6A::LEU2 W. Xiao Xiao etal.,  1996
WXY 642 DBY 747 with mms2A::HlS3 W. Xiao Xiao etal., 2000
WXY 731 DBY747 with rad5A::hisG-URA3-hisG W. Xiao Xiao etal., 2000
WXY 732 DBY 747 with mms2A::HIS3 rad5A::hisG-URA3-hisG W. Xiao Xiao etal., 2000
PJM 36 DBY 747 with rad4A::KanMX4 rad5A::hisG-URA3-hisG This study -
BY4741 MATa his3Al leu2A0metl5A0 ura3A0 SGDP* -
2085 BY4741  with rev3A::KanMX4 SGDP -
4255 BY4741  with rad30A::KanMX4 SGDP -
6067 BY4741  with unglA::KanMX4 SGDP -
393 BY4741  with ntgl A::KanMX4 SGDP -
1734 BY4741  with ntg2A::KanMX4 SGDP -
510 BY4741  with ogglA::KanMX4 SGDP -
*   Sacchciromyces Genome Deletion Project
Table 4.3  Saccharomyces cerevisiae strains used in this study.
After  drug  treatment,  cells  were  harvested,  washed  twice  in  PBS  solution  and 
resuspended  in  a  final  volume  of  1   ml  of dH20.  A  series  of  1:10 dilutions  were 
performed for each strain, down to 500 cells/ml.  10 pi of the last three dilutions was
237spotted  onto  square  YEPD/agar  plates  with  a  premarked  grid  layout.  Each  line 
comprised a series of “spots” of one  strain,  containing sequentially 5000,  500,  50 
cells / patch.  Typically 4 or 5 strains were spotted on any one plate, and plates were 
spotted  in  triplicate.  The  growth  phenotypes  of  the  strains  on  the  plates  were 
assessed after 3 days incubation at 28°C, when plates were photographed.
4.2.2.2 Yeast survival curves
Culture  conditions as above.  Cells  were  pelleted  as  above  and  adjusted  to  a final 
density of 2 x  107 cells/ml  this time,  in cold  PBS.  2 ml aliquots were then treated 
with TH-III-151  and AS-I-145  as above.  After drug treatment,  cells  were  washed 
twice in  PBS  solution and resuspended  in a final  volume of  1ml.  Subsequent  1:10 
serial  dilutions  of  the  stock  cell  suspension  were  performed,  down  to  2  x  103  
cells/ml.  100 pi of the last dilution was plated in triplicate, onto YEPD/agar plates 
at a density  giving  rise to about 200 colonies  per  plate  in  untreated controls.  The 
number of yeast colonies per plate was scored after 3 days incubation at 28°C. Any 
experiments giving rise to more than 250 colonies/plate in  untreated controls were 
rejected. Results are expressed as percentage of the number of colonies arising from 
an  untreated  control,  to  enable  comparison  between  different  strains  and 
experiments.
4.2.2.3 Single-strand ligation polymerase chain reaction (sslig-PCR).
Sslig-PCR  oligonucleotides  were  synthesised,  modified  and  purified  by  MWG, 
Milton Keynes, UK. All oligonucleotides were high purity salt free (HSPF) purified 
following synthesis and where necessary modification, and were stored at -20 °C.
For the MFA2 gene transcribed strand (TS):
2.5B 5’ biotin CAT TGA CAT CAC TAG AGA CA 3’ Tm = 51 °C
2.5C 5’ AGA CAC CAG CGA GCT ATC AT 3’ Tm = 58 °C
2.5D 5’ AGC GAG CTA TCA TCT TCA TAC AA 3’ Tm = 61 °C
238For the MFA2 gene non-transcribed strand (NTS):
2.4B 5’ biotin TAT AAG AGT TTA TAG TGG TGA AG 3’  Tm = 52°C
2.4C 5’ AGT GGT GAA GAT AGT ACG GA 3’  Tm = 54°C
2.4D 5’ GAT AGT ACG GAC TTG ATG CAC GTG 3’  Tm = 61 °C
Ligation oligonucleotide:
5’ p-ATC GTA GAT CAT GCA TAG TCA TA-n 3’
Ligation primer:
5’ TAT GAC TAT GCA TGA TCT ACG 3’
The PCR-based technique, employed to detect induction of damage and follow the 
repair  of  the  DNA  adducts  at  the  nucleotide  level  in  cells,  has  been  previously 
described for use with mammalian cells (Grimaldi et al,  1994;  1997). Its application 
on yeast cells has also been reported (Brooks et al., 2000). A schematic diagram of 
the technique is featured in Figure 4.6.
A  single colony from the appropriate yeast  strain  was  grown  overnight in  100 ml 
YEPD.  Cells were counted,  pelleted  (500 g,  10 min.) and  were resuspended  in 60 
ml  PBS at a concentration of 3  x  107 cells/ml.  50 ml of cells were treated with  10 
pM TH-III-151  for 3 h at 28°C in an orbital  shaker, and  10 ml of cells were mock- 
treated with drug solvent. After drug treatment, cells were washed twice with PBS, 
10 ml of cells were removed for the time 0 h sample and the remaining 40 ml was 
resuspended in YEPD medium and  incubated at 28° C for 2, 4, 6 or 8 h. The mock 
treated samples were also incubated for 8 h. After this post treatment incubation, the 
cells  were  centrifuged  at 500  g for  10  min  at 20°C.  The  pellet was  lyophilised  to 
dryness and resuspended in  100 ml of distilled H2 0. After vigorous vortexing, DNA 
was allowed to elute in distilled water overnight, at 4° C.
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240Genomic  DNA,  from  each  of  the  time  points  for  the  repair  experiments,  was 
purified using a Nucleon Mini  Kit for yeast DNA extraction (Nucleon Biosciences, 
UK). The genomic DNA was enzymatically cut with an appropriate endonuclease, 
depending  on  the  strand  under  examination.  10  units  of  Rsa  I  (10  U  /  pi;  New 
England  Biolabs,  Hitchin,  UK)  were  used  for  analysis  of  the  TS  and  the  same 
amount of Dde I  (10 U / pi;  New  England  Biolabs), for analysis of the NTS. The 
enzymatic  DNA  digestions  were  incubated  at  37*C,  overnight.  The  DNA  was 
finally precipitated and its concentration determined fluorimetrically.
First-Round Linear PCR
First round primer extension was carried out, in a volume of 40 pi, using 0.04 pg of 
the digested DNA (in  10 pi  of dH20). The single primer used in this first-round of 
PCR  determines  which  region  and  on  what  strand,  damage  is  measured  (i.e.  a 
primer complementary to the TS detects damage on the TS). Gelatin was used in the 
first-round  linear PCR to help improve  primer specificity.  All  the reagents for the 
PCR steps were stored at -20° C (except MgCl2  and gelatin which were stored at 4° 
C), thawed if necessary and kept on ice until just prior to use, with the exception of 
the polymerase which was kept at -20° C at all times.
A  PCR coctail  mix  was  prepared  in  a  1.5-ml  tube  using  the  volumes  below  after 
multiplying by the number of samples.
4.0 pi  of  10 x Thermophilic  DNA  polymerase  buffer  [as supplied  with the 
enzyme; when diluted  1:10 it has a composition of 10 mMTris-HCI (pH 9.0 
at 25° C), 50 mM KCI and 0.1% Triton® X-100J.
5.0 pi of a mixture containing 2.5 mM each dNTP
6.4  pi  of MgCI2   (provided  with  the  enzyme  as  a  stock  of 25  mM)  (4mM 
final concentration)
2.0 pi of 0.2% Gelatin
1.0 pi of biotinylated primer B (0.06 pmoles)
0.2 pi (1  U) of Taq DNA Polymerase (5U / pi)
11.4 pi ddH20
24130  pi  of the  above  PCR  coctail  mix  was  placed  directly  into  each  of the  0.5-ml 
tubes with the digested DNA and mixed well.
The DNA was initially denatured at 94° C for 4 min and then subjected to 30 cycles 
of 94  C for  1   min, Tm for  1   min, 72  C for  1   min +  1   second extension/cycle on a 
PT-100 thermal  cycler  with  a  hot  bonnet  (MJ  Research,  Watertown,  MA,  USA). 
The mixture was subjected to a final extension at 72° C for 5 min and then cooled to 
4*C.
Capture and ligation
To capture and  purify  the  products of biotinylated  primer extension,  10 pi  of 5  x 
washing  and  binding  buffer  (WBB;  5  mM  Tris-HCl  pH  7.5,  1   mM  EDTA,  1   M 
NaCl)  was  added  to  the  PCR  mixture,  followed  by  5  pi  streptavidin  M-280 
Dynabeads®  (Dynal,  Wirral,  UK).  The  Dynabeads  has  been  washed  three  times 
with and resuspended in  1   x WBB. The suspension was incubated for 30 min at 37° 
C  to  allow  the  streptavidin  coated  Dynabeads  to  bind  to  the  biotinylated  PCR 
products with occasional agitation for gentle mixing. The beads were sedimented in 
a magnetic rack and washed three times with 200 pi of 10 mM TE (pH 7.6).
After  the  final  wash,  the  supernatant  was  carefully  removed  and  the  beads  were 
resuspended  in  10  pi  ligation  mixture.  The  ligation  mix  was prepared  in  a  1.5-ml 
tube using the volumes below after multiplying by the number of samples.
1.0 pi of 10 x T4 RNA ligase buffer 110 x  is: 500 mM Tris-HCl (pH 8.0 at 
25° C),  100 mM  MgCl2,  10 mM  hexamine (III) cobalt chloride,  100 pg/ml 
bovine serum albumin, and 200 pM ATP)
1.0 pi of 20 mM ligation oligonucleotide (20 pmoles final concentration)
5.0 pi of 50% (w/v) polyethylene glycol 800 (PEG 8000)
1.0 pi (20 U) of T4 RNA ligase (20 U / ml; Promega, Southampton, UK)
2.0 pi ddH20
24210 ml of the above mix was placed into the tubes containing the Dynabeads (using a 
pipette  tip  with  the  end  cut  off  to  allow  the  extremely  viscous  mixture  to  be 
pipetted) and mixed by repeating pipetting against the walls of the tubes.
The ligation reaction was incubated overnight at 22’ C. The ligation oligonucleotide 
was supplied with a 5’  phosphate, essential for ligation, and a 3’  terminal amine to 
block its self-ligation. After ligation the beads were washed 3 times with 200 pi TE 
pH 7.6 and resuspended in 40 pi dH20  for the second round PCR.
Second-Round Exponential PCR
The  second  round  PCR  mixture,  in  a  volume  of  100  pi,  contained  10  pmoles  of 
each of the primer C and the ligation primer that was complementary to the ligated 
oligonucleotide. The buffer composition was as for the first round PCR except that
2.5  U  of  Taq  polymerase  were  used.  The  cycling  conditions  were:  an  initial 
denaturation at 94’C for 4 min, then  15 cycles of 94° C,  1   min, Tm,  1   min, 72’ C  1  
min  +  1   second  extension/cycle.  The  mixture  was finally  incubated  at 72°C for 5 
min and cooled to 4*C for  lh.
Third-Round PCR -  Electrophoresis
The third round labelling reaction was carried out by adding to the  100 pi of each of 
the  PCR-2  tubes,  10  pi  of 32P 5’  end-labelled  primer  D  (5  pmoles)  and  1   U  Taq 
polymerase in PCR reaction buffer. 5' end labelling of primer D was carried out as 
described in section 2.1.2.1. The mixture was subjected to 4 further cycles of 94° C,
1   min, Tm,  1   min  and  72° C,  1   min,  72’ C,  5  min  and  4° C,  1   h.  The  beads  were 
sedimented  by  spinning  briefly  in  a  microcentrifuge  and  the  supernatant  was 
carefully  removed to fresh  1.5-mI  tubes. The  beads were rinsed  with  100 pi  dH20  
and  the  supernatant  removed  and  added  to  the  1.5-ml  tubes.  The  DNA  of  the 
collected  supernatants  was  precipitated  with  ethanol  and  3M  NaOAc  and  washed 
twice with 70% ethanol. The lyophilised  samples were finally resuspended in 5  pi 
formamide loading buffer. The 5  pi samples were in turn transferred to fresh tubes 
and the levels of radioactivity (CPM) measured with a scintillation counter. In most
243cases  no great deviations  were  recorded.  This extra  step was  performed  to ensure 
consistency in the levels of radioactivity in the loadings per lane.
The samples were denatured at 95  C for 3 min, cooled on ice and electrophoresed at 
1500V for 3  h  in a 50 cm  x 21  cm x 0.4 mm, 6%  polyacrylamide sequencing gel 
(SequaGel 6;  National  Diagnostics,  UK). The gel  was dried and autoradiographed 
(Kodak  Hyper film, Amersham.  UK).  Densitometry  was  performed  on  a  Bio-Rad 
GS-670 imaging densitometer using the Molecular Dynamics software.
4.2.2.4 DNA measurement by fluorimetry
The DNA samples were measured after extraction and enzymatic digestion for their 
DNA content by fluorimetry. This is one of the most accurate methods available for 
measuring DNA and especially  very  small  quantities (Kowalski,  1979). The  DNA 
concentration  of  each  sample  was  determined  with  the  Perkin-Elmer  L2-SB 
fluorimetre  using  the  Hoechst  33258  dye  (Sigma-Aldrich,  Poole,  UK)  and  assay 
(Cesarone et al.,  1979). A standard curve was generated using 0 to  10 pg of salmon 
sperm DNA  (Sigma-Aldrich)  in  1   x SSC (15  mM sodium citrate pH 7.0,  150 mM 
NaCl). 2 pi of aliquots of the DNA samples were resuspended in  1   x SSC to a total 
volume of 2ml  and  1   ml  Hoechst 33258 dye (10 pg/ml).  The  DNA  samples were 
fully  resuspended and  mixed  by  invertion,  before measurement.  After determining 
their DNA concentration, samples were stored at -20°C.
4.2.2.5 DNA sequencing
Di-deoxy double-stranded sequencing was carried out using the Sequenase™  2.0 kit 
(Amersham Pharmacia Biotech, Little Chalfont, UK), to determine the sequence of 
the  drug  binding  sites  detected  by  sslig-PCR.  The  DNA  fragments  used  for 
sequencing were generated  by  PCR using  unmodified,  restriction enzyme-digested 
DNA  as  a  template.  Typically  10-100  ng  of  DNA  would  suffice  to  provide  high 
yield  and  high  specificity.  For  the TS  strand  sequencing,  the  PCR fragment  was
244generated  by  the  primers  2.3B  (radiolabelled),  which  binds  the  NTS  at  positions 
+349 to +368 (where +1  is the start of the coding region of MFA2) and 2.5 C, which 
binds  the  TS  at  positions  +943  to  +924.  For  the  NTS  sequencing,  the  primers 
employed  were  2.5C  (radiolabelled)  and  2.4C,  which  binds  the  NTS  at  positions 
+922 to +899. The fragment generated for TS  is 574 bp while the one for NTS  is 
595  bp.  Both  PCR  products  were amplified for 35  cycles.  The end  products  were 
verified by visualising on a mini agarose gel.
Sequencing  was  carried  out  according  to  the  manufacturer’s  protocol  using  the 
buffers and enzymes provided in the kit. The sequencing products were resolved in 
parallel to the sslig-PCR products by gel electrophoresis.
4.2.2.6  PCR-based gene disruption
The following deletion primers (MWG) bearing 45 bp homology to the RAD4 gene 
and  20  bp  of  overlap  with  the  selective  marker,  were  designed  to  generate  the 
cassette:
RAD4 5' DEL
5'-GGA CGA CAA GCA GAG ACA TAA CGA CAC TAT TTT TCC GCT AAA 
ATG CGG ATC CCC GGG TTA ATT AA-3'
RAD4 y  DEL
5'-AAA  ACA TAC TTT  CCT AAT TAT TCA  AAC CGT TTC AGC CTC ATT 
TCA GAA TTC GAG CTC GTT TAA AC-3'
The regions of homology between the primer sequences and the endogenous gene, 
lay at the 5' and 3' ends of the coding sequence {RAD4 5'  DEL and RAD4 3'  DEL 
respectively), to ensure complete disruption. The KanMX4 cassette template (a gift 
from  Professor M.  Longtime,  Universitat  Basel,  Switzerland)  was  used to provide 
kanamycin selection.
245Reaction mixtures were prepared in a total  volume of  100 pi, comprising:  100 ng 
(in  10 pi) of the pFA6a KanMX4 vector; 10 pi of 1   x Thermopol buffer (NEB); 2 pi 
of 100 mM magnesium sulphate;  12.5 pi of 2 mM dNTPs, 250 pmol of each primer 
(in  2.5  pi  each);  2  units of Vent  Polymerase  (NEB)  (in  1   pi)  and  the  rest of the 
volume made up with dH20.
The PCR conditions were: 94°C for 4 min; 94°C for 1   min, 55°C 1   min, 72°C 2 min 
+  1   s/cycle,  30  cycles;  72°C  5  min.  PCR  was  performed  on  a  MJ  thermocycler 
machine.
Six identical PCR reactions were carried out as described above. The PCR products 
were  subsequently  combined  and  a  1:1  volume  of phenol-chloroform  was  added. 
This  was  centrifuged  for  5  min  at  full  speed  and  the  aqueous  (upper)  layer 
containing the DNA, was transferred to a fresh eppendorf and subsequently mixed 
with 3  volumes of 95 % ethanol  and  V.o volume of 3M sodium acetate.  DNA  was 
left  to  precipitate  in  a dry  ice  bath  for 20  min.  After  spinning for 5  mins  at full 
speed, the supenatant was carefully removed and the pellet washed twice in cold 70 
%  ethanol.  After  a final  round  of centrifugation  and  drying,  the  DNA  pellet  was 
resuspended in  11  pi of sterile water.  1   pi of this DNA preparation was run on an 
ethidium-stained,  1   % agarose gel, in 0.5 x TBE buffer,
Transformation of S. cerevisiae
A  single colony from a rad5 YEPD stock plate was inoculated in 50 ml of YEPD 
medium and grown overnight.  After a  100-fold dilution,  10 ml  of these rad.5 cells 
were  counted  with  a  heamacytometer,  to  confirm  that  they  were  in  exponential 
phase (2 xlO6 -  2 x  107 cells/ml). The cells were transformed with a single cassette 
using the BIO  101  Alkali-cation Yeast Transformation kit (Anachem), according to 
the manufacturer’s instructions. Briefly, 50 ml of rad5 cells were centrifuged at 400 
x g for 5 min and the supernatant discarded. Cells were then resuspended in a total 
of  10  ml  of TE  solution  (pH  7.5)  and  spun  down  further.  After  removal  of the 
supernatant, the pelleted cells were resuspended in 5 ml of lithium / caesium acetate 
solution (100 mM) and incubated for 30 min at 30°C. The cells were subsequently
246spun  and  resuspended  in  1   ml  of TE  (pH  7.5),  ready  for  transformation.  A  {/l0 Q  
aliquot of these yeast cells (100 pi) was mixed with  10 pi  of salmon sperm DNA 
and  10 pi of histidine solution and the  10 pi of the RAD4-KanMX4-RAD4 cassette 
preparation. This suspension was mixed well and incubated at room temperature for 
15  min.  1   ml  of  a  PEG/TE/CationMixx  was  then  added  to  the  transformation 
reaction, and incubated for a further  10 min at 30°C.  Reactions were heat-shocked 
in  a  water  bath  at  42°C  for  10  min,  cooled  to  30°C  and  the  cells  pelleted  by 
spinning. The pellet was resuspended in  1   ml of warm YEPD and incubated for 3 h 
at 28 °C to initiate expression of the selectable marker, before plating on selective 
media.  After  the  incubation  period,  the  cells  were  spun  down,  the  supernatant 
removed and the pellet resuspended in 200 pi of YEPD.
Selection of G418-resistant cells
100 pi of the transformed cells was plated onto G418-plates (in duplicates), in order 
to select the cassette-bearing yeast cells. G418 (dissolved in water) had been added 
at a concentration  of 300 mg/L  in  the  YEPD medium  (containing  agar).  The  two 
G418-plates were incubated at 30°C for 48 hours. At this point, it was necessary to 
replica  plate  the  G418-plates  twice,  in  order to  eliminate  the  background  growth 
and obtain more prominent G418-resistant colonies. These replica plates were then 
incubated  for  a  further  48-72  h  at  30°C.  The  more  prominent  colonies  of  the 
transformants were then selected from the more dilute replica plate. Half of each of 
these  colonies  was  then  restreaked  onto  G418-plates,  while  the  other  half  was 
grown  in  10  ml  of  liquid  G418-YEPD  medium.  Growth  of the  former,  allowed 
further confirmation  of the resistance to G418,  while  DNA  preps were carried out 
from the cells grown in the liquid G418-YEPD.
Isolation of yeast genomic DNA
Genomic  DNA  was isolated from the cells that were grown  in liquid G418-YEPD 
medium,  using  the  Nucleon  Yeast  DNA  Mini-prep  kit  (Tepnel  Life  Sciences, 
Manchester,  UK).  Cells were pelleted by centrifugation and resuspended in 540 pi
247solution  A  and  60  pi  solution  B  (supplied  with  the  Mini-prep  kit).  The  cell 
suspension was vortexed for 30 s and incubated in a 70°C heat block for 20 min. A 
1:1  volume of phenol-chloroform was then added  instead of the provided solution 
C, as this was found to result in an  improved  DNA yield.  Samples were vortexed 
and spun in a microcentrifuge at full speed. The aqueous layer was transferred to a 
fresh  eppendorf  and  an  equal  volume  of  isopropanol  was  added.  Samples  were 
mixed  by  inversion  and  spun  for a  further 5  min.  The  supernatant  was  carefully 
discarded and the pellet was washed twice with  100 pi of 70% ethanol. Pellets were 
dried  at a 65°C heat block for 3  mins and  resuspended  in  100 pi  of sterile  water. 
The resuspended DNA was stored at 4 °C until use.
Confirmation of the disruption of gene disruption
Integration  of the  cassette  at  the  correct  locus  was  confirmed  by  PCR  across  the 
gene,  using  specific  gene  primers  designed  to  flank  the  disrupted  region,  and 
template  DNA  derived  from  a  single  transformant  colony.  The  primers  (MWG) 
employed for confirmation of the RAD4 disruption, defined as “RAD4 5'-CHECK” 
and “RAD4 3'- CHECK” are the following:
RAD4 5'-CHECK
5'-TGC ATG CAC AAT ATA TGC AA-3'  Tm = 48 °C
RAD4 3'-CHECK
5'-GTT CTC ATT CAT TAC AAA GT-3'  Tm = 49.1 °C
PCR reactions to check the disrupted gene were performed in a total volume of 100 
pi,  containing:  10  pi  (100  ng)  of the  genomic  DNA  isolated  from  a  transformant 
colony.  10 pi of 10 x Thermopol  buffer, 2 pi of 100 mM MgS04,  12.5 pi of 2 mM 
dNTPs, 2.5 pi of each “CHECK” primer (at a concentration of 10 pmol /pi), 2 units 
of Vent DNA polymerase (1  pi) and the rest of the volume made up with distilled 
water. The PCR conditions used were: 94°C 4 min; 94°C lmin, 47°C 1   min, 72°C 2
248min +  1   s/cycle, 30 cycles; 72°C 5min. The PCR reactions were performed on a MJ 
thermocycler machine.
The size of the PCR product alone, could distinguish between disrupted genes and 
the  wild-type.  However,  further  verification  was  also  obtained  from  restriction 
enzyme  digests  performed  on  the  PCR  products.  Two  restriction  enzymes,  Pvu I 
and EcoR V (NEB) were chosen that would each yield a distinct array of fragments, 
allowing to distinguish  between  the  normal  and  disrupted  genes,  as  visualised  by 
agarose  gel  electrophoresis.  Restriction  digests  were  performed  on  10  pi  of PCR 
reaction  in  a total  volume  of 20  pi,  for  1   h  in  a  37°C  heat  block  and  the  entire 
reaction was subsequently  run on  an ethidium bromide-stained,  1% agarose gel  in 
0.5  x TBE  buffer.  Both  cut and  uncut control  samples  (containing  the  wild-type 
RAD4  gene)  were  also  run,  along  with  the  DNA  markers,  1   kb  and  X  Hind  III 
(NEB).
2494.3 Results - TH-III-151 repair studies
The first compound  selected for yeast  repair studies was TH-III-151,  a seco-CFQ 
agent  that  was  shown  to  alkylate  DNA  at  the  N3  position  of  adenine,  with  a 
sequence selectivity indistinguishable to that of adozelesin (section 2.3 ).
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Figure 4.7 Structure of TH-III-151  (also featured in Figure 2.13).
4.3.1  NER-defective  veast  cells  are  sensitive  to  TH-III-151.  NER  is  the 
predominant excision repair event.
The colony-spotting assay was employed as an initial indication for the involvement 
of specific  DNA  repair and damage tolerance responses to the TH-III-151  induced 
A-N3  adducts.  This  is  a  qualitative  screening  of  drug  sensitivities  and  the 
involvement  of  the  various  pathways  is  assessed  by  examining  the  growth 
phenotypes  of  the  strains  defective  in  specific  repair  functions,  relative  to  their 
isogenic repair proficient parental strain.  Figure 4.8 shows the growth of the parent 
strain and  key  mutants belonging to the two major excision pathways,  NER (rad4) 
and  BER  {magi).  The  effect  of simultaneous  elimination  of  BER  and  NER  was 
assessed by also including the double mutant rad4magl.
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Figure  4.8  Sensitivity  of the  excision  repair  mutants magi  (BER)  and  rad4 
(NER)  treated  with  increasing  concentrations of TH-III-151.  DBY474  is  the 
repair proficient wild type.
251The rad4 cells are completely deficient in  NER, as the  gene  has  been  assigned  a 
role in an early step of the repair reaction and its function is an absolute prerequisite 
for the dual  incision  of damaged  DNA  by  NER (Guzder et al.,  1995;  1998). The 
NER defective strain is sensitive to TH-111-151, as at a concentration of 1   pM there 
is no growth  evident, even  in the 5000 cells patch.  This observation  suggests that 
the TH-III-151  adducts are NER substrate, as was the case for the lead compound 
CC-1065. The BER mutant, magi, is defective for the activity of 3-methyladenine 
DNA glycosylase, an enzyme known to repair simple guanine-N7 and adenine-N3 
monalkylations (Berdal et al.,  1990; Bjoras et al., 1995). This mutant strain displays 
no increased sensitivity, showing a growth pattern comparable to that of the repair 
proficient DBY747 parental strain and remaining resistant to the killing effect of up 
to 1   pM of TH-III-151.
For  some  alkylating  agents,  including  methylmethane  sulphonate  (MMS)  and 
simple nitrogen mustards, such as mechlorethamine, the actions of BER and NER, 
overlap,  in  the removal  of the  relevant adducts (Xiao et al.,  1996; McHugh et al. 
1999b; Brooks et al., 2000). The gene action and the functional contribution of the 
pathways they represent, in the process of the TH-III-151  damage, can be assessed 
with the inclusion in our yeast sensitivity studies, of double mutants, by comparing 
their phenotypes to those of each individual  mutant. The level of sensitivity of the 
double  mutant,  rad4magl,  was  found  to  be  comparable  to  that  of rad4  alone  as 
shown in Figure 4.8, suggesting a predominant role for the NER.
A more accurate determination of sensitivity, which offers an insight in the epistatic 
relationship  between  the  two  excision  pathways,  requires  the  construction  of the 
corresponding survival curves of the above-mentioned strains. Figure 4.9 compares 
the  sensitivity  of  the  parent  strain  DBY747,  to  its  isogenic  rad4  and  magi 
disruptants and the rad4magl double mutant. If competition for a common lesion is 
occurring  then  a  synergistic  increase  in  damage  sensitivity  would  be  expected, 
when  the  relevant  pathways  are  eliminated  simultaneously.  In this  case  the  rad4 
strain was highly sensitive to the agent compared with the parental strain. The magi 
cells showed  no  increased  sensitivity over the  wild type,  while the double  mutant
252was  as  sensitive  as  the  most  sensitive  single  mutant,  i.e  the  NER-deficient  rad4 
cells. This suggests that the observed sensitivity of the double disruptant is solely 
dependent on the NER defect. These responses mirror the relative growth rates of 
the strains, as observed in the colony-spotting assay (Figure 4.8), validating its use 
for  qualitative  large-scale  screening.  It  is  therefore  evident  that  NER  is  the 
predominant pathway in the elimination of the TH-III-151 adducts.
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Figure  4.9 TH-III-151  sensitivity  of rad4,  magi,  and  rad4magl  cells  compared 
with their isogenic parent (DBY747). Exponentially growing cells were treated with 
the  stated  doses for 3  h  at 30°C.  All  results  shown  are the  mean of at least three 
independent experiments. The error bars represent the standard error of the mean.
The same pattern of sensitivity was observed for another BER deficient strain, oggl 
(8-oxoguanine/formadopyrimidine  glycosylase).  The  OGGI  gene  encodes  a 
glycosylase endowed with an AP lyase activity (Van der Kemp et al.,  1996). Figure 
4.10  compares  the  sensitivity  of  oggl,  its  parent  strain  W303a,  and  the  double 
mutant  ogglradl4.  The  radl4  strain  is  another  completely  NER  defective
253disruptant, essential for the damage recognition and the subsequent incision by the 
Radi-Rad 10  nuclease  (Prakash  &  Prakash,  2000;  Guzder et al.,  2006).  While  the 
oggl  mutant  does  not  show  any  increase  in  sensitivity  over  the  wild  type, 
elimination  of  both  BER  and  NER  activities  confers  increased  sensitivity 
comparable  to  that  of the  rad4magl  double  mutant.  The  sensitivity  of the  rad 14 
cells to the agent is indistinguishable to that exhibited by the rad4 mutants, further 
establishing the important role of NER for the cellular sensitivity to TH-III-151.
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Figure 4.10 TH-III-151  sensitivity of oggl  with  its isogenic  parent W303a, radl4 
and the double mutant ogglrad!4.
In  order  to  assess  the  potential  involvement  of  alternative  BER  activities,  other 
known  BER mutants were screened for sensitivity, including the bifunctional  DNA 
glycosylase  /  AP  lyases  ntgl  (8-oxoguanine  glycosylase/lyase),  ntg2  (related  to 
Escherichia  coli  endonuclease  III)  (Alseth  et  al.,  1999)  and  ungl  (uracil-DNA 
glycosylase)  (Percival  et  al.,  1989).  Figure  4.11  shows  a  panel  of  these  BER
254deficient strains along with their corresponding isogenic parent. The mutant strains 
grew  at  rates  comparable  to  that  of  the  corresponding  wild  type,  after  drug 
treatment with  1   pM of TH-III-151. Again it was only the rad4 cells that exhibited 
sensitivity  at  this  drug  concentration,  implying  that  NER  is  the  predominant 
pathway involved in the elimination of the TH-III-151  adducts.
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Figure 4.11 Sensitivity of the BER repair mutants ntgl, ntg2 and ungl treated with 
increasing concentrations of TH-III-151, compared to their isogenic parental strain. 
For comparison  reasons,  another  BER  mutant magi  and  the  NER  defective  rad4 
strain,  along  with  their  repair  proficient  wild  type  is  also  included  (bottom 
“matrix”).
2554.3.2 rad 18 cells are sensitive to TH-III-151
The rad 18 strain from the RAD6 epistasis group, has been  previously shown to be 
sensitive  to  the  highly  sequence  specific  minor  groove  adducts  produced  by  a 
benzoic  acid  mustard  tethering  three  pyrrole  ring  (Figure 4.2).  A  marked TH-III- 
151  sensitivity  was  also observed  in  a radl8 disruptant strain  as shown  in  Figure 
4.12. The double disruptant rad4radl8 was more sensitive than either of the rad4 
and rad!8 single mutants.
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Figure 4.12 TH-III-151  sensitivity of rad4, rad!8 and rad4 radl8 cells, compared 
with  their  isogenic  parent  (DBY747).  All  results  are  the  mean  of  at  least  three 
independent experiments. The error bars show the standard error of the mean.
This  indicates that RAD4  and RAD 18 are  not epistatic for the TH-III-151  damage 
response. The lack of epistasis in toxicity in survival assays is often taken to suggest 
that  the  genes  act  in  different  pathways  and  reactions.  Inactivation  of  the  NER
256pathway might result in the lesions that would have been repaired by this pathway, 
to being channelled through, what seems to be a competitive pathway controlled by 
Rad6-Radl8,  hence  the  synergistic  interaction  between  the  two  mutations. 
Alternatively  the  TH-III-151  adducts  might  elicit  multiple  damage  responses 
(including NER or a related excision repair process involving NER factors), which 
are  all  controlled  by  Rad6-Radl8.  Elimination,  therefore,  of  this  additional 
excision-related Rad 18 function, would produce an increase in sensitivity in a strain 
defective in both NER and RADI8 over either single mutant.
The sensitivity of a yeast strain defective in a particular function is indicative of the 
involvement of a specific  gene  in  the  DNA  damage  response  as  a determinant of 
chemosensitivity to the agent.  However, functions at molecular level are not always 
mirrored  in  the  phenotypes  and  the  responses obtained  in  such  sensitivity  assays. 
For  example,  in  a  rad26  disruption  mutant,  preferential  repair  of  UV-induced 
cyclobutane pyrimidine dimers in the transcribed strand of the active RBP2 gene is 
severely impaired.  Surprisingly, and in contrast to the human CS mutant, the yeast 
RAD26 disruption does not confer any UV, cisplatin, or X-ray sensitivity (Van Gool 
et al.,  1994). This is particularly  relevant to minor groove lesions as the sequence 
specific adducts induced by a nitrogen mustard-tethered distamycin analogue, while 
excised  in  the  wild  type  strain,  in  a rad!8 mutant were  not eliminated  (Brooks et 
al., 2000).
A  molecular approach,  employing a PCR-based  technique  was  used  to  investigate 
whether  the  sensitivity  of  the  radl8  cells  as  exhibited  in  Figure  4.12,  could  be 
attributable  to  decreased  elimination  of  the  TH-III-151  adducts.  Such  possibility 
would  extend  the  requirement  of  functional  Rad 18  for  the  excision  of  sequence 
specific adducts to yet another class of minor groove binding agents, the CC-1065 / 
duocarmycin family of compounds.
2574.3.3  Induction and repair of TH-III-151 adducts at nucleotide resolution in cells
Single-strand  ligation  PCR,  (slig-PCR)  was employed  to follow  the  induction and 
repair  of TH-III-151  adducts  at  nucleotide  resolution  in  intact  cells  of  key  yeast 
strains. The repair capacity of the highly sensitive rad4 and radl8 mutants (as well 
as  the  rad6  strain)  was  compared  to  their  isogenic  parent  DBY747.  This  study 
provides  insight  in  the  contribution  of the  post replication  repair  pathway  (rad18 
and rad6 strains)  in the elimination of the TH-III-151  adducts and its requirement 
for the excision of minor groove sequence specific adducts.
The  repair  efficiencies  of  the  various  yeast  strains  were  assessed  using  primers 
specific for  both  the transcribed  and  nontranscibed  strands of the transcriptionally 
active  MFA2  gene.  This  gene  produces  a2  factor,  a  protein  involved  in  the 
pheromone  response  pathway  and  has  a  known  sequence  (Mallet  et  al.  1995). 
MFA2 is an a-specific gene and has an a2 operator in the control region involved in 
the chromatin-coupled repression of a-specific genes in a cells, through the binding 
of repressors (Mcml  / a2) and nucleosome positioning in adjacent sequences (Teng 
et  al.,  2000).  In  its  active  form  however,  in  a  cells,  the  gene  exists  in  “open” 
chromatin  conformation.  The  MFA2  gene  has  been  adopted  as  a  model  gene  for 
various  DNA  repair investigations at  nucleotide  resolution,  including the  study  of 
the  repair  of  UV-induced  cyclobutane  pyrimidine  dimers  (CPDs)  and  the 
elucidation of the role of specific yeast genes in excision repair (Teng et al.,  1997; 
1998;  Teng  &  Waters,  2000).  The  same  gene  was  also  selected  for the  previous 
study  of  the  repair  of  sequence  specific  minor  groove  adducts  at  nucleotide 
resolution in yeast (Brooks et al., 2000).
Genomic  DNA  extracted  immediately  after  drug  treatment  and  at  various  repair 
time points was digested with the Rsa I restriction enzyme. The first Rsa I site is -  
337 from the start of the coding sequence of MFA2, which is  117 bp in length, and 
the  second  is + 416 after the end of the coding sequence.  The  resulting  restriction 
fragment (869 bp) therefore contains the transcribed region of the MFA2 gene (328
258bp),  the  Mem  1   binding  site  (part  of the  a2  operator)  and  the TATA  box  in  the 
upstream control region, and downstream flanking sequences (Figure 4.13).
Q  MFA2 TATA
Figure 4.13 The regions of the MFA2 gene. The Rsa I restriction fragment contains 
the Mcml  binding site at -251  and the TATA box at -125 in the upstream control 
region of the MFA2 coding region, and downstream sequences. The Dde I digestion 
was performed for analysis on the NTS. The numbers placed vertically represent the 
nucleotide position with respect to the MFA2's coding region start point (+1).
The  primers  selected  for  the  study  of the  transcribed  strand  (TS)  define  a  region 
from -20 (from the start of the coding region) to the Rsa I site distal. Figure  4.14 
depicts an  autoradiograph from  initial  experiments examining TH-III-151  damage 
on the TS strand of the Rsa I restriction fragment of the DBY-747 wild type strain, 
and on isolated “naked” DNA from the same cells. This experiment was carried out 
to detect the level of lesions along the MFA2 gene induced by  1   and  10 pM of TH- 
III-151  in  order  to  determine  the  dose  that  gives  the  optimal  signal  under  the 
experimental  conditions  employed.  While  bands  representing  TH-III-151  adducts 
could  be detected  at the  lower dose  of  1   pM  in  isolated  DNA,  in  DNA  extracted 
from cells treated with the agent, the higher dose of 10 pM, produced a better signal 
and allows detection by sslig-PCR of a wider distribution of DNA adducts formed. 
At this concentration, the same pattern of damage is detected between treated cells 
and treated naked DNA (incubation time was in both cases 3 h).
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Figure 4.14 A comparison of the levels of PCR signal detected in cells and isolated 
DNA  with  different TH-III-151  concentrations.  Sslig-PCR  was carried  out on  the 
TS of the MFA2 of DBY747 cells, treated with  1   and  10 pM of TH-III-151  for 3 h 
at  30°C.  Isolated  (“naked”)  DNA  was treated  with  the same concentration for the 
same  incubation  time  (3  h).  The  bands  on  the  autoradiograph  represent  DNA 
fragments  of varying  lengths,  which  correspond  to  the  positions  of drug  adducts 
along the sequence.
260The  cellular  environment,  despite  the  presence  and  binding  of  proteins  does  not 
therefore  seem  to  significantly  affect  the  occurrence  of  TH-III-151  adduct 
formation. The untreated control lane (U) in cells contained a ladder of background 
bands primarily due to non-specific polymerase stops.
In  order  to  characterise  the  sites  of TH-III-151  adduct  formation,  the  sslig-PCR 
products  were  run  alongside  di-deoxy  sequencing  products.  The  MFA2  fragment 
subjected to sequencing was amplified  by  PCR and defined by the sets of primers 
2.3B  and  2.5C  for  the  TS  and  2.5C  and  2.4C  for  the  NTS  (For  the  primers’ 
sequence  and  conditions for the  generation  of PCR fragments for sequencing  see 
Methods-section 4.2.2.5). The PCR should optimally yield a single specific product 
of the  expected  size,  subsequently  verified  with  a  mini  agarose  gel.  Figure  4.15 
shows the amplified PCR products for the sequencing of TS and NTS.
TS NTS
lkb 10  100  ng lkb  10 100  ng
Marker
Figure 4.15 Agarose gel  showing the PCR fragments  used for di-deoxy sequencing. The 
PCR  product specific for TS  (left  image),  has  a size of 574 bp, while the  NTS  specific 
fragment was 595 bps (right; since the two are not generated by identical sets of primers). 
A  molecular mass  marker (1  kb;  Invitrogen) was also included as a standard. The yield 
differed on using different amount of the target sequence to be amplified.
In  each  case,  one  of the  primers  was  radiolabelled  and  the  resulting  sequencing 
ladder,  as  exhibited  in  Figure  4.16  refers  to  the  opposite  strand  of  that  being 
analysed for TH-III-151  lesions.
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Figure 4.16 Sequencing of the TS of MFA2 to determine sites of TH-III-151 binding. Drug 
treated cells and treated isolated DNA are denoted. Sequencing ladders are indicated as A, 
T, C, G. The full length fragments are indicated by an asterisk.
Lane U has untreated isolated genomic DNA. The single band at the top of the gel 
represents the intact restriction fragment. Lane T has the same DNA, treated in vitro 
with  10  pM  of TH-III-151,  the  same  drug  concentration  as  the  one  used  for the 
treatment of the yeast cells.  Lane 0 has DNA extracted from DBY747 cells, mock- 
treated with solvent only, while lane  10 contains DNA from cells treated with TH- 
III-151  for three hours, and extracted immediately after drug treatment. There is a
262clear decrease  in  the  amount of intact  undamaged  fragments  at the top of the  gel 
between  both  pairs of lanes, due to the drug lesions causing downstream blockage 
of the Taq polymerase and resulting in the amplification of shorter fragments. In the 
several  prominent  sites of DNA  adduct formation,  are  evident  along the  length of 
the MFA2 gene. In lane T (naked DNA), the intensity of the bands is less than those 
corresponding  to  the  same  adducts  in  lane  10  (cells).  This  is  possibly  due  to  the 
higher level of adduct formation on isolated DNA, induced by the  10 pM of TH-III- 
151, which produced this distortion, where adducts closest to the primer correspond 
to  more  intense  bands,  while  those  further appear as fading  (especially  when  the 
upper portion of the gel, close to the full length fragment is presented, as in Figure
4.16). In this case, the intensity of a band no longer relates to the relative frequency 
of the adducts at that particular position, as single-hit kinetics is exceeded and more 
than  one  adduct  per  DNA  fragment  is  occurring.  However,  a  darker  copy  or 
treatment of the isolated  DNA  with a smaller concentration of agent (Figure 4.17), 
allows comparison of the damage pattern.
By cross reference to the sequencing ladder, run with the samples, it was possible to 
deduce the sequence of the adducts, as shown by the arrows in Figures 4.17. The di- 
deoxy products were not processed by the sslig-PCR technique, therefore due to the 
addition  of  the  ligation  oligonucleotide,  the  sequencing  products  migrated  23 
nucleotides further on the gel than the corresponding sslig-PCR products.
TH-III-151  reacted exclusively with adenines, showing preference for long A-tracts 
and AT mixed sequences, i.e the sequence specificity in the cellular environment is 
similar  to  that  previously  observed  in  plasmid  DNA  (chapter  2.2).  In  a  previous 
study, sslig-PCR revealed a novel binding site for cisplatin in cells (Grimaldi et al., 
1994).  In  TH-III-151  treated  cells  however,  the  same  set  of  adducts  with  those 
found  in  isolated,  drug  treated  genomic  DNA  were  detected,  within  the  same 
sequence context, and with no additional lesions forming in cells (Figures  4.16 and
4.17).
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Figure  4.17  Comparison  of  the  damage  induced  by  I  pM  of  TH-III-151  in  isolated 
genomic  DNA  and  that  produced  in  cells  by  10  pM  of the  agent.  The  damage  pattern 
between the isolated DNA treated with the smaller drug concentration and that in cells, are 
identical. The sequencing ladders help identify the sequence and position of the adducts.
264This  observation  suggests  that  the  main  factor  determining  TH-III-151  adduct 
formation in cells is the primary DNA sequence.
Having established that TH-III-151  targets essentially the same CC- 1065-preferred 
sequences both  in vitro and in vivo we compared the repair efficiencies of key yeast 
strains to the repair competent DBY747 cells. Figure 4.18 shows the repair capacity 
of the DBY747 cells, on the TS of the MFA2 gene. For the repair studies, cells were 
subjected to post-treatment incubation in fresh medium (YEPD), to allow repair, for 
up to 8 hours. The decrease of the signal intensity at a specific band, corresponding 
to a discrete fragment for each A-N3 adduct, is suggestive of DNA repair. Repair is 
slow on the TS,  however the TH-III-151  adducts are gradually eliminated.  During 
the experiments, and for each time point of the post-treatment incubation, the cells 
were counted.  No cell  division  was observed during the 8  hour incubation  period, 
for any strain studied.  Moreover, no increase in DNA concentration is found when 
the  samples  from  various  repair  time  points  were  measured  fluorometrically 
suggesting  that  the  cell  population  remained  arrested.  During  the  post-incubation 
periods no DNA  replication should occur, which would result in reduction in band 
signal  and  diluting  the  TH-III-151  adducts.  The  band  fading  perceived  as  repair 
therefore  cannot  be  the  result of cell  growth  in DBY747  but is  because of adduct 
removal. The results in the DBY747 cells establish that repair of the adducts formed 
by TH-III-151  involve elimination from the DNA and are not simply tolerated.
The  sequence  context  of the  sites  of covalent  modification  by TH-III-151,  on  the 
resolvable  portion  of  the  gel  presented  here  (and  all  the  later  figures),  was 
determined based on the sequencing analysis of the autoradiographs and is shown in 
Figure  4.19.
265DBY747
5'
3'
U  0  2  4  6  8
B1F
ffT f
+287
3'-AAAAA-5'
3'-AAAAAA-5'
+276
+237
3'-GAAAAT-5'
3'-GAAAAAG-5'
+229
3'-TAAATAA-5'
+186
3'-AAATAAAT-5'
+162
106
fc  #—  4  to W «
3'-AATTAAAA-5'
+113
Figure 4.18  Repair  of TH-III-151  adducts  on  the  TS  of  MFA2.  Exponentially  growing  DBY747 
cells were  treated with  10 |xM TH-III-151  for 3 h at 30°C.  Cells were harvested and  DNA  extracted 
immediately (0 h  lane), or were resuspended  in YEPD and allowed to repair for a further 2, 4, 6 and 
h prior to DNA extraction. Sslig-PCR was performed as described in the Methods section. The major 
adducts  are  indicated  by  arrows,  along  with  their  position  relative  to  the  start  (+1)  of  the  coding 
region  on  MFA2.The  sequence  was  deduced  from  the  analysis  of the  di-deoxy  sequencing  ladders 
performed previously.
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Figure 4.19 Sequence of the resolvable portion of the autoradiographs presented in 
Figure 4.18 (and onwards). The extended sequence context of the sites of covalent 
modification by TH-III-151  (shaded) were determined by the analysis of the sslig- 
PCR  products  in  relation to di-deoxy  sequencing  ladders, and taking into account 
the size of the ligation oligonucleotide (23 bp). The numbers indicate the nucleotide 
position in relation to the start (+1) of the coding region of MFA2.
Figure 4.20 includes autoradiographs depicting TH-III-151  induced damage and its 
repair in the same fragment of the MFA2 in rad4 cells. These cells are completely 
NER-defective,  were  sensitive  in  the  yeast cytotoxicity assays and  no excision  of 
the adducts was expected to occur.
Sslig-PCR  on  the  BER-deficient  magi  strain  was  also  performed  for comparison 
(Figure 4.21).
The  magi  cells,  which  had  not exhibited  increased  sensitivity  to the  agent  in  our 
previous  experiments,  would  still  have  functional  NER  and  should  therefore  be 
capable of removing the TH-III-151  adducts.
267In  sharp  contrast  to  the  repair  competent  DBY747  cells,  as  well  as  the  NER 
functioning magi cells, no repair was evident in the NER defective strain. The rad4 
cells failed to eliminate any of the adducts on the TS, irrespective of their position 
with  100% of the damage persisting after 8 hours of post-treatment incubation. This 
observation  suggests  that  the  adduct  recognition  and  elimination  observed  in  the 
wild  type  strain  must  be  the  result of an  excision  process  involving  NER factors. 
This  differentiates  the  excision  event  seen  for  the  TH-III-151  with  the  one 
previously  observed  for  the  distamycin  analogues  of  BAM,  where  the  excision 
process was not identified, yet the  removal of the adducts did not seem to involve 
NER factors  (Brooks  et al,  2000).  A  clear gradient of repair was  observed  in  the 
magi  strain, as expected,  attributed to the function of the NER machinery (Figure 
4.21).
Subsequent experiments addressed whether the high level of sensitivity of the radl8 
cells to TH-III-151  previously identified could be the result of a defect in the adduct 
elimination.  Figure 4.22 (left) shows the repair capacity of the rad!8 strain.  Repair 
in  this  strain  was  not  simply  impaired  but  totally  defective.  Strikingly  the  radl8 
cells were as disabled as the rad4 cells in the elimination of the adducts on the TS. 
As  discussed  previously,  the  Rad 18  protein  physically  associates  with  Rad6 
forming a stable complex.  In  an  attempt to clarify  if the excision deficiency  is the 
result of inactivation of the the  Rad6-Radl8  complex or a phenomenon  limited to 
Rad 18 alone, rad6 cells were also assessed for their ability to eliminate the TH-III- 
151  adducts.  As shown in Figure 4.22 (right), rad6 cells exhibited the same adduct 
repair defect. The indistinguishable defective repair profiles of both rad6 and radl8 
cells,  indicate  that  both  proteins  are  required  for  the  removal  of the  TH-III-151 
adducts from the TS of MFA2.
These  observations  suggest that  the  excision  of the A-N3  adducts  induced  by  this 
novel CC-1065 analogue require functional Rad 18.
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Figure 4.20  Repair of TH-III-151  adducts on the TS of MFA2.  Exponentially growing rad4 cells 
were  treated  with  10  pM  TH-III-151  for 3  h  at 30°C.  Cells were harvested  and  DNA  extracted 
immediately  (0  h  lane), or  allowed  to  repair  in  YEPD  for a further 2, 4, 6  and  h  prior to  DNA 
extraction. Sslig-PCR was performed as described  in the Methods section. The major adducts are 
indicated by arrow, and their sequence and nucleotide positions in relation the start of the coding 
region are denoted. The sequence of the portion of the gels presented here stretches from positions 
106 to 300.
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Figure 4.21 Exponentially growing magi cells were treated with  10 pM TH-III-151  for 3 h at 30 °C. 
Cells were harvested and DNA extracted immediately (0 h lane), or allowed to repair in YEPD for a 
further 2,4, 6 and h prior to DNA extraction. Sslig-PCR was performed as described in the Methods 
section. The major adducts are indicated by arrow, and their sequence context in relation to the start 
of the coding  region are denoted. The sequence of the portion of the gels presented  here stretches 
from positions 125 to 350.
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Figure 4.22 Repair of TH-III-151  adducts on the TS of MFA2 in radJ8 and rad6 cells treated with 
10 pM TH-III-151 for 3 h at 30°C. Cells were harvested and DNA extracted immediately (0 h lane), 
or resuspended in YEPD and allowed to repair for a further 2, 4, 6 and h prior to DNA extraction. 
Sslig-PCR was performed as described  in the Methods section. The sequence of the portion of the 
gels presented here stretches from positions 106 to 300. The locations of the major adducts is shown 
by the arrows. The positions of the adducts relative to the start of the coding region is also indicated.
271This  provides  further  support  for  a  key  role for  Rad 18  in  the  repair of sequence 
specific adducts in the minor groove of DNA The rates of adduct repair between the 
parental  strain  and  the  repair  deficient  rad4  and  radl8  were  determined  by 
densitometric scanning of the relevant autoradiogaphs. The fraction of each adduct 
remaining at each time point (2, 4, 6, and 8 h) was determined relative to the initial 
value (0 h sample).  As shown  in  Figure 4.23 the adduct half-life on the TS of the 
repair proficient DBY747 was between 4 and 7 h.
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Figure 4.23 Repair rates of TH-III-151  adducts on the TS of the MFA2 gene in the 
DBY747  (parental),  rad4 and  radJ8  strains. The  half life of each  adduct  is  in  h. 
Values are the mean of at least three repeats.  U  indicates that none of the adducts 
was repaired after 8 h of post-treatment incubation.
2724.3.4  Repair of TH-III-151  adducts is transcription-coupled
NER is a genetically heterogeneous process and acts upon various different types of 
lesions  (e.g.  UV-induced  cyclobutane  pyrimidine  photoproducts,  cisplatin 
intrastrand  crosslinks).  Transcriptionally  active  regions  of  the  genome  can  be 
subject to faster repair than silent regions and that is manifested with the TS  being 
repaired  at  significantly  faster  rate  that  the  NTS.  This  process  is  known  as 
transcription-coupled repair (Hanawalt,  1989; Balajee & Bohr, 2000).
The induction and repair of the TH-III-151  adducts was also assessed using primers 
specific for the  NTS  of the MFA2  gene.  Figure 4.24 shows the  sequencing of the 
NTS  of  the  MFA2  gene.  The  PCR  amplified  region  which  was  subjected  to  di- 
deoxy  sequencing,  was  defined  by  primers  2.5C  (-49  relative  to  the  start  of the 
coding  region)  and  2.4C  (+547).  A  radiolabelled  marker,  giving  bands  at  10  bp 
increments,  was  also  run  along  the  sequencing  ladders  as  a  molecular  mass 
standard.  This  acted  as  an  alternative  for  sequence  determination,  when  the  di- 
deoxy reactions were not optimal. Again, the bands in the sequencing lanes were 23 
nucleotides  shorter  than  the  corresponding  sslig-PCR  generated  products.  The 
damage patterns on the isolated  DNA and the cells, treated  with  10 pM of TH-III- 
151  was identical, as the case was for the TS strand.
Figure 4.25 shows the repair of the TH-III-151  adducts on the NTS of the DBY747 
parental strain. No repair in the DBY747 cells is evident at post-incubation times of 
up to 8 hours.  A  visual comparison of the repair profiles of the wild type, between 
the  two  strands  (Figures 4.18  and 4.25),  suggests  that the  NER component of the 
repair observed only on the TS may be transcription coupled, as removal of adducts 
preferentially  occurs  on  this  strand  alone.  The  NTS  analysis  depicted  in  the 
autoradiographs  of  Figures 4.25  and  4.26 encompassed  sequences  downstream  of 
the transcription termination site (+328), because no prominent TH-III-151  adducts 
were  detectable  further  upstream  and  along  the  region  examined  in  the  repair 
analysis of the TS.
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Figure  4.24  Sequencing  of  the  NTS  of  MFA2  gene,  using  primers  2.5C  and  2.4C.  Di-deoxy 
sequencing  ladders  are  indicated  as  A,  T,  C,  G  and  used  to  determine  the  sites  of TH-III-151 
binding. Exponentially growing DBY cells were treated with  10 pM of TH-III-151 for 3 h at t 30°C. 
TH-III-151  lesions were detected using the sslig-PCR technique as described in the Methods section. 
Lane U has untreated genomic DNA and T is for the same DNA treated with  10 pM of the agent. A 
molecular  mass  marker  (increments  of  lObp)  was  also  included.  The  bands  represent  DNA 
fragments of vary ing lengths, which correspond to the positions of drug adducts along the sequence.
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Figure 4.25  Repair of TH-III-151  adducts on  the NTS of MFA2.  Exponentially growing 
DBY747 cells were treated with 10 pM of TH-III-151 for 3 h at 30°C. Cells were harvested 
and  DNA  extracted  immediately  (0  h  lane),  or  cells  were  resuspended  in  YEPD  and 
allowed  to  repair for  a  further  2,  4,  6  and  h  prior  to  DNA  extraction.  Sslig-PCR  was 
performed as described in the Methods section. The locations of the major adducts is shown 
by the arrows and their position  in relation  to the start of the coding region of MFA2 is 
denoted. The sequence of the portion of the gels presented  here stretches from  positions 
460 to 230.
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Figure  4.26  Portion  of an  autoradiograph  showing  TH-III-151  adducts  on  the  NTS  of 
MFA2, run alongside a molecular mass marker, which generates bands at 10 bp increments. 
Further upstream the coding region of the gene (transcription terminates at + 328), there is 
no visible, marked adduct formation.
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Figure  4.27  Repair  of  the  TH-III-151  adducts  on  the  NTS  of MFA2  of exponentially 
growing radl8 and rad6 cells. Conditions, Sslig-PCR analysis and labelling as described in 
legend for Figure 4.25.
277As can  be  seen from the  sequence  in  Figure 4.19,  within the region that stretches 
from +100 to +300, no consensus sequences of the 5'-AAAAA-3' type are present 
on  the  NTS  and  only  a  limited  number  of  AT  mixed  stretches  exists.  These 
sequences however are right opposite the TH-III-151  binding sites on the TS. Even 
for those  adducts  however which  are  positioned  within  the transcribed  portion  of 
the gene, no gradient of repair is observed.
TCR  has  been  previously  identified  in  the  MFA2  gene,  with  enhanced  NER  of 
CPDs on the TS  strand occurring at a faster rate, over repair on NTS (Teng et a/., 
1997).
Finally,  as  shown  in  Figure 4.27  (back) the radl8 and rad6 disruptants were also 
completely deficient in the removal of TH-III-151 adducts, the occurrence of which 
is identical among the different strains studied.
2784.3.5  RAD5 disruptants are extremely sensitive to TH-III-151
As discussed in the introduction, RAD6 and RAD18 are the putative members of the 
PRR  pathway  centrally  controlling  error-free  and  mutagenesis  (TLS)  activities. 
These  functions  have  been  divided  in  subpathways,  regulated  by  a  number  of 
proteins (see  Figure 4.4).  In  this way, it is  possible to dissect out the contribution 
made to the  drug  response  by  each  of the  major subpathways. To this effect,  key 
members  of  these  subpathways  were  screened  for  TH-III-151  sensitivity.  Initial 
studies  concentrated  on  the  rev3  and  rad30  mutants,  lacking  the  functions  of 
translesion polymerases £ and r\, respectively (Johnson, et al.,  1999).
Figure 4.28  shows the sensitivity of these  strains to TH-III-151, as exibited  in  the 
plate-based sensitivity screen.
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Figure 4.28 TH-III-151  sensitivity of the rev3 and rad30 mutant cells compared to 
the repair competent wild type cells.
Figure 4.29 shows the survival  curve of the rev3 strain.  Disruption  of REV3  does 
not confer markedly  increased  sensitivity to the agent. These observations  suggest 
that the PRR subpathways which contain rev3 and rad30 should not be involved in 
the  processing  of  the  TH-III-151  adducts.  The  NER  defect  therefore,  reported 
earlier for the radl8 and rad6 cells, cannot be explained by the loss of the activities 
of either of these  proteins.
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Figure 4.29 Sensitivity of rev3 cells compared with the wild type DBY747.
Mms2  and  rad5  disruptants  were  also  tested.  Mms2  and  Rad5  have  both  been 
assigned  to  the  error-free  branch  of  the  RAD6  pathway.  Mms2  forms  a  stable 
complex  with  Ubcl3  while  Rad5  physically  interacts  with  Rad 18  (see  section
4.1.4). Individual error-free PRR proteins may function in separate, but coordinated, 
processes,  adding  to the  complexity  of PRR.  The  double  mutant rad5 mms2  was 
therefore  also  included  to  provide  an  insight  on  the  relative  contribution  of each 
protein to the TH-III-151  sensitivity. As shown in figure 4.30 the rad5 disruptant is 
extremely sensitive to the agent while the mms2 strain is moderately sensitive.  It is 
therefore  the  RADS  defect  in  the  double  mutant  which  most  contributes  to  its 
sensitivity,  suggesting  that  Rad5  has  the  overall  control  of  this  specific  Rad6- 
dependent subpathway for this particular response.
280Having  established  that  the  error-free  Rad5-controlled  PRR  subpathway  is 
predominantly  required  for  resistance  to  TH-III-151  toxicity,  its  relationship  to 
NER was investigated.
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Figure 4.30 TH-III-151  sensitivity of rad5, mms2, and rad5 mms2 cells compared 
with their isogenic parent DBY747.
To  this  effect,  the  rad4  rad5  double  mutant  was  constructed  and  its  sensitivity 
compared to the individual single mutants.
In order to create the double mutant, a PCR-mediated gene disruption method was 
utilised (see Methods, section 4.2.2.6). This efficient technique uses gene disruption 
cassettes  to  create  mutant  genes  in  budding  yeast  and  only  requires  the  flanking 
sequences  of  the  relevant  gene.  To  construct  the  disruption  cassettes,  DNA 
sequences that flank the gene  to  be  mutated, are cloned left and right of a marker 
gene  using  PCR.  These  cassettes  are  subsequently  transformed  into  appropriate
281yeast cells. Homologous recombination between the flanking regions on the cassette 
and the wild type gene in the cells,  results in the disruption  of the wild type gene 
and the simultaneous integration of the marker gene. Thus, this technique allows the 
disruption of the desired gene,  in addition to incorporating a selection  marker in a 
single step (Guldener et al., 1996; Longtine et al., 1998).
In  creating  the  rad4rad5  double  mutant,  rad5  cells  were  transformed  with  the 
disruption  cassette  for  RAD4.  The  marker  used  in  this  case  was  the  KanMX4 
expression  module,  which  is  derived  from the Escherichia  coli transposon Tn903 
and  the  TEF  promotor/terminator  sequences  of  the  fungus  Ashbya  gossypii 
(Guldener et al.,  1996). This marker is particularly useful, since it confers resistance 
to  the  aminoglycoside  antibiotic  Geneticin  (G418)  and  therefore,  provides  a 
convenient  selection  for  the  transformed  yeast  cells.  Additionally,  since  the 
KanMX4  marker  is  completely  heterologous,  there  is  no  possibility  of the  yeast 
cells being resistant to G418 prior to transformation with the cassette or the marker 
recombining with the endogenous marker gene. The gene disruption procedure for 
the creation of the rad4 rad5 is outlined in Figure 4.32. Eventually, the yeast cells 
that  have  been  successfully  transformed  with  the  cassette  can  easily  be  selected 
based on the growth on G418 enriched plates.
Growth on G418 plates alone is not sufficient proof for the disruption of the RAD4 
gene  by  the RAD4-KanMX4-Rad4  cassette,  in  the rad5 cells.  This  only  indicated 
that the  yeast cells  have  been  successfully  transformed  with  the  cassette,  yet  it is 
possible  (around  30%  possibility)  for  the  cassette  to  integrate  elsewhere  in  the 
genome (Guldener et al.,  1996).
In order to confirm that the cassette has been integrated correctly and that the RAD4 
gene  has  been  disrupted,  gel  analysis of a number of enzymatic  digestions on the 
PCR products from the rad5 strain and its rad4::kanMX4 disruptant was performed 
as a confirmation test.
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Figure  4.31  The  PCR-mediated  gene  disruption  procedure followed  to create  the 
rad4 rad5 double mutant.
283Figure  4.32  shows  the  confirmation  strategy  involving  PCR  and  enzymatic 
digestions.  PCR  conducted  with  another  set  of  primers  (defined  as  “CHECK” 
primers),  which  are  only  complementary  to the flanking  ends  of the  RAD4  gene, 
yield  different  sized  PCR  products  for  the  rad5  cells  with  intact  and  disrupted 
RAD4  genes.  More  specifically,  the  rad5  strain  that  has  not  been  disrupted  for 
RAD4, should produce with this set of primers, a 2443  bp PCR product, while the 
rad4::kanMX4 mutant would  generate a  1662 bp product.  When digested  with the 
EcoR  V endonuclease, the former PCR product should produce two bands of  1436 
and  1007 bp, while the latter sample, should yield an intact  1662 bp product as the 
site of this enzyme is abolished once the KanMX4 cassete is integrated in the rad5 
cells. Digestion with Pvu I should produce two products of 1181  and  1262 bp from 
the rad5 cells, which should migrate at a very similar distance on an agarose gel, as 
they  are  of very  similar  size.  On  the  rad5  cells  mutated  with  rad4::kanMX4,  the 
same digestion will produce two bands of smaller sizes, 922 and 740 bp.
Figure  4.33  shows  the  gel  analysis  of  the  above-described  PCR  products  and 
digestions.  DNA from two diferent colonies grown on G418-plate after two rounds 
of replica plating were tested for disruption of the RAD4. The fragments produced 
by  PCR  and  enzymatic  digestion,  compared  to  samples  from  the  wild-type  rad5 
cells,  correspond  to  those  expected  from  the  RAD4-KanMX4-RAD4  cassette, 
therefore confirming the RAD4 disruption.
Having  constructed  the  double  mutant,  epistasis  analysis  was  performed  for  its 
sensitivity  to TH-III-151.  Figure 4.34 shows the  sensitivity  of the  single  mutants, 
rad4  and  rad5,  and  the  double  rad4rad5  mutant  to  the  agent.  Comparison  of the 
rad5 disruptant  with  the rad4  indicates that the  rad5 strain  was  more sensitive to 
TH-III-151  at  lower  doses  (below  1   pM).  In  addition,  the  double  disruptant  was 
more sensitive that the most sensitive, rad5, single mutant.
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Figure 4.32 Confirmation of RAD4 disruption using PCR and Pm I and EcoR V digestion. 
PCR conducted with the CHECK primers yields different sized PCR products for the rad5 
strain  with  intact  and  disrupted  RAD4.  Digestion  with  the  two endonucleases  generates 
fragments of differing sizes and acts as another way of further confirming that the RAD4 
gene has indeed been disrupted in the rad5 mutants.
285rQd5  rad4 rad5-1 rad4 rad5-2
1   1   1   1  
1  kb  X .  control  EcoR V  Puv 1   control  EcoRV  Puv 1
1   1
control  EcoR V Puv 1   X  1  kb
kb
2.5-#
2.0— #
1.5—#
1.0— »
F igure  4.33  Gel analysis of undigested and EcoR  V or Pvu I digested samples to confirm
the creation of the rad4 rad5 double mutant.  1   kb and X . (Lamda DNA-Hind III digest) are
molecular  weight  standards.  DNA  samples  from  two different colonies  grown  on  G418
plates (denoted as rad4 rad5-1  and rad4 rad5-2) were tested and gave identical results. As 
expected  (and  schematically  drawn  in  Figure  4.32A  and  B),  samples  from  rad5  cells, 
produces  a single  PCR  product after amplification  with  the CHECK  primers  of 2.4 kb. 
When this is digested with EcoR  V, it is fragmented to give two distinct  1   kb and  1.4 kb 
bands (lane 4 from left). Digestion with Puv I gives two closely migrating bands of around 
1.2  kb  (lane  5  from  left).  Samples  from  G418  resistant  colonies  gave  identical  results 
between them. PCR amplification produced a product of 1.6 kb and In contrast to the rad5 
cells,  digestion  with  the  same  endonucleases  produced  distinct  fragments  of  the  sizes 
shown in Figure 4.32B.
These  cytotoxicy  profiles  emphasise  the  importance  of  the  Rad5  defect  as  a 
determinant of the sensitivity of  the NER-defective rad4 cells to the agent.The high 
level of TH-III-151  sensitivity in the rad5 strain and the exhibited complex pattern 
of  epistasis  with  the  rad4  mutant,  warranted  direct  investigation  for  functional 
evidence through the repair of the TH-III-151-induced adducts in rad5 cells.
Figure 4.35 shows the induction and repair of TH-III-151  adducts along the TS of 
the  MFA2  gene on  the  parental  DBY747  strain  (left) and the rad5  mutant (right).
286The sslig-PCR analysis  revealed  the  same adduct elimination  defect as previously 
seen in the rad4 and rad  18 cells.
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Figure 4.34 TH-III-151  sensitivity of rad5, rad4 and rad4rad5 cells compared with 
their isogenic parent DBY747.
The  rad5  cells  failed  to  remove  any  of  the  adducts  and  100%  of  the  damage 
persisted during the 8 hour post treatment recovery period. That is in sharp contrast 
to  the  repair  competent  DBY747  cells.  It  therefore  appears  that  it  is  the  RAD5 
branch of the RAD6 pathway which influences the elimination by NER of the minor 
groove adducts produced by this novel agent and that the interaction between these 
two pathways is important in controlling drug sensitivity.
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Figure  4.35  Comparison  of  the  repair  profiles  of  DBY747  and  rad5  cells  on  the  TS  of 
M FA2.  Cells  were  treated  with  10  pM  TH-III-151  for  3  h  at  30°C  and  harvested 
immediately  (0  h  lane),  or  resuspended  in  YEPD  and  allowed  to  repair for a further 2, 4,  6  
and  8   h  prior  to  DNA  extraction.  Sslig-PCR  was  performed  as  described  in  the  Methods 
section. The sequence of the  portion of the  gels  presented  here stretches from positions  106 
to  350.  The  locations  of  the  major  adducts  is  shown  by  the  arrows  and  their  position 
relative to the start of the coding region is also indicated.
2884.4 Results - AS-I-145 repair studies
AS-I-145  is  a  novel  CC-1065/duocarmycin  analogue,  distinct  from  all  other 
analogues previously  reported from other groups,  in that it lacks the characteristic 
stereocentre of the  lead compounds.  As discussed  in  chapter 3, the agent retained 
the  characteristic  AT-rich  sequence  specificity  of  this  class  of  compounds, 
selectively  alkylating  A-N3  groups  in  the  minor  groove  of  DNA.  AS-I-145 
exhibited comparable sequence selectivity to TH-III-151  and comparable cytotoxic 
activity in K562 cells (Chapters  2 and  3).
Me
nh2
AS-1-145 
NSC D716970
Figure 4.36 Structure of AS-I-145, also featured in Figure 3.11.
The  fact  that  AS-I-145  and  TH-III-151  are  chemically  closely  related  does  not 
guarantee that their repair profiles would be identical.  Differences in the sensitivity 
of yeast  strains  between  a  lead  compound  and  an  analogue  have  been  previously 
reported as in the case of methotrexate and trimetrexate (Simon et al., 2000). 
Although both TH-III-151  and AS-I-145 induce the same type of damage on DNA, 
as demonstrated  in  plasmid  DNA  studies,  the  unique,  novel  structure of AS-I-145 
and  its  markedly  enhanced  in  vivo  antitumour  activity  (see  Chapter  6  -   general 
discussion) made it a suitable candidate for yeast sensitivity screening.
289As previously for TH-III-151, Saccharomyces cerevisiae strains totally defective in 
specific  DNA  repair  pathways  were  screened  for  sensitivity  to  the  agent,  in  an 
attempt  to  delineate  the  main  mechanisms  involved  in  the  repair  of  the  minor 
groove targeted adducts.
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Figure  4.37  Sensitivity  of  the  excision  repair  mutants  magi  (BER),  and  rad4 
(NER)  treated  with  increasing  concentrations  of AS-I-145.  DBY747  is  the  repair 
proficient parental strain.
As was the  case for TH-III-151,  the  NER defective  strain rad4 exhibited elevated 
sensitivity,  since  very  little  growth  was  evident at  a  drug  concentration  of  1   pM 
(Figure 4.37). In contrast, the insensitivity exhibited by BER mutant magi suggests 
that the AS-I-145 adducts in yeast, are not substrate for this glycosylase.
The  potential  involvement  of  other  BER  functions  was  investigated  with  the 
screening  of other  glycosylases,  since  initiation  of  BER  depends  on  the  damage 
recognition  by  these  enzymes  (see  section  4.1.4).  Figure  4.38  compares  the 
sensitivity  of  other  known  BER  glycosylases  to  the  isogenic  parent.  Again,  no 
marked sensitivity was evident for any of these mutant strains, suggesting that NER 
is the crucial process for the elimination of the AS-I-145 adducts.
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Figure 4.38 Sensitivity of the BER repair mutants ntgl, ntg2 and ungl, all deficient in a 
glycosylase activity, treated with increasing concentrations of AS-I-145 compared to their 
isogenic  parental  strain.  For  comparison,  another  BER  mutant  magi  and  the  sensitive 
NER defective rad4 strain, along with their repair proficient wild type are also included 
(bottom “matrix”).
To further confirm  the  NER  role  as  the  predominant excision  pathway  involved  in  the 
repair of the AS-I-145 adducts, epistasis analysis was performed for the sensitivity of the 
rad4  and  the  magi  cells,  and  the  double  mutant  rad4magl.  Figure  4.39  shows  the 
relevant survival  curves. It is evident that the sensitivity possessed by the double mutant 
is mostly  due  to the  NER defect as  simultaneous  elimination of both  pathways did  not 
markedly  increase  the  sensitivity  of the  rad4  mutant.  This  confirms  that  BER  has  no 
major  contribution  to  the  repair  process  and  that  NER  is  the  predominant  excision 
process.
291Yeast  survival  curves  were  also  produced  for radl8  cells.  The  functional  relationship 
between  Rad 18  and  NER  was  investigated  with  the  inclusion  of the  rad4rad!8 double 
mutant. Figure 4.40 shows the sensitivities of the rad4, radl8 and rad4 rad!8 cells. Both 
the rad4 and radl8 disruptants displayed marked sensitivity to AS-I-145. Comparison of 
the  AS-I-145  sensitivity  of  the  rad4radl8  double  disruptant  with  the  single  mutants 
indicated that RAD4 and RAD 18 are not epistatic for the AS-I-145 damage response.
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Figure  4.39  AS-I-145  sensitivity  of rad4,  magi,  and  rad4  magi  cells  compared 
with  their  isogenic  parent  (DBY747).  All  results  shown  are  the  mean  of at  least 
three  independent experiments.  The  error  bars  represent the  standard  error of the 
mean,
The  rad4  radl8  strain  was  more  sensitive  than  either  the  rad4  or  radl8  single 
mutants,  in  an  at  least  additive  fashion.  The TH-III-151  and  AS-I-145  sensitivity 
profiles  of the  yeast  strains  studied,  are  highly  similar  indicating  that  a common 
response to A-N3 adducts is induced by this family of drugs.
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Figure 4.40 AS-I-145  sensitivity  of rad]8,  rad4,  and  rad4  radl8 cells compared 
with  their  isogenic  parent  (DBY747).  All  results  shown  are  the  mean  of at  least 
three  independent  experiments.  The  error  bars  represent the  standard  error of the 
mean.
The importance of the Rad 18 function was previously shown to lie in the function 
of NER.  Sslig-PCR was employed to follow the induction and repair of the AS-I- 
145  addducts  along  the  the  MFA2  gene.  The  repair capacity  of the  rad4  and  the 
radl8  mutants  compared  to  their  isogenic  parent  DBY747  was  assessed  using 
primers specific for the TS  of the MFA2.  Figure 4.41  shows the detection  of the 
adducts  by  sslig-PCR,  in  DBY747,  rad4  and  rad!8  cells.  The  incidence  of  the 
adducts along this region of the gene is almost identical between AS-I-145 and TH- 
III-151, extending our observation of their similar sequence  specificity in  plasmid 
DNA,  to  the  cellular  environment  of  yeast  cells.  It  is  clear  that  the  AS-I-145 
adducts  are  eliminated  in  the  repair  proficient  parental  strain,  with  most  of the 
damage  being  repaired  within  8  hours of post-treatment  recovery.  In  contrast,  no 
repair is observed in the rad4 and rad!8 cells.
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Figure 4.41  Repair of AS-I-145  adducts  on  the TS  of MFA2.  Exponentially  growing  DBY474, 
rad4 and  radI8 cells were  treated  with  10  pM AS-I-145  for 3  h at 30  °C. Cells  were  harvested and 
DNA  extracted  immediately  (0  h  lane),  or allowed  to  repair  in  YEPD  for up  to  8  h  prior  to  DNA 
extraction.  U is the untreated control.  Sslig-PCR was performed as described in the Methods section. 
The major adducts are indicated by arrow, and their sequence and nucleotide positions in relation the 
start of the  coding  region  (+1)  are  denoted.  The  sequence of the  portion  of the  gels  presented  here 
stretches from positions +60 to +230 from the start of the gene’s coding region.
294Adduct elimination  in  the  repair competent  DBY747 cells,  was also examined on 
the NTS of the MFA2 gene. Figure 4.42 shows the adduct formation right after drug 
treatment (0 h) and after 8 hours of post incubation treatment in growth medium.
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Figure 4.42  Repair of AS-I-145  adducts on  the  NTS of MFA2.  Exponentially growing 
DBY747 cells were treated with  10 pM of AS-I-145 for 3 h at 30°C. Cells were harvested 
and DNA extracted immediately (0 h lane), or were resuspended in YEPD and allowed to 
repair for a further 2, 4, 6  and  h  prior to DNA extraction.  Sslig-PCR  was  performed as 
described  in  the  Methods  section.  The  locations  of the  major adducts  is  shown  by  the 
arrows and their position in relation to the start of the coding region of MFA2 is denoted. 
The sequence of the portion of the gels presented here stretches from positions 460 to 230.
295No repair of any of the adducts formed along the NTS is evident. This suggests that 
the repair of the wild type observed in Figure 4.41  is transcription coupled.
In the case of TH-III-151  and AS-I-145, the excision event is believed to be  NER, 
and appears to require functional Rad 18 in yeast.
2964.5 Discussion
The yeast repair studies of the novel  chiral  agent TH-III-151  and the achiral  agent 
AS-I-145  showed  that the adducts of both compounds are substrates for the  NER. 
The NER defective rad4 cells were sensitive to both agents (in the case of TH-III- 
151,  the  rad 14  cells  also,  exhibited  identical  levels  of  sensitivity  as  the  rad4 
disruptants) and failed to eliminate the relevant adenine-N3  adducts. The observed 
involvement  of  NER  is  in  agreement  with  previous  repair  studies  on  the  lead 
compound CC-1065, which  was also shown to be  substrate for the NER apparatus 
(Gunz et al.,  1996; Selby & Sancar,  1988; Nazimiec et al., 2001). The repair of the 
adducts  of  the  two  agents  in  the  wild  type,  also  seemed  to  be  confined  on  the 
transcription  strand  of  the  gene  tested.  Such  occurrence  is  most  commonly 
associated with NER (Hanawalt  1989; Balajee & Bohr, 2000).
NER is proposed to be the prominent excision pathway involved in the repair of the 
TH-III-151  and  AS-I-145  adducts.  Of all  the  BER  glycosylases  tested,  none  was 
found to be  more sensitive compared to the wild  type, to either agent, while magi 
mutants were  proficient  in eliminating the TH-III-151  lesions. These results are in 
agreement  with  previous  findings  suggesting  that  BER  is  not  a  crucial  cellular 
response  to alkylation  by  this  class of agents.  It  was  previously  shown  that the  3- 
methyladenine-DNA-glycosylase, the glycosylase  most associated with the BER of 
lesions induced  by alkylating agents, does not play a major role in the repair of the 
adenine adducts formed by CC-1065, as the introduction of the bacterial gene (tag) 
encoding this enzyme in different murine cells did not change the sensitivity of the 
cells to the drug (Imperatori  et al.,  1994). Additionally,  no correlation  between the 
levels of the  glycosylase and the sensitivity to CC-1065  in human cancer cell  lines 
was  found  in  another  study  (Damia  et al.,  1996a).  Finally,  an  adenine-N3  adduct 
formed by adozelesin was shown to be a substrate for the NER action of the E.coli 
endonuclease  UvrABC.  In  sharp  contrast  however,  the  E.coli,  3-methyladenine 
glysocylase failed to excise the adozelesin lesions (Jin et al., 2001).
297This  is  the  second  time  an  interconnection  of  the  RAD6  pathway  and  NER  is 
proposed for the repair of highly sequence specific minor groove adducts.  For both 
agents  in  this  study,  the  excision  of  their  adducts  by  NER  appeared  to  require 
functional  Rad 18.  RADI8 is a pivotal  gene controlling through its interaction with 
RAD6  a  variety  of subpathways  and  processes,  which  could  be  utilised  following 
inactivation  of  NER,  as  in  the  case  of  a  rad4  mutant.  Interestingly,  the  lack  of 
Rad 18,  not  only  increased  the  sensitivity  of the  cells  to  the  two  compounds,  but 
impaired the NER of their adducts. Additionally, in the case of TH-III-151, further 
enhancement  in  sensitivity  and  again  a  clear  NER  defect  was  also  observed  in  a 
rad5 strain, indicating that RAD5 could also be involved in the proposed interplay 
of the  Rad6-Radl8 complex  with NER. An early indication that Rad5  might affect 
lesion  excision  came  from  a  study  of  the  kinetics  of  repair  of  UVC-induced 
cyclobutane  dimers  and  6-5  photoproducts  in  a  large  collection  of yeast  mutants 
(McCready,  1994).  Both a rad 18 and a rad5 mutant exhibited  reduced capacity  in 
eliminating both classes of adducts.
MMS2,  which  has  been  assigned  to  the  same  subpathway  as  RADS  (see  section
4.1.4)  was  initially  shown  to  be  epistatic  to rad4 for  UV  response  (Broomfield  et 
al.,  1998). However, later epistasis analysis found a synergistic enhancement in UV 
sensitivity in a combination of a rad4 and an mms2 mutation (Torres-Ramos et al., 
2002).  RAD5  has  been  shown  to  be  epistatic  to MMS for  UV  response  (Ulrich  & 
Jentsch, 2000; Torres-Ramos et al., 2002).  Although the mms2 strain is not as UV 
sensitive  as  the  radS  strain,  yet  it  displays  a  much  more  severe  repair  defect 
(Torres-Ramos et al., 2002). The discrepancy between the sensitivities of radS and 
mms2 led the authors to hypothesize that RadS could have an additional role to that 
in  post  replication  repair,  and  possibly  promote  the  repair  of  UV  lesions  by 
participating in other processes.  Additionally, such inconsistency between levels of 
sensitivity  and  repair efficiencies,  also  previously  found  for RAD26 (Van  Gool  et 
al.,  1994), further supports the idea of seeking functional evidence for the role of a 
repair gene product, as in this thesis, though the study of the repair rates on a gene.
298The findings in chapter 4 suggest that such an additional  role of Rad5 could  be in 
the NER of, in this case, the TH-III-151  minor groove lesions. Rad5 could possibly 
help preferentially target, through its interaction with Rad6 and Rad 18, NER repair 
factors  to  the  poorly  “displayed”  lesions  of TH-III-151  in  the  minor groove.  CC- 
1065  adducts have  been  shown to be  poorly  recognised  by  human  NER factors in 
vitro  (Gunz  et  al.,  1996).  This  is  attributed  to  the  low  level  of helical  distortion 
induced  by  CC-1065  and  the  thermodynamic  stabilisation  of  the  double  helix 
(Reynolds et al.,  1986).  Recognition  of minor  groove  adducts  and  recruitment  of 
repair factors required for their elimination has been previously assigned to Rad 18 
(Brooks et al., 2000). This could also be the case for both the TH-III-151  and AS-I- 
145 adducts. This function of Rad 18 may be influenced by Rad5, (as it derives from 
the  TH-III-151  studies),  acting  in  the  error-free  subpathway,  downstream  of the 
Rad6-Radl8 complex.
299CHAPTER  5
CYTOTOXICITY OF AS-I-145 IN NER DEFECTIVE CHINESE HAMSTER
OVARY CELL LINES
5.1  Introduction - Aim
Chinese hamster ovary (CHO) cell lines provide a useful model mammalian system 
for  identifying  the  pattern  of  sensitivity  and  understanding  the  mechanisms  of 
cytotoxicity of a number of chemotherapeutic agents. Mutant cell lines with defined 
deficiencies in DNA repair pathways can be utilised to investigate the mechanisms 
involved in the repair of the adducts of a number of compounds, such as alkylating 
agents  to  which  DNA  repair-deficient  cells  often  show  altered  sensitivity.  Such 
studies in CHO cells have been conducted for both the minor groove binding drugs 
discussed in the  introduction and currently in clinical trials, ET-743 (Damia et al., 
2001a;  Takebayashi  et  al.,  2001b)  and  SJG-136  (Clingen  et  al.,  2005).  The 
sensitivity  of  CHO  cells  to  CC-1065,  the  lead  compound  of  the  analogues 
investigated in this thesis, has also been reported (Damia et al.,  1996b).
To complement the studies in yeast and further corroborate the critical role of NER 
in  the  repair  of  the  adducts  induced  by  the  novel  achiral  analogue,  AS-I-145,  a 
panel of CHO cell lines (Table 5.1) with specific defects in  different  components of
the NER apparatus was employed in cytotoxicity studies.
The aim is to investigate the relative role of various NER  functional defects in  the
sensitivity of mammalian cells to the agent AS-I-145.
3005.2  Materials and Methods
5.2.1  Materials
Cell lines and culture conditions
The cells used in this study are listed in Table 5.1. The AA8, UV23, UV42, UV61, 
and  UV96  cell  lines  were  obtained  from  Dr.  M.  Stefanini  (Istituto  di  Genetica 
Biochimica ed  Evoluzionistica,  Pavia,  Italy),  and  UV135  was  purchased from  the 
American Type Culture Collection (ATCC number CRL-1867). All cell  lines were 
grown  in  T80  cm2   tissue  culture  flasks  (Gibco  Life  Technologies,  UK),  as  a 
monoloayer,  in  F12-Ham-HEPES  medium  (Sigma,  Poole,  U.K.),  supplemented 
with 2 mM glutamine (Sigma) and  10% foetal calf serum (FCS) (Autogenbioclear, 
Witshire,  UK).  The  latter  had  been  heat-inactivated  by  a  30  minutes treatment at 
65°C.  Cells were grown  at 37°C in a 5%  C 02 humidified  incubator and  harvested 
using trypsin-EDTA  lx solution (Autogenbioclear, Witshire, UK).
Investigational compounds
AS-I-145  was  kindly  provided  by  Professor  Moses  Lee,  Furman  University, 
Greenville, South Carolina, USA. The drug was dissolved in DMA (Sigma) at a  10 
mM stock concentration and stored at -20°C until immediately prior to use.
Materials
•  0.4% (wt/vol) SRB in  1% acetic acid.
•  lOmMTrisBase
•  10% Trichloroacetic acid (TCA)
•  1% Acetic acid
•  96-well flat-bottomed tissue culture plates (VWR International).
301•  Sulphorhodamine B (Sigma)
5.2.2  Methods
Sulphorhodamine B Growth Inhibition Assay
Growth inhibition was assessed using the Sulphorhodamine B (SRB) assay (Skehan 
et al.,  1990). This assay  was developed as an  alternative to tetrazolium assays for 
use in the NCI in vitro primary drug screen. A series of protein and biomass stains 
were investigated and the SRB reagent gave the best combination of stain intensity, 
signal-to-noise  ratio,  and  linearity  with  cell  number.  SRB  is a  bright  pink anionic 
dye  that  in  dilute  acetic  acid  binds  electrostatically  to  the  basic  amino  acids  of 
(TCA)-fixed  cells.  The  SRB  assay  also  has  the  distinct  advantage  of  a  stable 
endpoint (i.e., not time-critical, in contrast to the tetrazolium assays (Boyd,  2004).
Stock cultures were trypsinised and 3  x  103  cells were seeded into each well of 96- 
well,  flat-bottomed  microtiter  plates,  in  a  volume  of  100  pi  and  left  to  adhere 
overnight at 37°C. The desired concentrations of AS-I-145 were prepared in culture 
medium (without FCS) immediately before use.  Medium in wells was removed and 
100 pi  of drug-medium  mixture was added.  Six replicates were used for each drug 
concentration.  One  solvent  control  lane  was  included  in  each  experiment.  Plates 
were incubated for  1   hour at 37°C. At the end of the drug treatment, the media was 
replaced with 200 pi of fresh complete growth medium, and the plates were further 
incubated  for  three  days  in  a  humidified  incubator  at  37°C  with  5%  C02.  The 
medium  in  the  wells  was  removed and  100  pi  of ice-cold  10%  (wt/vol) TCA  was 
added  per  well,  to  fix  the  cells.  The  plates  were  then  incubated  at  4°C  for  20 
minutes  and  were  subsequently  washed  four  times  with  tap  water.  Cells  were 
stained  with  100  pi  of 0.4%  (wt/vol)  SRB  in  1%  acetic  acid,  per  well,  to  allow 
visualisation of cellular proteins, for 20 minutes at room temperature.  Unbound dye 
was removed by washing five times with  1% acetic acid, and plates were left to air-
302dry  overnight at  room  temperature.  The  next day,  the  dye  was  solubilised  by  the 
addition  of  100  pi  of  10  mM  Tris  base  into  each  well.  Plates  were  left  at  room 
temperature for 20 minutes, and the optical density (OD) at 540 nm was determined 
using  a  Tecan  microplate  reader  (Flow  laboratories).  Growth  inhibition  was 
expressed as the fraction of control  (surviving fraction) and calculated from the 
following  equation:  Fraction  of control  =  OD  of drug-treated  wells  /  OD  of 
untreated  control.  The  mean  surviving  fraction  for  each  drug  concentration  with 
standard deviations was calculated.  Dose response curves were plotted and the IC^ 
values,  i.e.  the  drug  concentration  required  to  produce  50%  of  the  OD  of  the 
untreated  control,  were  determined  from  the  respective  curves.  When  comparing 
parental  and  mutant  cell  lines,  the  relative  sensitivity  was  determined  by  the 
following equation:
Relative  sensitivity  =  IC50  value  in  parent  cell  line /  IC^ value  in the  mutant cell 
line.
5.3 Results and discussion
The  mutant  cell  lines  UV47  and  UV96  are  defective  in  XPF  and  ERCC1, 
respectively.  These  two  proteins  form  a  tight  heterodimeric  complex  with  a 
structure-specific endonuclease activity and are responsible for the 5’  incision,  16- 
25  nucleotides from the damage site, during  NER (Bessho et al.  1997;  De  Laat et 
al.,  1998).  Similar to its yeast counterpart (Rad  1   and RadlO proteins) XPF/ERCC1 
is  multifunctional,  also  participating  in  homology-dependent  recombination 
reactions,  including DNA  single  strand annealing (SSA) and gene targeting (Adair 
et al., 2000; Motycka et al., 2004) and in the repair of DNA interstrand crosslinks, 
where  it  is  needed  to  release  one  arm  of  the  cross-link  or  to  remove  them  by 
recombination (De Silva et al., 2002; Clingen et al., 2005).
UV23 and UV42 cell  lines bear mutations in the XPB and XPD gene products. The 
two  helicases  have opposite  polarities (3'— >5' and  5'— »3',  respectively)  and  induce 
localised  unwinding  of  double-stranded  DNA  at  the  damaged  regions.  The  two
303helicases are subunits of the basal transcription factor TFIIH, which is implicated in 
both  trancription  initiation  and  NER  (Hwang  et al,  1996;  Schaeffer et al.,  1994). 
UV135 cells are defective in XPG, a structure-specific endonuclease responsible for 
the initial incision step, which occurs approximately 2-9 nucleotides to the 3' side of 
the  damage  during  NER  of  DNA  (O’Donovan  et  al.,  1994).  Besides  its  catalytic 
endonuclease activity, the physical presence of XPG is also required for subsequent 
5' incision by ERCC1/XPF (Wakasugi et al.,  1997).
Finally  the  DNA  repair  defect  in  the  UV61  cells  is  homologous  to  that  of 
Cockayne’s syndrome complementation group B (CSB) cells. These cells, unlike all 
the previous ones which have total NER deficiency, have proficient global-genome, 
GG-NER but deficient transcription-coupled, TC-NER (Orren et al.,  1996).
Figure 5.1 features a schematic representation of the human GG-NER, also showing 
the  function  of the  gene  products  that  are  defective  in  the  mutant CHO  cell  lines 
under  investigation  (Table 5.1).  All  these  NER factors  participate  in  the  common 
steps of GC-NER and TC-NER, with the exception of CSB, which converges with 
CSA  at  the  damaged  sites  on  the  transcribed  strand,  where  RNA  polymerase  II 
becomes stalled.
Mutant cell line Parent cell line Defective gene
UV23 AA8 XPB
UV42 AA8 XPD
UV47 AA8 XPF
UV61 AA8 CSB
UV96 AA8 ERCCl
UV 135 AA8 XPG
Table 5.1 The NER-deficient Chinese hamster cell lines used in this study.
304Figure  5.1  Schematic  representation  of  the  “recognition”,  “formation  of  the  open 
structure”,  “dual  incision  and  excision  of  the  damage-containing,  single-stranded 
oligonucleotide”,  steps  of  GG-NER  in  human  cells.  Repair  is  completed  with  DNA 
resynthesis (gap-filling) and ligation in the presence of DNA replication factors.The sensitivity of the CHO cells to AS-I-145 was assessed using the SRB growth 
inhibition assay after a 1-hour exposure to increasing concentrations of the agent. 
The data presented in Figure 5.2 show the sensitivity of the wild type (AA8) and the 
NER defective repair mutants to AS-I-145.
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Figure  5.2  AS-I-145  sensitivity  in  parental  AA8  cells  and  NER  mutants  XPB 
(UV23),  XPD  (UV42),  XPF  (UV47),  CSB  (UV61),  ERCCl  (UV96)  and  XPG 
(UV135). Growth  inhibition was determined  using the SRB assay and the fraction 
of control A^o calculated as described in the Methods. AH the results are the mean 
of at least two independent experiments and error bars show the  standard error of 
the mean.
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to be more sensitive to AS-I-145 than the repair proficient, parental AA8 cell line. 
Table 5.2 shows a comparison of the AS-I-145 IC^ values (concentration of drug to 
give  an  A ^ reading  of treated  cells 50%  of the  reading of the  control-untreated 
cells)  obtained  in  the  AA8  and  the  mutant  cell  lines.  Among  those,  UV47  and 
UV96,  defective  in  XPF  and  ERCC1  were  the  most  sensitive  to  the  cytotoxic 
effects of AS-I-145, with IC^ values 7.3- and 7.9- times lower, respectively, when 
compared to their isogenic parent cell line.
Cell line Gene Defect
AS-I-145
ICjoO a M)
Sensitivity
Ratio
AA8 0.19
UV23 XPB 0.0285 ± 0.0007 6.6
UV42 XPD 0.036 ± 0.0056 5.3
UV47 XPF 0.026 ± 0.007 7.3
UV61 CSB 0.047 ± 0.0028 4.0
UV96 ERCC1 0.024 ±0.0113 7.9
UV 135 XPG 0.0346 ± 0.0032 5.5
Table 5.2  ICso values  of AS-I-145  in  the CHO parental  (AA8) and  repair deficient 
mutant  cell  lines,  as  obtained  by  interpolation  of  the  dose-response  curves  in  the 
different  cell  lines.  Each  value  is  the  mean  ±  S.D  of  at  least  two  independent 
experiments. Numbers in the ratio column represent the fold increase in sensitivity of 
the mutant cell lines compared to the parental cell line AA8.
Cellular sensitivity  to AS-I-145 seems to be comparably dependent to all the other 
components of the  core  NER pathway considered  in this study as compromise of 
these NER functions confers a similar degree of chemosensitivity. This is expressed 
with  an  increase  in  the  relative  rate of sensitivities of all  other repair mutant cell
307lines  ranging from 4 to 6.6-fold. This  similar  degree  of sensitivities  indicates  an 
equally  important  role  of these  NER  proteins  in  the  response  to  the  adenine-N3 
lesions induced by the compound.
These  results  are  in  agreement  with  a  previous  study  on  the  sensitivity  of  CHO 
mutants to various anticancer agents. In that case, the UV23, UV42, UV47, and UV96 
cells  displayed  increased  sensitivity  (2-fold)  to  the  minor groove  alkylating  agents 
tallimustine and CC-1065, in a colony formation assay (Damia et al.,  1996b). 
Additionally, the  implication of TC-NER in  the cellular response to the AS-I-145 
adducts, as suggested by the observations on the removal of the AS-I-145 adducts 
in  the  yeast  studies  was  confirmed  in  this  mammalian  system,  with  a  TC-NER 
deficiency  contributing  to  the  agent’s  cytotoxicity.  More  specifically,  a  4-fold 
enhanced  activity  of AS-I-145  was  observed  in  the  UV61  cell  line,  defective  in 
CSB,  the  Cockayne’s  syndrome-related  factor  involved  in  the  transcriptional 
coupling  of  NER.  Relevant  to  this  result,  higher  efficiency  of  CC-1065  adduct 
removal  and  significantly  faster  repair  in  the  transcribed  strand  than  in  the 
nontranscribed strand of the dihydrofolate reductase (DHFR) gene was previously 
observed  in  CHO  cells.  This  preferential  repair  was  attributed  to  transcription- 
coupled repair of active genes (Tang et al., 1994).
The cytotoxicity  profiles of the  mutant cell  lines emphasised  the  importance of the 
defects  in  NER  as  a  determinant  of  chemosensitivity  to  the  AS-I-145  adducts  in 
mammalian cells.
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GENERAL DISCUSSION
The therapeutic area of oncology is characterised by a pressing need for new drugs, 
as  it  remains  one  of  the  most  challenging  medical  fields  for  the  discovery  of 
efficient therapies.  With an  average of only  one in  nine experimental  compounds 
making  it  through  development  and  acquiring  approval  by  the  US  /  European 
regulatory authorities and an overall clinical  success rate of  11%, as featured  in a 
study of the various therapeutic areas, oncology  has a successful  rate of 5%, only 
one quarter of that  of cardiovascular disease  (20%)  (Kola  &  Landis,  2004).  It is 
indicative that the failure  rate of investigational  oncology  compounds in  phase  II 
clinical trials is 70%, in phase  III, 59% and even at the registration stage, 30% of 
experimental anticancer agents undergo attrition (Kola & Landis 2004). Amidst the 
poor results, the urgent need for new treatments is reflected in the fact that there are 
currently more than 550 phase I trials open to cancer patients in the United States at 
any  given  time,  and  this  number  is  steadily  increasing  (Roberts  et  al.,  2004). 
According to a 2003  survey,  there  were 395 agents for the treatment of cancer in 
clinical  trials,  more  than  any  other  therapeutic  class  of  medicine  (Chabner  & 
Roberts  Jr,  2005;  Reference  therein).  On  the  other  hand,  the  overall  objective 
response  rate  for  213  single-agent,  phase  I  trials,  involving 6474 cancer  patients 
with solid tumours and  spanning a  12-year period (1991-2002) was determined to 
be 3.8%, with the odds of a patient responding decreasing in the later years of the 
study period (1999-2002) (Roberts et al., 2004).
In  recent years there  has  been  a focus shift  in  cancer drug discovery  towards the 
development  of  targeted  agents  for  cancer  therapeutics,  selectively  exploiting 
dominant  molecular  aberrations  between  cancer  and  normal  cells.  Such  efforts 
culminated  in  the discovery of imatinib mesylate (STI571, Gleevec;  Novartis), an 
inhibitor of the tyrosine kinase BCR-ABL. The drug is currently used as a first-line 
therapy  for  chronic  myeloid  leukemia  (CML),  surpassing  previous  therapies,
309including alkylating agents (Capdeville et al., 2002).  However,  most tumours are 
characterized  by  multiple  molecular alterations and conventional  cytotoxic  agents 
are in many instances the only therapeutic option still available.
Alkylating  agents  still  remain  at  the  core  of several  single-agent  or combination 
chemotherapeutic regimens, despite being the oldest class of drugs introduced in the 
clinic  for  the  treatment  of  cancer  since  the  1950s.  Chlorambucil  for  example 
remains  the  preferred  first-line  therapy  for chronic  lymphocytic  leukemia  (CLL) 
(Andritsos  &  Khoury,  2002)  and  oxaliplatin  for  colorectal  cancer  (Saunders  & 
Iveson,  2006),  while  alone  or  in  combination,  cisplatin  is  part  of  the  standard 
chemotherapy for testicular germ-cell tumours (today more than 80% of men with 
metastatic  TGCTs  can  be  cured  with  cisplatin-based  combination  chemotherapy) 
(Einhorn, L.H. 2002), melphalan for multiple myeloma (MM) (Jagannath, S. 2005), 
cyclophosphamide  for  breast  cancer  (Kirshner  et  al.,  2004)  to  name  but  a  few. 
Apart from  the  established  compounds,  novel  alkylating agents  currently  emerge 
from the  pipeline  providing  previously  unavailable therapeutic  interventions.  One 
such  recent  example,  the  naturally  derived  ET-743  (Yondelis;  section  1.3.3)  was 
granted orphan drug status by the  FDA for the treatment of soft tissue sarcoma in 
April  2005.  It is the first active agent for this type of tumour in the  last 25 years 
(Jimeno  et  al.,  2004).  This  drug  highlights  not  only  the  potential  the  alkylating 
agents still hold, but also the continuing role that natural products have in the cancer 
drug discovery.
Natural  products  have  been  the  source  of many  human  therapeutics.  Of the  877 
small-molecule  “New  Chemical  Entities”  (NCE),  introduced  between  1981-2002, 
approximately  half,  (49%),  were  natural  products,  semi-synthetic  analogues  or 
synthetic  compounds  based  on  natural  product  pharmacophores  (Newman  et  al.,
2003).  More  specifically,  in the area of cancer and  between the same time frame, 
62% of the introduced small molecule, new chemical entities that are nonsynthetic, 
were of natural origin (Newman et al., 2003).
Natural  products  can  also  serve  as  leads  for  the  design  of  novel,  synthetic, 
biologically active structures with potentially improved properties. A series of novel
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were  presented  in  this thesis  (Chapters  2 and  3).  The  alkylation  properties of all 
analogues were determined on  plasmid  DNA.  Sites of covalent modification were 
revealed using the Taq polymerase stop assay and purine-N3 alkylation in the minor 
groove was probed using the thermally-induced cleavage assay. The cytotoxicity of 
the agents was also determined in most cases, using the MTT assay. The objective 
of the alkylation studies was to determine whether the structural  modifications of 
the  analogues  would  have  any  effect  on  their  alkylation  efficiencies  /  sequence 
selectivity  compared  to those  reported  for the  natural  lead  compounds.  A  recent 
paper highlighted the validity of such studies on naked-DNA and their importance 
as  a  valuable  tool  and  a  good  approximation  to  the  agents’   properties  in  cells 
(Trzupek  et  al.,  2006).  More  specifically,  the  DNA  alkylation  properties  of both 
enantiomers of DU MSA and Yatakemycin were determined on protein-free DNA 
and on the same sequence bound in nucleosome core particle (NCP), modeling the 
state of DNA in eukaryotic cells. The relative efficiencies of the agents to alkylate 
DNA  and  their  sequence  selectivity  were  shown  to  remain  unaltered  in  both 
instances. The observed alkylation  sites were the  same,  no unexpected  sites were 
detected and alkylation proceeded even at the most accessible challenging sites on 
NCPs, unaffected by the conformational perturbations and in an identical manner to 
free-DNA. The NCPs packaging is a close approximation of nuclear DNA and these 
findings  highlighted  that  for  this  class  of  compounds,  observations  on  their 
sequence-selective  alkylation  deriving  from  studies  on  free-DNA  could  actually 
correlate well with their intracellular behaviour and binding in vivo (Trzupek et al., 
2006). The same has recently  been demonstrated for another minor-groove agent, 
SJG-136. Sslig-PCR experiments showed that the agent would bind the same sites 
with the same degree of sequence selectivity in naked DNA and in cells (Martin et 
al., 2005). The same assay was also previously employed to study lesion formation 
by alkylating agents, such as nitrogen mustards. The pattern of adduct formation by 
uracil  and quinacrine  mustards was identical  in isolated  DNA,  in cells and to that 
observed earlier, in plasmid DNA (Grimaldi et al., 1994; Ponti et al.,  1991).
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pharmacophores  like  the  seco-CI  alkylating  moiety  coupled  to  varying,  extended 
DNA  binding  subunits  (sections  2.2  and  2.4)  or  incorporation  of  the  novel 
pharmacophores  seco-iso-CFI  and  seco-CFQ  (section  2.3).  All  the  analogues 
studied readily alkylated  the  high affinity CC-1065 alkylation  site 5’-AAAAA-3\ 
with variations observed for the alkylation of secondary AT sites.
The secYMSO-CFI  indoline  agent TH-III-149 and the 5ec<?-CFQ quinoline, TH-III- 
151  were assessed in the National Cancer Institute’s large scale in vitro cell screen 
(Boyd,  2004).  The  current  model  of this  screen  uses  approximately  60  human 
tumour cell  lines representing  haematologic malignancies, melanoma and cancers 
of the lung, colon, breast, brain, kidney, and prostate. The method uses continuous 
drug incubation for 48 hours and the viability of the cells is evaluated by staining 
cells  with  the  protein-binding  dye,  sulforhodamine  (SRB).  The  screen  data  are 
visualised with the characteristic “fingerprint” chart. The mean graph representation 
for the LC*) values, of all the cell lines responses (concentration for killing 50% of 
the cells) to TH-III-149 and TH-III-151  can  be seen  in Appendix-I  (Professor M. 
Lee - personal communication). The two agents exhibited differential toxicity and 
were  most  active  primarily  against  cells  derived  from  solid  tumours  such  as 
melanoma, renal and certain CNS and colon cell  lines. None of the leukemic cell 
lines included in the screen exhibited increased sensitivity to either of the agents. 
Both compounds then advanced to preliminary in vivo assessment of their potential 
anticancer activity based on the hollow fibre assay (Hollingshead et al., 2004). TH- 
III-149 received an IP (referring to hollow fibres implanted intraperitoneally) score 
of 14 and an SC (hollow fibres implanted subcutaneously) score of 4, resulting to a 
total  score  of  18.  T  H-III-151  received  an  IP  score  of  16  and  an  SC  score  of 4, 
acquiring a total  score of 20.  Both agents were  found to be capable of producing 
cell  kill  (Professor  M.  Lee  -  personal  communication). The criteria for further in 
vivo evaluation of an experimental agent subjected to the hollow fibre assay are a 
minimum combined  IP + SC score of 20, a SC score 8 or a net cell  kill of one or 
more  cell  lines.  Finally  the  cytotoxicity  of TH-III-159 and TH-III-151  to  murine
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assay  (StemCell  technologies,  Inc.,  Vancouver,  Canada).  While  TH-III-149  was 
found to be toxic (no colonies), TH-III-151  displayed significantly less toxicity (45 
± 10 colonies, compared to 60 ± 3 colonies for untreated control) (Professor M. Lee 
- personal communication).
The favourable activity against tumour cell  lines, the “active” status based on the 
hollow fibre assessment and the  low toxicity to murine bone marrow cells render, 
primarily  TH-III-151,  a  worthy  candidate  for  further  drug  development  studies. 
These results underline the potential of structurally modifying the alkylation subunit 
of the  lead  compounds.  The  introduction  therefore  of the  furan  ring  with  a  new 
orientation in the case of TH-III-149 and the unique seco-CFQ warhead of TH-III- 
151  which  was  an  “unexpected”  product,  derived  from  the  rearrangement  of the 
intermediate permitted  by the  reaction  kinetics during synthesis, generated  active 
compounds  with  anti-cancer  activity.  These  novel  alkylating  functionalities  may 
serve as valid alternatives to the established CBI pharmacophore.
In the quest for improved antitumour agents a series of novel achiral analogues was 
also  assessed  for  their  alkylation  properties  and  cytotoxicity  (Chapter  3).  The 
introduction  of an  achiral  pharmacophore was a strategy  that  was not extensively 
pursued in the past. Chirality has now emerged as a central issue in drug design and 
development. A clear trend for the development of enatiomerically-pure compounds 
over racemates, which dominated previous decades, was gradually established due 
to a better appreciation of stereoselective pharmacology and the differential relative 
contributions  of  each  enantiomer  to  the  overall  drug  action.  Single-enantiomer 
drugs now comprise -75% of the new drugs that are introduced to the market, rising 
from  -25%  ten  years  ago  (Agranat  et  al.,  2002).  This  trend  however  does  not 
preclude the development of achiral agents. The advantages of the design of achiral 
compounds over racemates was discussed in the introduction. Of the new molecular 
entitites approved  in  the  U.S  between  1998-2001,  52%  were  achiral,  30%  single 
enantiomers  with  several  chiral  centres,  7%  single  enantiomers  with  one  chiral 
centre,  7%  racemates  and  4%  multiple  diastereomers.  The  corresponding
313distribution for the NCEs approved in the UK, between  1996-2000 is: 36% achiral, 
48%  single enantiomers  and  16%  racemates (Agranat et al.,  2002 and  references 
therein).
Embarking on the design of achiral agents it was initially imperative to determine 
whether the chiral centre present in all CC-1065 / duocarmycin analogues reported 
in the literature and in this thesis, was absolutely required for DNA interaction and 
cytotoxicity. The “first generation” of achiral  analogues, incorporating the achiral 
.seco-hydroxy-CI  and seco-amino-CI  alkylation subunits (section 3.2) were  shown 
to be able to efficiently perform the characteristic adenine-N3 alkylation of the lead 
compounds.
The  achiral  .seco-hydroxy-CI-TMI  compound  SC-III-147  (Figure  3.5)  was 
submitted for testing in the NCI 60 cell  line screen. The agent exhibited activity in 
the  micromolar  range  while  the  screening  profile  manifested  differential 
cytotoxicity.  Again  none  of the  leukaemia  cell  lines  included  in  the  assay  were 
found  to  be  more  sensitive  than  the  average  sensitivity  of the  full  60-cell  panel 
(Appendix-II).  In  sharp  contrast,  all  the  melanoma  cells  exhibited  increased 
sensitivity to SC-III-147. The agent was selected for preliminary in vivo testing with 
the hollow fibre assay. The composite IP and SC score was 22, however no cell kill 
was  observed.  Based  on  the  combined  score  being  >  20  and  its  unique  achiral 
structure, the compound advanced for further in  vivo testing using human tumour 
xenografts. The tumour model tested was the human UACC-257 melanoma. SC-III- 
147  treatments  were  initiated  on  day  16  after  implantation,  at  the  maximum 
tolerated dose of 134 mg/kg/dose and administered IP. Therapeutic results from the 
experiments are presented in terms of increases in lifespan reflected by the median 
survival times of treated (T) versus control (C) groups of mice (%T/C) and any long 
term survivors (> 60 days). The T/C value at day 51  was 40, which according to the 
NCI’s evaluation  criteria,  renders  SC-III-147 an “active” compound (Alley  et al.,
2004).  At  the  dose  administered  to  the  animals,  no  significant  weight  loss  was 
observed, indicating that the compound was relatively non-toxic (Professor M. Lee, 
personal communication).
314Compounds  incorporating  the  achiral  seco-hydroxy-CBI  and  ^co-amino-CBI 
alkylating  moieties were also able to efficiently alkylate  in  the cluster of the five 
adenines  and  did  so  with  enhanced  efficiency  compared  to  their  achiral-CI 
counterparts (section  3.3). The achiral .seco-amino-CBI-TMI  compound, AS-I-145 
(Figure 3.11) was also submitted for in vitro cytotoxicity testing at the NCI 60-cell 
screen.  The agent exhibited  activity  in the  sub-micromolar range and  similarly to 
the sensitivity  profiles obtained for the previous compounds tested, AS-I-145 was 
not particularly active against leukemic cells but showed differential activity against 
certain cell lines from solid tumours including melanoma, lung, colon, renal, breast 
and CNS (Appendix-Ill).
AS-I-145  was subsequently accepted for in  vivo anticancer activity assessment by 
the NCI standard hollow fibre assay. It received an IP score of 46 and an SC score 
of 8, resulting to a total score of 54 (out of a possible 96). These results render AS- 
I-145 one of the most active compounds (top 5%) tested in this assay to date. This is 
particularly important as of the compounds tested up until 2004, only  16.3% had a 
total  score  of 20  or  greater  (Hollingshead  et  al.,  2004).  Such  level  of activity 
guaranteed  further  in  vivo  evaluation  of  the  agent.  Tumour  xenograft  studies 
involved a model of the advanced stage human SC-OVCAR-3 ovarian cancer and 
were carried by the NCI.  Drug treatments of 11.20 mg/kg, IP were able to inhibit 
the growth of the tumour cells, providing a % T/C value of 24% on day 33.  The 
mean time for doubling of the tumour weight was 25.3 days, compared to  13 days 
for  the  control  untreated  animals.  According  to  the  NCI  evaluation  criteria,  this 
result deems AS-I-145 as an active compound. Importantly, the treated animals did 
not experience any toxicity or weight loss, indicating that the agent is well tolerated. 
This compound is significantly  less toxic than its chiral counterparts including the 
clinically investigated adozelesin, which was found to be toxic at a dose of 1  mg/kg. 
Further in vivo studies on the B16-F0 murine melanoma cells, and the MDA-MB- 
435, human breast cancer xenograft, were conducted by Taiho Pharmaceutical Co., 
Ltd,  Japan.  AS-I-145  exhibited  significant  activity  when  administered  IP  (15 
mg/kg) without toxicity and was also active when administered orally. Finally, the
315toxicity  of AS-I-145  against  hematopoietic  progenitor  cells  was  assessed.  Bone 
marrow  cells  were  taken  from  the  fermus  of healthy  mice  that  had  not  been 
previously  treated  with  the  agent.  The  cells  were  then  treated  with  equal 
concentrations (0.0084 pM, the IC50 value of the racemic .seco-hydroxy-CBI-TMI 
against  LI210  cells,  for  a  3-days  continuous  exposure)  of AS-I-145  and  seco- 
hydroxy-CBI-TMI. No colonies were observed for the chiral agent. However, AS-I- 
145  was  less  toxic,  allowing  formation  of colonies  (25  versus  0,  respectively; 
untreated control gave 60 colonies) (Professor M. Lee - personal communication). 
The results of the studies on the achiral agents revealed that the chiral centre of CC- 
1065 and the duocarmycins is  not absolutely required for DNA sequence specific 
interaction  and  anticancer activity. The achiral  seco-amino / hydroxy-CBI  and Cl 
alkylating moieties constitute therefore feasible substitutes to the established chiral 
pharmacophores  and  offer  a  template  for  alternative  drug  design  of  novel 
analogues.
TH-III-151  incorporating  the  novel  5ec<?-CFQ warhead  and  AS-I-145, one  of the 
most active compounds ever tested in the NCI in  vitro screen and representing the 
novel class of achiral analogues, were chosen for DNA repair studies.
In  the  yeast  Saccharomyces  cerevisiae,  nucleotide  excision  repair  is  the 
predominant pathway for the repair of the adenine-N3 adducts of both TH-III-151 
and  AS-I-145,  which  seem  to  share  common  mechanisms of cytotoxicity  despite 
their  different  stereochemistry  (Chapter  4).  This  excision  repair  was  in  both 
instances transcription coupled and appeared to depend upon functional Rad 18. The 
role of Rad 18 as a potential  sensor of damage  by this class of compounds and its 
function as a prerequisite for the elimination of the relevant adducts by NER, render 
Rad 18 a key determinant of chemosensitivity to these agents. Studies in mammalian 
cells, also revealed a role of NER in the repair of AS-I-145 induced damage, judged 
by the increased sensitivity of a panel of NER deficient CHO cell lines compared to 
the repair proficient wild type (Chapter 5).
A reported potential determinant of chemosensitivity to the CC-1065/duocarmycins 
class  of  compounds  is  the  cellular  protein,  named  duocarmycin-DNA  adduct
316recognising  protein  (DARP)  (Asai  et  al.,  1999).  This  protein  of  an  estimated 
molecular weight  - 60  kDa  was  present  in  nuclear extracts from  human  cervical 
carcinoma  HeLa  S3  cells.  DARP  was detected  through  gel  mobility  shift  assays, 
shown  to  bind  with  increased  affinity  to  DUMSA  modified  DNA  and  was 
subsequently partially purified. Apart from DUMSA, DARP was also shown to be 
capable of recognising the DNA adduct of the structurally related CC-1065 and that 
of anthramycin, another potent minor groove binder, but did not recognised damage 
induced  by  major  groove  binding  drugs  such  cisplatin  (Asai  et  al.,  1999).  The 
selective interaction of DARP with DNA adducts generated only by certain minor 
groove  agents  was  attributed  to  the  protein’s  ability  to  recognise  the  altered 
structure of DNA upon modification by these drugs,  and particularly the  induced 
bend  toward  the  minor  groove,  a  characteristic  shared  by  these  specific  agents. 
Despite the lack of further molecular and functional characterisation, it was initially 
suggested that DARP could be one of the components involved in the nucleotide 
excision repair pathway,  as CC-1065  adducts are known NER substrates (Asai et 
al., 1999).
Human Rad 18 gene encodes for a protein of an expected size of 56 kDa. Use of the 
commercially available RAD 18 antibody in a western blot, detects a band of - 60 
kDa (Abeam pic, Cambridge, UK).
DARP also appeared to be different from another protein of-100 kDa, previously 
identified  to  recognise  DNA  damage  induced  specifically  by  AT-specific,  minor 
groove binding agents such as distamycin, Hoechst 33258 and CC-1065 (Colela et 
al.,  1996).  Since DARP’s specificity was restricted only to a certain chemotype of 
minor groove drugs, it presented a potential  factor that might selectively modulate 
the antitumour activity of the CC-1065/duocarmycin class of compounds in tumour 
cells. The protein was eventually further purified and sequenced by the same group 
(Taguchi  et  al.,  2004).  DARP  was  once  again  detected  by  its  ability  to  bind  to 
DUMSA-DNA adduct in gel shift assays. Three partial amino acid sequences were 
obtained  which  were  found  to  completely  match  parts  of the  predicted  human 
heterogenous nuclear ribonucleoprotein L  (hnRNP L), thus rendering hnRNP L a
317candidate  for  DARP’s  described  activity.  There  are  approximately  20  major 
members of the hnRNP family and participate in a variety of processes involving 
RNA, including transcription, splicing, processing, translation etc. High expression 
of some of these proteins has been reported in several human malignancies like lung 
and  breast  cancer.  Differential  intracellular  localisation  of  hnRNP  L  was 
demonstrated  among  human  lung  cancer  cell  lines.  Transfectants  of hnRNP  L 
possessed  increased  sensitivity  to  the  growth  inhibitory  effect  of  KW-2189,  a 
duocarmycin derivative. hnRNP L therefore enhances cell sensitivity to a member 
of the CC-1065/duocarmycin class of compounds while no difference in sensitivity 
was observed to cisplatin and mitomycin C (Taguchi et al., 2004). Similarly DARP 
had not been able to recognise the DNA adducts of those two major groove agents 
in the initial study (Asai et al.  1999). These observations suggest that DARP could 
be  hnRNP  L.  Critically  however,  the  use  of anti-hnRNP  L  antibody  failed  to 
produce a supershift of the retardation complex of DUMSA modified DNA in a gel 
mobility shift assay.
TH-III-151  and AS-I-145  coulbe  be  used  to damage the oligonucleotide  used  by 
Asai et al. This modified template can be subsequently used for gel mobility shift 
assays  to  detect  a  possible  hRadl8  binding  manifested  as  a  retarded  band 
corresponding to the hRadl8/DNA complex. The use of the commercially available 
hRadl8 antibody would result in a band of even lower mobility (“supershift”) at the 
expense of the original retarded band. That would indicate binding of the complex 
by the antibody and  would  unambiguously confirm the  binding of hRadl8 to the 
damaged  DNA  probe.  This  method  could  help  further  establish  the  notion  of 
hRadl8 as a damage recognition factor of minor groove agents and assign hRadl8 
as another possible candidate for the DARP activity.
The  identification  of the  key  pathways  involved  in  the  repair  of  DNA  damage 
induced  by  chemotherapeutic  agents  is  important for understanding the ability  of 
cancer  cells  to  recognize  damage  and  initiate  DNA  repair  and  in  some  cases 
explaining mechanisms of therapeutic resistance. At the same time, these pathways
318constitute potential sites for intervention, which could enhance the efficacy of DNA 
damaging agents.  The  resistance  phenotype for example,  of a  series of cisplatin- 
resistant, human ovarian cancer cell lines was shown to be due to overexpression of 
NER associated proteins, in particular ERCC1, resulting in increased DNA adduct 
removal (Ferry et al., 2000). NER, the main pathway responsible for the removal of 
cisplatin  damage  and  ERCC1  in  particular,  the  NER  component correlated  with 
resistance,  were  subsequently  “targeted”  in  an  attempt  to  sensitise  the  resistant 
ovarian cell lines to the cytotoxic effects of cisplatin. Disturbing the NER in those 
cells by perturbing levels of ERCC1  resulted in enhanced cisplatin cytotoxicity up 
to  8.1-fold,  in  the  cell  lines  under  investigation  (Selvakumaran  et  al.,  2003). 
Another way of modulating DNA repair is through pharmacological intervention. A 
small molecule inhibitor of vascular endothelial growth factor, SU5416 was shown 
to downregulate  DNA  repair activity  by  reducing the  expression  of ERCC1  and 
enhancing cisplatin cytotoxicity  up to 5.5-fold,  in  resistant human ovarian cancer 
cells (Zhong et al., 2003).
The repair studies of TH-III-151  and AS-I-145  revealed that Radl8  has a special 
role in the function of the  NER of the minor groove adducts induced by the two 
agents.  In  light of the  above  examples  where  DNA  repair inhibition  is used  as a 
means for modulating chemosensitivity, this Rad 18 function described in this thesis 
could  be  further  exploited  as  an  alternative  way  of  impairing  NER.  Instead  of 
directly targeting an NER component, as described above for ERCC1 and cisplatin 
sensitivity, NER could be modulated by targeting Rad 18, for agents like TH-III-151 
and AS-I-145. Our observations for the moment are restricted in yeast. The role of 
mammalian  RADI8 and  its  possible  involvement  in  the  mammalian  NER of the 
adducts of this class of minor groove agents should be also investigated. Imbalances 
in the levels of hRadl8 exist in  many tumours and could lead to changes in drug 
sensitivity.  hRAD18,  the  human  homologue  of  the  yeast  RAD18  maps  on 
chromosome  3p24-25,  where deletions are often found in  lung,  breast, ovary and 
testis cancers (Tateishi et al., 2000).  As with their yeast counterparts, hRadl8 has 
been  shown  to  physically  associate  in  vivo  with  hHR6A/hHR6B  (hHR6A  and
319hHR6B  being  the  human  homologues  of  the  yeast  RAD6  gene  (Tateishi  et  al., 
2000). Human breast cancer cells engineered to overexpress hHR6B were shown to 
be resistant to the cytotoxic effects of cisplatin.  In contrast, cells depleted of this 
protein exhibited increased sensitivity (Lyakhovich & Shekhar, 2004). Cells could 
be sensitized in vitro by the employment of RADJ8 antisense RNA to downregulate 
the  levels of hRadl8.  It would  be  interesting to assess the extent of the  NER of 
minor groove adducts, in hHR6B or hRadl8 depleted cells. Would an NER defect 
be observed in such cells as it was in yeast for TH-III-151, AS-I-145 and BAM-Py3  
induced, sequence specific lesions? (Brooks et al., 2000; this thesis). Deficiency of 
the human cells to excise the adenine-N3 adducts when hRAD18 is silenced would 
confirm the involvement of hRadl8 in the NER of these adducts. It is important to 
also investigate any correlation in the levels of Rad 18 expression in various tumour 
types  with  the  sensitivity  to  the  above-mentioned  agents  and  the  extent  and 
efficiency  of  NER.  If  such  a  correlation  is  established,  it  could  be  used  as  a 
predictive  tool  for  susceptibility  of  specific  tumours  to  drug  toxicity.  It  is 
conceivable that altered levels of hRadl8 or hRad6, either occurring constitutively 
in certain cancers, as mentioned above, or resulting through modulatation (e.g. by 
the identification and use of a small molecule inhibitor) could cause cancer cells to 
be  impacted  more,  by  such  DNA  damaging  agents,  through  crippling  their  NER 
capacity.  This  would  be  most  important  in  cases  of  resistance  emerging  due  to 
enhanced activity of NER, where the toxic effects of agents are neutralized. 
hRadl8’s possible requirement in mammalian NER and particularly its implication 
in the early, recognition steps of NER and subsequent recruitment of NER proteins 
could be, as mentioned above, an attractive target for pharmacological intervention. 
Block or disruption  of the of hRadl8-DNA  interaction through  interference  with 
hRadl8’s ability to bind DNA, will  ultimately interfere with DNA repair and help 
manipulate cellular sensitivity to TH-III-151  and AS-I-145. In a similar attempt, a 
high-throughput screen for the identification of inhibitors of replication protein A, 
RPA’s binding to DNA was described by Andrews & Turchi  in 2004.  From 2000 
pure and synthetic products provided by the structural diversity set of the NCI, their
320fluorescence-based screen identified 79 compounds as potential inhibitors. Of those, 
9 were further validated with gel mobility shift assays and an in vitro NER incision 
assay  employing  site-directed  cisplatin  adducts  and  were  shown  to  efficiently 
inhibit RPA’s binding to DNA (Andrews & Turchi, 2004).
In  chapter  4,  it  was  shown  that  rad6  cells  were  as  disabled  as  radl8  in  the 
elimination of the TH-III-151  damage, suggesting that it is the inactivation of the 
Radl8-Rad6  complex  that  impairs  the  NER  of  these  adducts  and  is  not  a 
phenomenon  only  limited to  Rad 18.  The  interaction  of the two proteins  presents 
another  potential  site  for  intervention  that  could  ultimately  impair  NER,  once 
established that hRadl8 / hRad6 are required for the NER removal of TH-III-151 / 
AS-I-145  adducts  in  mammalian  cells.  In  an  analogous  manner,  it  has  been 
previously  shown  that  reduction  between  the  binding of ERCC1  to  XPA  in  cell 
extracts, induced by the agent UCN-01, caused reduction of the amount of the NER 
incision and therefore suppression of the NER of cisplatin-induced lesions (Jiang & 
Yang,  1999).  Such  interventions  however have to be  vigorously tested for  safety 
and efficacy  validation, ensuring that the desired therapeutic  phenotype does  not 
occur with  other off-target activities.  Rad6 for example  in  yeast  is  a  pleiotropic 
protein involved in many cellular functions, unlike Rad 18, which plays no known 
additional  role  in  cellular  metabolism  (Bailly  et  al.,  1994).  Deletion  of  hRAD6 
(hHR6A and hHR6B) showed that the gene is “necessary but not central” to normal 
human  breast  cell  profileration  and  growth.  Cells  lacking  hRad6  failed  to  plate 
down  and  proliferate  effectively  while  cells  expressing  low  amounts  of  hRad6 
retained ability of those functions (Lyakovich & Shekhar, 2004). Such implications 
must  be  addressed  when  considering  the  feasibily  of developing  dual  therapies 
consisting  of  agents,  which  would  interfere  with  relevant  repair  pathways  and 
potentiate the efficacy of specific DNA damaging drugs.
The  natural  anti-tumour  compound  illudin  S  and  its  semisynthetic  derivative 
irofulven  (MGI-114,  6-hydroxymethylacylfulvene,  HMAF;  NSC  683863)  both 
belong in the family of illudins. Although the exact mechanism of action of the two
321agents  has  not  been  elucidated,  their  capacity  to  bind  covalently  to  DNA  and 
proteins, characterise them as alkylating agents (Herzig et al.,  1999).  Radioactive 
irofulven in particular, was shown to bind to intracellular DNA in a non-reversible 
manner while the lack of bifunctional lesions led to the further characterisation of 
irofulven  as  a  monofunctional  alkylating  agent (Woynarowski  et  al.,  1997).  The 
two agents have been shown to induce DNA damage processed by NER in human 
fibroblasts.  CS-A  and  CS-B  cells  with  a  selective  defect  in  TC-NER  were  also 
sensitive to the drugs, at levels similar to the XP mutants, suggesting that illudin / 
irofulven cell survival depends on TC-NER. Additionally no increased sensitivity to 
a BER mutant CHO cell  line was observed suggesting that BER does not play  a 
crucial  role  in  the  processing  of  the  adducts.  Finally,  RAD 18-deficient  chicken 
lympoma  cells  were  hypersensitive  to  illudin  S  while  absence  of  polymerase  r\ 
(RAD30A) in  XP-variant fibroblasts did  not affect illudin toxicity (Jaspers et al., 
2002).  NER as a crucial  factor in  the cellular sensitivity to irofulven was further 
confirmed  in  a  later  study,  where  human  NER-deficient  cells  showed  increased 
sensitivity to the cytotoxic effects of the drug e.g. 30-fold in the case of XPA cells, 
20-fold in XPB and XPD and >  10 in CS cells, compared to NER-proficient cells 
(Koeppel  et  al.,  2004). The  susceptibility  to  NER deficiency,  the  involvement of 
TC-NER  and  the  sensitisation  in  RAD 18  mutants  comprise  a  repair  pattern 
reminiscent of the findings in yeast for TH-III-151  and AS-I-145, as described in 
chapter 4.
Irofulven exhibits activity in  vitro towards a panel of human carcinoma cell lines. 
The cytotoxic effect of irofulven was most pronounced toward non-small cell lung 
and ovarian carcinomas while also showing potent activity toward malignant glioma 
cells.  In contrast, limited activity  was observed against leukemia cell lines. These 
findings correlated well with the results obtained for the same cell lines at the NCI 
60 cell  line  screen  (Poindessous  et al.,  2003).  Irofulven  has  been  investigated  in 
several clinical trials including phase I (Bomgaars et al., 2006) and phase II (Seiden 
et al., 2006) for pediatric solid tumours and ovarian cancer, respectively. Currently, 
irofulven remains in various phase II clinical trials against a wide variety of solid
322tumors and has demonstrated activity in ovarian, prostate, gastrointestinal, and non­
small cell lung cancer (Paci et al., 2006; references therein). Again the preferential 
activity  of  irofulven  against  solid  tumours  over  leukemias  is  reminiscent  of the 
sensitivity patterns obtained forTH-IIl-151 and AS-I-145 in the NCI in vitro screen 
(Appendix-I, III).
The reported involvement of the same mechanisms for the repair of the respective 
adducts and the similar tissue specific sensitivities suggests that irofulven and TH- 
III-151/AS-I-145 could elicit similar cellular responses. The full characterization of 
the  DNA  interaction  of  irofulven  is  however  required  to  extrapolate  further 
conclusions. The observation in one of the early studies, of (partial) inhibition of 
Taq Polymerase extension on a DNA template isolated from irofulven-treated cells 
(Woynarowski  et al.,  1997), along with the reported  interaction of irofulven with 
calf-thymus DNA (Herzig et al.,  1999) suggests that the Taq Polymerase stop assay 
could initially be a useful technique to gain more insight in the sequence specificity 
of the interaction of the agent with  DNA. Finally, the COMPARE program based 
on the sensitivity profiles to the agents of the cells at the NCI 60-line screen could 
be  also  used  to determine  the  correlation  coefficient  between  the  two  classes  of 
agents.  Such  comparison  could  provide  more  insight  to  a  possible  common 
mechanism of action.
The National Cancer Institute estimates that approximately  10.1  million Americans 
with a history of cancer were alive in January 2002. Some of these individuals were 
cancer-free, while other still had evidence of cancer and may have been undergoing 
treatment.  The  5-year  survival  rate  for  all  cancers  diagnosed  between  1995  and 
2001  is  65%,  up  from  50%  in  1974-1976.  This  improvement  is  largely  due  to 
advances  in  detection  and  new  and/or  improved  treatments.  While  these  have 
helped  some  developed  nations  lower  incidence  and  improve  survival  rate  for 
certain cancers, for most parts of the world cancer is a growing problem.  Cancer 
killed 6.7 million people around the world in 2002 and this figure is expected to rise 
to  10.3  million  in  2020  (World  cancer  report  -  World  Health  Organisation).
323Despite  increased  cure  rates for certain  cancer types and  survival  improvements, 
routine cure or long term management of cancer as a chronic disease remain elusive 
with treatment options for cancer patients still being marginal for most cancer types. 
The  need  for  the  development  of  new  therapeutic  compounds  with  improved 
antitumour  activity  and  decreased  clinical  toxicity  remains  persistent  and 
demanding.  In  the  current,  postgenomic  era,  there  has  been  a  transition  in  drug 
development  from  cytotoxic  drugs  to  targeted  therapies.  However,  the  same 
principles that have hampered the “cytotoxic era” like variations of response due to 
tumour  heterogeneity,  tumour  relapse  and  eventual  development  of  therapy 
resistance  seem  to also  pertain  the targeted  strategies.  Combination  therapies are 
therefore  one  alternative  for  a  more  efficient  tumour  eradication.  Studies  have 
demonstrated  synergy  between  targeted  molecules  and  traditional  chemotherapy. 
Gleevec for example synergistically sensitizes CLL cells to chlorambucil, from 2 to 
20 fold (Aloyz et al., 2005). A synergistic interaction between Gleevec and cisplatin 
has also been demonstrated in vitro in adenoic cystic carcinoma and squamous cell 
carcinoma  of  the  head  and  neck  (HNSCC)  (Bruce  et  al.,  2005).  Concurrent 
administration  of  Gleevec  and  chemotherapy  has  finally  been  shown  to  have  a 
greater antileukemic  effect  in  patients  with  acute  lymphoblastic  leukemia  (ALL) 
(Wassman et al., 2006).
The potent toxicities of existing  DNA-reactive  agents can  result in  an  immediate 
reduction  in  tumour  burden  and  this  can  be  a  prerequisite for optimal  results of 
newer sophisticated targeted therapies.  Such a setting of minimal  residual  disease 
achieved with standard chemotherapy has been suggested to be the best strategy for 
the  use of telomerase  inhibitors.  In  that  way,  it is  believed  that  rare cancer stem 
cells,  a  possible  source  of chemoresistance,  which  also  happen  to  be  telomerase- 
positive, are best targeted by use of combination regimens (Shay & Wright, 2006). 
Conventional cytotoxics, like the alkylating agents will therefore still  hold a place 
in the cancer therapeutic regimens for the years to come.
324As part of a long lasting programme of rational drug design, this thesis presented a 
series of novel chiral and achiral analogues of the natural products CC-1065 and the 
duocarmycins. A new platform for the development of active analogues is provided 
and could be exploited in various synthetic schemes in the future. Compounds like 
ET-743 and irofulven  have been associated with  what could be a “resurgence for 
alkylating  therapy  in  cancer”  (Dent  &  Grant,  2004).  The  achiral  design  can 
therefore become a new  paradigm and  a new focus in further exploiting nature’s 
lead compounds CC-1065/duocarmycins and maintaining their relevance in today’s 
drug development. The identification on the other hand of key cellular determinants 
that are implicated in the DNA damage response can explain susceptibility to drug 
toxicity and provide leads for the modulation of the drug response.
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